WO2017001655A1 - Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b - Google Patents

Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b Download PDF

Info

Publication number
WO2017001655A1
WO2017001655A1 PCT/EP2016/065488 EP2016065488W WO2017001655A1 WO 2017001655 A1 WO2017001655 A1 WO 2017001655A1 EP 2016065488 W EP2016065488 W EP 2016065488W WO 2017001655 A1 WO2017001655 A1 WO 2017001655A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
compound
methyl
independently selected
group
Prior art date
Application number
PCT/EP2016/065488
Other languages
French (fr)
Inventor
Sandrine Marie Helene Vendeville
Stefaan Julien Last
Samuël Dominique DEMIN
Sandrine Céline GROSSE
Geerwin Yvonne Paul HACHÉ
Lili Hu
Serge Maria Aloysius Pieters
Geert Rombouts
Koen Vandyck
Wim Gaston Verschueren
Pierre Jean-Marie Bernard Raboisson
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP19186044.4A priority Critical patent/EP3590943A1/en
Priority to SI201630448T priority patent/SI3317286T1/en
Priority to CR20180069A priority patent/CR20180069A/en
Priority to MDE20180475T priority patent/MD3317286T2/en
Priority to MA42292A priority patent/MA42292B1/en
Priority to UAA201800908A priority patent/UA124054C2/en
Priority to AU2016287472A priority patent/AU2016287472B2/en
Priority to MX2017016781A priority patent/MX2017016781A/en
Priority to EA201890200A priority patent/EA036629B1/en
Priority to DK16733102T priority patent/DK3317286T3/en
Priority to KR1020187001757A priority patent/KR20180022818A/en
Priority to RS20191509A priority patent/RS59609B1/en
Priority to BR112017028504A priority patent/BR112017028504A2/en
Priority to EP16733102.4A priority patent/EP3317286B1/en
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Priority to PL16733102T priority patent/PL3317286T3/en
Priority to CN201680038835.3A priority patent/CN107735400B/en
Priority to TNP/2017/000535A priority patent/TN2017000535A1/en
Priority to ES16733102T priority patent/ES2759775T3/en
Priority to JP2017567064A priority patent/JP6914201B2/en
Priority to CA2986344A priority patent/CA2986344A1/en
Publication of WO2017001655A1 publication Critical patent/WO2017001655A1/en
Priority to CONC2017/0012268A priority patent/CO2017012268A2/en
Priority to PH12017502316A priority patent/PH12017502316A1/en
Priority to IL256392A priority patent/IL256392A/en
Priority to HK18109558.5A priority patent/HK1250031A1/en
Priority to HK18112631.0A priority patent/HK1253337B/en
Priority to HRP20191901TT priority patent/HRP20191901T1/en
Priority to CY20191101240T priority patent/CY1122688T1/en
Priority to IL276333A priority patent/IL276333B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to inhibitors of HBV replication.
  • the invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
  • the Hepatitis B virus is an enveloped, partially double-stranded DNA (dsDNA) virus of the Hepadnavirus family (Hepadnaviridae). Its genome contains 4 overlapping reading frames: the precore/core gene; the polymerase gene; the L, M, and S genes, which encode for the 3 envelope proteins; and the X gene.
  • the partially double-stranded DNA genome (the relaxed circular DNA; rcDNA) is converted to a covalently closed circular DNA (cccDNA) in the nucleus of the host cell and the viral mRNAs are transcribed.
  • the pregenomic RNA (pgRNA), which also codes for core protein and Pol, serves as the template for reverse transcription, which regenerates the partially dsDNA genome (rcDNA) in the nucleocapsid.
  • HBV has caused epidemics in parts of Asia and Africa, and it is endemic in China. HBV has infected approximately 2 billion people worldwide of which approximately 350 million people have developed chronic infections. The virus causes the disease hepatitis B and chronic infection is correlated with a strongly increased risk for the development cirrhosis and hepatocellular carcinoma. Additionally, HBV acts as a helper virus to hepatitis delta virus (HDV), and it is estimated that more than 15 million people may be HBV/HDV co-infected worldwide, with an increased risk of rapid progression to cirrhosis and increased hepatic decompensation, than patients suffering from HBV alone (Hughes, S.A. et al. Lancet 2011, 378, 73-85).
  • HDV hepatitis delta virus
  • Transmission of hepatitis B virus results from exposure to infectious blood or body fluids, while viral DNA has been detected in the saliva, tears, and urine of chronic carriers with high titer DNA in serum.
  • HAPs heteroaryldihydropyrimidines
  • WO2013/006394 published on January 10, 2013, relates to a subclass of sulfamoyl- arylamides active against HBV.
  • WO2013/096744 published on June 26, 2013 relates to compounds active against HBV.
  • problems which HBV direct antivirals may encounter are toxicity, mutagenicity, lack of selectivity, poor efficacy, poor bioavailability, low solubility and difficulty of synthesis.
  • HBV inhibitors that may overcome at least one of these disadvantages or that have additional advantages such as increased potency or an increased safety window.
  • the present invention relates to a compound of Formula (I-A)
  • aryl represents a monocyclic 5 or 6 membered aryl optionally containing one or two heteroatoms, such aryl optionally being substituted with one or more substituents each independently selected from the group consisting of Ci-C 3 alkyl, in particular methyl, C 3 -C 4 cycloalkyl, -CN and halogen; represents a 6 membered aryl optionally containing one nitrogen atom;
  • X represents -CR 2 R 3 -;
  • Y represents Ci_C 7 alkanediyl or C 2 -C 7 alkenediyl, each optionally substituted with one or more substituents each independently selected from the group consisting of Ci-C 4 alkyl, fluoro, and -OH;
  • Z represents a heteroatom, preferably NH or oxygen and more preferably oxygen, or a single bond
  • R a , R b , R c and R d are each independently selected from the group consisting of hydrogen, halogen, -CHF 2 , -CF 2 -methyl, -CH 2 F, -CF 3 , -OCF 3 , -CN, C 3 -C 4 cycloalkyl and -Ci-C 4 alkyl;
  • R 1 is hydrogen or Ci-Cioalkyl optionally substituted with one or more substituents each independently selected from the group consisting of -OH, fluoro, and oxo;
  • Ci-C 3 alkyl-R 7 , 3-7 membered saturated ring or the monocyclic aryl are each
  • Ci-C 4 alkyl optionally substituted with one or more substituents each independently selected from fluoro and/or -OH;
  • the invention further relates to a pharmaceutical composition comprising a compound of Formula (I-A), and a pharmaceutically acceptable carrier.
  • the invention also relates to the compounds of Formula (I-A) for use as a medicament, preferably for use in the prevention or treatment of an HBV infection in a mammal.
  • the invention relates to a combination of a compound of Formula (I-A), and another HBV inhibitor.
  • the present invention relates to a compound of Formula (I-A) as defined hereinbefore.
  • the present invention relates to a compound of Formula (I-A)
  • aryl represents a monocyclic 5 or 6 membered aryl optionally containing one or two heteroatoms, such aryl optionally being substituted with one or more substituents each independently selected from the group consisting of Ci-C 3 alkyl, in particular methyl, C 3 -C 4 cycloalkyl, -CN and halogen;
  • X represents -CR 2 R 3 -;
  • Y represents Ci_C 7 alkanediyl or C 2 -C 7 alkenediyl each optionally being substituted with one or more substituents each independently selected from Ci-C 4 alkyl and -OH;
  • Z represents a heteroatom, preferably oxygen, or a single bond;
  • R a , R b , R c and R d are each independently selected from the group consisting of Hydrogen, halogen, -CHF 2 , -CF 2 -methyl, -CH 2 F, -CF 3 , -OCF 3 , -CN, C 3 -C 4 cycloalkyl and -Ci-C 4 alkyl;
  • R 1 is Hydrogen or Ci-C 6 alkyl, such Ci-C 6 alkyl optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, Fluoro, oxo, and Ci-C 4 alkyl optionally substituted with one or more Fluoro and/or -OH;
  • R 2 is selected from the group consisting of hydrogen, Ci-C 6 alkyl, Ci-C 3 alkyl-R 7 , a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, and monocyclic
  • R is hydrogen or Ci_ 6 alkyl; in particular, hydrogen or methyl; or R 2 and R 3 taken together form together with the carbon atom to which they are attached a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N,
  • such 3-7 membered saturated ring optionally being substituted with one or more R ;
  • the invention relates to a compound of Formula (I-A)
  • aryl represents a monocyclic 5 or 6 membered aryl optionally containing one or two heteroatoms, such aryl optionally being substituted with one or more substituents each independently selected from the group consisting of Ci-C 3 alkyl, in particular methyl, C 3 -C 4 cycloalkyl, -CN and halogen;
  • X represents -CR 2 R 3 -;
  • Y represents Ci_C7alkanediyl or C 2 -C7alkenediyl each optionally being substituted with one or more substituents each independently selected from Ci-C 4 alkyl and -OH;
  • Z represents a heteroatom, preferably oxygen, or a single bond;
  • R a , R b , R c and R d are each independently selected from the group consisting of hydrogen, halogen, -CHF 2 , -CF 2 -methyl, -CH 2 F, -CF 3 , -OCF 3 , -CN, C 3 -C 4 cycloalkyl and -Ci-C 4 alkyl;
  • R 1 is hydrogen or Ci-Cealkyl, such Ci-Cealkyl optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, Fluoro, oxo, and Ci-C 4 alkyl optionally substituted with one or more Fluoro and/or -OH;
  • R 2 is selected from the group consisting of hydrogen, Ci-C 6 alkyl, Ci-C 3 alkyl-R 7 , a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, and monocyclic aryl optionally containing one or two heteroatoms, such Ci-C 6 alkyl, Ci-C 3 alkyl-R 7 , 3-7 membered saturated ring or monocyclic aryl optionally being substituted with one or more R 8 ;
  • R is hydrogen; or R 2 and R 3 taken together form together with the carbon atom to which they are attached a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N,
  • such 3-7 membered saturated ring optionally being substituted with one or more R ;
  • R 7 represents a monocyclic aryl optionally containing one or two heteroatoms; a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N; or -NR 9 R 10 ; wherein R 9 and R 10 are each independently selected from hydrogen and Ci-C 3 alkyl;
  • the invention relates to a compound of Formula (I-A) as defined herein, or a stereoisomer or tautomeric form thereof, wherein: represents a monocyclic 5 or 6 membered aryl optionally containing one or two heteroatoms, such aryl optionally being substituted with one or more substituents each independently selected from the group consisting of Ci-C 3 alkyl, in particular methyl, C 3 -C 4 cycloalkyl, -CN and halogen; ⁇ B ;
  • X represents -CR 2 R 3 -;
  • Y represents a Ci_C 7 alkanediyl or C2_C 7 alkenediyl each optionally substituted with one or more Ci-C 4 alkyl or -OH;
  • Z represents a heteroatom, preferably oxygen, or a single bond
  • R a , R b , R c and R d are independently selected from the group consisting of Hydrogen, halogen, -CHF 2 , -CF 2 -methyl, -CH 2 F, -CF 3 , -OCF 3 , -CN, C 3 -C 4 cycloalkyl and -Ci-C 4 alkyl;
  • R 1 is Hydrogen or Ci-C 6 alkyl, such Ci-C 6 alkyl optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, Fluoro, oxo, and Ci-C 4 alkyl optionally substituted with one or more Fluoro and/or -OH;
  • R 2 is selected from the group consisting of hydrogen, Ci-C 6 alkyl, Ci-C 3 alkyl-R 7 , a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, and monocyclic aryl optionally containing one or two heteroatoms, such Ci-C 6 alkyl, Ci-C 3 alkyl-R 7 , 3-7 membered saturated ring or monocyclic aryl optionally being substituted with one or more R ;
  • R is hydrogen; or R 2 and R 3 taken together form together with the carbon atom to which they are attached a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N,
  • R 7 represents a monocyclic aryl optionally containing one or two heteroatoms
  • the invention relates to a compound of Formula (I -A) as defined herein, or a stereoisomer or tautomeric form thereof, wherein:
  • R 4 is hydrogen, -Ci-C 3 alkyl or C 3 -C 4 cycloalkyl; in particular methyl;
  • R 5 is hydrogen or halogen; in particular fluoro
  • R 6 is selected from hydrogen, methyl, -CN and halogen; in particular, hydrogen or methyl; in particular, hydrogen or fluoro, in particular hydrogen;
  • the present invention further relates in particular to a compound of Formula (A)
  • X represents -CR 2 R 3 -;
  • Y represents a Ci_C7alkanediyl or C 2 -C7alkenediyl each optionally substituted with one or more Ci-C 4 alkyl or -OH;
  • Z represents a heteroatom, preferably oxygen, or a single bond
  • R a , R b , R c and R d are independently selected from the group consisting of Hydrogen, halogen, -CHF 2 , -CF 2 -methyl, -CH 2 F, -CF 3 , -OCF 3 , -CN, C 3 -C 4 cycloalkyl and -Ci-C 4 alkyl;
  • R 1 is Hydrogen or Ci-C 6 alkyl, such Ci-C 6 alkyl optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, Fluoro, oxo, and Ci-C 4 alkyl optionally substituted with one or more Fluoro and/or -OH;
  • R 2 is selected from the group consisting of hydrogen, Ci-C 6 alkyl, Ci-C 3 alkyl-R 7 , a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, and monocyclic aryl optionally containing one or two heteroatoms, such Ci-C 6 alkyl, Ci-C 3 alkyl-R 7 , 3-7 membered saturated ring or monocyclic aryl optionally being substituted with one or more R ;
  • R is hydrogen; or R 2 and R 3 taken together form together with the carbon atom to which they are attached a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N,
  • R 7 represents a monocyclic aryl optionally containing one or two heteroatoms
  • the invention further relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula (A), and a pharmaceutically acceptable carrier.
  • the invention also relates to the compounds of Formula (A) for use as a medicament, preferably for use in the prevention or treatment of an HBV infection in a mammal.
  • the invention relates to a combination of a compound of Formula (A), and another HBV inhibitor.
  • the present compounds or similar term is meant to include all compounds of general Formula (I- A), (A), (A*), (B), or (C), salts, stereoisomeric forms and racemic mixtures or any subgroups thereof.
  • the present invention relates in particular to compounds of Formula (A)
  • aryl represents a monocyclic 5 or 6 membered aryl optionally containing one or two heteroatoms, such aryl optionally substituted with one or more methyl, -CN or halogen;
  • X represents -CR 2 R 3 -;
  • Y represents a Ci_C 7 alkanediyl or C2_C 7 alkenediyl each optionally substituted with one or more Ci-C 4 alkyl or -OH;
  • Z represents a heteroatom, preferably oxygen, or a single bond
  • R a , R b , R c and R d are independently selected from the group consisting of Hydrogen, halogen, -CHF 2 , -CF 2 -methyl, -CH 2 F, -CF 3 , -OCF 3 , -CN, C 3 -C 4 cycloalkyl and -Ci-C 4 alkyl;
  • R 1 is Hydrogen or Ci-C 6 alkyl, such Ci-C 6 alkyl optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, Fluoro, oxo, and Ci-C 4 alkyl optionally substituted with one or more Fluoro and/or -OH;
  • R 2 is selected from the group consisting of hydrogen, Ci-C 6 alkyl, Ci-C 3 alkyl-R 7 , a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, and monocyclic aryl optionally containing one or two heteroatoms, such Ci-C 6 alkyl, Ci-C 3 alkyl-R 7 , 3-7 membered saturated ring or monocyclic aryl optionally being substituted with one or more R ;
  • R is hydrogen; or R 2 and R 3 taken together form together with the carbon atom to which they are attached a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N,
  • R 7 represents a monocyclic aryl optionally containing one or two heteroatoms
  • the present invention relates to compounds of Formula (A) or a stereoisomer or tautomeric form thereof, wherein:
  • aryl represents a monocyclic 5 or 6 membered aryl optionally containing one or two heteroatoms, such aryl optionally substituted with one or more methyl, -CN or halogen;
  • X represents -CR 2 R 3 -;
  • Y represents a Ci_C7alkanediyl or C 2 -C7alkenediyl each optionally substituted with one or more Ci-C 4 alkyl;
  • Z represents a heteroatom, preferably oxygen, or a single bond
  • R a , R b , R c and R d are independently selected from the group consisting of Hydrogen, halogen, -CHF 2 , -CF 2 -methyl, -CH 2 F, -CF 3 , -OCF 3 , -CN, C 3 -C 4 cycloalkyl and -Ci-C 4 alkyl;
  • R 1 is Hydrogen or Ci-Cealkyl, such Ci-Cealkyl optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, Fluoro, oxo, and Ci-C 4 alkyl optionally substituted with one or more Fluoro and/or -OH;
  • R 2 is selected from the group consisting of hydrogen, Ci-Cealkyl, Ci-C 3 alkyl-R 7 and monocyclic aryl optionally containing one or two heteroatoms, such Ci-Cealkyl, Ci-C 3 alkyl-R 7 or monocyclic aryl optionally being substituted with one or more R 8 ;
  • R is hydrogen; or R 2 and R 3 taken together form together with the carbon atom to which they are attached a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring optionally substituted with one or more Fluoro and/or -OH, or Ci-C 4 alkyl optionally substituted with one or more Fluoro and/or -OH;
  • R 7 represents a monocyclic aryl optionally containing one or two heteroatoms; Each R independently is selected from the group consisting of -OH, Fluoro, methoxy, oxo, and Ci-C 4 alkyl optionally substituted with one or more Fluoro and/or -OH; or a pharmaceutically acceptable salt or a solvate thereof.
  • the invention relates to compounds of Formula (B)
  • R a , R b , R c and R d are independently selected from the group consisting of Hydrogen, halogen, -CHF 2 , -CF 2 -methyl, -CH 2 F, -CF 3 , -OCF 3 , -CN, C 3 -C 4 cycloalkyl and -Ci-C 4 alkyl;
  • R 1 is Hydrogen or Ci-Cealkyl, such Ci-Cealkyl optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, Fluoro, oxo, and Ci-C 4 alkyl optionally substituted with one or more Fluoro and/or -OH;
  • R 2 is selected from the group consisting of hydrogen, Ci-C 6 alkyl, Ci-C 3 alkyl-R 7 and monocyclic aryl optionally containing one or two heteroatoms, such Ci-C 6 alkyl,
  • R is hydrogen;
  • R 4 is Hydrogen, -Ci-C 3 alkyl or C 3 -C 4 cycloalkyl, preferably methyl;
  • R 5 is Hydrogen or Halogen, preferably Fluoro
  • R 6 is selected from hydrogen, methyl, -CN and halogen
  • R 7 represents a monocyclic aryl optionally containing one or two heteroatoms
  • each R independently is selected from the group consisting of -OH, Fluoro, methoxy, oxo, and Ci-C 4 alkyl optionally substituted with one or more Fluoro and/or -OH; or a pharmaceutically acceptable salt or a solvate thereof.
  • the invention relates to compounds of Formula (I-A), (A), (A*), (B) or (C) as described herein, wherein R 1 is Hydrogen or Ci-C 6 alkyl optionally substituted with one or more substituents, in particular 1-3 substituents, each
  • An additional embodiment of the present invention relates to compounds of Formula (I-A) having, in particular, Formula (I-AA1) or Formula (I-AA2)
  • Ring B represents phenyl or 4-pyridyl
  • R 2 is selected from the group consisting of hydrogen, Ci-C 6 alkyl, Ci-C 3 alkyl-R 7 , a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, and monocyclic aryl optionally containing one or two heteroatoms, such Ci-C 6 alkyl, Ci-C 3 alkyl-R 7 , 3-7 membered saturated ring or monocyclic aryl optionally being substituted with one or more R ;
  • R 3 is hydrogen or Ci-C 6 alkyl, in particular hydrogen or methyl
  • R 4 is Ci-C 3 alkyl, in particular methyl
  • R 6 is hydrogen or methyl
  • R 7 is selected from the group consisting of a monocyclic aryl optionally containing one or two heteroatoms; a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N; or -NR 9 R 10 ;
  • R 9 and R 10 are each independently selected from hydrogen and Ci-C 3 alkyl
  • R a is selected from hydrogen and halogen, in particular hydrogen
  • R b is absent when ring B is pyridyl or is hydrogen or a halogen, in particular a halogen, when ring B is phenyl;
  • R c is selected from halogen, CH 3 , CHF 2 , CF 3 , and -CN;
  • R d is selected from hydrogen and halogen, in particular hydrogen
  • a further embodiment the present invention relates to compounds of Formula (I -A) having, in particular, Formula (I-Al) or Formula (I-A2)
  • Ring B represents phenyl or 4-pyridyl
  • R 2 is selected from the group consisting of hydrogen, Ci-Cealkyl, Ci-C 3 alkyl-R 7 , a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, and monocyclic aryl optionally containing one or two heteroatoms, such Ci-Cealkyl, Ci-C 3 alkyl-R 7 , 3-7 membered saturated ring or monocyclic aryl optionally being substituted with one or more R ;
  • R 4 is Ci-C 3 alkyl, in particular methyl
  • R 6 is hydrogen or methyl
  • R 7 is selected from the group consisting of a monocyclic aryl optionally containing one or two heteroatoms; a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N; or -NR 9 R 10 ;
  • R 9 and R 10 are each independently selected from hydrogen and Ci-C 3 alkyl
  • R a is selected from hydrogen and halogen, in particular hydrogen
  • R b is absent when ring B is pyridyl or is hydrogen or a halogen, in particular a halogen, when ring B is phenyl;
  • R c is selected from halogen, C3 ⁇ 4, CHF 2 , CF 3 , and -CN;
  • R d is selected from hydrogen and halogen, in particular hydrogen
  • the present invention relates to compounds of Formula (I- A) having, in particular, Formula (I-Al ') or Formula (I-A2')
  • Ring B represents phenyl or 4-pyridyl
  • R 2 is selected from the group consisting of Ci-Cealkyl, Ci-C 3 alkyl-R 7 , a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, and monocyclic aryl optionally containing one or two heteroatoms, such Ci-Cealkyl, Ci-C 3 alkyl-R 7 , 3-7 membered
  • R 4 is Ci-C 3 alkyl, in particular methyl
  • R 6 is hydrogen or methyl
  • R 7 is selected from the group consisting of a monocyclic aryl optionally containing one or two heteroatoms; a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N; or -NR 9 R 10 ;
  • R 9 and R 10 are each independently selected from hydrogen and Ci-C 3 alkyl
  • R a is selected from hydrogen and halogen, in particular hydrogen
  • R b is absent when ring B is pyridyl or is hydrogen or a halogen, in particular a halogen, when ring B is phenyl;
  • R c is selected from halogen, C3 ⁇ 4, CHF 2 , CF 3 , and -CN;
  • R d is selected from hydrogen and halogen, in particular hydrogen
  • the present invention relates to compounds of Formula (I- A) having, in particular, Formula (I-Al ') or Formula (I-A2'), as defined herein wherein R is Ci-Cealkyl optionally substituted with 1-4 substituents each independently selected from the group consisting of -OH, fluoro, and methoxy, in particular -OH and fluoro; Ring B represents phenyl; R a is selected from hydrogen and halogen; R b is hydrogen or a halogen, in particular a halogen; and R c is selected from halogen, CH 3 , CHF 2 , CF 3 , and -CN; and the rest of the variables are as defined herein.
  • Another embodiment of the present invention relates to those compounds of Formula (I-A), Formula (I-AAl), Formula (I-AA2), Formula (I-Al), Formula (I-A2), Formula (I-Al '), Formula (I-A2'), Formula (A), Formula (B), or Formula (C) or any subgroup thereof as mentioned in any of the other embodiments wherein one or more of the following restrictions apply: (a) Ring C consists of 6 to 8 atoms, preferably 7 atoms.
  • Y represents linear Ci_C 7 alkanediyl or C 2 _C 7 alkenediyl, each optionally
  • Y represents linear Ci_C 7 alkanediyl or C 2 _C 7 alkenediyl, each optionally
  • R is Ci-C 6 alkyl optionally substituted with one or more Fluoro and/or -OH substituents, each independently selected.
  • R is a branched
  • Ci-C 6 alkyl substituted with one or more Fluoro substituents are particularly preferred.
  • R is Ci-C 6 alkyl optionally substituted with one or more -OH substituents.
  • R is Ci_ 6 alkyl substituted with one -OH.
  • R is Ci-C 4 alkyl optionally substituted with one or more fluoro substituents.
  • R is C 3 -C 6 alkyl optionally substituted with one or more fluoro substituents.
  • R is Ci-C 4 alkyl, in particular methyl.
  • R 3 is Ci-C 4 alkyl, in particular methyl; and R 2 is selected from the group
  • Ci-C 6 alkyl consisting of Ci-C 6 alkyl, and monocyclic aryl optionally containing one or two heteroatoms, such Ci-C 6 alkyl or monocyclic aryl optionally being substituted with one or more R 8 , wherein R 8 is as defined herein,
  • R 4 is Ci-C 3 alkyl, preferably methyl
  • R b is Hydrogen or Fluoro.
  • R b and R c are independently selected from hydrogen, fluoro and -CN.
  • R b and R c are independently selected from Hydrogen or Fluoro.
  • R b and R c are independently selected from fluoro and -CN.
  • R a and R d are both Hydrogen.
  • R b and/or R c are Fluoro.
  • R 1 is hydrogen or Ci-C 6 alkyl optionally substituted with one or more
  • R 1 is hydrogen
  • (t) represents phenyl
  • (u) represents phenyl substituted with one or more halogen substituents.
  • (v) represents phenyl substituted with at least one Halogen, more
  • (w) 7 is a 3-7 membered saturated ring, in particular cyclopropyl.
  • (x) R is selected from the group consisting of methyl, ethyl, isopropyl,
  • R a , R b , R c and R d are each independently selected from the group consisting of hydrogen, halogen, -CHF 2 , -CF 2 -methyl, -CF 3 , -OCF 3 , -CN, C 3 -C 4 cycloalkyl and -Ci-C 4 alkyl.
  • (aa) represents phenyl, and R a is selected from hydrogen and halogen; R b is hydrogen or a halogen, in particular a halogen; R c is selected from halogen, CH , CHF 2 , CF , and -CN; and R d is selected from hydrogen and halogen, in particular hydrogen.
  • (bb) represents phenyl, and R a is selected from hydrogen and
  • R b is hydrogen or a halogen, in particular a halogen
  • R c is selected from halogen, CH , CF , and -CN
  • R d is selected from hydrogen and halogen, in particular hydrogen.
  • the present invention relates to a compound of Formula (I -A) as defined herein, or a stereoisomer or tautomeric form thereof, wherein represents a monocyclic 5 or 6 membered aryl or heteroaryl selected from the group consisting of pyrrolyl, thiophenyl, pyrazolyl, phenyl, and pyridyl, each optionally substituted with one or two substituents each independently selected from the group consisting of Ci-C 3 alkyl, in particular methyl, C 3 -C 4 cycloalkyl, -CN and halogen;
  • X represents -CR 2 R 3 -;
  • Y represents linear Ci_C7alkanediyl or C 2 _C7alkenediyl, each optionally substituted with one, two or three substituents each independently selected from the group consisting of fluoro and -OH;
  • Z represents oxygen, or a single bond
  • R a , R b , R c and R d are each independently selected from the group consisting of hydrogen, halogen, -CHF 2 , -CF 2 -methyl, -CH 2 F, -CF 3 , -OCF 3 , -CN, C 3 -C 4 cycloalkyl and -Ci-C 4 alkyl;
  • R 1 is hydrogen or Ci-Cealkyl optionally substituted with one, two, three or four substituents each independently selected from the group consisting of -OH and fluoro; 2
  • R is hydrogen or Ci_ 6 alkyl optionally substituted with -OH; in particular, hydrogen or methyl; or R 2 and R 3 taken together with the carbon atom to which they are attached form a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, and optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, fluoro, methoxy, oxo, benzyl, and Ci-C 4 alkyl;
  • R 7 represents a monocyclic aryl optionally containing one or two heteroatoms, and optionally being substituted with one or two substituents each independently selected from the group consisting of halo and Ci_ 3 alkyl; a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N; or -NR 9 R 10 ; wherein R 9 and R 10 are each independently selected from hydrogen and Ci-C 3 alkyl optionally substituted with one or more fluoro substituents;
  • the present invention relates to a compound of Formula ) as defined herein, or a stereoisomer or tautomeric form thereof, wherein represents a monocyclic 5 membered heteroaryl selected from the group consisting of pyrrolyl, thiophenyl and pyrazolyl, each optionally substituted with one or two substituents each independently selected from the group consisting of Ci- C 3 alkyl, in particular methyl; represents phenyl or pyridyl; X represents -CR 2 R 3 -;
  • Y represents linear Ci_C 7 alkanediyl or C2_C 7 alkenediyl, each optionally substituted with one or two substituents each independently selected from the group consisting of fluoro and -OH;
  • Z represents oxygen, or a single bond
  • R a , R b , R c and R d are each independently selected from the group consisting of hydrogen, halogen, -CHF 2 , -CF 2 -methyl, -CH 2 F, -CF 3 , -OCF 3 , -CN, C 3 -C 4 cycloalkyl and -Ci-C 4 alkyl;
  • R 1 is hydrogen or Ci-C 3 alkyl optionally substituted with one, two or three substituents each independently selected from the group consisting of -OH and fluoro; more in particular, hydrogen;
  • R is selected from the group consisting of hydrogen; Ci-C 6 alkyl optionally substituted with one, two, three or four substituents each independently selected from the group consisting of
  • Ci-C 3 alkyl-R 7 C 2 -C 4 alkynyl; 3-7 membered saturated ring optionally containing one or two heteroatoms each independently selected from the group consisting of O, S and N selected from the group consisting of
  • cyclopropyl, tetrahydropyranyl and piperidinyl and monocyclic aryl optionally containing one or two heteroatoms selected from the group consisting of phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyrazolyl, imidazolyl, and oxazolyl; wherein the Ci-C 3 alkyl-R 7 , 3-7 membered saturated ring or the monocyclic aryl are each
  • R is hydrogen or Ci_ 3 alkyl optionally substituted with -OH; in particular, hydrogen or methyl; or R 2 and R 3 taken together with the carbon atom to which they are attached form a cyclopropyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl or piperidinyl ring, each optionally being substituted with benzyl;
  • R 7 is selected from the group consisting of phenyl, pyridyl, pyrazolyl, imidazolyl, and oxazolyl, each optionally substituted with one or two substituents each independently selected from the group consisting of halo and Ci_ 3 alkyl; cyclopropyl; and -NR 9 R 10 ; wherein R 9 and R 10 are each independently selected from hydrogen and Ci-C 3 alkyl optionally substituted with one or more fluoro substituents;
  • the invention relates to compounds of Formula (I -A), (A) or (A*), as defined herein, wherein s selected from the group consisting of pyrrolyl, thienyl and pyrazolyl, each optionally substituted with one or two substituents each independently selected from the group consisting of Ci-C 3 alkyl, in particular methyl, -CN and halo.
  • the invention relates to compounds of the invention, as defined herein, wherein
  • R is selected from the group consisting of hydrogen, Ci-C 6 alkyl optionally substituted with 1 -4 substituents each independently selected from the group consisting of -OH, fluoro and methoxy; Ci-C 3 alkyl-R 7 optionally substituted with -OH; a heterocyclyl selected from piperidinyl and tetrahydropyranyl, each optionally substituted with Ci-C 4 alkyl, which may be optionally substituted with 1-3 fluoro substituents; and aryl or heteroaryl selected from the group consisting of phenyl, pyridyl, pyrazinyl, pyrimidinyl, and oxazolyl, each ptionally substituted with methyl; wherein R 7 is selected from the group consisting of cyclopropyl, phenyl, pyridyl, oxazolyl, pyrazolyl and imidazolyl, each optionally substituted with 1 -3 substituents each independently selected from halo and
  • R is hydrogen or Ci_ 6 alkyl optionally substituted with -OH; in particular, hydrogen or methyl; or R 2 and R 3 taken together with the carbon atom to which they are attached form a cyclopropyl, an oxetanyl, a tetrahydrofuranyl or a pyrrolidinyl ring optionally substituted with benzyl, in particular an oxetanyl or a tetrahydrofuranyl ring.
  • the invention relates to compounds of the invention, as defined herein, wherein
  • R is selected from the group consisting of Ci-C 6 alkyl optionally substituted with 1-4 substituents each independently selected from the group consisting of -OH and fluoro; Ci-C 3 alkyl-R 7 ; optionally substituted with -OH;
  • piperidinyl or tetrahydropyranyl each of which may be optionally substituted with Ci-C 4 alkyl, which may be optionally substituted with 1-3 fluoro substituents;
  • R 7 is selected from cyclopropyl, phenyl, pyridyl, oxazolyl, pyrazolyl and imidazolyl, each of which optionally being substituted with 1-3 substituents each independently selected from halo and methyl; and -NR 9 R 10 , wherein R 9 and R 10 are each independently selected from hydrogen and Ci-C 3 alkyl; R is hydrogen or Ci_6alkyl; in particular, hydrogen or methyl; or R 2 and R 3 taken together with the carbon atom to which they are attached form a cyclopropyl, an oxetanyl or a tetrahydrofuranyl, in particular an oxetanyl or a tetrahydrofuranyl ring.
  • Preferred compounds according to the invention are compound or a stereoisomer or tautomeric form thereof with a Formula as represented in the synthesis of compounds section and of which the activity is displayed in Table 1.
  • aryl means a monocyclic or polycyclic aromatic ring comprising carbon atoms, and hydrogen atoms. If indicated, such aromatic ring may include one or more heteroatoms (then also referred to as heteroaryl), preferably, 1 to 3 heteroatoms, independently selected from nitrogen, oxygen, and sulfur, preferably nitrogen. As is well known to those skilled in the art, heteroaryl rings have less aromatic character than their all-carbon counter parts. Thus, for the purposes of the present invention, a heteroaryl group need only have some degree of aromatic character. Illustrative examples of aryl groups are optionally substituted phenyl. Illustrative examples of heteroaryl groups according to the invention include optionally substituted pyrrole, pyridine, and imidazole.
  • monocyclic aryl optionally containing one or more heteroatoms refers for example, to a 5- or 6-membered aryl or heteroaryl group such as, but not limited to, phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl and oxazolyl.
  • Ci_ x alkyl and Ci-C x alkyl can be used interchangeably.
  • Ci_ioalkyl refers to a hydrocarbyl radical of Formula C n H2 n+ i wherein n is a number ranging from 1 to 10, from 1 to 6, or from 1 to 3.
  • n is a number ranging from 1 to 10, from 1 to 6, or from 1 to 3.
  • Ci_ 3 alkyl is coupled to a further radical, it refers to a Formula C n H 2n .
  • Ci_ 3 alkyl groups comprise from 1 to 3 carbon atoms, more preferably 1 to 2 carbon atoms.
  • Ci_ 3 alkyl includes all linear, or branched alkyl groups with between 1 and 3 carbon atoms, and thus includes such as for example methyl, ethyl, n-propyl, and /-propyl.
  • Ci_ 4 alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radical having from 1 to 4 carbon atoms such as the group defined for Ci_3 alkyl and butyl and the like.
  • Ci_ 6 alkyl and C 2 _ 6 alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms, or from 2 to 6 carbon atoms such as the groups defined for Ci_ 4 alkyl and pentyl, hexyl, 2-methylbutyl and the like.
  • Ci_ 7 alkanediyl as a group or part of a group defines bivalent straight or branched chained saturated hydrocarbon radicals having from 1 to 7 carbon atoms such as, for example, methanediyl, ethanediyl, propanediyl, butanediyl, pentanediyl, hexanediyl and heptanediyl.
  • C2_ 7 alkenediyl as a group or part of a group defines straight or branched chain bivalent hydrocarbon radicals having from 2 to 7 carbon atoms and having at least one double bond, preferably one double bond, such as ethenediyl, propenediyl, butenediyl, pentenediyl, hexenediyl and heptenediyl and the like.
  • C3-C 4 cycloalkyl is generic to cyclopropyl and cyclobutyl.
  • 3-7 membered saturated ring means saturated cyclic hydrocarbon (cycloalkyl) with 3, 4, 5, 6 or 7 carbon atoms and is generic to
  • Such saturated ring optionally contains one or more heteroatoms (also referred to as heterocyclyl), such that at least one carbon atom is replaced by a heteroatom selected from N, O and S, in particular from N and O.
  • heteroatoms also referred to as heterocyclyl
  • Examples include oxetanyl, tetrahydro- 2H-pyranyl, piperidinyl, tetrahydrofuranyl, morpholinyl, thiolane 1,1 -dioxide and pyrrolidinyl.
  • Preferred are saturated cyclic hydrocarbons with 3 or 4 carbon atoms and 1 oxygen atom. Examples include oxetanyl, and tetrahydrofuranyl.
  • pyrrolyl may be lH-pyrrolyl or 2H-pyrrolyl.
  • halo and halogen are generic to Fluoro, Chloro, Bromo or Iodo. Preferred halogens are Bromo, Fluoro and Chloro.
  • heteroatom refers to an atom other than carbon or hydrogen in a ring structure or a saturated backbone as defined herein. Typical heteroatoms include N(H), O, S.
  • *R and *S depicted in a structural formula indicate that a racemic mixture of the compound is separated into its 2 enantiomers.
  • the first eluting enantiomer is indicated with *R and the second eluting enantiomer is indicated with *S.
  • *R and *S therefore indicate a specific separated enantiomer, but the sterocenter conformation is not established.
  • the radical positions on any molecular moiety used in the definitions may be anywhere on such moiety as long as it is chemically stable.
  • pyridyl includes 2-pyridyl, 3-pyridyl and 4-pyridyl
  • pentyl includes 1-pentyl, 2-pentyl and 3-pentyl.
  • ring B represents a 6 membered aryl optionally containing one nitrogen atom. Ring B can therefore be referred to as phenyl or pyridyl. a monocyclic 5 or 6 membered aryl optionally containing one or two heteroatoms, such aryl optionally being substituted with one or more substituents each independently selected from the group consisting of Ci-C 3 alkyl, in particular methyl, C 3 -C 4 cycloalkyl, -CN and halogen.
  • Such monocyclic 5 or 6 membered aryl or heteroaryl groups include, but are not limited to phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl and oxazolyl.
  • Ring A can alternatively be depicted bearing the optional substituents
  • Positions indicated on ring B are indicated relative to the bond connecting aryl B to the main structure.
  • An example with regard to the position of meta R a , location is indicated relative to the nitrogen (*) connected to the main structure as shown in Formula (A*).
  • substituents refers in particular to 1, 2, 3, 4, or more substituents, in particular to 1, 2, 3, or 4 substituents, more in particular, to 1 , 2, or 3 substituents. Combinations of substituents and/or variables are permissible only if such combinations result in chemically stable compounds. "Stable compound” is meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into a therapeutic agent.
  • the salts of the compounds of Formula (I- A), (A), (B), (C), are those wherein the counter ion is pharmaceutically or physiologically acceptable.
  • salts having a pharmaceutically unacceptable counter ion may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound of Formula (I- A), (A), (B), (C). All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.
  • the pharmaceutically acceptable or physiologically tolerable addition salt forms which the compounds of the present invention are able to form can conveniently be prepared using the appropriate acids, such as, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, hemisulphuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, aspartic,
  • inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, hemisulphuric, nitric, phosphoric and the like acids
  • organic acids such as, for example, acetic, aspartic
  • dodecyl-sulphuric dodecyl-sulphuric, heptanoic, hexanoic, nicotinic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric,
  • methane-sulfonic methane-sulfonic, ethanesulfonic, benzenesulfonic, /?-toluenesulfonic, cyclamic, salicylic, / ⁇ -aminosalicylic, pamoic and the like acids.
  • solvate comprises the solvent addition forms as well as the salts thereof, which the compounds of the present invention are able to form.
  • solvent addition forms are, e.g. hydrates, alcoholates and the like.
  • present compounds may also exist in their tautomeric forms.
  • Tautomeric forms although not explicitly indicated in the structural formulae represented herein, are intended to be included within the scope of the present invention.
  • stereochemically isomeric forms of compounds of the present invention defines all possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which the compounds of the present invention may possess.
  • chemical designation of a compound encompasses the mixture of all possible stereochemically isomeric forms which said compound may possess. Said mixture may contain all diastereomers and/or enantiomers of the basic molecular structure of said compound.
  • All stereochemically isomeric forms of the compounds of the present invention both in pure form or in a mixture with each other are intended to be embraced within the scope of the present invention.
  • stereoisomeric forms of the compounds and intermediates as mentioned herein are defined as isomers substantially free of other enantiomeric or diastereomeric forms of the same basic molecular structure of said compounds or intermediates.
  • the term 'stereoisomerically pure' concerns compounds or intermediates having a stereoisomeric excess of at least 80% (i. e. minimum 90% of one isomer and maximum 10%) of the other possible isomers) up to a stereoisomeric excess of 100% (i.e. 100% of one isomer and none of the other), more in particular, compounds or intermediates having a stereoisomeric excess of 90% up to 100%, even more in particular having a stereoisomeric excess of 94% up to 100% and most in particular having a
  • Pure stereoisomeric forms of the compounds and intermediates of this invention may be obtained by the application of art-known procedures.
  • enantiomers may be separated from each other by the selective crystallization of their diastereomeric salts with optically active acids or bases. Examples thereof are tartaric acid, dibenzoyltartaric acid, ditoluoyltartaric acid and camphosulfonic acid.
  • enantiomers may be separated by chromatographic techniques using chiral stationary phases.
  • Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically.
  • said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.
  • stereomeric forms of compounds of Formula (I- A), (A), (B), or (C), can be obtained separately by conventional methods.
  • Appropriate physical separation methods that may advantageously be employed are, for example, selective crystallization and chromatography, e.g. column chromatography.
  • the present invention is also intended to include all isotopes of atoms occurring on the present compounds.
  • Isotopes include those atoms having the same atomic number but different mass numbers.
  • Hydrogen includes the tritium and deuterium isotopes.
  • Carbon includes the C-13 and C-14 isotopes.
  • the present invention concerns a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically or prophylactically effective amount of a compound of Formula (I -A), or of Formula (A), (B) or (C) as specified herein, and a pharmaceutically acceptable carrier.
  • a prophylactically effective amount in this context is an amount sufficient to prevent HBV infection in subjects being at risk of being infected.
  • a therapeutically effective amount in this context is an amount sufficient to stabilize HBV infection, to reduce HBV infection, or to eradicate HBV infection, in infected subjects.
  • this invention relates to a process of preparing a pharmaceutical composition as specified herein, which comprises intimately mixing a pharmaceutically acceptable carrier with a therapeutically or prophylactically effective amount of a compound of Formula (I- A), (A) (B) or (C), as specified herein.
  • compositions of the present invention may be formulated into various pharmaceutical forms for administration purposes.
  • compositions there may be cited all compositions usually employed for systemically administering drugs.
  • an effective amount of the particular compound, optionally in addition salt form or solvate form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • a pharmaceutically acceptable carrier which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are employed.
  • the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.
  • injectable solutions for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution.
  • injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.
  • solid form preparations intended to be converted, shortly before use, to liquid form preparations.
  • the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin.
  • the compounds of the present invention may also be administered via oral inhalation or insufflation in the form of a solution, a suspension or a dry powder using any art-known delivery system.
  • Unit dosage form refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • unit dosage forms are tablets (including scored or coated tablets), capsules, pills, suppositories, powder packets, wafers, injectable solutions or suspensions and the like, and segregated multiples thereof.
  • the compounds of Formula (I- A), (A), (B), or (C) are active as inhibitors of the HBV replication cycle and can be used in the treatment and prophylaxis of HBV infection or diseases associated with HBV. The latter include progressive liver fibrosis,
  • HBV acts as a helper virus to HDV, which infects only subjects suffering from HBV infection. Therefore, in a particular embodiment, said compounds of Formula (I -A), (A), (B), or (C) can be used in the treatment and/or prophylaxis of HBV/HDV co-infection, or diseases associated with HBV/HDV co-infection. Due to their antiviral properties, particularly their anti-HBV properties, the compounds of Formula (I -A), (A), (B), or (C), or any subgroup thereof, are useful in the inhibition of the HBV replication cycle, in particular in the treatment of warm-blooded animals, in particular humans, infected with HBV, and for the prophylaxis of HBV infections.
  • the present invention furthermore relates to a method of treating a warm-blooded animal, in particular a human, infected by HBV, or being at risk of infection by HBV, said method comprising the administration of a therapeutically effective amount of a compound of Formula (I-A), (A), (B), or (C).
  • the warm-blooded animal, in particular the human may be HB V/HDV co-infected, or be at risk of HBV/HDV co-infection.
  • the compounds of Formula (I-A), (A), (B), or (C), as specified herein, may therefore be used as a medicine, in particular as medicine to treat or prevent HBV infection.
  • Said use as a medicine or method of treatment comprises the systemic administration to HBV infected subjects or to subjects susceptible to HBV infection of an amount effective to combat the conditions associated with HBV infection or an amount effective to prevent HBV infection.
  • said HBV infection is in particular
  • the present invention also relates to the use of the present compounds in the
  • the present invention also relates to the use of the present compounds in the manufacture of a medicament for the treatment or the prevention of HBV infection.
  • the invention relates to the use of the present compounds in the manufacture of a medicament for the treatment or the prevention of HBV/HDV co-infection.
  • an antiviral effective daily amount would be from about 0.01 to about 50 mg/kg, or about 0.01 to about 30 mg/kg body weight. It may be appropriate to administer the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing about 1 to about 500 mg, or about 1 to about 300 mg, or about 1 to about 100 mg, or about 2 to about 50 mg of active ingredient per unit dosage form.
  • the present invention also concerns combinations of a compound of Formula (I-A), (A), (B), or (C), or any subgroup thereof, as specified herein with other anti-HBV agents.
  • the term "combination” may relate to a product or kit containing (a) a compound of Formula (I-A), (A), (B), or (C), as specified above, and (b) at least one other compound/agent capable of treating HBV infection (herein designated as anti-HBV agent), as a combined preparation for simultaneous, separate or sequential use in treatment of HBV infections.
  • anti-HBV agent a compound/agent capable of treating HBV infection
  • the invention concerns a combination of a compound of Formula (I-A), (A), (B), or (C), or any subgroup thereof with at least one anti-HBV agent.
  • the invention concerns a combination of a compound of Formula (I -A), (A), (B), or (C), or any subgroup thereof with at least two anti-HBV agents.
  • the invention concerns a combination of a compound of Formula (I -A), (A), (B), or (C), or any subgroup thereof with at least three anti-HBV agents.
  • the invention concerns a combination of a compound of Formula (I- A), (A), (B), or (C), or any subgroup thereof with at least four anti-HBV agents.
  • anti-HBV agent also includes compounds that are therapeutic nucleic acids, antibodies or proteins either in their natural form or chemically modified and/or stabilized.
  • therapeutic nucleic acid includes but is not limited to nucleotides and nucleosides, oligonucleotides, polynucleotides, of which non limiting examples are antisense oligonucleotides, miR A, siR A, shRNA, therapeutic vectors and
  • anti-HBV agent also includes compounds capable of treating HBV infection via immunomodulation.
  • immunomodulators are interferon-a (IFN-a), pegylated interferon-a or stimulants of the innate immune system such as Toll-like receptor 7 and/or 8 agonists and therapeutic or prophylactic vaccines.
  • IFN-a interferon-a
  • pegylated interferon-a or stimulants of the innate immune system such as Toll-like receptor 7 and/or 8 agonists and therapeutic or prophylactic vaccines.
  • One embodiment of the present invention relates to combinations of a compound of Formula (I -A), (A), (B), or (C), or any subgroup thereof, as specified herein, with an immunomodulating compound, more specifically a Toll-like receptor 7 and/or 8 agonist.
  • the additional HBV antiviral(s) can be selected for example, from therapeutic vaccines;
  • RNA interference therapeutic/antisense oligonucleotides siRNA, ddRNA, shRNA
  • immunomodulators TLR agonists (TLR7, TLR8 or TLR9 agonists); STING agonists;
  • RIG-I modulators NKT modulators; IL agonists; Interleukin or other immune active proteins, therapeutic and prophylactic vaccines and immune checkpoint modulators);
  • HBV entry inhibitors cccDNA modulators; capsid assembly inhibitors/modulators; core or X protein targeting agents; nucleotide analogues; nucleoside analogues;
  • interferons or modified interferons HBV antivirals of distinct or unknown mechanism
  • cyclophilin inhibitors cyclophilin inhibitors
  • sAg release inhibitors cyclophilin inhibitors
  • the combination of previously known anti-HBV agents such as interferon- ⁇ (IFN- ⁇ ), pegylated interferon- ⁇ , 3TC, tenofovir, lamivudine, entecavir, telbivudine, and adefovir or a combination thereof, and, a compound of Formula (I -A), (A), (B), or (C), or any subgroup thereof can be used as a medicine in a combination therapy.
  • IFN- ⁇ interferon- ⁇
  • pegylated interferon- ⁇ 3TC
  • tenofovir tenofovir
  • lamivudine lamivudine
  • entecavir entecavir
  • telbivudine adefovir or a combination thereof
  • a compound of Formula (I -A), (A), (B), or (C), or any subgroup thereof can be used as a medicine in a combination therapy.
  • HBV antiviral(s) include, but are not limited to: - R A interference (RNAi) therapeutics: TKM-HBV (also known as ARB- 1467), ARB-1740, ARC-520, ARC-521, BB-HB-331, REP-2139, ALN-HBV, ALN-PDL, LUNAR-HBV, GS3228836, , and GS3389404;
  • RNAi interference
  • - HBV entry inhibitors Myrcludex B, IVIG-Tonrol, GC-1102;
  • - HBV capsid inhibitor/modulators core or X targeting agents, direct cccDNA inhibitors, cccDNA formation inhibitors or cccDNA epigenetic modifiers: BAY
  • NVR 3-778 GLS-4, NZ-4 (also known as W28F), Y101, ARB-423,
  • ARB-199, ARB-596, JNJ-56136379, ASMB-101 also known as AB-V102
  • entecavir Baraclude, Entavir
  • lamivudine (3TC, Zeffix, Heptovir, Epivir, and Epivir-HBV)
  • telbivudine Tyzeka, Sebivo
  • clevudine besifovir, adefovir (hepsera), tenofovir (in particular tenofovir disoproxil fumarate (Viread), tenofovir alafenamide fumarate (TAF)), tenofovir disoproxil orotate (also known as DA-2802), tenofovir disopropxil aspartate (also known as CKD-390), AGX-1009, and CMX157);
  • OCB-030 also known as NVP-018
  • SCY-635 also known as SCY-635
  • SCY-575 also known as CPI-431-32;
  • AT-61 ((E)-N-( 1 -chloro-3-oxo- 1 -phenyl-3-(piperidin- 1 -yl)prop- 1 -en-2-yl)benzamide), ((E)-N-( 1 -bromo- 1 -(2-methoxyphenyl)-3 -oxo-3 -(piperidin- 1 -yl)prop- 1 -3n-2-yl)-4- nitrobenzamide), and similar analogs; REP-9AC (also known as REP-2055), REP-9AC (also known as REP-2139), REP-2165 and HBV-0259;
  • TLR7, 8 and/or 9 TLR agonists (TLR7, 8 and/or 9): RG7795 (also known as RO-6864018), GS-9620, SM360320 (9-benzyl-8-hydroxy-2-(2-methoxy-ethoxy)adenine) and AZD 8848 (methyl [3-( ⁇ [3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-pyrin-9-yl)propyl][3-(4- morpholinyl)propyl]amino ⁇ methyl)phenyl]acetate); ARB- 1598;
  • HBsAG-HBIG HB-Vac
  • ABX203 NASVAC
  • GS-4774 GX- 110
  • GX- 110 also known as HB-110E
  • CVI-HBV-002 CVI-HBV-002
  • RG7944 also known as
  • the additional HBV antiviral compound is selected from the compounds disclosed in WO2013102655, WO2013174962, WO2014033167,
  • the additional HBV antiviral compound is selected from the compounds based on the HAP scaffold, in particular those disclosed in Roche
  • R a ' b ' c ' d or R 1 in this general synthesis section are meant to include any substituent or reactive species that is suitable for transformation into any pa,b,c,d or j ⁇ i su b s ti men t according to the present invention without undue burden for the person skilled in the art.
  • a possible synthesis of compound of general formula (I) is described in schemes 1, 2, 3 and 4.
  • Ci-C 6 alkanediyl optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, Fluoro, and oxo, for example in an organic solvent like acetonitrile or DCM possibly in the presence of an organic base like for example triethylamine or DIPEA, or an inorganic base like for example sodium bicarbonate.
  • the formed compound of general formula (IV) can be ring closed under Heck conditions with a ligand like bis(tri-tert-butylphosphine)palladium(0) to a compound of general formula (V).
  • Compound of general formula (IV) can also be reacted with potassium allyltrifluoroborate under Suzuki conditions with a ligand like bis(tri-tert-butylphosphine)palladium(0) in the presence of an inorganic base like CS 2 CO 3 to give a mixture of compound of general formula (VII) and compound of general formula (VIII).
  • Compound of general formula (VII) or compound of general formula (VIII) can be ring closed under metathesis conditions with a catalyst like Grubbs catalyst 2 nd generation, resulting in the formation of a compound of general formula (V).
  • the compound of general formula (V) can be reacted with an amine of general formula (VI) in the presence of a base like for example lithium
  • a compound of general formula (la) wherein Y represents an alkenediyl and Z a single bond.
  • Hydrogenation of the double bond forms a compound of general formula (lb), wherein Y represents an alkanediyl and Z a single bond.
  • the amide can be formed via the classical routes known by the person skilled in the art
  • Compound of general formula (IV) can also be reacted with an amine of general formula (VI) in the presence of a base like for example lithium bis(trimethylsilyl)amide, in a solvent like for example THF, resulting in the formation of a compound of general formula (XXXIV).
  • the formed compound of general formula (XXXIV) can be ring closed under Heck conditions with a ligand like bis(tri-tert- butylphosphine)palladium(O) to a compound of general formula (la), wherein Y represents an alkenediyl and Z a single bond.
  • Compound of general formula (II) can be reacted with an aminoalcohol of general formula (XXXI), wherein X has the meaning as defined in the claims, for example a Ci-C 6 alkanediyl optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, Fluoro, and oxo, for example in an organic solvent like acetonitrile or DCM possibly in the presence of an organic base like for example triethylamine or DIPEA, or an inorganic base like for example sodium bicarbonate.
  • X has the meaning as defined in the claims, for example a Ci-C 6 alkanediyl optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, Fluoro, and oxo, for example in an organic solvent like acetonitrile or DCM possibly in the presence of an organic base like for example triethylamine or DIPEA, or an inorganic base like for example
  • the formed compound of general formula (XXXII) can be oxidized in a solvent like THF with an oxidant like 2-iodoxybenzoic acid resulting in a compound of general formula (XXXIII).
  • Compound of general formula (XXXIII) can be reacted under Wittig conditions to a compound of general formula (IV).
  • a compound of formula (II) can be reacted with an amine of general formula (IX), for example in an organic solvent like acetonitrile or DCM possibly in the presence of an organic base like for example triethylamine or DIPEA, or an inorganic base like for example sodium bicarbonate.
  • the formed compound of general formula (X) can be reacted with potassium allyltrifluoroborate under Suzuki conditions with a ligand like bis(tri-tert-butylphosphine)palladium(0) in the presence of an inorganic base like CS 2 CO 3 to give a mixture of compound of general formula (XI) and compound of general formula (XII).
  • a compound of general formula (XI) or a compound of general formula (XII) can be reacted with an amine of general formula (VI) in the presence of a base like for example lithium bis(trimethylsilyl)amide, in a solvent like for example THF, results in the formation of a compound of general formula (XIII) or general formula (XV).
  • a base like for example lithium bis(trimethylsilyl)amide
  • a compound of general formula (XIII) or a compound of general formula (XV) can be reacted under Mitsonobu conditions with an alcohol of general formula (XVII), wherein X has the meaning as defined in the claims, for example a Ci-Cealkanediyl optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, Fluoro, and oxo, and results in a compound of general formula (XIV) or a compound of general formula (XVI).
  • a compound of general formula (XIV) or a compound of general formula (XVI) can be ring closed under metathesis conditions with a catalyst like Grubbs catalyst 2 nd generation, resulting in the formation of a compound of general
  • a compound of formula (XVIII) can be reacted with an alcohol of general formula (XIX), for example in an organic solvent like THF or DCM possibly in the presence of an organic base like for example triethylamine or DIPEA, or an inorganic base like for example sodium bicarbonate.
  • the formed compound of general formula (XX) can be coupled with an amine of general formula (VI) in the presence of a base like for example lithium bis(trimethylsilyl)amide, in a solvent like for example THF.
  • the formed compound of general formula (XXI) can be ring closed in the presence of a base like CsF, resulting in a compound of general formula (Ic) wherein Z is oxygen.
  • a compound of formula (XXII) can be reacted with an alcohol of general formula (XIX), for example in a mixture of an organic solvent like THF or DCM with water, possibly in the presence of an organic base like for example triethylamine or DIPEA, or an inorganic base like for example sodium carbonate.
  • the formed compound of general formula (XXIII) can be coupled with an amine of general formula (VI) in the presence of an activating reagent like for example HATU and an organic base like triethylamine or DIPEA, resulting in a compound of general formula (XXI).
  • a compound of formula (II) can be treated with ammonia in a solvent like dioxane, resulting in a compound of general formula (XXIV).
  • the formed compound (XXIV) can either be coupled with a 1-3-diketoalkane like pentane-2,4-dione or heptane-3,5-dione resulting in a compound of general formula (XXV) wherein Ry is a Ci-C 4 alkyl or under Stille conditions with a stannane like (Z)-l-ethoxy-2-(tributylstannyl)ethene resulting in a compound of general formula (XXIX).
  • Compounds of general formula's (XXV) can be ring closed under acidic conditions using an acid like TFA to a compound of general formula (XXVI) wherein Rz is a Ci-C 4 alkyl.
  • Compounds of general formula's (XXIX) can be ring closed under acidic conditions using an acid like TFA to a compound of general formula (XXVI) where Rz is hydrogen.
  • the formed compound of general formula (XXVI) can either be hydrogenated to form a compound of general formula (XXVII) or coupled with and amine of general formula (VI) in the presence of a base like for example lithium bis(trimethylsilyl)amide, in a solvent like for example THF, resulting in a compound of general formula (XXX).
  • the compound of general formula (XXVII) can be alkylated for example with an alkylbromide, followed by a coupling with and amine of general formula (VI) in the presence of a base like for example lithium bis(trimethylsilyl)- amide, in a solvent like for example THF, resulting in a compound of general formula (lb), wherein Y represents an alkanediyl and Z a single bond.
  • a base like for example lithium bis(trimethylsilyl)- amide
  • a solvent like for example THF resulting in a compound of general formula (lb), wherein Y represents an alkanediyl and Z a single bond.
  • Compound of general formula (XXX) can be hydrogenated to a compound of general formula (Id), wherein Y represents an alkanediyl and Z a single bond.
  • a compound of general formula (XXVII) can be coupled with an amine of general formula (VI) in the presence of a base like for example lithium bis(trimethylsilyl)amide, in a solvent like for example THF, resulting in a compound of general formula (Id), wherein Y represents an alkanediyl and Z a single bond.
  • a base like for example lithium bis(trimethylsilyl)amide
  • a solvent like for example THF
  • a compound of formula (XXXV) can be reacted with a compound of general formula (XXXVI), wherein X has the meaning as defined in the claims, for example a Ci-C 6 alkanediyl optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, Fluoro, and oxo, for example in a solvent like DMF under Suzuki conditions with a ligand like bis(tri-tert-butylphosphine)palladium(0) in the presence of an organic base like Hunigs' base.
  • the formed compound of general formula (XXXVII) can be reduced under catalytic conditions using palladium on carbon under a hydrogen gas atmosphere.
  • the formed compound of general formula (XXXVIII) can be deprotected with a reagent like ethylenediamine in a solvent like n-butanol to form a compound of general formula (XXXIX).
  • a compound of general formula (XXXIX) can be chlorosulfonated in the presence of chlorosulfonic acid and thionyl chloride and then ring closed via quenching in a saturated aqueous solution of an inorganic base like NaHC0 3 or Na 2 C0 3 to a compound of general formula (XXXX) wherein wherein Y represents an alkanediyl and Z a single bond.
  • a compound of formula (XXXXI) can be reacted with a compound of general formula (XXXXII), wherein X has the meaning as defined in the claims, for example a Ci-Cealkanediyl optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, Fluoro, and oxo, for example in a solvent like ACN in the presence of an organic base like Hunigs' base.
  • the formed compound of general formula (XXXXIII) can be ring closed via Mitsunobu conditions.
  • a compound of formula (XXXXV) can be reacted with a compound of general formula (XXXXVI), for example in a solvent like dioxane in the presence of silver carbonate.
  • the tert-butyl ester of the formed compound of general formula (XXXXVII) can be cleaved using TFA in a solvent like DCM. Consecutive esterification in a solvent like DMF with methyliodide in the presence of an inorganic base like CS 2 CO 3 can result in a compound of general formula (XXXXVIII).
  • a compound of general formula (XXXXVIII) can be chlorosulfonated in the presence of chlorosulfonic acid and thionyl chloride and then ring closed via quenching in a saturated aqueous solution of an inorganic base like NaHC0 3 or
  • the resulting compound of formula (XXXXIX) can be reacted with a Grignard reagent like methylmagnesium bromide in a solvent like THF to form a compound of general formula (XXXXX).
  • the formed compound of general formula (XXXXX) can be reacted with an amine of general formula (VI) in the presence of a base like for example lithium bis(trimethylsilyl)amide, in a solvent like for example THF, resulting in the formation of a compound of general formula (XXXXI).
  • HPLC High Performance Liquid Chromatography
  • MS Mass Spectrometer
  • tune parameters e.g. scanning range, dwell time
  • ions allowing the identification of the compound's nominal monoisotopic molecular weight (MW).
  • Data acquisition was performed with appropriate software.
  • Compounds are described by their experimental retention times (R t ) and ions. If not specified differently in the table of data, the reported molecular ion corresponds to the [M+H] + (protonated molecule) and/or [M-H] ⁇ (deprotonated molecule).
  • the type of adduct is specified (i.e. [M+NH 4 ] + , [M+HCOO] " , etc). All results were obtained with experimental uncertainties that are commonly associated with the method used.
  • SQL Single Quadrupole Detector
  • MSD Mass Selective Detector
  • RT room temperature
  • BEH bridged ethylsiloxane/silica hybrid
  • DAD Diode Array Detector
  • HSS High Strength silica.
  • Q-To ' Quadrupole Time-of-flight mass spectrometers "CLND”, Chem i L um i nescent Nitrogen Detector.
  • ELSD Evaporative Light Scanning Detector
  • the SFC measurement was performed using an Analytical Supercritical fluid chromatography (SFC) system composed by a binary pump for delivering carbon 5 dioxide (C02) and modifier, an autosampler, a column oven, a diode array detector equipped with a high-pressure flow cell standing up to 400 bars. If configured with a Mass Spectrometer (MS) the flow from the column was brought to the (MS). It is within the knowledge of the skilled person to set the tune parameters (e.g. scanning range, dwell time%) in order to obtain ions allowing the identification of the compound's 10 nominal monoisotopic molecular weight (MW). Data acquisition was performed with appropriate software.
  • SFC Analytical Supercritical fluid chromatography
  • Methyl 3-bromo-l -methyl -4-(l-methylhept-6-enylsulfamoyl)pyrrole-2-carboxylate 100 mg, 0.25 mmol
  • potassium allyltrifluoroborate 109 mg, 0.74 mmol
  • bis(tri- tert-butylphosphine)palladium(O) 12.6 mg, 0.025 mmol
  • Cs 2 C0 3 240 mg, 0.74 mmol
  • Methyl 3-allyl-l-methyl-4-(l-methylhept-6-enylsulfamoyl)pyrrole-2-carboxylate (62 mg, 0.17 mmol) was dissolved in DCE (50 mL) and heated to 80°C while bubbling N 2 through the reaction mixture.
  • Grubbs catalyst 2 nd generation (14.3 mg, 0.017 mmol) was added and heating was continued for 2 hours.
  • Methyl 3-allyl-l-methyl-4-[[(E)-l-methylhept-5-enyl]sulfamoyl]pyrrole-2-carboxylate (258 mg, 0.7 mmol) was dissolved in DCE (50 mL) and N 2 was bubbled through the reaction mixture.
  • Grubbs catalyst 2 nd generation 38.7 mg, 0.046 mmol was added and the reaction mixture was heated for 5 hours.
  • reaction mixture was quenched with NH4C1 (aq., sat., 5 mL).
  • the organic layer was removed and the aqueous layer extracted with DCM (2 X 5 mL).
  • the combined organic layers were evaporated to dryness and the residue purified on silica using a heptane to EtOAc gradient.
  • Methyl 1 -methyl-3-[(E)-prop- 1 -enyl]-4-[[(lR)-2,2,2-trif uoro- 1 -methyl-ethyl] - sulfamoyl]pyrrole-2-carboxylate (1.18 g, 3.33 mmol) and 3,4-difluoroaniline (404 ⁇ , 1.29 g/mL, 4 mmol) were dissolved in THF (25 mL). Lithium bis(trimethylsilyl)amide (10 mL, 1 M in THF, 10 mmol) was added and the reaction mixture was stirred overnight at room temperature.
  • reaction mixture was quenched with NH 4 C1 (aq., sat., 10 mL).
  • the organic layer was removed and the aqueous layer extracted with DCM (2 X 5 mL).
  • the combined organic layers were evaporated to dryness and the residue purified on silica using a heptane to EtOAc gradient yielding N-(3,4-difluoro- phenyl)-l-methyl-3-[(E)-prop-l-enyl]-4-[[(lR)-2,2,2-trifluoro-l-methyl-ethyl]sulfa- moyl]pyrrole-2-carboxamide (1.08 g) as a brown powder.
  • Methyl 3-bromo-l-methyl-4-(l-methylallylsulfamoyl)pyrrole-2-carboxylate 200 mg, 0.57 mmol
  • potassium allyltrifluoroborate (253 mg, 1.71 mmol)
  • bis(tri-tert-butyl- phosphine)palladium(O) 29 mg, 0.057 mmol
  • CS 2 CO 3 557 mg, 1.71 mmol
  • Methyl 3-allyl-l -methyl-4-(l-methylallylsulfamoyl)pyrrole-2-carboxylate (47 mg, 0.15 mmol) was dissolved in DCE (100 mL) and N 2 was bubbled through the reaction mixture.
  • Grubbs catalyst 2 nd generation (26 mg, 0.03 mmol) was added and the reaction mixture was heated at 80°C overnight.
  • Compound 8 N-(3,4-difluorophenyl)-7-methyl-l,l-dioxo-3-(trifluoromethyl)-2,3-di- hydropyrrolo[3,4-
  • Methyl 3-bromo-l -methyl -4-[l-(trif uoromethyl)allylsulfamoyl]pyrrole-2-carboxylate (837 mg, 2.07 mmol), bis(tri-tert-butylphosphine)palladium(0) (211 mg, 0.41 mmol) and TEA (286 ⁇ , 0.73 g/mL, 2.07 mmol) were dissolved in DMF (5 mL). The reaction mixture was heated in the microwave oven for 30 minutes at 120°C.
  • N-(3 ,4-difiuorophenyl)-3 ,6-dimethyl- 1 , 1 -dioxo-2H-pyrrolo[3 ,4-e]thiazine-5- carboxamide (33 mg, 0.093 mmol) was dissolved in THF (40 mL) and under a nitrogen atmosphere Pd/C (10%) (56 mg, 0.053 mmol) was added. The reaction mixture was hydrogenated for 1 hour. The reaction mixture was filtered over decalite. The filter was washed with THF (3 x 50 mL).
  • N-(3,4-difluorophenyl)-2,6-difluoro-3-[(2-hydroxy-l-methyl-ethyl)sulfamoyl]- benzamide (887 mg, 2.18 mmol) in DMF (8 mL) was treated with NaH (437 mg, 60% dispersion in mineral oil, 10.9 mmol) at room temperature and this was stirred for 2 minutes. Then it was heated under microwave irradiation to 110°C for 40 minutes. The reaction mixture was poured into ice water (100 mL) and this was extracted using EtOAc (3 X 100 mL).
  • Methyl 3 -bromo- 1 -methyl -4-( 1 -methylbut-3 -enylsulfamoyl)pyrrole-2-carboxylate (97 mg, 0.28 mmol), bis(tri-tert-butylphosphine)palladium(0) (13.6 mg, 0.027 mmol) and TEA (36.8 ⁇ , 0.73 g/mL, 0.27 mmol) were dissolved in DMF (5 mL) and heated in the microwave oven at 150°C for 30 minutes.
  • reaction mixture was purified via Prep HPLC (Stationary phase: RP XBridge Prep C18 OBD- ⁇ , 30x150mm, Mobile phase: 0.25% NH 4 HCO 3 solution in water, ACN) yielding methyl (5Z)-3,8-dimethyl- l,l-dioxo-3,4-dihydro-2H-pyrrolo[3,4-g]thiazocine-7-carboxylate (41 mg).
  • Methyl 3-ethyl-6-methyl-l,l-dioxo-2H-pyrrolo[3,4-e]thiazine-5-carboxylate was prepared similarly as described for methyl 3,6-dimethyl-l,l-dioxo-2H-pyrrolo[3,4-e]- thiazine-5-carboxylate, using heptane-3,5-dione instead of pentane-2,4-dione.
  • Methyl 3-ethyl-6-methyl-l,l-dioxo-2H-pyrrolo[3,4-e]thiazine-5-carboxylate (128 mg, 0.18 mmol) was dissolved in MeOH (10 mL) and under a nitrogen atmosphere Pd/C (10%) (20 mg, 0.018 mmol) was added. The reaction mixture was hydrogenated for 18 hours. Pd/C (10%>) (20 mg, 0.018 mmol) was added under nitrogen atmosphere.
  • Trimethylsulfoxonium iodide (123 mg, 0.56 mmol) and potassium tert-butoxide (58 mg, 0.52 mmol) were dissolved in DMSO (5 mL) at 50°C.
  • Compound 7 (100 mg,
  • Compound 42 (3*S)-3,7-dimethyl-lJ-dioxo-N-[2-(trifluoromethyl)-4-pyridyll-2,3- dihydropyrrolo[3,4-f
  • Methyl 7-methyl-l,l-dioxo-3-(trifluoromethyl)-2,3-dihydropyrrolo[3,4-f]thiazepine-6- carboxylate 152 mg
  • Pd/C (10%) 50 mg, 0.047 mmol
  • the reaction mixture was set under a hydrogen atmosphere and stirred for 2 hours.
  • the reaction mixture was filtered and the volatiles were removed under reduced pressure yielding methyl 7 -methyl- l,l-dioxo-3-(trifluoromethyl)-2, 3,4,5- tetrahydropyrrolo[3,4-f]thiazepine-6-carboxylate (153 mg) as a white powder.
  • 6-carboxylate 400 mg, 1.48 mmol was dissolved in MeOH (40 mL). Under a nitrogen atmosphere Pd/C (10%>) (157 mg, 0.15 mmol) was added. The reaction mixture was hydrogenated for 30 minutes. The reaction mixture was filtered over decalite. The filtrate was evaporated to dryness to afford methyl (3S)-3,7-dimethyl-l,l-dioxo- 2,3,4,5-tetrahydropyrrolo[3,4-fJthiazepine-6-carboxylate (360 mg) as a white powder.
  • (2S)-2-amino-3,3,3-trifluoropropan-l-ol hydrochloride (153 mg, 0.93 mmol) were dissolved in pyridine (2 mL) and stirred overnight at room temperature. The volatiles were removed under reduced pressure and the residue was purified on silica using a heptane to EtOAc gradient yielding ethyl 3-fluoro-l-methyl-4-[[(l S)-2,2,2-trifluoro- l-(hydroxymethyl)ethyl]sulfamoyl]pyrrole-2-carboxylate (254 mg).
  • reaction mixture was directly loaded on a silica cartridge and a gradient from heptane to EtOAc:EtOH:AcOH 3:1 :0.1 was applied yielding (2S,3R)-2-[(5-ethoxycarbonyl-4-fluoro-l-methyl-pyrrol- 3-yl)sulfonylamino]-3-methoxy-butanoic acid as an off-white powder (310 mg).
  • N-(3 ,4-difluorophenyl)-3 -f uoro-4- [[( 1 R,2R)- 1 -(hydro xymethyl)-2-methoxy-propyl] - sulfamoyl]-l-methyl-pyrrole-2-carboxamide 50 mg was dissolved in DMF (5 mL).
  • Cesium fluoride 70 mg, 0.46 mmol was added and the reaction mixture was heated overnight at 100 °C.
  • the reaction mixture was directly loaded on a silica cartridge and a gradient from heptane to EtOAc was applied yielding compound 62 (23.9 mg) as an off-white powder.
  • a microwave vial was charged with 4-[(2-amino-l-methyl-ethyl)sulfamoyl]-N- (3,4-difluorophenyl)-3-fluoro-l-methyl-pyrrole-2-carboxamide (200 mg), water (15 mL) and 1,4-dioxane (3 mL). The vial was capped and the mixture was irradiated at 150 °C for 6 hours. The mixture was neutralized with HCl (aq., 1M). The mixture was extracted with DCM and the organic phase was separated, dried (MgS04), filtered and concentrated in vacuo. The residue was purified via prep.
  • Osmium tetroxide (2.43 g, 2.5 % in t-butanol, 0.239 mmol) was added to ethyl 3-allyl- 1 -methyl-pyrrole -2-carboxylate (1 156 mg, 5.982 mmol) in ACN (50 mL) and stirred 10 minutes. Water (10 mL) was added followed by benzyloxycarbonylamino
  • camphorsulfonic acid 100 mg, 0.43 mmol
  • Et 3 N 5 mL
  • 3,4-difluoroaniline (21 mg, 0.16 mmol) was added followed by lithium bis(trimethylsilyl)amide (1 mL, 1 M in THF, 1 mmol).
  • the reaction mixture was stirred at room temperature for 30 minutes.
  • NH 4 C1 (sat., aq., 5 mL) was added and the organic layer was separated.
  • the aqueous layer was extracted with DCM (2 X 5 mL) and the combined organic layers were evaporated to dryness.
  • the residue was purified using silica gel column chromatography twice (ethyl acetate in heptane from 0 to 100 %) and then by prep.
  • Compound 72 fert-butyl 4-[6-[(3,4-difluorophenyl)carbamoyll-7-methyl- 1 , 1 -dioxo- 3 ⁇ -dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepin-3-yllpiperidine-l-carboxylate.
  • Methyl 3-bromo-4-chlorosulfonyl-l-methyl-pyrrole-2-carboxylate (2 g, 6.32 mmol) was dissolved in DCM (100 mL). To this was added Hunig's base (4.36 mL, 25.3 mmol). To this was added 4-methyl-l-penten-3 -amine (1.71 g, 12.6 mmol) in DCM (100 mL).
  • Methyl 3-bromo-4-(l-isopropylallylsulfamoyl)-l -methyl-pyrrole -2-carboxylate (1.70 g, 4.48 mmol) and TEA (0.62 mL, 0.73 g/mL, 4.48 mmol) in DMF (10 mL) was stirred and purged with nitrogen for 5 minutes. Then bis(tri-tert-butylphosphine)palladium(0) (458 mg, 0.90 mmol) was added and stirring and purging was continued for 5 more minutes. The mixture was heated under microwave irradiation to 100°C for 75 minutes.
  • reaction mixture was cooled to room temperature and filtered through a pad of dicalite and rinsed with 150 mL of EtOAc. Then the filtrate was concentrated in vacuo and purified using silica gel column chromatography (gradient elution: EtOAc:heptane 0:100 to 100:0) yielding a mixture of 2 isomers.

Abstract

Inhibitors of HBV replication of Formula (I-A), including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein Ra to Rd, and R1 to R8 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

Description

CYCLIZED SULFAMOYLARYL AMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B
FIELD OF THE INVENTION
The present invention relates to inhibitors of HBV replication. The invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy. BACKGROUND OF THE INVENTION
The Hepatitis B virus (HBV) is an enveloped, partially double-stranded DNA (dsDNA) virus of the Hepadnavirus family (Hepadnaviridae). Its genome contains 4 overlapping reading frames: the precore/core gene; the polymerase gene; the L, M, and S genes, which encode for the 3 envelope proteins; and the X gene.
Upon infection, the partially double-stranded DNA genome (the relaxed circular DNA; rcDNA) is converted to a covalently closed circular DNA (cccDNA) in the nucleus of the host cell and the viral mRNAs are transcribed. Once encapsidated, the pregenomic RNA (pgRNA), which also codes for core protein and Pol, serves as the template for reverse transcription, which regenerates the partially dsDNA genome (rcDNA) in the nucleocapsid.
HBV has caused epidemics in parts of Asia and Africa, and it is endemic in China. HBV has infected approximately 2 billion people worldwide of which approximately 350 million people have developed chronic infections. The virus causes the disease hepatitis B and chronic infection is correlated with a strongly increased risk for the development cirrhosis and hepatocellular carcinoma. Additionally, HBV acts as a helper virus to hepatitis delta virus (HDV), and it is estimated that more than 15 million people may be HBV/HDV co-infected worldwide, with an increased risk of rapid progression to cirrhosis and increased hepatic decompensation, than patients suffering from HBV alone (Hughes, S.A. et al. Lancet 2011, 378, 73-85).
Transmission of hepatitis B virus results from exposure to infectious blood or body fluids, while viral DNA has been detected in the saliva, tears, and urine of chronic carriers with high titer DNA in serum.
An effective and well-tolerated vaccine exists, but direct treatment options are currently limited to interferon and the following antivirals; tenofovir, lamivudine, adefovir, entecavir and telbivudine. In addition, heteroaryldihydropyrimidines (HAPs) were identified as a class of HBV inhibitors in tissue culture and animal models (Weber et al., Antiviral Res. 54: 69-78).
WO2013/006394, published on January 10, 2013, relates to a subclass of sulfamoyl- arylamides active against HBV.
WO2013/096744, published on June 26, 2013 relates to compounds active against HBV. Amongst the problems which HBV direct antivirals may encounter are toxicity, mutagenicity, lack of selectivity, poor efficacy, poor bioavailability, low solubility and difficulty of synthesis.
There is a need for additional HBV inhibitors that may overcome at least one of these disadvantages or that have additional advantages such as increased potency or an increased safety window.
SUMMARY OF THE INVENTION
The present invention relates to a compound of Formula (I-A)
Figure imgf000004_0001
or a stereoisomer or tautomeric form thereof, wherein
Figure imgf000004_0002
represents a monocyclic 5 or 6 membered aryl optionally containing one or two heteroatoms, such aryl optionally being substituted with one or more substituents each independently selected from the group consisting of Ci-C3alkyl, in particular methyl, C3-C4cycloalkyl, -CN and halogen;
Figure imgf000004_0003
represents a 6 membered aryl optionally containing one nitrogen atom;
X represents -CR2R3-; Y represents Ci_C7alkanediyl or C2-C7alkenediyl, each optionally substituted with one or more substituents each independently selected from the group consisting of Ci-C4alkyl, fluoro, and -OH;
Z represents a heteroatom, preferably NH or oxygen and more preferably oxygen, or a single bond;
Ra, Rb, Rc and Rd are each independently selected from the group consisting of hydrogen, halogen, -CHF2, -CF2-methyl, -CH2F, -CF3, -OCF3, -CN, C3-C4cycloalkyl and -Ci-C4alkyl;
R1 is hydrogen or Ci-Cioalkyl optionally substituted with one or more substituents each independently selected from the group consisting of -OH, fluoro, and oxo;
R is selected from the group consisting of hydrogen; Ci-Cioalkyl optionally substituted with one or more substituents each independently selected from the group consisting of -OH, fluoro, methoxy, oxo, and -C(=0)OCi-C4alkyl; Ci-C3alkyl-R7;
C2-C4alkynyl; a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N; and monocyclic aryl optionally containing one or two heteroatoms; wherein the Ci-C3alkyl-R7, 3-7 membered saturated ring or the monocyclic aryl are each
Q
optionally substituted with one or more R substituents;
R is hydrogen or Ci_6alkyl optionally substituted with -OH; in particular, hydrogen or methyl; or R 2 and R 3 taken together with the carbon atom to which they are attached form a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, and optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, fluoro, methoxy, oxo, -C(=0)OCi-C4alkyl, benzyl, and
Ci-C4alkyl optionally substituted with one or more substituents each independently selected from fluoro and/or -OH;
R7 represents a monocyclic aryl optionally containing one or two heteroatoms, and optionally being substituted with one or two substituents each independently selected from the group consisting of halo and Ci_3alkyl; a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N; or -NR9R10; wherein R9 and R10 are each independently selected from hydrogen and Ci-C3alkyl optionally substituted with one or more fluoro substituents; each R is independently selected from the group consisting of -OH, fluoro, methoxy, oxo, -C(=0)OCi-C4alkyl, Ci-C4alkyloxyCi-C4alkyloxy, and Ci-C4alkyl optionally substituted with one or more substituents each independently selected from fluoro and/or -OH; or a pharmaceutically acceptable salt or a solvate thereof.
The invention further relates to a pharmaceutical composition comprising a compound of Formula (I-A), and a pharmaceutically acceptable carrier. The invention also relates to the compounds of Formula (I-A) for use as a medicament, preferably for use in the prevention or treatment of an HBV infection in a mammal.
In a further aspect, the invention relates to a combination of a compound of Formula (I-A), and another HBV inhibitor.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a compound of Formula (I-A) as defined hereinbefore.
More in particular, the present invention relates to a compound of Formula (I-A)
Figure imgf000006_0001
or a stereoisomer or tautomeric form thereof, wherein
Figure imgf000006_0002
represents a monocyclic 5 or 6 membered aryl optionally containing one or two heteroatoms, such aryl optionally being substituted with one or more substituents each independently selected from the group consisting of Ci-C3alkyl, in particular methyl, C3-C4cycloalkyl, -CN and halogen;
^ B ;
represents a 6 membered aryl optionally containing one nitrogen atom;
X represents -CR2R3-;
Y represents Ci_C7alkanediyl or C2-C7alkenediyl each optionally being substituted with one or more substituents each independently selected from Ci-C4alkyl and -OH; Z represents a heteroatom, preferably oxygen, or a single bond;
Ra, Rb, Rc and Rd are each independently selected from the group consisting of Hydrogen, halogen, -CHF2, -CF2-methyl, -CH2F, -CF3, -OCF3, -CN, C3-C4cycloalkyl and -Ci-C4alkyl; R1 is Hydrogen or Ci-C6alkyl, such Ci-C6alkyl optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, Fluoro, oxo, and Ci-C4alkyl optionally substituted with one or more Fluoro and/or -OH; R 2 is selected from the group consisting of hydrogen, Ci-C6alkyl, Ci-C3alkyl-R 7 , a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, and monocyclic aryl optionally containing one or two heteroatoms, such Ci-C6alkyl, Ci-C3alkyl-R7, 3-7 membered saturated ring or monocyclic aryl optionally being substituted with one or more R8;
R is hydrogen or Ci_6alkyl; in particular, hydrogen or methyl; or R 2 and R 3 taken together form together with the carbon atom to which they are attached a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N,
Q
such 3-7 membered saturated ring optionally being substituted with one or more R ;
R7 represents a monocyclic aryl optionally containing one or two heteroatoms; a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N; or -NR9R10; wherein R9 and R10 are each independently selected from Hydrogen and Ci-C3alkyl; each R independently is selected from the group consisting of -OH, Fluoro, methoxy, oxo, -C(=0)OCi-C4alkyl and Ci-C4alkyl optionally substituted with one or more substituents each independently selected from Fluoro and/or -OH; or a pharmaceutically acceptable salt or a solvate thereof.
In a particular embodiment, the invention relates to a compound of Formula (I-A)
Figure imgf000008_0001
or a stereoisomer or tautomeric form thereof, wherein:
Figure imgf000008_0002
represents a monocyclic 5 or 6 membered aryl optionally containing one or two heteroatoms, such aryl optionally being substituted with one or more substituents each independently selected from the group consisting of Ci-C3alkyl, in particular methyl, C3-C4cycloalkyl, -CN and halogen;
represents a 6 membered aryl optionally containing one nitrogen atom;
X represents -CR2R3-;
Y represents Ci_C7alkanediyl or C2-C7alkenediyl each optionally being substituted with one or more substituents each independently selected from Ci-C4alkyl and -OH; Z represents a heteroatom, preferably oxygen, or a single bond;
Ra, Rb, Rc and Rd are each independently selected from the group consisting of hydrogen, halogen, -CHF2, -CF2-methyl, -CH2F, -CF3, -OCF3, -CN, C3-C4cycloalkyl and -Ci-C4alkyl;
R1 is hydrogen or Ci-Cealkyl, such Ci-Cealkyl optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, Fluoro, oxo, and Ci-C4alkyl optionally substituted with one or more Fluoro and/or -OH;
R 2 is selected from the group consisting of hydrogen, Ci-C6alkyl, Ci-C3alkyl-R 7 , a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, and monocyclic aryl optionally containing one or two heteroatoms, such Ci-C6alkyl, Ci-C3alkyl-R7, 3-7 membered saturated ring or monocyclic aryl optionally being substituted with one or more R8;
R is hydrogen; or R 2 and R 3 taken together form together with the carbon atom to which they are attached a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N,
Q
such 3-7 membered saturated ring optionally being substituted with one or more R ;
R7 represents a monocyclic aryl optionally containing one or two heteroatoms; a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N; or -NR9R10; wherein R9 and R10 are each independently selected from hydrogen and Ci-C3alkyl;
Q
each R independently is selected from the group consisting of -OH, Fluoro, methoxy, oxo, -C(=0)OCi-C4alkyl and Ci-C4alkyl optionally substituted with one or more substituents each independently selected from Fluoro and/or -OH; or a pharmaceutically acceptable salt or a solvate thereof. In a further particular embodiment, the invention relates to a compound of Formula (I-A) as defined herein, or a stereoisomer or tautomeric form thereof, wherein:
Figure imgf000009_0001
represents a monocyclic 5 or 6 membered aryl optionally containing one or two heteroatoms, such aryl optionally being substituted with one or more substituents each independently selected from the group consisting of Ci-C3alkyl, in particular methyl, C3-C4cycloalkyl, -CN and halogen; ^ B ;
represents a 6 membered aryl optionally containing one nitrogen atom;
X represents -CR2 R3-;
Y represents a Ci_C7alkanediyl or C2_C7alkenediyl each optionally substituted with one or more Ci-C4alkyl or -OH;
Z represents a heteroatom, preferably oxygen, or a single bond;
Ra, Rb, Rc and Rd are independently selected from the group consisting of Hydrogen, halogen, -CHF2, -CF2-methyl, -CH2F, -CF3, -OCF3, -CN, C3-C4cycloalkyl and -Ci-C4alkyl;
R1 is Hydrogen or Ci-C6alkyl, such Ci-C6alkyl optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, Fluoro, oxo, and Ci-C4alkyl optionally substituted with one or more Fluoro and/or -OH;
R 2 is selected from the group consisting of hydrogen, Ci-C6alkyl, Ci-C3alkyl-R 7 , a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, and monocyclic aryl optionally containing one or two heteroatoms, such Ci-C6alkyl, Ci-C3alkyl-R7, 3-7 membered saturated ring or monocyclic aryl optionally being substituted with one or more R ; R is hydrogen; or R 2 and R 3 taken together form together with the carbon atom to which they are attached a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N,
Q
such 3-7 membered saturated ring optionally substituted with one or more R ;
R7 represents a monocyclic aryl optionally containing one or two heteroatoms;
Q
each R independently is selected from the group consisting of -OH, Fluoro, methoxy, oxo, -C(=0)OCi-C4alkyl and Ci-C4alkyl optionally substituted with one or more Fluoro and/or -OH; or a pharmaceutically acceptable salt or a solvate thereof.
In a further embodiment, the invention relates to a compound of Formula (I -A) as defined herein, or a stereoisomer or tautomeric form thereof, wherein:
Figure imgf000011_0001
; wherein
R4 is hydrogen, -Ci-C3alkyl or C3-C4cycloalkyl; in particular methyl;
R5 is hydrogen or halogen; in particular fluoro;
and wherein R6 is selected from hydrogen, methyl, -CN and halogen; in particular, hydrogen or methyl; in particular, hydrogen or fluoro, in particular hydrogen;
and all other variables are as defined in Formula (I-A);
or a pharmaceutically acceptable salt or a solvate thereof.
The present invention further relates in particular to a compound of Formula (A)
Figure imgf000011_0002
or a stereoisomer or tautomeric form thereof, wherein:
Figure imgf000011_0003
represents a monocyclic 5 or 6 membered aryl optionally containing one or two heteroatoms, such aryl optionally substituted with one or more methyl, -CN or halogen;
Figure imgf000011_0004
represents a 6 membered aryl optionally containing one nitrogen atom; X represents -CR2 R3-;
Y represents a Ci_C7alkanediyl or C2-C7alkenediyl each optionally substituted with one or more Ci-C4alkyl or -OH;
Z represents a heteroatom, preferably oxygen, or a single bond; Ra, Rb, Rc and Rd are independently selected from the group consisting of Hydrogen, halogen, -CHF2, -CF2-methyl, -CH2F, -CF3, -OCF3, -CN, C3-C4cycloalkyl and -Ci-C4alkyl;
R1 is Hydrogen or Ci-C6alkyl, such Ci-C6alkyl optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, Fluoro, oxo, and Ci-C4alkyl optionally substituted with one or more Fluoro and/or -OH;
R 2 is selected from the group consisting of hydrogen, Ci-C6alkyl, Ci-C3alkyl-R 7 , a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, and monocyclic aryl optionally containing one or two heteroatoms, such Ci-C6alkyl, Ci-C3alkyl-R7, 3-7 membered saturated ring or monocyclic aryl optionally being substituted with one or more R ;
R is hydrogen; or R 2 and R 3 taken together form together with the carbon atom to which they are attached a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N,
Q
such 3-7 membered saturated ring optionally substituted with one or more R ; R7 represents a monocyclic aryl optionally containing one or two heteroatoms;
Q
Each R independently is selected from the group consisting of -OH, Fluoro, methoxy, oxo, -C(=0)OCi-C4alkyl and Ci-C4alkyl optionally substituted with one or more Fluoro and/or -OH; or a pharmaceutically acceptable salt or a solvate thereof.
The invention further relates to a pharmaceutical composition comprising a compound of Formula (A), and a pharmaceutically acceptable carrier.
The invention also relates to the compounds of Formula (A) for use as a medicament, preferably for use in the prevention or treatment of an HBV infection in a mammal. In a further aspect, the invention relates to a combination of a compound of Formula (A), and another HBV inhibitor.
Whenever used hereinafter, the term "compounds of Formula (I -A)" or "compounds of Formula (A)",
Figure imgf000013_0001
or "the present compounds" or similar term is meant to include all compounds of general Formula (I- A), (A), (A*), (B), or (C), salts, stereoisomeric forms and racemic mixtures or any subgroups thereof.
The present invention relates in particular to compounds of Formula (A)
Figure imgf000013_0002
or a stereoisomer or tautomeric form thereof, wherein:
Figure imgf000013_0003
represents a monocyclic 5 or 6 membered aryl optionally containing one or two heteroatoms, such aryl optionally substituted with one or more methyl, -CN or halogen;
represents a 6 membered aryl optionally containing one nitrogen atom; X represents -CR2 R3-;
Y represents a Ci_C7alkanediyl or C2_C7alkenediyl each optionally substituted with one or more Ci-C4alkyl or -OH;
Z represents a heteroatom, preferably oxygen, or a single bond; Ra, Rb, Rc and Rd are independently selected from the group consisting of Hydrogen, halogen, -CHF2, -CF2-methyl, -CH2F, -CF3, -OCF3, -CN, C3-C4cycloalkyl and -Ci-C4alkyl;
R1 is Hydrogen or Ci-C6alkyl, such Ci-C6alkyl optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, Fluoro, oxo, and Ci-C4alkyl optionally substituted with one or more Fluoro and/or -OH;
R 2 is selected from the group consisting of hydrogen, Ci-C6alkyl, Ci-C3alkyl-R 7 , a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, and monocyclic aryl optionally containing one or two heteroatoms, such Ci-C6alkyl, Ci-C3alkyl-R7, 3-7 membered saturated ring or monocyclic aryl optionally being substituted with one or more R ;
R is hydrogen; or R 2 and R 3 taken together form together with the carbon atom to which they are attached a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N,
Q
such 3-7 membered saturated ring optionally substituted with one or more R ; R7 represents a monocyclic aryl optionally containing one or two heteroatoms;
Q
Each R independently is selected from the group consisting of -OH, Fluoro, methoxy, oxo, -C(=0)OCi-C4alkyl and Ci-C4alkyl optionally substituted with one or more Fluoro and/or -OH; or a pharmaceutically acceptable salt or a solvate thereof. one embodiment, the present invention relates to compounds of Formula (A)
Figure imgf000015_0001
or a stereoisomer or tautomeric form thereof, wherein:
Figure imgf000015_0002
represents a monocyclic 5 or 6 membered aryl optionally containing one or two heteroatoms, such aryl optionally substituted with one or more methyl, -CN or halogen;
represents a 6 membered aryl optionally containing one nitrogen atom;
X represents -CR2 R3-;
Y represents a Ci_C7alkanediyl or C2-C7alkenediyl each optionally substituted with one or more Ci-C4alkyl;
Z represents a heteroatom, preferably oxygen, or a single bond;
Ra, Rb, Rc and Rd are independently selected from the group consisting of Hydrogen, halogen, -CHF2, -CF2-methyl, -CH2F, -CF3, -OCF3, -CN, C3-C4cycloalkyl and -Ci-C4alkyl;
R1 is Hydrogen or Ci-Cealkyl, such Ci-Cealkyl optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, Fluoro, oxo, and Ci-C4alkyl optionally substituted with one or more Fluoro and/or -OH;
R 2 is selected from the group consisting of hydrogen, Ci-Cealkyl, Ci-C3alkyl-R 7 and monocyclic aryl optionally containing one or two heteroatoms, such Ci-Cealkyl, Ci-C3alkyl-R 7 or monocyclic aryl optionally being substituted with one or more R 8 ;
R is hydrogen; or R 2 and R 3 taken together form together with the carbon atom to which they are attached a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring optionally substituted with one or more Fluoro and/or -OH, or Ci-C4alkyl optionally substituted with one or more Fluoro and/or -OH;
R7 represents a monocyclic aryl optionally containing one or two heteroatoms; Each R independently is selected from the group consisting of -OH, Fluoro, methoxy, oxo, and Ci-C4alkyl optionally substituted with one or more Fluoro and/or -OH; or a pharmaceutically acceptable salt or a solvate thereof.
one embodiment, the invention relates to compounds of Formula (B)
Figure imgf000016_0001
or Formula (C)
Figure imgf000016_0002
wherein Ra, Rb, Rc and Rd are independently selected from the group consisting of Hydrogen, halogen, -CHF2, -CF2-methyl, -CH2F, -CF3, -OCF3, -CN, C3-C4cycloalkyl and -Ci-C4alkyl;
R1 is Hydrogen or Ci-Cealkyl, such Ci-Cealkyl optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, Fluoro, oxo, and Ci-C4alkyl optionally substituted with one or more Fluoro and/or -OH;
R 2 is selected from the group consisting of hydrogen, Ci-C6alkyl, Ci-C3alkyl-R 7 and monocyclic aryl optionally containing one or two heteroatoms, such Ci-C6alkyl,
Ci-C3alkyl-R 7 or monocyclic aryl optionally being substituted with one or more R 8 ; R is hydrogen;
2 3
or R and R taken together form together with the carbon atom to which they are attached a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring optionally substituted with one or more Fluoro and/or -OH, or Ci-C4alkyl optionally substituted with one or more Fluoro and/or -OH;
R4 is Hydrogen, -Ci-C3alkyl or C3-C4cycloalkyl, preferably methyl;
R5 is Hydrogen or Halogen, preferably Fluoro;
R6 is selected from hydrogen, methyl, -CN and halogen;
R7 represents a monocyclic aryl optionally containing one or two heteroatoms;
Q
And each R independently is selected from the group consisting of -OH, Fluoro, methoxy, oxo, and Ci-C4alkyl optionally substituted with one or more Fluoro and/or -OH; or a pharmaceutically acceptable salt or a solvate thereof.
In an additional embodiment, the invention relates to compounds of Formula (I-A), (A), (A*), (B) or (C) as described herein, wherein R1 is Hydrogen or Ci-C6alkyl optionally substituted with one or more substituents, in particular 1-3 substituents, each
independently selected from the group consisting of -OH, and Fluoro.
An additional embodiment of the present invention relates to compounds of Formula (I-A) having, in particular, Formula (I-AA1) or Formula (I-AA2)
Figure imgf000018_0001
(I-AA1), or (I-AA2), wherein
Ring B represents phenyl or 4-pyridyl;
wherein in Formula (I-AA2) represents a single or a double bond;
R 2 is selected from the group consisting of hydrogen, Ci-C6alkyl, Ci-C3alkyl-R 7 , a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, and monocyclic aryl optionally containing one or two heteroatoms, such Ci-C6alkyl, Ci-C3alkyl-R7, 3-7 membered saturated ring or monocyclic aryl optionally being substituted with one or more R ;
R3 is hydrogen or Ci-C6alkyl, in particular hydrogen or methyl;
R4 is Ci-C3alkyl, in particular methyl;
R6 is hydrogen or methyl;
R7 is selected from the group consisting of a monocyclic aryl optionally containing one or two heteroatoms; a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N; or -NR9R10;
wherein R9 and R10 are each independently selected from hydrogen and Ci-C3alkyl;
Q
each R independently is selected from the group consisting of -OH, fluoro, methoxy, oxo, -C(=0)OCi-C4alkyl and Ci-C4alkyl optionally substituted with one or more substituents each independently selected from fluoro and/or -OH;
Ra is selected from hydrogen and halogen, in particular hydrogen;
Rb is absent when ring B is pyridyl or is hydrogen or a halogen, in particular a halogen, when ring B is phenyl;
Rc is selected from halogen, CH3, CHF2, CF3, and -CN;
Rd is selected from hydrogen and halogen, in particular hydrogen;
or a pharmaceutically acceptable salt or a solvate thereof.
A further embodiment the present invention relates to compounds of Formula (I -A) having, in particular, Formula (I-Al) or Formula (I-A2)
Figure imgf000019_0001
(I-Al), or (I-A2), wherein
Ring B represents phenyl or 4-pyridyl;
wherein in Formula (I-A2) represents a single or a double bond;
R 2 is selected from the group consisting of hydrogen, Ci-Cealkyl, Ci-C3alkyl-R 7 , a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, and monocyclic aryl optionally containing one or two heteroatoms, such Ci-Cealkyl, Ci-C3alkyl-R7, 3-7 membered saturated ring or monocyclic aryl optionally being substituted with one or more R ;
R4 is Ci-C3alkyl, in particular methyl;
R6 is hydrogen or methyl;
R7 is selected from the group consisting of a monocyclic aryl optionally containing one or two heteroatoms; a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N; or -NR9R10;
wherein R9 and R10 are each independently selected from hydrogen and Ci-C3alkyl;
Q
each R independently is selected from the group consisting of -OH, fluoro, methoxy, oxo, -C(=0)OCi-C4alkyl and Ci-C4alkyl optionally substituted with one or more substituents each independently selected from fluoro and/or -OH;
Ra is selected from hydrogen and halogen, in particular hydrogen;
Rb is absent when ring B is pyridyl or is hydrogen or a halogen, in particular a halogen, when ring B is phenyl;
Rc is selected from halogen, C¾, CHF2, CF3, and -CN;
Rd is selected from hydrogen and halogen, in particular hydrogen;
or a pharmaceutically acceptable salt or a solvate thereof.
In a further embodiment the present invention relates to compounds of Formula (I- A) having, in particular, Formula (I-Al ') or Formula (I-A2')
Figure imgf000020_0001
(I-Al '), or (Ι-Α2'), wherein
Ring B represents phenyl or 4-pyridyl;
wherein in Formula (I-A2) represents a single or a double bond;
R 2 is selected from the group consisting of Ci-Cealkyl, Ci-C3alkyl-R 7 , a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, and monocyclic aryl optionally containing one or two heteroatoms, such Ci-Cealkyl, Ci-C3alkyl-R7, 3-7 membered
Q
saturated ring or monocyclic aryl optionally being substituted with one or more R ; R4 is Ci-C3alkyl, in particular methyl;
R6 is hydrogen or methyl;
R7 is selected from the group consisting of a monocyclic aryl optionally containing one or two heteroatoms; a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N; or -NR9R10;
wherein R9 and R10 are each independently selected from hydrogen and Ci-C3alkyl;
Q
each R independently is selected from the group consisting of -OH, fluoro, methoxy, oxo, -C(=0)OCi-C4alkyl and Ci-C4alkyl optionally substituted with one or more substituents each independently selected from fluoro and/or -OH;
Ra is selected from hydrogen and halogen, in particular hydrogen;
Rb is absent when ring B is pyridyl or is hydrogen or a halogen, in particular a halogen, when ring B is phenyl;
Rc is selected from halogen, C¾, CHF2, CF3, and -CN;
Rd is selected from hydrogen and halogen, in particular hydrogen;
or a pharmaceutically acceptable salt or a solvate thereof.
In a further embodiment the present invention relates to compounds of Formula (I- A) having, in particular, Formula (I-Al ') or Formula (I-A2'), as defined herein wherein R is Ci-Cealkyl optionally substituted with 1-4 substituents each independently selected from the group consisting of -OH, fluoro, and methoxy, in particular -OH and fluoro; Ring B represents phenyl; Ra is selected from hydrogen and halogen; Rb is hydrogen or a halogen, in particular a halogen; and Rc is selected from halogen, CH3, CHF2, CF3, and -CN; and the rest of the variables are as defined herein.
Another embodiment of the present invention relates to those compounds of Formula (I-A), Formula (I-AAl), Formula (I-AA2), Formula (I-Al), Formula (I-A2), Formula (I-Al '), Formula (I-A2'), Formula (A), Formula (B), or Formula (C) or any subgroup thereof as mentioned in any of the other embodiments wherein one or more of the following restrictions apply: (a) Ring C consists of 6 to 8 atoms, preferably 7 atoms.
(b) Y represents linear Ci_C7alkanediyl or C2_C7alkenediyl, each optionally
substituted with 1-3 substituents each independently selected from the group consisting of fluoro and -OH.
(c) Y represents linear Ci_C7alkanediyl or C2_C7alkenediyl, each optionally
substituted with -OH.
(d) R is Ci-C6alkyl optionally substituted with one or more Fluoro and/or -OH substituents, each independently selected. Preferably, R is a branched
Ci-C6alkyl substituted with one or more Fluoro substituents.
(e) R is Ci-C6alkyl optionally substituted with one or more -OH substituents. In particular, R is Ci_6alkyl substituted with one -OH.
2
(f) R is Ci-C4alkyl optionally substituted with one or more fluoro substituents.
(g) R is C3-C6alkyl optionally substituted with one or more fluoro substituents.
(h) R is Ci-C4alkyl, in particular methyl.
(i) R 3 is Ci-C4alkyl, in particular methyl; and R 2 is selected from the group
consisting of Ci-C6alkyl, and monocyclic aryl optionally containing one or two heteroatoms, such Ci-C6alkyl or monocyclic aryl optionally being substituted with one or more R 8 , wherein R 8 is as defined herein,
(j) R4 is Ci-C3alkyl, preferably methyl,
(k) Rb is Hydrogen or Fluoro.
(1) Rb and Rc are independently selected from hydrogen, fluoro and -CN.
(m) Rb and Rc are independently selected from Hydrogen or Fluoro.
(n) Rb and Rc are independently selected from fluoro and -CN.
(o) Ra and/or Rd is Hydrogen
(p) Ra and Rd are both Hydrogen.
(q) Rb and/or Rc are Fluoro.
(r) R1 is hydrogen or Ci-C6alkyl optionally substituted with one or more
substituents, in particular 1-4 substituents, each independently selected from the group consisting of -OH and fluoro. (s) R1 is hydrogen.
ΛΛ
(t) represents phenyl.
ΛΛ
(u) represents phenyl substituted with one or more halogen substituents.
(v) represents phenyl substituted with at least one Halogen, more
preferably at least one Fluoro, even more preferably 2 Fluoro.
(w) 7 is a 3-7 membered saturated ring, in particular cyclopropyl.
Figure imgf000022_0001
(x) R is selected from the group consisting of methyl, ethyl, isopropyl,
CF3, CHF2, CF2CH3,
Figure imgf000022_0002
(y)
Figure imgf000022_0003
, CF3, CF2CH3,
Figure imgf000022_0004
Figure imgf000022_0005
(z) represents phenyl, and Ra, Rb, Rc and Rd are each independently selected from the group consisting of hydrogen, halogen, -CHF2, -CF2-methyl, -CF3, -OCF3, -CN, C3-C4cycloalkyl and -Ci-C4alkyl.
JWj β
(aa) represents phenyl, and Ra is selected from hydrogen and halogen; Rb is hydrogen or a halogen, in particular a halogen; Rc is selected from halogen, CH , CHF2, CF , and -CN; and Rd is selected from hydrogen and halogen, in particular hydrogen.
(bb) represents phenyl, and Ra is selected from hydrogen and
halogen; Rb is hydrogen or a halogen, in particular a halogen; Rc is selected from halogen, CH , CF , and -CN; and Rd is selected from hydrogen and halogen, in particular hydrogen.
Further combinations of any of the embodiments are also envisioned to be in the scope of the present invention.
In an additional embodiment, the present invention relates to a compound of Formula (I -A) as defined herein, or a stereoisomer or tautomeric form thereof, wherein
Figure imgf000023_0001
represents a monocyclic 5 or 6 membered aryl or heteroaryl selected from the group consisting of pyrrolyl, thiophenyl, pyrazolyl, phenyl, and pyridyl, each optionally substituted with one or two substituents each independently selected from the group consisting of Ci-C3alkyl, in particular methyl, C3-C4cycloalkyl, -CN and halogen;
represents phenyl or pyridyl;
X represents -CR2R3-;
Y represents linear Ci_C7alkanediyl or C2_C7alkenediyl, each optionally substituted with one, two or three substituents each independently selected from the group consisting of fluoro and -OH;
Z represents oxygen, or a single bond;
Ra, Rb, Rc and Rd are each independently selected from the group consisting of hydrogen, halogen, -CHF2, -CF2-methyl, -CH2F, -CF3, -OCF3, -CN, C3-C4cycloalkyl and -Ci-C4alkyl;
R1 is hydrogen or Ci-Cealkyl optionally substituted with one, two, three or four substituents each independently selected from the group consisting of -OH and fluoro; 2
R is selected from the group consisting of hydrogen; Ci-C6alkyl optionally substituted with 1-4 substituents each independently selected from the group consisting of -OH, fluoro, methoxy, oxo, and -C(=0)OCi-C4alkyl; Ci-C3alkyl-R7; C2-C4alkynyl; a 3-7 membered saturated ring optionally containing one or two heteroatoms each independently selected from the group consisting of O, S and N; and monocyclic aryl optionally containing one or two heteroatoms; wherein the Ci-C3alkyl-R7, 3-7 membered saturated ring or the monocyclic aryl are each
Q
optionally substituted with one or more R substituents; R is hydrogen or Ci_6alkyl optionally substituted with -OH; in particular, hydrogen or methyl; or R 2 and R 3 taken together with the carbon atom to which they are attached form a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, and optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, fluoro, methoxy, oxo, benzyl, and Ci-C4alkyl;
R7 represents a monocyclic aryl optionally containing one or two heteroatoms, and optionally being substituted with one or two substituents each independently selected from the group consisting of halo and Ci_3alkyl; a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N; or -NR9R10; wherein R9 and R10 are each independently selected from hydrogen and Ci-C3alkyl optionally substituted with one or more fluoro substituents;
Q
each R is independently selected from the group consisting of -OH, fluoro, methoxy, oxo, -C(=0)OCi-C4alkyl, Ci-C4alkyloxyCi-C4alkyloxy, and Ci-C4alkyl optionally substituted with one or more substituents each independently selected from fluoro and/or -OH; or a pharmaceutically acceptable salt or a solvate thereof. an additional embodiment, the present invention relates to a compound of Formula ) as defined herein, or a stereoisomer or tautomeric form thereof, wherein
Figure imgf000025_0001
represents a monocyclic 5 membered heteroaryl selected from the group consisting of pyrrolyl, thiophenyl and pyrazolyl, each optionally substituted with one or two substituents each independently selected from the group consisting of Ci- C3alkyl, in particular methyl;
Figure imgf000025_0002
represents phenyl or pyridyl; X represents -CR2R3-;
Y represents linear Ci_C7alkanediyl or C2_C7alkenediyl, each optionally substituted with one or two substituents each independently selected from the group consisting of fluoro and -OH;
Z represents oxygen, or a single bond;
Ra, Rb, Rc and Rd are each independently selected from the group consisting of hydrogen, halogen, -CHF2, -CF2-methyl, -CH2F, -CF3, -OCF3, -CN, C3-C4cycloalkyl and -Ci-C4alkyl;
R1 is hydrogen or Ci-C3alkyl optionally substituted with one, two or three substituents each independently selected from the group consisting of -OH and fluoro; more in particular, hydrogen;
R is selected from the group consisting of hydrogen; Ci-C6alkyl optionally substituted with one, two, three or four substituents each independently selected from the group consisting of
-OH, fluoro, and methoxy; Ci-C3alkyl-R7; C2-C4alkynyl; 3-7 membered saturated ring optionally containing one or two heteroatoms each independently selected from the group consisting of O, S and N selected from the group consisting of
cyclopropyl, tetrahydropyranyl and piperidinyl; and monocyclic aryl optionally containing one or two heteroatoms selected from the group consisting of phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyrazolyl, imidazolyl, and oxazolyl; wherein the Ci-C3alkyl-R7, 3-7 membered saturated ring or the monocyclic aryl are each
Q
optionally substituted with one or more R substituents; R is hydrogen or Ci_3alkyl optionally substituted with -OH; in particular, hydrogen or methyl; or R 2 and R 3 taken together with the carbon atom to which they are attached form a cyclopropyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl or piperidinyl ring, each optionally being substituted with benzyl;
R7 is selected from the group consisting of phenyl, pyridyl, pyrazolyl, imidazolyl, and oxazolyl, each optionally substituted with one or two substituents each independently selected from the group consisting of halo and Ci_3alkyl; cyclopropyl; and -NR9R10; wherein R9 and R10 are each independently selected from hydrogen and Ci-C3alkyl optionally substituted with one or more fluoro substituents;
Q
each R is independently selected from the group consisting of -OH, fluoro, methoxy, oxo, -C(=0)OCi-C4alkyl, Ci-C4alkyloxyCi-C4alkyloxy, and Ci-C4alkyl optionally substituted with one or more substituents each independently selected from fluoro and/or -OH; or a pharmaceutically acceptable salt or a solvate thereof.
In a further embodiment, the invention relates to compounds of Formula (I -A), (A) or (A*), as defined herein, wherein
Figure imgf000026_0001
s selected from the group consisting of pyrrolyl, thienyl and pyrazolyl, each optionally substituted with one or two substituents each independently selected from the group consisting of Ci-C3alkyl, in particular methyl, -CN and halo.
In an additional embodiment, the invention relates to compounds of the invention, as defined herein, wherein
R is selected from the group consisting of hydrogen, Ci-C6alkyl optionally substituted with 1 -4 substituents each independently selected from the group consisting of -OH, fluoro and methoxy; Ci-C3alkyl-R7 optionally substituted with -OH; a heterocyclyl selected from piperidinyl and tetrahydropyranyl, each optionally substituted with Ci-C4alkyl, which may be optionally substituted with 1-3 fluoro substituents; and aryl or heteroaryl selected from the group consisting of phenyl, pyridyl, pyrazinyl, pyrimidinyl, and oxazolyl, each ptionally substituted with methyl; wherein R7 is selected from the group consisting of cyclopropyl, phenyl, pyridyl, oxazolyl, pyrazolyl and imidazolyl, each optionally substituted with 1 -3 substituents each independently selected from halo and methyl; and -NR9R10, wherein R9 and R10 are each independently selected from hydrogen, Ci-C3alkyl and Ci-C3alkyl substituted with 1 -3 fluoro substituents;
R is hydrogen or Ci_6alkyl optionally substituted with -OH; in particular, hydrogen or methyl; or R 2 and R 3 taken together with the carbon atom to which they are attached form a cyclopropyl, an oxetanyl, a tetrahydrofuranyl or a pyrrolidinyl ring optionally substituted with benzyl, in particular an oxetanyl or a tetrahydrofuranyl ring.
In an additional embodiment, the invention relates to compounds of the invention, as defined herein, wherein
R is selected from the group consisting of Ci-C6alkyl optionally substituted with 1-4 substituents each independently selected from the group consisting of -OH and fluoro; Ci-C3alkyl-R7; optionally substituted with -OH;
piperidinyl or tetrahydropyranyl, each of which may be optionally substituted with Ci-C4alkyl, which may be optionally substituted with 1-3 fluoro substituents;
phenyl, pyridyl, pyrazinyl, pyrimidinyl, oxazolyl, each of which optionally being substituted with methyl;
wherein R7 is selected from cyclopropyl, phenyl, pyridyl, oxazolyl, pyrazolyl and imidazolyl, each of which optionally being substituted with 1-3 substituents each independently selected from halo and methyl; and -NR9R10, wherein R9 and R10 are each independently selected from hydrogen and Ci-C3alkyl; R is hydrogen or Ci_6alkyl; in particular, hydrogen or methyl; or R 2 and R 3 taken together with the carbon atom to which they are attached form a cyclopropyl, an oxetanyl or a tetrahydrofuranyl, in particular an oxetanyl or a tetrahydrofuranyl ring.
Preferred compounds according to the invention are compound or a stereoisomer or tautomeric form thereof with a Formula as represented in the synthesis of compounds section and of which the activity is displayed in Table 1. DEFINITIONS
The term "aryl" means a monocyclic or polycyclic aromatic ring comprising carbon atoms, and hydrogen atoms. If indicated, such aromatic ring may include one or more heteroatoms (then also referred to as heteroaryl), preferably, 1 to 3 heteroatoms, independently selected from nitrogen, oxygen, and sulfur, preferably nitrogen. As is well known to those skilled in the art, heteroaryl rings have less aromatic character than their all-carbon counter parts. Thus, for the purposes of the present invention, a heteroaryl group need only have some degree of aromatic character. Illustrative examples of aryl groups are optionally substituted phenyl. Illustrative examples of heteroaryl groups according to the invention include optionally substituted pyrrole, pyridine, and imidazole. Thus, the term monocyclic aryl optionally containing one or more heteroatoms, for example one or two heteroatoms, refers for example, to a 5- or 6-membered aryl or heteroaryl group such as, but not limited to, phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl and oxazolyl.
The terms "Ci_xalkyl" and Ci-Cxalkyl can be used interchangeably.
The term "Ci_ioalkyl", "Ci_6alkyl", "Ci_3alkyl" as a group or part of a group refers to a hydrocarbyl radical of Formula CnH2n+i wherein n is a number ranging from 1 to 10, from 1 to 6, or from 1 to 3. For example, in the case that Ci_3alkyl is coupled to a further radical, it refers to a Formula CnH2n. Ci_3alkyl groups comprise from 1 to 3 carbon atoms, more preferably 1 to 2 carbon atoms. Ci_3alkyl includes all linear, or branched alkyl groups with between 1 and 3 carbon atoms, and thus includes such as for example methyl, ethyl, n-propyl, and /-propyl.
Ci_4alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radical having from 1 to 4 carbon atoms such as the group defined for Ci_3 alkyl and butyl and the like.
Ci_6alkyl and C2_6alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms, or from 2 to 6 carbon atoms such as the groups defined for Ci_4alkyl and pentyl, hexyl, 2-methylbutyl and the like.
The term "Ci_7alkanediyl" as a group or part of a group defines bivalent straight or branched chained saturated hydrocarbon radicals having from 1 to 7 carbon atoms such as, for example, methanediyl, ethanediyl, propanediyl, butanediyl, pentanediyl, hexanediyl and heptanediyl. The term "C2_7alkenediyl" as a group or part of a group defines straight or branched chain bivalent hydrocarbon radicals having from 2 to 7 carbon atoms and having at least one double bond, preferably one double bond, such as ethenediyl, propenediyl, butenediyl, pentenediyl, hexenediyl and heptenediyl and the like.
The term "C3-C4cycloalkyl" is generic to cyclopropyl and cyclobutyl.
As used herein, the term "3-7 membered saturated ring" means saturated cyclic hydrocarbon (cycloalkyl) with 3, 4, 5, 6 or 7 carbon atoms and is generic to
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
Such saturated ring optionally contains one or more heteroatoms (also referred to as heterocyclyl), such that at least one carbon atom is replaced by a heteroatom selected from N, O and S, in particular from N and O. Examples include oxetanyl, tetrahydro- 2H-pyranyl, piperidinyl, tetrahydrofuranyl, morpholinyl, thiolane 1,1 -dioxide and pyrrolidinyl. Preferred are saturated cyclic hydrocarbons with 3 or 4 carbon atoms and 1 oxygen atom. Examples include oxetanyl, and tetrahydrofuranyl.
It should be noted that different isomers of the various heterocycles may exist within the definitions as used throughout the specification. For example, pyrrolyl may be lH-pyrrolyl or 2H-pyrrolyl.
The term halo and halogen are generic to Fluoro, Chloro, Bromo or Iodo. Preferred halogens are Bromo, Fluoro and Chloro. The term "heteroatom" refers to an atom other than carbon or hydrogen in a ring structure or a saturated backbone as defined herein. Typical heteroatoms include N(H), O, S.
The term *R and *S depicted in a structural formula indicate that a racemic mixture of the compound is separated into its 2 enantiomers. The first eluting enantiomer is indicated with *R and the second eluting enantiomer is indicated with *S. Both *R and *S therefore indicate a specific separated enantiomer, but the sterocenter conformation is not established. It should also be noted that the radical positions on any molecular moiety used in the definitions may be anywhere on such moiety as long as it is chemically stable. For instance pyridyl includes 2-pyridyl, 3-pyridyl and 4-pyridyl; pentyl includes 1-pentyl, 2-pentyl and 3-pentyl. The term *· *■- ' or ring B represents a 6 membered aryl optionally containing one nitrogen atom. Ring B can therefore be referred to as phenyl or pyridyl.
Figure imgf000030_0001
a monocyclic 5 or 6 membered aryl optionally containing one or two heteroatoms, such aryl optionally being substituted with one or more substituents each independently selected from the group consisting of Ci-C3alkyl, in particular methyl, C3-C4cycloalkyl, -CN and halogen. Such monocyclic 5 or 6 membered aryl or heteroaryl groups, as defined herein, include, but are not limited to phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl and oxazolyl. Ring A can alternatively be depicted bearing the optional substituents
Ci-C3alkyl, C3-C4cycloalkyl, -CN and halogen at particular positions, as defined herein, by referring to such substituents as R4, R5 and R6, as applicable.
Lines drawn from substituents into ring systems indicate that the bond may be attached to any of the suitable ring atoms.
Positions indicated on ring B (e.g. ortho, meta and/or para) are indicated relative to the bond connecting aryl B to the main structure. An example with regard to the position of meta Ra, location is indicated relative to the nitrogen (*) connected to the main structure as shown in Formula (A*).
Figure imgf000030_0002
When any variable (e.g. halogen or Ci_4alkyl) occurs more than one time in any constituent, each definition is independent.
The expression "one or more substituents" refers in particular to 1, 2, 3, 4, or more substituents, in particular to 1, 2, 3, or 4 substituents, more in particular, to 1 , 2, or 3 substituents. Combinations of substituents and/or variables are permissible only if such combinations result in chemically stable compounds. "Stable compound" is meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into a therapeutic agent.
For therapeutic use, the salts of the compounds of Formula (I- A), (A), (B), (C), are those wherein the counter ion is pharmaceutically or physiologically acceptable.
However, salts having a pharmaceutically unacceptable counter ion may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound of Formula (I- A), (A), (B), (C). All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.
The pharmaceutically acceptable or physiologically tolerable addition salt forms which the compounds of the present invention are able to form can conveniently be prepared using the appropriate acids, such as, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, hemisulphuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, aspartic,
dodecyl-sulphuric, heptanoic, hexanoic, nicotinic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric,
methane-sulfonic, ethanesulfonic, benzenesulfonic, /?-toluenesulfonic, cyclamic, salicylic, /^-aminosalicylic, pamoic and the like acids.
Conversely said acid addition salt forms can be converted by treatment with an appropriate base into the free base form.
The term "solvate" comprises the solvent addition forms as well as the salts thereof, which the compounds of the present invention are able to form. Examples of such solvent addition forms are, e.g. hydrates, alcoholates and the like.
The present compounds may also exist in their tautomeric forms. For example, tautomeric forms of amide (-C(=0)-NH-) groups are iminoalcohols (-C(OH)=N-). Tautomeric forms, although not explicitly indicated in the structural formulae represented herein, are intended to be included within the scope of the present invention.
The term stereochemically isomeric forms of compounds of the present invention, as used hereinbefore, defines all possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which the compounds of the present invention may possess. Unless otherwise mentioned or indicated, the chemical designation of a compound encompasses the mixture of all possible stereochemically isomeric forms which said compound may possess. Said mixture may contain all diastereomers and/or enantiomers of the basic molecular structure of said compound. All stereochemically isomeric forms of the compounds of the present invention both in pure form or in a mixture with each other are intended to be embraced within the scope of the present invention. Pure stereoisomeric forms of the compounds and intermediates as mentioned herein are defined as isomers substantially free of other enantiomeric or diastereomeric forms of the same basic molecular structure of said compounds or intermediates. In particular, the term 'stereoisomerically pure' concerns compounds or intermediates having a stereoisomeric excess of at least 80% (i. e. minimum 90% of one isomer and maximum 10%) of the other possible isomers) up to a stereoisomeric excess of 100% (i.e. 100% of one isomer and none of the other), more in particular, compounds or intermediates having a stereoisomeric excess of 90% up to 100%, even more in particular having a stereoisomeric excess of 94% up to 100% and most in particular having a
stereo-isomeric excess of 97% up to 100%. The terms 'enantiomerically pure' and 'diastereomerically pure' should be understood in a similar way, but then having regard to the enantiomeric excess or the diastereomeric excess, respectively, of the mixture in question.
Pure stereoisomeric forms of the compounds and intermediates of this invention may be obtained by the application of art-known procedures. For instance, enantiomers may be separated from each other by the selective crystallization of their diastereomeric salts with optically active acids or bases. Examples thereof are tartaric acid, dibenzoyltartaric acid, ditoluoyltartaric acid and camphosulfonic acid. Alternatively, enantiomers may be separated by chromatographic techniques using chiral stationary phases. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably, if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.
The stereomeric forms of compounds of Formula (I- A), (A), (B), or (C), can be obtained separately by conventional methods. Appropriate physical separation methods that may advantageously be employed are, for example, selective crystallization and chromatography, e.g. column chromatography.
The present invention is also intended to include all isotopes of atoms occurring on the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, Hydrogen includes the tritium and deuterium isotopes. Carbon includes the C-13 and C-14 isotopes.
In a further aspect, the present invention concerns a pharmaceutical composition comprising a therapeutically or prophylactically effective amount of a compound of Formula (I -A), or of Formula (A), (B) or (C) as specified herein, and a pharmaceutically acceptable carrier. A prophylactically effective amount in this context is an amount sufficient to prevent HBV infection in subjects being at risk of being infected. A therapeutically effective amount in this context is an amount sufficient to stabilize HBV infection, to reduce HBV infection, or to eradicate HBV infection, in infected subjects. In still a further aspect, this invention relates to a process of preparing a pharmaceutical composition as specified herein, which comprises intimately mixing a pharmaceutically acceptable carrier with a therapeutically or prophylactically effective amount of a compound of Formula (I- A), (A) (B) or (C), as specified herein.
Therefore, the compounds of the present invention or any subgroup thereof may be formulated into various pharmaceutical forms for administration purposes. As appropriate compositions there may be cited all compositions usually employed for systemically administering drugs. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, optionally in addition salt form or solvate form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirable in unitary dosage form suitable, particularly, for
administration orally, rectally, percutaneous ly, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations intended to be converted, shortly before use, to liquid form preparations. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. The compounds of the present invention may also be administered via oral inhalation or insufflation in the form of a solution, a suspension or a dry powder using any art-known delivery system.
It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, suppositories, powder packets, wafers, injectable solutions or suspensions and the like, and segregated multiples thereof. The compounds of Formula (I- A), (A), (B), or (C) are active as inhibitors of the HBV replication cycle and can be used in the treatment and prophylaxis of HBV infection or diseases associated with HBV. The latter include progressive liver fibrosis,
inflammation and necrosis leading to cirrhosis, end-stage liver disease, and
hepatocellular carcinoma. HBV acts as a helper virus to HDV, which infects only subjects suffering from HBV infection. Therefore, in a particular embodiment, said compounds of Formula (I -A), (A), (B), or (C) can be used in the treatment and/or prophylaxis of HBV/HDV co-infection, or diseases associated with HBV/HDV co-infection. Due to their antiviral properties, particularly their anti-HBV properties, the compounds of Formula (I -A), (A), (B), or (C), or any subgroup thereof, are useful in the inhibition of the HBV replication cycle, in particular in the treatment of warm-blooded animals, in particular humans, infected with HBV, and for the prophylaxis of HBV infections. The present invention furthermore relates to a method of treating a warm-blooded animal, in particular a human, infected by HBV, or being at risk of infection by HBV, said method comprising the administration of a therapeutically effective amount of a compound of Formula (I-A), (A), (B), or (C). In a particular embodiment, the warm-blooded animal, in particular the human, may be HB V/HDV co-infected, or be at risk of HBV/HDV co-infection.
The compounds of Formula (I-A), (A), (B), or (C), as specified herein, may therefore be used as a medicine, in particular as medicine to treat or prevent HBV infection. Said use as a medicine or method of treatment comprises the systemic administration to HBV infected subjects or to subjects susceptible to HBV infection of an amount effective to combat the conditions associated with HBV infection or an amount effective to prevent HBV infection. In a particular embodiment, said HBV infection is in particular
HBV/HDV co-infection.
The present invention also relates to the use of the present compounds in the
manufacture of a medicament. The present invention also relates to the use of the present compounds in the manufacture of a medicament for the treatment or the prevention of HBV infection. In a particular embodiment, the invention relates to the use of the present compounds in the manufacture of a medicament for the treatment or the prevention of HBV/HDV co-infection.
In general it is contemplated that an antiviral effective daily amount would be from about 0.01 to about 50 mg/kg, or about 0.01 to about 30 mg/kg body weight. It may be appropriate to administer the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing about 1 to about 500 mg, or about 1 to about 300 mg, or about 1 to about 100 mg, or about 2 to about 50 mg of active ingredient per unit dosage form.
The present invention also concerns combinations of a compound of Formula (I-A), (A), (B), or (C), or any subgroup thereof, as specified herein with other anti-HBV agents. The term "combination" may relate to a product or kit containing (a) a compound of Formula (I-A), (A), (B), or (C), as specified above, and (b) at least one other compound/agent capable of treating HBV infection (herein designated as anti-HBV agent), as a combined preparation for simultaneous, separate or sequential use in treatment of HBV infections. In an embodiment, the invention concerns a
combination of a compound of Formula (I-A), (A), (B), or (C), or any subgroup thereof with at least one anti-HBV agent. In a particular embodiment, the invention concerns a combination of a compound of Formula (I -A), (A), (B), or (C), or any subgroup thereof with at least two anti-HBV agents. In a particular embodiment, the invention concerns a combination of a compound of Formula (I -A), (A), (B), or (C), or any subgroup thereof with at least three anti-HBV agents. In a particular embodiment, the invention concerns a combination of a compound of Formula (I- A), (A), (B), or (C), or any subgroup thereof with at least four anti-HBV agents.
The term anti-HBV agent also includes compounds that are therapeutic nucleic acids, antibodies or proteins either in their natural form or chemically modified and/or stabilized. The term therapeutic nucleic acid includes but is not limited to nucleotides and nucleosides, oligonucleotides, polynucleotides, of which non limiting examples are antisense oligonucleotides, miR A, siR A, shRNA, therapeutic vectors and
DNA/RNA editing components.
The term anti-HBV agent also includes compounds capable of treating HBV infection via immunomodulation. Examples of immunomodulators are interferon-a (IFN-a), pegylated interferon-a or stimulants of the innate immune system such as Toll-like receptor 7 and/or 8 agonists and therapeutic or prophylactic vaccines. One embodiment of the present invention relates to combinations of a compound of Formula (I -A), (A), (B), or (C), or any subgroup thereof, as specified herein, with an immunomodulating compound, more specifically a Toll-like receptor 7 and/or 8 agonist.
The additional HBV antiviral(s) can be selected for example, from therapeutic vaccines;
RNA interference therapeutic/antisense oligonucleotides (siRNA, ddRNA, shRNA); immunomodulators (TLR agonists (TLR7, TLR8 or TLR9 agonists); STING agonists;
RIG-I modulators; NKT modulators; IL agonists; Interleukin or other immune active proteins, therapeutic and prophylactic vaccines and immune checkpoint modulators);
HBV entry inhibitors; cccDNA modulators; capsid assembly inhibitors/modulators; core or X protein targeting agents; nucleotide analogues; nucleoside analogues;
interferons or modified interferons; HBV antivirals of distinct or unknown mechanism; cyclophilin inhibitors; and sAg release inhibitors.
In particular, the combination of previously known anti-HBV agents, such as interferon- α (IFN-α), pegylated interferon-α, 3TC, tenofovir, lamivudine, entecavir, telbivudine, and adefovir or a combination thereof, and, a compound of Formula (I -A), (A), (B), or (C), or any subgroup thereof can be used as a medicine in a combination therapy.
Particular examples of such HBV antiviral(s) include, but are not limited to: - R A interference (RNAi) therapeutics: TKM-HBV (also known as ARB- 1467), ARB-1740, ARC-520, ARC-521, BB-HB-331, REP-2139, ALN-HBV, ALN-PDL, LUNAR-HBV, GS3228836, , and GS3389404;
- HBV entry inhibitors: Myrcludex B, IVIG-Tonrol, GC-1102;
- HBV capsid inhibitor/modulators, core or X targeting agents, direct cccDNA inhibitors, cccDNA formation inhibitors or cccDNA epigenetic modifiers: BAY
41-4109, NVR 3-778, GLS-4, NZ-4 (also known as W28F), Y101, ARB-423,
ARB-199, ARB-596, JNJ-56136379, ASMB-101 (also known as AB-V102),
ASMB-103, CHR-101, CC-31326; AT-130
- HBV polymerase inhibitors: entecavir (Baraclude, Entavir), lamivudine (3TC, Zeffix, Heptovir, Epivir, and Epivir-HBV), telbivudine (Tyzeka, Sebivo), clevudine, besifovir, adefovir (hepsera), tenofovir (in particular tenofovir disoproxil fumarate (Viread), tenofovir alafenamide fumarate (TAF)), tenofovir disoproxil orotate (also known as DA-2802), tenofovir disopropxil aspartate (also known as CKD-390), AGX-1009, and CMX157);
- Zidovudine, Didanosine, Zalcitabine, Stavudine, and Abacavir;
- cyclophilin inhibitors: OCB-030 (also known as NVP-018), SCY-635, SCY-575, and CPI-431-32;
- dinucleotides: SB9200;
- compounds of distinct or unknown mechanism, such as but not limited to AT-61 ((E)-N-( 1 -chloro-3-oxo- 1 -phenyl-3-(piperidin- 1 -yl)prop- 1 -en-2-yl)benzamide), ((E)-N-( 1 -bromo- 1 -(2-methoxyphenyl)-3 -oxo-3 -(piperidin- 1 -yl)prop- 1 -3n-2-yl)-4- nitrobenzamide), and similar analogs; REP-9AC (also known as REP-2055), REP-9AC (also known as REP-2139), REP-2165 and HBV-0259;
- TLR agonists (TLR7, 8 and/or 9): RG7795 (also known as RO-6864018), GS-9620, SM360320 (9-benzyl-8-hydroxy-2-(2-methoxy-ethoxy)adenine) and AZD 8848 (methyl [3-({[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-pyrin-9-yl)propyl][3-(4- morpholinyl)propyl]amino}methyl)phenyl]acetate); ARB- 1598;
- RIG-I modulators: SB-9200;
- SMAC inhibitor: Birinapant
- Check Point inhibitors: BMS-936558 (Opdivo (nivolumab)), KEYTRUDA®
(pembrolizumab);
- therapeutic vaccines: HBsAG-HBIG, HB-Vac, ABX203, NASVAC, GS-4774, GX- 110 (also known as HB-110E), CVI-HBV-002, RG7944 (also known as
INO-1800), TG-1050, FP-02 (Hepsyn-B), AIC649, VGX-6200, KW-2,
TomegaVax-HBV, ISA-204, NU-500, INX-102-00557 HBV MVA, PepTcell;
- IL agonists and immune acting proteins: INO-9112; recombinant IL12; - interferons: interferon alpha (IFN-a), interferon alpha-2a, recombinant interferon alpha-2a, peginterferon alpha-2a (Pegasys), interferon alpha-2b (Intron A), recombinant interferon alpha-2b, interferon alpha-2b XL, peginterferon alpha-2b, glycosylated interferon alpha-2b, interferon alpha-2c, recombinant interferon alpha-2c, interferon beta, interferon beta- la, peginterferon beta- la, interferon delta, interferon lambda (IFN-λ), peginterferon lambda- 1, interferon omega, interferon tau, interferon gamma (IFN-γ), interferon alfacon-1, interferon alpha-nl, interferon alpha-n3, albinterferon alpha-2b, BLX-883, DA-3021, PI 101 (also known as AOP2014), PEG-infergen, Belerofon, INTEFEN-IFN, albumin/interferon alpha 2a fusion protein, rHSA-IFN alpha 2a, rHSA-IFN alpha 2b, PEG-IFN-SA, interferon alpha biobetter; in particular, peginterferon alpha-2a, peginterferon alpha-2b, glycosylated interferon alpha-2b, peginterferon beta- la, and peginterferon lambda- 1; more in particular, peginterferon alpha-2a;
- HDV targeting agent: Lonafamib.
In a further embodiment, the additional HBV antiviral compound is selected from the compounds disclosed in WO2013102655, WO2013174962, WO2014033167,
WO2014033170, WO2014033176, WO2014131847, WO2014161888,
WO2014184350, WO2014184365, WO2015011281, WO2015059212,
WO2015118057, WO2013/096744, WO2014/165128, WO2015/073774,
WO2015/109130.
In a further embodiment, the additional HBV antiviral compound is selected from the compounds based on the HAP scaffold, in particular those disclosed in Roche
US20160083383, in particular compounds 19, 21, 22, 25, 27, 30, 34, 36; 38, 42, 43, 54,
55, 59, 62, 73, 76, 82B, 86B, 87B, 88B and 91B WO2014184328, WO2014037480,
US20150252057, WO2015132276(Al), WO 2013144129.
Medshine Discovery Inc
WO 2015180631
Sunshine lake pharma co
WO 2015144093
GENERIC SYNTHESIS
The substituents represented by Ra'b'c'd or R1 in this general synthesis section are meant to include any substituent or reactive species that is suitable for transformation into any pa,b,c,d or j^i substiment according to the present invention without undue burden for the person skilled in the art. A possible synthesis of compound of general formula (I) is described in schemes 1, 2, 3 and 4.
Compound of general formula (II) can be reacted with an amine of general formula (III), wherein X has the meaning as defined in the claims, for example a
Ci-C6alkanediyl optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, Fluoro, and oxo, for example in an organic solvent like acetonitrile or DCM possibly in the presence of an organic base like for example triethylamine or DIPEA, or an inorganic base like for example sodium bicarbonate. The formed compound of general formula (IV) can be ring closed under Heck conditions with a ligand like bis(tri-tert-butylphosphine)palladium(0) to a compound of general formula (V). Compound of general formula (IV) can also be reacted with potassium allyltrifluoroborate under Suzuki conditions with a ligand like bis(tri-tert-butylphosphine)palladium(0) in the presence of an inorganic base like CS2CO3 to give a mixture of compound of general formula (VII) and compound of general formula (VIII). Compound of general formula (VII) or compound of general formula (VIII) can be ring closed under metathesis conditions with a catalyst like Grubbs catalyst 2nd generation, resulting in the formation of a compound of general formula (V). The compound of general formula (V) can be reacted with an amine of general formula (VI) in the presence of a base like for example lithium
bis(trimethylsilyl)amide, in a solvent like for example THF, resulting in the formation of a compound of general formula (la), wherein Y represents an alkenediyl and Z a single bond. Hydrogenation of the double bond forms a compound of general formula (lb), wherein Y represents an alkanediyl and Z a single bond. Alternatively the amide can be formed via the classical routes known by the person skilled in the art
like -without any limitations- via the acid and a coupling reagent like HATU or via activation to the acid chloride and reaction with an amine of general formula (VI).
Compound of general formula (IV) can also be reacted with an amine of general formula (VI) in the presence of a base like for example lithium bis(trimethylsilyl)amide, in a solvent like for example THF, resulting in the formation of a compound of general formula (XXXIV). The formed compound of general formula (XXXIV) can be ring closed under Heck conditions with a ligand like bis(tri-tert- butylphosphine)palladium(O) to a compound of general formula (la), wherein Y represents an alkenediyl and Z a single bond.
Compound of general formula (II) can be reacted with an aminoalcohol of general formula (XXXI), wherein X has the meaning as defined in the claims, for example a Ci-C6alkanediyl optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, Fluoro, and oxo, for example in an organic solvent like acetonitrile or DCM possibly in the presence of an organic base like for example triethylamine or DIPEA, or an inorganic base like for example sodium bicarbonate. The formed compound of general formula (XXXII) can be oxidized in a solvent like THF with an oxidant like 2-iodoxybenzoic acid resulting in a compound of general formula (XXXIII). Compound of general formula (XXXIII) can be reacted under Wittig conditions to a compound of general formula (IV).
-39-
Figure imgf000041_0001
Alternatively, as described in Scheme 2, a compound of formula (II) can be reacted with an amine of general formula (IX), for example in an organic solvent like acetonitrile or DCM possibly in the presence of an organic base like for example triethylamine or DIPEA, or an inorganic base like for example sodium bicarbonate. The formed compound of general formula (X) can be reacted with potassium allyltrifluoroborate under Suzuki conditions with a ligand like bis(tri-tert-butylphosphine)palladium(0) in the presence of an inorganic base like CS2CO3 to give a mixture of compound of general formula (XI) and compound of general formula (XII). A compound of general formula (XI) or a compound of general formula (XII) can be reacted with an amine of general formula (VI) in the presence of a base like for example lithium bis(trimethylsilyl)amide, in a solvent like for example THF, results in the formation of a compound of general formula (XIII) or general formula (XV). A compound of general formula (XIII) or a compound of general formula (XV) can be reacted under Mitsonobu conditions with an alcohol of general formula (XVII), wherein X has the meaning as defined in the claims, for example a Ci-Cealkanediyl optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, Fluoro, and oxo, and results in a compound of general formula (XIV) or a compound of general formula (XVI). A compound of general formula (XIV) or a compound of general formula (XVI) can be ring closed under metathesis conditions with a catalyst like Grubbs catalyst 2nd generation, resulting in the formation of a compound of general
Formula (la), wherein Y represents an alkenediyl and Z a single bond. Hydrogenation of the double bond forms a compound of general formula (lb), wherein Y represents an alkanediyl and Z a single bond.
Figure imgf000042_0001
(XII) -41-
Figure imgf000043_0001
Figure imgf000044_0001
Figure imgf000044_0002
Scheme 2
Alternatively, as described in Scheme 3, a compound of formula (XVIII) can be reacted with an alcohol of general formula (XIX), for example in an organic solvent like THF or DCM possibly in the presence of an organic base like for example triethylamine or DIPEA, or an inorganic base like for example sodium bicarbonate. The formed compound of general formula (XX) can be coupled with an amine of general formula (VI) in the presence of a base like for example lithium bis(trimethylsilyl)amide, in a solvent like for example THF. The formed compound of general formula (XXI) can be ring closed in the presence of a base like CsF, resulting in a compound of general formula (Ic) wherein Z is oxygen.
A compound of formula (XXII) can be reacted with an alcohol of general formula (XIX), for example in a mixture of an organic solvent like THF or DCM with water, possibly in the presence of an organic base like for example triethylamine or DIPEA, or an inorganic base like for example sodium carbonate. The formed compound of general formula (XXIII) can be coupled with an amine of general formula (VI) in the presence of an activating reagent like for example HATU and an organic base like triethylamine or DIPEA, resulting in a compound of general formula (XXI).
Figure imgf000045_0001
(lc)
Scheme 3 Alternatively, as described in Scheme 4, a compound of formula (II) can be treated with ammonia in a solvent like dioxane, resulting in a compound of general formula (XXIV). The formed compound (XXIV) can either be coupled with a 1-3-diketoalkane like pentane-2,4-dione or heptane-3,5-dione resulting in a compound of general formula (XXV) wherein Ry is a Ci-C4alkyl or under Stille conditions with a stannane like (Z)-l-ethoxy-2-(tributylstannyl)ethene resulting in a compound of general formula (XXIX). Compounds of general formula's (XXV) can be ring closed under acidic conditions using an acid like TFA to a compound of general formula (XXVI) wherein Rz is a Ci-C4alkyl. Compounds of general formula's (XXIX) can be ring closed under acidic conditions using an acid like TFA to a compound of general formula (XXVI) where Rz is hydrogen. The formed compound of general formula (XXVI) can either be hydrogenated to form a compound of general formula (XXVII) or coupled with and amine of general formula (VI) in the presence of a base like for example lithium bis(trimethylsilyl)amide, in a solvent like for example THF, resulting in a compound of general formula (XXX). The compound of general formula (XXVII) can be alkylated for example with an alkylbromide, followed by a coupling with and amine of general formula (VI) in the presence of a base like for example lithium bis(trimethylsilyl)- amide, in a solvent like for example THF, resulting in a compound of general formula (lb), wherein Y represents an alkanediyl and Z a single bond. Compound of general formula (XXX) can be hydrogenated to a compound of general formula (Id), wherein Y represents an alkanediyl and Z a single bond. A compound of general formula (XXVII) can be coupled with an amine of general formula (VI) in the presence of a base like for example lithium bis(trimethylsilyl)amide, in a solvent like for example THF, resulting in a compound of general formula (Id), wherein Y represents an alkanediyl and Z a single bond.
Figure imgf000047_0001
Scheme 4 Alternatively, as described in Scheme 5, a compound of formula (XXXV) can be reacted with a compound of general formula (XXXVI), wherein X has the meaning as defined in the claims, for example a Ci-C6alkanediyl optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, Fluoro, and oxo, for example in a solvent like DMF under Suzuki conditions with a ligand like bis(tri-tert-butylphosphine)palladium(0) in the presence of an organic base like Hunigs' base. The formed compound of general formula (XXXVII) can be reduced under catalytic conditions using palladium on carbon under a hydrogen gas atmosphere. The formed compound of general formula (XXXVIII) can be deprotected with a reagent like ethylenediamine in a solvent like n-butanol to form a compound of general formula (XXXIX). A compound of general formula (XXXIX) can be chlorosulfonated in the presence of chlorosulfonic acid and thionyl chloride and then ring closed via quenching in a saturated aqueous solution of an inorganic base like NaHC03 or Na2C03 to a compound of general formula (XXXX) wherein wherein Y represents an alkanediyl and Z a single bond. Compound of general formula (XXXX) can be reacted with an amine of general formula (VI) in the presence of a base like for example lithium bis(trimethylsilyl)amide, in a solvent like for example THF, resulting in the formation of a compound of general formula (lb).
Figure imgf000048_0001
Scheme 5
Alternatively, as described in Scheme 6, a compound of formula (XXXXI) can be reacted with a compound of general formula (XXXXII), wherein X has the meaning as defined in the claims, for example a Ci-Cealkanediyl optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, Fluoro, and oxo, for example in a solvent like ACN in the presence of an organic base like Hunigs' base. The formed compound of general formula (XXXXIII) can be ring closed via Mitsunobu conditions. After deprotection of the formed compound of general formula (XXXXIV) and reaction with an amine of general formula (VI) in the presence of a base like for example lithium bis(trimethylsilyl)amide, in a solvent like for example THF, a compound of general formula (Ic) can be formed.
Figure imgf000049_0001
Figure imgf000049_0002
Scheme 6 Alternatively, as described in Scheme 7, a compound of formula (XXXXV) can be reacted with a compound of general formula (XXXXVI), for example in a solvent like dioxane in the presence of silver carbonate. The tert-butyl ester of the formed compound of general formula (XXXXVII) can be cleaved using TFA in a solvent like DCM. Consecutive esterification in a solvent like DMF with methyliodide in the presence of an inorganic base like CS2CO3 can result in a compound of general formula (XXXXVIII). A compound of general formula (XXXXVIII) can be chlorosulfonated in the presence of chlorosulfonic acid and thionyl chloride and then ring closed via quenching in a saturated aqueous solution of an inorganic base like NaHC03 or
Na2C03. The resulting compound of formula (XXXXIX) can be reacted with a Grignard reagent like methylmagnesium bromide in a solvent like THF to form a compound of general formula (XXXXX). The formed compound of general formula (XXXXX) can be reacted with an amine of general formula (VI) in the presence of a base like for example lithium bis(trimethylsilyl)amide, in a solvent like for example THF, resulting in the formation of a compound of general formula (XXXXXI).
Figure imgf000050_0001
Figure imgf000050_0002
χχχχιχ xxxxx xxxxxi
Scheme 7
General procedure LCMS methods
The High Performance Liquid Chromatography (HPLC) measurement was performed using a LC pump, a diode-array (DAD) or a UV detector and a column as specified in the respective methods. If necessary, additional detectors were included (see table of methods below).
Flow from the column was brought to the Mass Spectrometer (MS) which was configured with an atmospheric pressure ion source. It is within the knowledge of the skilled person to set the tune parameters (e.g. scanning range, dwell time...) in order to obtain ions allowing the identification of the compound's nominal monoisotopic molecular weight (MW). Data acquisition was performed with appropriate software. Compounds are described by their experimental retention times (Rt) and ions. If not specified differently in the table of data, the reported molecular ion corresponds to the [M+H]+ (protonated molecule) and/or [M-H]~ (deprotonated molecule). In case the compound was not directly ionizable the type of adduct is specified (i.e. [M+NH4]+, [M+HCOO]", etc...). All results were obtained with experimental uncertainties that are commonly associated with the method used.
Hereinafter, "SQD" means Single Quadrupole Detector, "MSD" Mass Selective Detector, "RT" room temperature, "BEH" bridged ethylsiloxane/silica hybrid, "DAD" Diode Array Detector, "HSS" High Strength silica., "Q-To ' Quadrupole Time-of-flight mass spectrometers, "CLND", Chem i L um i nescent Nitrogen Detector. "ELSD" Evaporative Light Scanning Detector,
LCMS Methods
Flow expressed in mL/min; column temperature (T) in °C; Run time in minutes).
Figure imgf000051_0001
A: 70%
Waters: Atlantis 100% B to 5%
CH30H, 30%
Alliance®- T3 B in 9 min,
H20 1.5
DAD - column hold 3.0 min to z B: 0.1 formic 13.5
ZMD (5 μιη, 100% B in 1
acid 45
and CLND 4.6 x min and hold
in H20/
8060 Antek 100 mm) 0.5 min
CH30H 95/5
General procedure for SFC-MS methods
The SFC measurement was performed using an Analytical Supercritical fluid chromatography (SFC) system composed by a binary pump for delivering carbon 5 dioxide (C02) and modifier, an autosampler, a column oven, a diode array detector equipped with a high-pressure flow cell standing up to 400 bars. If configured with a Mass Spectrometer (MS) the flow from the column was brought to the (MS). It is within the knowledge of the skilled person to set the tune parameters (e.g. scanning range, dwell time...) in order to obtain ions allowing the identification of the compound's 10 nominal monoisotopic molecular weight (MW). Data acquisition was performed with appropriate software.
Analytical SFC-MS Methods (Flow expressed in mL/min; column temperature (T) °C; Run time in minutes, Backpressure (BPR) in bars).
Flow
Method code column mobile phase gradient
Col T
25% B hold 4
Daicel Chiralpak® A:C02 5
min, to 50%
AD-H column (5.0 B: EtOH+0.2%
in 1 min
μιη, 250 x 4.6 mm) iPrNH2 40
hold 2 min
30% B hold 4
Daicel Chiralpak® A:C02 5
min, to 50%
AD-H column (5.0 B: EtOH+0.2%
in 1 min
μιη, 250 x 4.6 mm) iPrNH2 40
hold 2 min
A:C02 35% B hold 4
Whelk®-0-(R,R) 5
B: min, to 50%
G column (5.0 μιη,
MeOH+0.2% in 1 min
250 x 4.6 mm) 40
iPrNH2 hold 2 min
10% B hold 4
Daicel Chiralpak® A:C02 5
min, to 50%
H AD-H column (5.0 B: EtOH+0.2%
in 1 min
μιη, 250 x 4.6 mm) iPrNH2 40
hold 2 min Flow Run time
Method code column mobile phase gradient
Col T BPR
20% B hold 4
Daicel Chiralpak® A:C02 5 7 min, to 50%
I AD-H column (5.0 B: EtOH+0.2%
in 1 min
μιη, 250 x 4.6 mm) iPrNH2 40 110 hold 2 min
45% B hold 4
Daicel Chiralpak® A:C02 5 7 min, to 50%)
J AD-H column (5.0 B: EtOH+0.2%
in 1 min
μιη, 250 x 4.6 mm) iPrNH2 40 110 hold 2 min
40% B hold 4
Daicel Chiralpak® A:C02 5 7 min, to 50%)
K AD-H column (5.0 B: EtOH+0.2%
in 1 min
μιη, 250 x 4.6 mm) iPrNH2 40 110 hold 2 min
40% B hold 4
Whelk®-0-(R,R) A:C02 5 7 min, to 50%)
L column (5.0 μιη, B: EtOH+0.2%
in 1 min
250 x 4.6 mm) iPrNH2 40 110 hold 2 min
40% B hold 4
Whelk®-0-(R,R) A:C02 5 7 min, to 50%)
M column (5.0 μιη, B: iPrOH+0.2%
in 1 min
250 x 4.6 mm) iPrNH2 40 110 hold 2 min
35% B hold 4
Daicel Chiralpak® A:C02 5 7 min, to 50%)
N AD-H column (5.0 B: EtOH+0.2%
in 1 min
μιη, 250 x 4.6 mm) iPrNH2 40 110 hold 2 min
35% B hold 4
Daicel Chiralpak® A:C02 5 7 min, to 50%)
0 ID-H column (5.0 B: EtOH+0.2%
in 1 min
μιη, 250 x 4.6 mm) iPrNH2 40 110 hold 2 min
A:C02 35% B hold 4
Daicel Chiralpak® 5 7
B: EtOH- min, to 50%o
P AD-H column (5.0
iPrOH+0.2% in 1 min
μιη, 250 x 4.6 mm) 40 110 iPrNH2 hold 2 min
5% B hold 4
Daicel Chiralpak® A:C02 5 7 min, to 50%o
Q AD-H column (5.0 B: EtOH+0.2%
in 1 min
μιη, 250 x 4.6 mm) iPrNH2 40 110 hold 2 min
Daicel Chiralpak® A:C02 10%-50% B 2.5 9.5
R AD3 column (3.0 B: EtOH+0.2% in 6 min,
μιη, 150 x 4.6 mm) iPrNH2 hold 3.5 min 40 110 Flow Run time
Method code column mobile phase gradient
Col T BPR
A:C02 35% B hold 4
Whelk®-0-(R,R) 5 7
B: EtOH- min, to 50%
S column (5.0 μιη,
iPrOH+0.2% in 1 min
250 x 4.6 mm) 40 110 iPrNH2 hold 2 min
Daicel Chiralpak® A:C02 10%-50% B 2.5 9.5
T AS3 column (3.0 B: EtOH+0.2% in 6 min,
μιη, 150 x 4.6 mm) iPrNH2+3%H20 hold 3.5 min 40 110
Daicel Chiralpak® A:C02 10%-50% B 2.5 9.5 u ID-H column (3.0 B: EtOH+0.2% in 6 min,
μιη, 150 x 4.6 mm) iPrNH2+3%H20 hold 3.5 min 40 110
Daicel Chiralpak® A:C02 10%-50% B 2.5 9.5
V AD-H column (3.0 B: MeOH+0.2% in 6 min,
μιη, 150 x 4.6 mm) iPrNH2+3%H20 hold 3.5 min 40 110
Daicel Chiralpak® A:C02 10%-50% B 2.5 9.5 w AD-H column (3.0 B: iPrOH+0.2% in 6 min,
μιη, 150 x 4.6 mm) iPrNH2+3%H20 hold 3.5 min 40 110
Whelk®-0- A:C02 10%-50% B 2.5 9.5
X (R,R) column (5.0 B: EtOH+0.2% in 6 min,
μιη, 250 x 4.6 mm) iPrNH2 hold 3.5 min 40 110
Daicel Chiralpak® A:C02 10%-50% B 2.5 9.5
Y OD-H column (3.0 B: EtOH+0.2% in 6 min,
μιη, 150 x 4.6 mm) iPrNH2+3%H20 hold 3.5 min 40 110
Daicel Chiralpak® A:C02 10%-50% B 2.5 9.5
AA IC-H column (3.0 B: EtOH+0.2% in 6 min,
μιη, 150 x 4.6 mm) iPrNH2+3%H20 hold 3.5 min 40 110
A:C02
Daicel Chiralpak® 10%-50% B 2.5 9.5
B:
AB AS3 column (3.0 in 6 min,
MeOH+0.2%
μιη, 150 x 4.6 mm) hold 3.5 min 40 110 iPrNH2
Daicel Chiralpak® A:C02 10%-50% B 2.5 9.5
AC AS3 column (3.0 B: iPrOH+0.2% in 6 min,
μιη, 150 x 4.6 mm) iPrNH2 hold 3.5 min 40 110 Flow Run time
Method code column mobile phase gradient
Col T BPR
A:C02
Daicel Chiralpak® 10%-50% B 2.5 9.5
B: EtOH-
AD AD-H column (3.0 in 6 min,
iPrOH+0.2%
μιη, 150 x 4.6 mm) hold 3.5 min 40 110 iPrNH2
Melting points (MP) reported in °C are referring to the peak observed in differential scanning calorimetry (DSC): From 30 to 300 °C at 10°C/min.
5
SYNTHESIS OF COMPOUNDS
Compound 1 : (9E)-JV-(3.4-difluorophenyl)-4.14-dimethyl-2,2-dioxo-2 6-thia-3.14- diazabicyclo[10.3.01pentadeca-l(15),9J2-triene-13-carboxamide.
Figure imgf000055_0001
Methyl 3-bromo-4-chlorosulfonyl-l-methyl-pyrrole-2-carboxylate (500 mg,
1.58 mmol), oct-7-en-2-amine (221 mg, 1.74 mmol) and Hunig's base (0.82 mL, 0.75 g/mL, 4.74 mmol) were dissolved in THF (5 mL) and stirred overnight at room temperature. The volatiles were removed under reduced pressure and the residue was
15 purified on silica using a heptane to EtOAc gradient yielding methyl 3-bromo-l-methyl- 4-(l-methylhept-6-enylsulfamoyl)pyrrole-2-carboxylate (507 mg) as an oil which solidified on standing. 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.09 (d, J=6.6 Hz, 3 H), 1.22 - 1.36 (m, 4 H), 1.37 - 1.50 (m, 2 H), 1.89 - 2.06 (m, 2 H), 3.11 - 3.38 (m, 1 H), 3.91 (s, 3 H), 3.92 - 3.95 (m, 3 H), 4.53 (d, J=7.7 Hz, 1 H),
20 4.89 - 5.01 (m, 2 H), 5.76 (ddt, J=17.1, 10.3, 6.7, 6.7 Hz, 1 H), 7.35 (s, 1 H).
Methyl 3-bromo-l -methyl -4-(l-methylhept-6-enylsulfamoyl)pyrrole-2-carboxylate (100 mg, 0.25 mmol), potassium allyltrifluoroborate (109 mg, 0.74 mmol), bis(tri- tert-butylphosphine)palladium(O) (12.6 mg, 0.025 mmol) and Cs2C03 (240 mg, 0.74 mmol) were dissolved in a mixture of DME (5 mL) and water (1 mL) and heated in 25 the microwave oven at 120°C for 30 minutes. The volatiles were removed under
reduced pressure and the residue was purified on silica using a heptane to EtOAc gradient yielding methyl 3-allyl-l-methyl-4-(l-methylhept-6-enylsulfamoyl)pyrrole- 2-carboxylate (62 mg) as a clear oil.
Methyl 3-allyl-l-methyl-4-(l-methylhept-6-enylsulfamoyl)pyrrole-2-carboxylate (62 mg, 0.17 mmol) was dissolved in DCE (50 mL) and heated to 80°C while bubbling N2 through the reaction mixture. Grubbs catalyst 2nd generation (14.3 mg, 0.017 mmol) was added and heating was continued for 2 hours. The volatiles were removed under reduced pressure and the residue was purified on silica using a heptane to EtOAc gradient yielding methyl (9Z)-4,14-dimethyl-2,2-dioxo-2-thia-3,14-diazabicyclo- [10.3.0]pentadeca-l(15),9,12-triene-13-carboxylate (35 mg). Method B; Rt: 1.19 min. m/z : 341 (M+H)+ Exact mass: 340.1.
Methyl (9Z)-4,14-dimethyl-2,2-dioxo-2-thia-3,14-diazabicyclo[10.3.0]pentadeca- l(15),9,12-triene-13-carboxylate (35 mg, 0.1 mmol) and 3,4-difluoroaniline (12.4 μΕ, 1.29 g/mL, 0.12 mmol) were dissolved in THF (5 mL). Lithium bis(trimethylsilyl)- amide (0.31 mL, 1 M in THF, 0.31 mmol) was added and the reaction mixture was stirred overnight at room temperature. The reaction mixture was quenched with NH4C1 (aq., sat., 5 mL). The organic layer was removed and the aqueous layer extracted with DCM (2 X 5 mL). The combined organic layers were evaporated to dryness and the residue purified on silica using a heptane to EtOAc gradient. The obtained product was crystallized from a DCM:DIPE mixture yielding compound 1 as an off-white powder. 1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.15 - 1.21 (m, 1 H) 1.22 (d, J=6.5 Hz, 3 H) 1.23 - 1.30 (m, 1 H) 1.41 - 1.49 (m, 3 H) 1.66 - 1.73 (m, 1 H) 2.02 - 2.10 (m, 1 H) 2.32 (br d, J=13.5 Hz, 1 H) 3.27 (dt, J=12.3, 6.2 Hz, 1 H) 3.64 (br d, J=18.5 Hz, 1 H) 3.85 (br dd, J=18.3, 5.0 Hz, 1 H) 3.91 (s, 3 H) 4.24 (d, J=6.2 Hz, 1 H) 5.28 - 5.36 (m, 1 H) 5.93 (br d, J=15.6 Hz, 1 H) 7.01 - 7.06 (m, 1 H) 7.06 - 7.12 (m, 1 H) 7.31 (s, 1 H) 7.58 (ddd, J=12.0, 7.1, 2.6 Hz, 1 H) 7.94 (br s, 1 H). Method B; Rt: 1.17 min. m/z : 438 (M+H)+ Exact mass: 437.2.
Compounds 2a and 2b: 8Z-N-(3,4-difluorophenyl)-4,13-dimethyl-2,2-dioxo-2 6-thia- 3 J3-diazabicyclo[9.3.01tetradeca-l(14),8J l-triene-12-carboxamide and 8E-N- (3,4-difluorophenyl)-4, 13-dimethyl-2,2-dioxo-2 6-thia-3, 13-diazabicyclo[9.3.0]tetra- deca- 1 ( 14), 8 , 11 -triene- 12-carboxamide.
Figure imgf000056_0001
Methyl 3-bromo-l -methyl -4-(l-methylhept-6-enylsulfamoyl)pyrrole-2-carboxylate (420 mg, 1.03 mmol), potassium allyltrifluoroborate (458 mg, 3.09 mmol),
bis(tri-tert-butylphosphine)palladium(0) (52.7 mg, 0.1 mmol) and CS2CO3 (1008 mg, 3.09 mmol) were dissolved in a mixture of DME (5 mL) and water (1 mL) and heated in the microwave oven at 120°C for 30 minutes. The volatiles were removed under reduced pressure and the residue was purified on silica using a heptane to EtOAc gradient yielding methyl 3-allyl-l-methyl-4-[[(E)-l-methylhept-5- enyl]sulfamoyl]pyrrole-2-carboxylate (258 mg) as a clear oil.
Methyl 3-allyl-l-methyl-4-[[(E)-l-methylhept-5-enyl]sulfamoyl]pyrrole-2-carboxylate (258 mg, 0.7 mmol) was dissolved in DCE (50 mL) and N2 was bubbled through the reaction mixture. Grubbs catalyst 2nd generation (38.7 mg, 0.046 mmol) was added and the reaction mixture was heated for 5 hours. The volatiles were removed under reduced pressure and the residue was purified on silica using a heptane to EtOac gradient yielding methyl (8Z)-4, 13-dimethyl-2,2-dioxo-2-thia-3, 13-diazabicyclo[9.3.0]tetradeca- 1(14), 8,1 l-triene-12-carboxylate as an off-white powder.
Methyl (8Z)-4, 13-dimethyl-2,2-dioxo-2-thia-3, 13-diazabicyclo[9.3.0]tetradeca- 1(14),-8,1 l-triene-12-carboxylate (22 mg, 0.067 mmol) and 3,4-difluoroaniline (8.2 μΕ, 1.29 g/mL, 0.081 mmol) were dissolved in THF (5 mL). Lithium bis(trimethylsilyl)- amide (1M in THF) (202 μί, 1 M in THF, 0.2 mmol) was added and the reaction mixture was stirred overnight at room temperature. The reaction mixture was quenched with NH4C1 (aq., sat., 5 mL). The organic layer was removed and the aqueous layer extracted with DCM (2 X 5 mL). The combined organic layers were evaporated to dryness and the residue purified on silica using a heptane to EtOAc gradient. The obtained product was purified via Prep HPLC (Stationary phase: RP XBridge Prep C18 ODB- 5μιη, 30x250mm, Mobile phase: 0.25% NH4HCO3 solution in water, ACN) yielding compound 2a (7.2 mg) 1H NMR (400 MHz, CHLOROFORM-;/) δ ppm 1.30 (d, J=6.4 Hz, 3 H), 1.36 - 1.48 (m, 4 H), 1.84 (br dd, J= 13.0, 5.1 Hz, 1 H), 1.93 - 2.10 (m, 1 H), 3.30 - 3.41 (m, 1 H), 3.56 - 3.68 (m, 1 H), 3.77 - 3.84 (m, 1 H), 3.85 (s, 3 H), 4.02 - 4.26 (m, 1 H), 5.54 - 5.74 (m, 2 H), 7.09 - 7.19 (m, 2 H), 7.26 (s, 1 H), 7.65 - 7.72 (m, 1 H), 8.11 (br s, 1 H). Method D; Rt: 2.05 min. m/z : 424 (M+H)+ Exact mass: 423.1 and compound 2b (18.2 mg) 1H NMR (400 MHz, CHLOROFORM-^) δ ppm -0.05 - 0.05 (m, 1 H), 1.25 (d, J=6.2 Hz, 3 H), 1.36 - 1.45 (m, 1 H), 1.47 - 1.65 (m, 3 H), 2.00 - 2.27 (m, 2 H), 3.05 (br s, 1 H), 3.48 - 3.69 (m, 2 H), 3.75 - 3.90 (m, 3 H), 4.34 (br s, 1 H), 5.34 (dt, J=15.6, 7.5 Hz, 1 H), 5.84 (dt, J=15.7, 4.1 Hz, 1 H), 7.08 - 7.22 (m, 2 H), 7.63 - 7.72 (m, 1 H), 7.91 (br s, 1 H). Method D; Rt: 2.09 min. m/z : 424 (M+H)+ Exact mass: 423.1. Compound 3 : (5ZyN-(3.4-difluorophenylV8-methyl- 1.1 -άϊοχο-2-Γ(1 R -2,2,2-trifluoro- l-methyl-ethyll-3^-dihydropyrrolo[3,4-glthiazocine-7-carboxamide.
Figure imgf000058_0001
Methyl 3-bromo-4-chlorosulfonyl-l-methyl-pyrrole-2-carboxylate (5 g, 15.79 mmol), (R)-l,l,l-trifluoro-2-propylamine (2.68 g, 23.7 mmol), NaHC03 (3.98 g, 47.4 mmol) and molecular sieves (10 g) were dispensed in ACN (75 mL) in a 150 mL pressure vessel. This suspension was stirred overnight at 80°C. The reaction mixture was filtered and the volatiles were removed under reduced pressure. The residue was purified on silica using a heptane to EtOAc gradient. The fractions containing the product were evaporated to dryness yielding methyl 3-bromo-l-methyl-4-[[(lR)-2,2,2- trif uoro-1 -methyl-ethyl] sulfamoyl]pyrrole-2-carboxylate (4.89 g) as a white powder.
Methyl 3-bromo-l -methyl -4-[[(lR)-2,2,2-trifluoro-l-methyl-ethyl]sulfamoyl]pyrrole- 2-carboxylate (2 g, 5.09 mmol), potassium allyltrif uoroborate (2.26 g, 15.3 mmol), bis(tri-tert-butylphosphine)palladium(0) (260 mg, 0.51 mmol) and Cs2C03 (4.97 g, 15.3 mmol) were dissolved in a mixture of DME (15 mL) and water (3 mL) and heated in the microwave oven at 100°C for 30 minutes. The volatiles were removed under reduced pressure and the residue was purified on silica using a heptane to EtOAc gradient yielding methyl l-methyl-3-[(E)-prop-l-enyl]-4-[[(lR)-2,2,2-trif uoro- 1 -methyl-ethyl] sulfamoyl]pyrrole-2-carboxyl ate (1.18 g) as a light brown powder. Methyl 1 -methyl-3-[(E)-prop- 1 -enyl]-4-[[(lR)-2,2,2-trif uoro- 1 -methyl-ethyl] - sulfamoyl]pyrrole-2-carboxylate (1.18 g, 3.33 mmol) and 3,4-difluoroaniline (404 μί, 1.29 g/mL, 4 mmol) were dissolved in THF (25 mL). Lithium bis(trimethylsilyl)amide (10 mL, 1 M in THF, 10 mmol) was added and the reaction mixture was stirred overnight at room temperature. The reaction mixture was quenched with NH4C1 (aq., sat., 10 mL). The organic layer was removed and the aqueous layer extracted with DCM (2 X 5 mL). The combined organic layers were evaporated to dryness and the residue purified on silica using a heptane to EtOAc gradient yielding N-(3,4-difluoro- phenyl)-l-methyl-3-[(E)-prop-l-enyl]-4-[[(lR)-2,2,2-trifluoro-l-methyl-ethyl]sulfa- moyl]pyrrole-2-carboxamide (1.08 g) as a brown powder.
DIAD (0.12 mL, 1.04 g/mL, 0.6 mmol) was added to a solution of N-(3,4-difluoro- phenyl)-l-methyl-3-[(E)-prop-l-enyl]-4-[[(lR)-2,2,2-trifluoro-l-methyl-ethyl]sulfa- moyl]pyrrole-2-carboxamide (180 mg, 0.4 mmol), 3-buten-l-ol (31.6 mg, 0.44 mmol) and triphenylphosphine (157 mg, 0.6 mmol) in THF (5 mL). The reaction mixture was stirred overnight at room temperature. LCMS showed 60% conversion to the desired product. 3-buten-l-ol (31.6 mg, 0.44 mmol), triphenylphosphine (157 mg, 0.6 mmol) and DIAD (0.12 mL, 1.04 g/mL, 0.6 mmol) were added and the reaction mixture was stirred for 1 hour. The volatiles were removed under reduced pressure and the residue was purified on silica using a heptane to EtOAc gradient yielding 4-[but-3-enyl-[(lR)- 2,2,2-trifluoro-l-methyl-ethyl]sulfamoyl]-N-(3,4-difluorophenyl)-l-methyl-3-[(E)-prop- l-enyl]pyrrole-2-carboxamide (120 mg) as a clear oil. 4-[but-3-enyl-[(lR)-2,2,2-trifluoro-l-methyl-ethyl]sulfamoyl]-N-(3,4-difluorophenyl)- l-methyl-3-[(E)-prop-l-enyl]pyrrole-2-carboxamide (120 mg, 0.24 mmol) was dissolved in DCE (150 mL) and N2 was bubbled through the reaction mixture. Grubbs catalyst 2nd generation (20.2 mg, 0.024 mmol) was added and the reaction mixture was heated at 80°C overnight. The volatiles were removed under reduced pressure and the residue was purified on silica using a heptane to EtOAc gradient yielding compound 3 (92 mg) as a white powder. 1H NMR (400 MHz, CHLOROFORM- ) δ ppm 1.37 (br d, J=7.0 Hz, 3 H), 2.39 (br s, 2 H), 3.49 - 3.61 (m, 2 H), 3.99 (s, 3 H), 4.71 (dt, J=14.9, 7.6 Hz, 1 H), 6.24 (dt, J=10.6, 8.8 Hz, 1 H), 6.75 (d, J=10.8 Hz, 1 H), 7.07 - 7.17 (m, 2 H), 7.30 (s, 1 H), 7.60 - 7.70 (m, 2 H); Method B; Rt: 1.13 min. m/z : 464 (M+H)+ Exact mass: 463.1.
Compound 4 : N-(3 ,4-difluorophenyl)-8-methyl- 1 , 1 -dioxo-2-|Y 1 R)-2,2,2-trifluoro- l-methyl-ethyll-3,4,5,6-tetrahydropyrrolo[3,4-glthiazocine-7-carboxamide.
Figure imgf000059_0001
Compound 3 (80 mg, 0.17 mmol) was dissolved in MeOH (20 mL), Pd/C (10%) (18 mg, 0.017 mmol) was added and the reaction mixture was stirred overnight under hydrogen atmosphere. The volatiles were removed under reduced pressure and the residue was purified on silica using a heptane to EtOac gradient yielding compound 4 (63.1 mg) as a white powder after crystallisation from DCM:DIPE. 1H NMR
(400 MHz, CHLOROFORM-;/) δ ppm 1.36 (d, J=7.0 Hz, 3 H), 1.63 - 1.73 (m, 2 H),
1.73 - 1.86 (m, 2 H), 3.13 - 3.34 (m, 2 H), 3.51 - 3.60 (m, 2 H), 3.84 (s, 3 H), 4.76 (dt, J=15.1, 7.5 Hz, 1 H), 7.08 - 7.20 (m, 3 H), 7.53 (s, 1 H), 7.67 (ddd, J=12.0, 7.2, 2.4 Hz, 1 H); Method B; Rt: 1.18 min. m/z : 466 (M+H)+ Exact mass: 465.1; MP: 137.3 °C. Compound 5 : (4Z)-N-(3 ,4-difluorophenyl)-3 ,8-dimethyl- 1 , 1 -dioxo-3 ,6-dihydro-2H- pyrrolo[3,4-glthiazocine-7-carboxamide.
Figure imgf000060_0001
Methyl 3-bromo-4-chlorosulfonyl-l-methyl-pyrrole-2-carboxylate (1000 mg,
3.16 mmol) and 3-buten-2-amine, hydrochloride (374 mg, 3.47 mmol) were dissolved in THF (5 mL). Hunig's base (1.63 mL, 0.75 g/mL, 9.48 mmol) was added and the reaction mixture was stirred overnight at room temperature. NH4C1 (sat., aq., 5 mL) was added and the organic layer was removed. The aqueous layer was extracted with DCM (2 X 5 mL) and the combined organic layers were evaporated to dryness. The residue was purified on silica using a heptane to EtOAc gradient yielding methyl 3-bromo-l-methyl-4-(l-methylallylsulfamoyl)pyrrole-2-carboxylate (981 mg) as a white powder.
Methyl 3-bromo-l-methyl-4-(l-methylallylsulfamoyl)pyrrole-2-carboxylate (200 mg, 0.57 mmol), potassium allyltrifluoroborate (253 mg, 1.71 mmol), bis(tri-tert-butyl- phosphine)palladium(O) (29 mg, 0.057 mmol) and CS2CO3 (557 mg, 1.71 mmol) were dissolved in a mixture of DME (5 mL) and water (1 mL) and heated in the microwave oven at 80°C for 30 minutes. The volatiles were removed under reduced pressure and the residue was purified on silica using a heptane to EtOAc gradient yielding methyl 3-allyl-l -methyl-4-(l-methylallylsulfamoyl)pyrrole-2-carboxylate (47 mg) and methyl 3,7-dimethyl-l ,l-dioxo-2,3-dihydropyrrolo[3,4-fJthiazepine-6-carboxylate (79 mg).
Methyl 3-allyl-l -methyl-4-(l-methylallylsulfamoyl)pyrrole-2-carboxylate (47 mg, 0.15 mmol) was dissolved in DCE (100 mL) and N2 was bubbled through the reaction mixture. Grubbs catalyst 2nd generation (26 mg, 0.03 mmol) was added and the reaction mixture was heated at 80°C overnight. The volatiles were removed under reduced pressure and the residue was purified on silica using a heptane to EtOAc gradient yielding methyl (4Z)-3 ,8-dimethyl- 1 , 1 -dioxo-3 ,6-dihydro-2H-pyrrolo [3 ,4-g]thiazocine- 7-carboxylate (31 mg).
Methyl (4Z)-3,8-dimethyl-l ,l-dioxo-3,6-dihydro-2H-pyrrolo[3,4-g]thiazocine-7- carboxylate (31 mg, 0.1 1 mmol) and 3,4-difluoroaniline (13.2 μί, 1.29 g/mL,
0.13 mmol) were dissolved in THF (5 mL). Lithium bis(trimethylsilyl)amide (0.33 mL, 1 M in THF, 0.33 mmol) was added and the reaction mixture was stirred overnight at room temperature. The reaction mixture was quenched with NH4C1 (aq., sat., 5 mL). The organic layer was removed and the aqueous layer extracted with DCM (2 X 5 mL). The combined organic layers were evaporated to dryness and the residue purified on silica using a heptane to EtOAc gradient. The obtained product was purified via prep. HPLC (Stationary phase: RP XBridge Prep C18 OBD-ΙΟμιη, 30x150mm, Mobile phase: 0.25% NH4HCO3 solution in water, MeOH) yielding compound 5 (9.7 mg) as a white powder. 1H NMR (400 MHz, DMSO- ¾ δ ppm 1.23 (d, J=6.8 Hz, 3 H), 3.16 -
3.29 (m, 1 H), 3.58 (dd, J=13.5, 10.2 Hz, 1 H), 3.68 (s, 3 H), 4.37 - 4.48 (m, 1 H),
5.30 (dd, J=10.0, 7.6 Hz, 1 H), 5.69 (q, J=9.1 Hz, 1 H), 7.28 (br d, J=9.9 Hz, 1 H), 7.39 (s, 1 H), 7.40 - 7.46 (m, 2 H), 7.81 - 7.90 (m, 1 H), 10.56 (s, 1 H); Method B; Rt:
0.97 min. m/z : 382 (M+H)+ Exact mass: 381.1.
Compound 6 : N-(3 ,4-difluorophenyl)-7-methyl- 1 , 1 -dioxo-2-|Y 1 R)-2,2,2-trifluoro- l-methyl-ethyll-3H-pyrrolo[3,4- |thiazepine-6-carboxamide.
Figure imgf000061_0001
DIAD (0.16 mL, 1.04 g/mL, 0.8 mmol) was added to a solution of N-(3,4-difluoro- phenyl)-l-methyl-3-[(E)-prop-l-enyl]-4-[[(lR)-2,2,2-trif uoro-l-methyl-ethyl]sulfa- moyl]pyrrole-2-carboxamide (180 mg, 0.4 mmol), 2-propen-l-ol (25.5 mg, 0.44 mmol) and triphenylphosphine (209 mg, 0.8 mmol) in THF (5 mL). The reaction mixture was stirred overnight at room temperature. The volatiles were removed under reduced pressure and the residue was purified on silica using a heptane to EtOAc gradient. The obtained residue was purified via prep. HPLC (Stationary phase: RP XBridge Prep CI 8 OBD-ΙΟμιη, 30x150mm, Mobile phase: 0.25% NH4HC03 solution in water, MeOH) yielding 4-[allyl-[(lR)-2,2,2-trif uoro-l-methyl-ethyl]sulfamoyl]-N-(3,4-difluoro- phenyl)- 1 -methyl-3-[(E)-prop-l -enyl]pyrrole-2-carboxamide (81 mg).
4-[allyl-[(lR)-2,2,2-trif uoro-l-methyl-ethyl]sulfamoyl]-N-(3,4-difluorophenyl)-l- methyl-3-[(E)-prop-l-enyl]pyrrole-2-carboxamide (81 mg, 0.16 mmol) was dissolved in DCE (100 mL) and N2 was bubbled through the reaction mixture. Grubbs catalyst 2nd generation (28 mg, 0.033 mmol) was added and the reaction mixture was heated at 80°C overnight. The volatiles were removed under reduced pressure and the residue was purified via prep. HPLC (Stationary phase: RP XBridge Prep C18 OBD-ΙΟμιη, 30x150mm, Mobile phase: 0.25% NH4HCO3 solution in water, MeOH) yielding compound 6 (50.1 mg) as a white powder after crystallization from DCM:DIPE. 1H NMR (360 MHz, DMSO-^) δ ppm 1.17 (d, J=7.0 Hz, 3 H), 3.74 (s, 3 H), 4.10 (dd, J=21.2, 4.8 Hz, 1 H), 4.28 - 4.37 (m, 1 H), 4.37 - 4.45 (m, 1 H), 5.68 - 5.75 (m, 1 H), 6.57 (br d, J=12.8 Hz, 1 H), 7.40 - 7.49 (m, 2 H), 7.67 (s, 1 H), 7.81 - 7.89 (m, 1 H), 10.76 (s, 1 H); Method B; Rt: 1.13 min. m/z : 450 (M+H)+ Exact mass: 449.1. Compound 7: N-(3,4-difluorophenyl)-3 ,7-dimethyl-l,l-dioxo-2,3-dihydropyrrolo-
[3,4-f|thiazepine-6-carboxamide.
Figure imgf000062_0001
Methyl 3 ,7-dimethyl- 1 , 1 -dioxo-2,3-dihydropyrrolo [3 ,4-f]thiazepine-6-carboxylate (79 mg, 0.29 mmol) and 3,4-difluoroaniline (36 μί, 1.29 g/mL, 0.35 mmol) were dissolved in THF (5 mL). Lithium bis(trimethylsilyl)amide (0.88 mL, 1 M in THF, 0.88 mmol) was added and the reaction mixture was stirred overnight at room temperature. The reaction mixture was quenched with NH4C1 (aq., sat., 5 mL). The organic layer was removed and the aqueous layer extracted with DCM (2 X 5 mL). The combined organic layers were evaporated to dryness and the residue purified on silica using a heptane to EtOAc gradient. The resulting product was purified via prep. HPLC (Stationary phase: RP XBridge Prep C18 ODB- 5μιη, 30x250mm, Mobile phase: 0.25% NH4HCO3 solution in water, ACN) yielding compound 7. 1H NMR (360 MHz, CHLOROFORM -(i) δ ppm 1.41 (d, J=7.3 Hz, 3 H), 3.71 (q, J=7.0 Hz, 1 H), 3.76 (s, 3 H), 4.40 (br s, 1 H), 5.61 (dd, J=12.4, 2.6 Hz, 1 H), 6.53 (dd, J=12.4, 2.2 Hz, 1 H), 7.10 - 7.26 (m, 3 H), 7.71 (ddd, J=12.0, 7.2, 2.4 Hz, 1 H), 8.20 (br s, 1 H); Method D; Rt: 1.72 min. m/z : 368 (M+H)+ Exact mass: 367.1. This racemic mixture was seperated in enantiomers 7a (19.5 mg) and 7b (13.4 mg) by preparative SFC (Stationary phase: Chiralpak Diacel AD 20 x 250 mm, Mobile phase: C02, EtOH with 0.4% iPrNH2). Method E; Rt : 7a: 1.80 min, 7b: 2.33 min.
Compound 8: N-(3,4-difluorophenyl)-7-methyl-l,l-dioxo-3-(trifluoromethyl)-2,3-di- hydropyrrolo[3,4- |thiazepine-6-carboxamide.
Figure imgf000062_0002
Methyl 3-bromo-4-chlorosulfonyl-l-methyl-pyrrole-2-carboxylate (1000 mg,
3.16 mmol), l,l,l-trifluorobut-3-en-2-ylamine (612 mg, 3.79 mmol), NaHC03
(1062 mg, 12.64 mmol) and molecular sieves (2 g) were dispensed in ACN (30 mL) and the reaction mixture was stirred 4 days at 80°C. The reaction mixture was filtered and the filtrate was evaporated to dryness. The residue was purified on silica using a heptane to EtOAc gradient yielding methyl 3-bromo-l-methyl-4-[l-(trif uoromethyl)- allylsulfamoyl]pyrrole-2-carboxylate (894 mg) as a white powder.
Methyl 3-bromo-l -methyl -4-[l-(trif uoromethyl)allylsulfamoyl]pyrrole-2-carboxylate (837 mg, 2.07 mmol), bis(tri-tert-butylphosphine)palladium(0) (211 mg, 0.41 mmol) and TEA (286 μί, 0.73 g/mL, 2.07 mmol) were dissolved in DMF (5 mL). The reaction mixture was heated in the microwave oven for 30 minutes at 120°C. The volatiles were removed under reduced pressure and the residue was purified on silica using a heptane to EtOac gradient yielding methyl 7 -methyl- l,l-dioxo-3-(trifluoro- methyl)-2,3-dihydropyrrolo[3,4-f]thiazepine-6-carboxylate (470 mg).
Methyl 7-methyl-l,l-dioxo-3-(trif uoromethyl)-2,3-dihydropyrrolo[3,4-f]thiazepine- 6-carboxylate (470 mg, 1.45 mmol) and 3,4-dif uoroaniline (176 μί, 1.29 g/mL, 1.74 mmol) were dissolved in THF (5 mL). Lithium bis(trimethylsilyl)amide (4.35 mL, 1 M in THF, 4.35 mmol) was added and the reaction mixture was stirred overnight at room temperature. The reaction mixture was quenched with NH4C1 (aq., sat., 5 mL). The organic layer was removed and the aqueous layer extracted with DCM (2 X 5 mL). The combined organic layers were evaporated to dryness and the residue purified via Prep HPLC (Stationary phase: RP XBridge Prep C18 OBD-ΙΟμιη, 30x150mm, Mobile phase: 0.25% NH4HC03 solution in water, MeOH) yielding compound 8 (28.1 mg) as a white powder. 1H NMR (360 MHz, DMSO-^) δ ppm 3.75 (s, 3 H), 4.88 (br s, 1 H),
5.80 (dd, J=12.2, 3.0 Hz, 1 H), 6.77 - 6.83 (m, 1 H), 7.41 - 7.49 (m, 2 H), 7.73 (s, 1 H),
7.81 - 7.89 (m, 1 H), 8.64 (br d, J=10.1 Hz, 1 H), 10.83 (s, 1 H); Method D; Rt:
1.89 min. m/z : 420 (M-H)~ Exact mass: 421.1; MP: 245.6 °C.
Compound 9: N-(3,4-difluorophenyl)-7-methyl-lJ-dioxo-2,3-dihydropyrrolo[3,4-f|- thiazepine-6-carboxamide.
Figure imgf000063_0001
Methyl 3-bromo-4-chlorosulfonyl-l-methyl-pyrrole-2-carboxylate (500 mg, 1.58 mmol) and allylamine (223 mg, 3.79 mmol) were dissolved in THF (5 mL). Hunig's base (1.63 mL, 0.75 g/mL, 9.48 mmol) was added and the reaction mixture was stirred overnight at room temperature. NH4C1 (sat., aq., 5 mL) was added and the organic layer was removed. The aqueous layer was extracted with DCM (2 X 5 mL) and the combined organic layers were evaporated to dryness. The residue was purified on silica using a heptane to EtOAc gradient yielding methyl 4-(allylsulfamoyl)-3-bromo-l- methyl-pyrrole-2-carboxylate (488 mg) as a white powder.
Methyl 4-(allylsulfamoyl)-3-bromo-l-methyl-pyrrole-2-carboxylate (430 mg,
1.28 mmol), bis(tri-tert-butylphosphine)palladium(0) (130 mg, 0.26 mmol) and TEA (177 μί, 0.73 g/mL, 1.28 mmol) were dissolved in DMF (5 mL) and heated in the microwave for 30 minutes at 140°C. The reaction mixture was directly purified via Prep HPLC (Stationary phase: RP XBridge Prep C18 OBD-ΙΟμιη, 30x150mm, Mobile phase: 0.25% NH4HCO3 solution in water, ACN) yielding methyl 7 -methyl- 1,1-dioxo- 2,3-dihydropyrrolo[3,4-f]thiazepine-6-carboxylate (75 mg).
Methyl 7-methyl-l,l-dioxo-2,3-dihydropyrrolo[3,4-fJthiazepine-6-carboxylate (75 mg, 0.29 mmol) and 3,4-difluoroaniline (36 μί, 1.29 g/mL, 0.35 mmol) were dissolved in THF (5 mL). Lithium bis(trimethylsilyl)amide (0.88 mL, 1 M in THF, 0.88 mmol) was added and the reaction mixture was stirred overnight at room temperature. The reaction mixture was quenched with NH4C1 (aq., sat., 5 mL). The organic layer was removed and the aqueous layer extracted with DCM (2 X 5 mL). The combined organic layers were evaporated to dryness and the residue purified on silica using a heptane to EtOac gradient yielding compound 9 as a light brown powder after crystallization from a DCM:DIPE mixture. 1H NMR (360 MHz, DMSO- ¾ δ ppm 3.71 (s, 3 H), 3.89 (ddd, J=6.4, 3.9, 1.8 Hz, 2 H), 5.65 (dt, J=12.5, 4.0 Hz, 1 H), 6.52 (dt, J=12.8, 1.7 Hz, 1 H), 7.39 - 7.48 (m, 2 H), 7.55 (s, 1 H), 7.62 (t, J=6.5 Hz, 1 H), 7.82 - 7.89 (m, 1 H), 10.76 (s, 1 H); Method B; Rt: 0.84 min. m/z : 352 (M-H)~ Exact mass: 353.1; MP: 221.9 °C.
Compound 10 : N-(3 ,4-difluorophenyl)-3 ,7-dimethyl- 1 , 1 -dioxo-2,3 ,4,5-tetrahydro- pyrrolo[3,4-f|thiazepine-6-carboxamide.
Figure imgf000064_0001
Compound 7a (120 mg, 0.33 mmol) and Pd/C (10%) (35 mg, 0.033 mmol) were dispensed in MeOH (20 mL). The reaction mixture was set under a hydrogen atmosphere and stirred for 2 hours. The reaction mixture was filtered and evaporated to dryness yielding compound 10a (111 mg) as a white powder. 1H NMR (400 MHz, DMSO- ¾ δ ppm 1.13 (d, J=6.8 Hz, 3 H), 1.23 - 1.40 (m, 1 H), 1.84 (br dd, J=14.2, 6.5 Hz, 1 H), 2.78 - 3.01 (m, 2 H), 3.58 - 3.66 (m, 1 H), 3.69 (s, 3 H), 6.89 - 7.17 (m, 1 H), 7.37 - 7.45 (m, 3 H), 7.81 - 7.89 (m, 1 H), 10.49 (br s, 1 H); Method B; Rt: 0.90 min. m/z : 368 (M-H)" Exact mass: 369.1; MP: 231.6 °C.
Compound 10b (35.6 mg) was prepared similarly as described for compound 10a, using compound 7b instead of compound 7a. 1H NMR (400 MHz, DMSO-<¾) δ ppm 1.13 (d, J=6.8 Hz, 3 H), 1.29 - 1.40 (m, 1 H), 1.84 (br dd, J=14.2, 6.5 Hz, 1 H), 2.78 - 3.02 (m, 2 H), 3.58 - 3.66 (m, 1 H), 3.69 (s, 3 H), 7.01 (br s, 1 H), 7.36 - 7.44 (m, 3 H),
7.81 - 7.88 (m, 1 H), 10.48 (br s, 1 H); Method B; Rt: 0.90 min. m/z : 368 (M-H)" Exact mass: 369.1; MP: 229.8 °C.
Compound 11 : N-(3 ,4-difluorophenyl)-3 ,6-dimethyl- 1 , 1 -dioxo-3 ,4-dihydro-2H-pyrrolo- [3,4-elthiazine-5-carboxamide.
Figure imgf000065_0001
Methyl 3-bromo-4-chlorosulfonyl-l-methyl-pyrrole-2-carboxylate (2.2 g, 6.95 mmol) was dissolved in ammonia (60 mL, 0.5 M in dioxane, 30 mmol). The reaction mixture was stirred at 4 days at room temperature. The volatiles were removed and the residue was dissolved in 2-Me-THF and washed with water. The organic layer was dried (MgS04), filtered, and evaporated to dryness to afford methyl 3-bromo-l-methyl- 4-sulfamoyl-pyrrole-2-carboxylate (2 g) as a white powder. Method B; Rt: 0.55 min. m/z : 295 (M-H)" Exact mass: 296.
A mixture of methyl 3-bromo-l-methyl-4-sulfamoyl-pyrrole-2-carboxylate (1.20 g, 3.92 mmol), pentane-2,4-dione (1.18 g, 11.8 mmol), copper(I) iodide (74.6 mg,
0.39 mmol) and potassium phosphate tribasic (1.66 g, 7.83 mmol) in DMSO (18 mL) was stirred under a N2 atmosphere at 90°C overnight. The mixture was quenched with HC1 (aq., 1M, 20 mL), the solution was extracted with EtOAc (3 X 50 mL). The organic layers were combined, dried over sodium sulfate and evaporated to dryness. The brown residue was purified using silica gel column chromatography (EtOAc in heptane from 0 to 100%) to afford methyl 3 -acetonyl-4-(acetylsulfamoyl)-l -methyl -pyrrole-2- carboxylate (1.22 g) as light brown powder. Method B; Rt: 0.41 min. m/z : 315 (M-H)" Exact mass: 316.0. Methyl 3 -acetonyl-4-(acetylsulfamoyl)-l -methyl -pyrrole-2-carboxylate (1.22 g, 3.86 mmol) was dissolved in TFA and heated at reflux for 2 hours. The reaction mixture was concentrated. The residue was dissolved in DCM (20 mL) and washed with NaHCC"3 (aq., sat., 2 X 5 mL), dried (Na2S04), filtered, the filtrate concentrated in vacuo and the crude residue was purified using silica gel column chromatography (EtOAc in heptane from 0 to 100%) to afford methyl 3,6-dimethyl-l,l-dioxo-2H- pyrrolo[3,4-e]thiazine-5-carboxylate (203 mg). 1H NMR (360 MHz, OMSO-d6) δ ppm 2.02 (d, J=l .l Hz, 3 H), 3.81 (s, 3 H), 3.92 (s, 3 H), 6.24 (br s, 1 H), 7.86 (s, 1 H), 10.52 (br s, 1 H); Method B; Rt: 0.59 min. m/z : 255 (M-H)~ Exact mass: 256.0.
To a solution of methyl 3,6-dimethyl-l,l-dioxo-2H-pyrrolo[3,4-e]thiazine-5-carbo- xylate (203 mg, 0.79 mmol) and 3,4-difluoroaniline (123 mg, 0.95 mmol) in THF (5 mL) was added lithium bis(trimethylsilyl)amide (3.17 mL, 1 M in THF, 3.17 mmol). The reaction mixture was stirred at room temperature for 40 minutes and quenched with NH4CI (aq., sat., 5 mL). The aqueous layer was extracted with DCM (3 X 50 mL). The combined organic layers were dried (Na2S04), concentrated and the residue was purified on silica using a heptane to EtOAc gradient yielding a brown powder which was triturated in methanol. The precipitation was filtered and the solids were washed with methanol to afford N-(3,4-difiuorophenyl)-3,6-dimethyl-l,l-dioxo-2H-pyrrolo- [3,4-e]thiazine-5-carboxamide (33 mg) as a white powder. Method B; Rt: 0.80 min. m/z : 354 (M+H)+ Exact mass: 353.0.
N-(3 ,4-difiuorophenyl)-3 ,6-dimethyl- 1 , 1 -dioxo-2H-pyrrolo[3 ,4-e]thiazine-5- carboxamide (33 mg, 0.093 mmol) was dissolved in THF (40 mL) and under a nitrogen atmosphere Pd/C (10%) (56 mg, 0.053 mmol) was added. The reaction mixture was hydrogenated for 1 hour. The reaction mixture was filtered over decalite. The filter was washed with THF (3 x 50 mL). The filtrate was evaporated to dryness and the residue was purified using silica gel column chromatography (EtOAc in heptane from 0 to 100%) to afford compound 11 (18 mg) as a white powder. 1H NMR (400 MHz, DMSO- ¾ δ ppm 1.26 (d, J=6.6 Hz, 3 H), 2.51 - 2.58 (m, 1 H), 2.83 (dd, J=16.3, 3.5 Hz, 1 H), 3.55 - 3.70 (m, 1 H), 3.77 (br s, 3 H), 7.08 (br d, J=10.9 Hz, 1 H), 7.37 - 7.46 (m, 2 H), 7.61 (s, 1 H), 7.77 - 7.85 (m, 1 H), 10.15 (s, 1 H); Method B; Rt: 0.87 min. m/z : 354 (M-H)" Exact mass: 355.0.
Compound 12 : N-(3 ,4-difluorophenyl)-7-fluoro-3 -methyl- 1 , 1 -dioxo-3 ,4-dihydro-2H- 5,l 6,2-benzoxathiazepine-6-carboxamide.
Figure imgf000067_0001
Na2C03 (2.06 g, 19.5 mmol) was dissolved in water (30 mL). To this was added DL-alaninol (2.93 g, 39.0 mmol) at once followed by THF (30 mL). The obtained solution was stirred and cooled in an ice bath. 3-(chlorosulfonyl)-2,6-difluorobenzoic acid (5.00 g, 19.5 mmol) was dissolved in THF (40 mL) and this was added drop wise to the stirring solution. The resulting mixture was stirred for 30 minutes while cooling was continued. Then the mixture was stirred for 3 hours at room temperature. The mixture was concentrated in vacuo until only water remained. Then 20 mL of water was added and the mixture was acidified with exactly 20 mL HCl (aq., 1M). This was extracted using 2-Me-THF (3 X 50 mL). The combined organics were washed with brine (50 mL), dried (Na2S04), filtered and concentrated in vacuo yielding 2,6-difluoro- 3-[(2-hydroxy-l-methyl-ethyl)sulfamoyl]benzoic acid as a yelow powder (4.9g).
Method D; Rt: 0.75 min. m/z : 294 (M-H)~ Exact mass: 295.0.
2,6-difluoro-3-[(2-hydroxy-l-methyl-ethyl)sulfamoyl]benzoic acid (1.00 g, 3.18 mmol), 3,4-difluoroaniline (623 mg, 4.78 mmol), HATU (1.33 mg, 3.5 mmol) and DIPEA (1.65 mL, 0.75 g/mL, 9.55 mmol) were dissolved in DMF (2 mL) and stirred at room temperature for 2 hours. This mixture was injected directly onto a silica plug and purified using silica gel column chromatography (gradient elution: EtOAc:heptane 0:100 to 100:0) yielding N-(3,4-difiuorophenyl)-2,6-difluoro-3-[(2-hydroxy-l-methyl- ethyl)sulfamoyl]benzamide (987 mg) as an oil.
N-(3,4-difluorophenyl)-2,6-difluoro-3-[(2-hydroxy-l-methyl-ethyl)sulfamoyl]- benzamide (887 mg, 2.18 mmol) in DMF (8 mL) was treated with NaH (437 mg, 60% dispersion in mineral oil, 10.9 mmol) at room temperature and this was stirred for 2 minutes. Then it was heated under microwave irradiation to 110°C for 40 minutes. The reaction mixture was poured into ice water (100 mL) and this was extracted using EtOAc (3 X 100 mL). The combined extracts were washed with brine (100 mL), dried (Na2S04), filtered and concentrated in vacuo. The crude was purified using silica gel column chromatography (gradient elution: EtOAc:heptane 0: 100 to 30:70) yielding an oil which was crystallised out of boiling diisopropylether/acetonitrile yielding compound 12 (191 mg) as a white powder. 1H NMR (400 MHz, OMSO-d6) δ ppm 1.10 (d, J=7.04 Hz, 3 H) 3.66 (dd, J=12.32, 9.68 Hz, 1 H) 3.77 - 3.88 (m, 1 H) 4.45 (dd, J=12.43, 2.31 Hz, 1 H) 7.32 (t, J=8.69 Hz, 1 H) 7.35 - 7.50 (m, 2 H) 7.79 - 7.91 (m, 3 H) 10.97 (s, 1 H); Method B; Rt: 0.89 min. m/z : 387 (M+H)+ Exact mass: 386.1.
Compound 13 : N-(3 ,4-difluorophenyl)-6-methyl- 1 , 1 -dioxo-3 ,4-dihydro-2H-pyrrolo- [3,4-elthiazine-5-carboxamide.
Figure imgf000068_0001
To a solution of methyl 3-bromo-l-methyl-4-sulfamoyl-pyrrole-2-carboxylate (300 mg, 0.98 mmol) in DMF (10 mL) was added (Z)-l-ethoxy-2-(tributylstannyl)ethene (490 μί, 1.08 g/mL, 1.47 mmol). The reaction mixture was purged with nitrogen for 5 minutes and bis(tri-tert-butylphosphine)palladium(0) (150 mg, 0.29 mmol) was added. The reaction mixture was heated at 140°C for 20 minutes. The reaction mixture was poured into water and extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with brine, dried (Na2S04) and concentrated to give a brown oil. This oil was dissolved in acetonitrile and washed with heptane. The solution was concentrated to dryness to afford methyl 3-[(E)-2-ethoxyvinyl]-l-methyl-4-sulfamoyl- pyrrole-2-carboxylate (707 mg) as a brown oil. Method B; Rt: 0.63 min. m/z :
289 (M+H)+ Exact mass: 288.0.
Methyl 3-[(Z)-2-ethoxyvinyl]-l-methyl-4-sulfamoyl-pyrrole-2-carboxylate (707 mg, 1.15 mmol) was dissolved TFA (5 mL) and stirred at room tempeature for 1 hour. The reaction mixture was concentrated and dissolved in THF (50 mL) and concentrated to methyl 6-methyl-l,l-dioxo-2H-pyrrolo[3,4-e]thiazine-5-carboxylate (600 mg) as a brown oil. Method D; Rt: 1.10 min. m/z : 243 (M+H)+ Exact mass: 242.0.
Methyl 6-methyl-l,l-dioxo-2H-pyrrolo[3,4-e]thiazine-5-carboxylate (70 mg,
0.29 mmol) was dissolved in THF (20 mL) and under a nitrogen atmosphere Pd/C (10%) (26.4 mg, 0.025 mmol) was added. The reaction mixture was hydrogenated for 18 hours. The reaction mixture was filtered over decalite. The filter was washed with THF (3 x 20 mL). The combined filtrates were evaporated to dryness. The residue was purified using silica gel column chromatography (EtOAc in heptane from 0 to 100%) to afford methyl 6-methyl-l,l-dioxo-3,4-dihydro-2H-pyrrolo[3,4-e]thiazine-5-carboxylate (73 mg) as a white powder. Method B; Rt: 0.62 min. m/z : 243 (M-H)~ Exact mass: 244.0.
To a solution of methyl 6-methyl-l,l-dioxo-3,4-dihydro-2H-pyrrolo[3,4-e]thiazine-5- carboxylate (20 mg, 0.078 mmol) and 3,4-difluoroaniline (12.1 mg, 0.093 mmol) in THF (2 mL) was added lithium bis(trimethylsilyl)amide (0.31 mL, 1 M in THF, 0.31 mmol). The reaction mixture was stirred at room temperature for 30 minutes and quenched with NH4C1 (aq., sat., 2 mL). The aqueous layer was extracted with DCM (3 x 5 mL) and ethyl acetate (15 mL). The combined organic layers were concentrated and the residue was purified twice on silica (EtOAc in heptane from 0 to 100%) and via Prep HPLC (Stationary phase: RP XBridge Prep C18 OBD-ΙΟμιη, 30x150mm, Mobile phase: 0.25% NH4HC03 solution in water, ACN) yielding compound 13 (15 mg) as a white powder. 1H NMR (360 MHz, DMSO- ¾ δ ppm 2.72 - 2.79 (m, 2 H), 3.42 - 3.50 (m, 2 H), 3.78 (br s, 3 H), 7.18 (br s, 1 H), 7.37 - 7.47 (m, 2 H), 7.63 (s, 1 H), 7.78 - 7.85 (m, 1 H), 10.21 (br s, 1 H); Method B; Rt: 0.82 min. m/z : 340 (M-H)~ Exact mass: 341.0.
Compound 14 : N-(3 ,4-difluorophenyl)-3 ,7-dimethyl- 1 , 1 -dioxo-3 ,4-dihydro-2H-pyrrolo-
[3,4-bl[l,4,51oxathiazepine-6-carboxamide.
Ethyl 4-chlorosulfonyl-3-fluoro-l-methyl-pyrrole-2-carboxylate (500 mg, 1.85 mmol), DL-alaninol (209 mg, 2.78 mmol) and Hunig's base (0.96 mL, 0.75 g/mL, 5.56 mmol) were dissolved in THF and stirred overnight at room temperature. The formed precipitate was filtered off and the filtrate was evaporated to dryness. The residue was purified on silica using a heptane to EtOAc gradient yielding ethyl 3-fluoro-4-
[(2-hydroxy-l-methyl-ethyl)sulfamoyl]-l-methyl-pyrrole-2-carboxylate (513 mg) as a white powder.
Ethyl 3-fluoro-4-[(2 -hydro xy-l-methyl-ethyl)sulfamoyl]-l-methyl-pyrrole-2- carboxylate (240 mg, 0.78 mmol) and 3,4-difluoroaniline (0.094 mL, 1.29 g/mL, 0.93 mmol) were dissolved in THF (5 mL). Lithium bis(trimethylsilyl)amide (2.34 mL, 1 M in THF, 2.34 mmol) was added and the reaction mixture was stirred overnight at room temperature. Lithium bis(trimethylsilyl)amide (0.5 mL, 1 M in THF, 0.5 mmol) was added and the reaction mixture was stirred 1 hour. NH4C1 (sat., aq., 5 mL) was added and the organic layer was removed. The aqueous layer was extracted with DCM (2 X 5 mL) and the combined organic layers were evaporated to dryness. The residue was purified on silica using a heptane to EtOac gradient yielding N-(3,4-difluoro- phenyl)-3 -fluoro-4- [(2-hydroxy- 1 -methyl-ethyl)sulfamoyl] - 1 -methyl-pyrrole-2- carboxamide (225 mg) as a white powder after crystallization from a DCM:DIPE mixture.
N-(3 ,4-difluorophenyl)-3 -fluoro-4- [(2-hydroxy- 1 -methyl-ethyl)sulfamoyl] - 1 -methyl- pyrrole -2-carboxamide (183 mg, 0.47 mmol) and cesium fluoride (15.5 mg, 0.94 mmol) were dispensed in DMF (3 mL). The reaction mixture was heated in the microwave oven for 2 hours at 140°C. The reaction mixture was purified via prep. HPLC
(Stationary phase: RP XBridge Prep C18 OBD-ΙΟμιη, 30x150mm, Mobile phase:
0.25% NH4HCO3 solution in water, ACN) yielding compound 14 (130 mg). 1H NMR (400 MHz, DMSO- ¾ δ ppm 1.10 - 1.20 (m, 3 H), 3.78 - 3.86 (m, 5 H), 4.51 - 4.59 (m, 1 H), 7.36 - 7.48 (m, 3 H), 7.61 (br s, 1 H), 7.85 (ddd, J=13.1, 7.4, 2.3 Hz, 1 H), 9.44 (s, 1 H); Method D; Rt: 1.82 min. m/z : 372 (M+H)+ Exact mass: 371.1. This racemic mixture was seperated in enantiomers 14a (40.6 mg) and 14b (36.9 mg) by preparative SFC (Stationary phase: Chiralpak Diacel AD 20 x 250 mm, Mobile phase: C02, EtOH with 0.4% iPrNH2). Metod F; Rt : 14a: 1.52 min, 14b: 2.14 min.
Compound 15 : (5Z)-N-(3 ,4-difluorophenyl)-3 ,8-dimethyl- 1 , 1 -dioxo-3 ,4-dihydro-2H- pyrrolo[3,4-glthiazocine-7-carboxamide.
Figure imgf000070_0001
Methyl 3-bromo-4-chlorosulfonyl-l-methyl-pyrrole-2-carboxylate (1000 mg,
3.16 mmol) and pent-4-en-2-ylamine hydrochloride (423 mg, 3.47 mmol) were dissolved in THF (5 mL). Hunig's base (1.63 mL, 0.75 g/mL, 9.48 mmol) was added and the reaction mixture was stirred overnight at room temperature. NH4CI (sat., aq., 5 mL) was added and the organic layer was removed. The aqueous layer was extracted with DCM (2 X 5 mL) and the combined organic layers were evaporated to dryness. The residue was purified on silica using a heptane to EtOAc gradient yielding methyl
3-bromo-l-methyl-4-(l-methylbut-3-enylsulfamoyl)pyrrole-2-carboxylate (965 mg) as a white powder.
Methyl 3 -bromo- 1 -methyl -4-( 1 -methylbut-3 -enylsulfamoyl)pyrrole-2-carboxylate (97 mg, 0.28 mmol), bis(tri-tert-butylphosphine)palladium(0) (13.6 mg, 0.027 mmol) and TEA (36.8 μί, 0.73 g/mL, 0.27 mmol) were dissolved in DMF (5 mL) and heated in the microwave oven at 150°C for 30 minutes. The reaction mixture was purified via Prep HPLC (Stationary phase: RP XBridge Prep C18 OBD-ΙΟμιη, 30x150mm, Mobile phase: 0.25% NH4HCO3 solution in water, ACN) yielding methyl (5Z)-3,8-dimethyl- l,l-dioxo-3,4-dihydro-2H-pyrrolo[3,4-g]thiazocine-7-carboxylate (41 mg).
Methyl (5Z)-3,8-dimethyl-l,l-dioxo-3,4-dihydro-2H-pyrrolo[3,4-g]thiazocine-7- carboxylate (41 mg, 0.14 mmol) and 3,4-difluoroaniline (17.5 μί, 1.29 g/mL,
0.17 mmol) were dissolved in THF (5 mL). Lithium bis(trimethylsilyl)amide (433 μί, 1 M in THF, 0.43 mmol) was added and the reaction mixture was stirred overnight at room temperature. The reaction mixture was quenched with NH4C1 (aq., sat., 5 mL). The organic layer was removed and the aqueous layer extracted with DCM (2 X 5 mL). The combined organic layers were evaporated to dryness and the residue purified via Prep HPLC (Stationary phase: RP XBridge Prep C18 OBD-ΙΟμιη, 30x150mm, Mobile phase: 0.25% NH4HC03 solution in water, MeOH) yielding compound 15. 1H NMR (400 MHz, DMSO- ¾ δ ppm 1.32 (d, J=7.0 Hz, 3 H), 2.08 - 2.16 (m, 1 H), 2.46 (ddd, J=13.6, 8.6, 1.8 Hz, 1 H), 3.51 (quind, J=6.9, 6.9, 6.9, 6.9, 1.8 Hz, 1 H), 3.92 (s, 3 H), 6.08 (dt, J=11.0, 8.8 Hz, 1 H), 6.77 (d, J=11.0 Hz, 1 H), 7.31 (dt, J=10.4, 9.0 Hz, 1 H), 7.38 - 7.44 (m, 2 H), 7.89 (ddd, J=13.0, 7.4, 2.6 Hz, 1 H); Method D; Rt: 1.78 min. m/z : 382 (M+H)+ Exact mass: 381.1. This racemic mixture was seperated in enantiomers 15a (4.7 mg) and 15b (4.2 mg) by preparative SFC (Stationary phase: Kromasil (R,R) Whelk-0 1 10/100, Mobile phase: C02, MeOH + 0.4 iPrNH2). Method G; Rt : 15a: 2.31 min, 15b: 2.75 min.
Compound 16 : N-(3 ,4-difluorophenyl)-2-isopropyl-6-methyl- 1 , 1 -dioxo-3 ,4-dihydro- p rrolo[3,4-elthiazine-5-carboxamide.
Figure imgf000071_0001
Methyl 6-methyl-l,l-dioxo-3,4-dihydro-2H-pyrrolo[3,4-e]thiazine-5-carboxylate (40 mg, 0.11 mmol) was dissolved in DMF (1 mL) and 2-bromopropane (17.2 μί, 2.28 g/mL, 0.32 mmol) was added. The reaction mixture was stirred at room
temperature for 66 hours. The reaction mixture was diluted with water and extracted with EtOAc (3 x 10 mL). The combined organic layers were dried and concentrated to dryness. The white solid was purified using silica gel column chromatography (EtOAc in heptane from 0 to 100%) to afford methyl 2 -isopropy 1-6 -methyl- 1,1 -dioxo-3, 4- dihydropyrrolo[3,4-e]thiazine-5-carboxylate (20 mg) as a white powder. Method B; Rt: 0.84 min. m/z : 287 (M+H)+ Exact mass: 286.0. To a solution of methyl 2-isopropyl-6-methyl-l,l-dioxo-3,4-dihydropyrrolo- [3,4-e]thiazine-5-carboxylate (20 mg, 0.07 mmol) and 3,4-difluoroaniline (10.82 mg, 0.084 mmol) in THF (2 mL) was added lithium bis(trimethylsilyl)amide (0.28 mL, 1 M in THF, 0.28 mmol) and the reaction mixture was stirred 1 hour at room temperature. Lithium bis(trimethylsilyl)amide (0.28 mL, 1 M in THF, 0.28 mmol) was added and the reaction mixture was stirred 5 minutes at room temperature and quenched with NH4C1 (aq., sat., 2 mL). The aqueous layer was extracted with DCM (3 x 5 mL). The combined organic layers were concentrated and the residue was purified on silica (EtOAc in heptane from 0 to 100%) to afford a brown powder. This was triturated in hot methanol. The white suspension was filtered to afford compound 16 (18 mg) as an off white solid. 1H NMR (400 MHz, DMSO- ¾ δ ppm 1.16 (d, J=6.8 Hz, 6 H), 2.83 - 2.90 (m, 2 H), 3.58 - 3.65 (m, 2 H), 3.78 (s, 3 H), 4.09 - 4.21 (m, 1 H), 7.36 - 7.46 (m, 2 H), 7.63 (s, 1 H), 7.77 - 7.83 (m, 1 H), 10.08 (br s, 1 H); Method B; Rt: 0.98 min. m/z : 384 (M+H)+ Exact mass: 383.0.
Compound 17: N-(3,4-difluorophenyl)-3-ethyl-6-methyl-l,l-dioxo-3,4-dihydro-2H- pyrrolo[3,4-elthiazine-5-carboxamide.
Figure imgf000072_0001
Methyl 3-ethyl-6-methyl-l,l-dioxo-2H-pyrrolo[3,4-e]thiazine-5-carboxylate was prepared similarly as described for methyl 3,6-dimethyl-l,l-dioxo-2H-pyrrolo[3,4-e]- thiazine-5-carboxylate, using heptane-3,5-dione instead of pentane-2,4-dione.
Methyl 3-ethyl-6-methyl-l,l-dioxo-2H-pyrrolo[3,4-e]thiazine-5-carboxylate (128 mg, 0.18 mmol) was dissolved in MeOH (10 mL) and under a nitrogen atmosphere Pd/C (10%) (20 mg, 0.018 mmol) was added. The reaction mixture was hydrogenated for 18 hours. Pd/C (10%>) (20 mg, 0.018 mmol) was added under nitrogen atmosphere.
The reaction mixture was hydrogenated for 18 hours at 50°C. The reaction mixture was filtered over decalite. The filter cake was washed with MeOH (3 x 20 mL). The filtrate was evaporated to dryness and the residue was purified using silica gel column chromatography (EtOAc in heptane from 0 to 100%) to afford methyl 3-ethyl-6-methyl- l,l-dioxo-3,4-dihydro-2H-pyrrolo[3,4-e]thiazine-5-carboxylate (20 mg). Method B; Rt: 0.74 min. m/z : 271 (M-H)~ Exact mass: 272.0. To a solution of methyl 3-ethyl-6-methyl-l,l-dioxo-3,4-dihydro-2H-pyrrolo- [3,4-e]thiazine-5-carboxylate (20 mg, 0.073 mmol) and 3,4-difluoroaniline (9.5 mg, 0.073 mmol) in THF (2 mL) was added lithium bis(trimethylsilyl)amide (0.29 mL, 1 M in THF, 0.29 mmol). The reaction mixture was stirred at room temperature for
30 minutes and quenched with NH4C1 (aq., sat., 2 mL). The aqueous layer was extracted with DCM (3 x 5 mL). The combined organic layers were concentrated and the residue was purified via Prep HPLC (Stationary phase: RP XBridge Prep CI 8 OBD- ΙΟμιη, 30x150mm, Mobile phase: 0.25% NH4HCO3 solution in water, ACN) yielding compound 17 (4.5 mg) as an off white powder. 1H NMR (400 MHz, DMSO-^) δ ppm 0.96 (tt, J=7.3, 1.0 Hz, 3 H), 1.54 - 1.63 (m, 2 H), 2.45-2.55 (m, 1 H), 2.80 - 2.92
(m, 1 H), 3.16 - 3.44 (m, 1 H), 3.77 (s, 3 H), 6.92 - 7.05 (m, 1 H), 7.37 - 7.46 (m, 2 H), 7.60 (s, 1 H), 7.77 - 7.84 (m, 1 H), 10.09 - 10.19 (m, 1 H); Method B; Rt: 0.91 min. m/z : 368 (M-H)~ Exact mass: 369.1. Compound 18 : N-(3 ,4-difluorophenyl)-2,3 ,7-trimethyl- 1 , 1 -dioxo-3H-pyrrolo-
[3,4-f|thiaze ine-6-carboxamide.
Figure imgf000073_0001
Trimethylsulfoxonium iodide (123 mg, 0.56 mmol) and potassium tert-butoxide (58 mg, 0.52 mmol) were dissolved in DMSO (5 mL) at 50°C. Compound 7 (100 mg,
0.27 mmol) dissolved in DMSO (5 mL) was added dropwise and the reaction mixture was stirred overnight at 50°C. Trimethylsulfoxonium iodide (123 mg, 0.56 mmol) and potassium tert-butoxide (58 mg, 0.52 mmol) were dissolved in DMSO (5 mL) and this was added to the reaction mixture which was stirred for another hour. The reaction mixture was purified via prep HPLC (Stationary phase: RP XBridge Prep CI 8 OBD- ΙΟμπι, 30x150mm, Mobile phase: 0.25% NH4HC03 solution in water, MeOH) yielding compound 18 (23.7 mg). 1H NMR (400 MHz, ACETONE-*/ ) δ ppm 1.41 (d, J=7.5 Hz, 3 H), 2.53 (s, 3 H), 3.86 (s, 3 H), 4.88 (qt, J=7.5, 2.6 Hz, 1 H), 5.40 (dd, J=12.4, 2.5 Hz, 1 H), 6.67 (dd, J=12.5, 2.9 Hz, 1 H), 7.34 (dt, J=10.4, 9.0 Hz, 1 H), 7.44 (s, 1 H), 7.47 - 7.56 (m, 1 H), 7.94 (ddd, J=12.9, 7.5, 2.6 Hz, 1 H), 9.84 (br s, 1 H); Method B; Rt: 0.99 min. m/z : 382 (M+H)+ Exact mass: 381.1.
Compound 19: N-(3,4-difluorophenyl)-7-methyl-l ,l-dioxo-spiro[2,4-dihydropyrrolo- [3,4-bl[l,4,51oxathiazepine-3J'-cyclopropanel-6-carboxamide.
Figure imgf000074_0001
Compound 19 (18.1 mg) was prepared similarly as described for compound 14, using 1-amino-cyclopropanemethanol instead of DL-alaninol. 1H NMR (400 MHz, DMSO- d6) δ ppm 0.91 - 1.04 (m, 4 H), 3.83 (s, 3 H), 4.15 (s, 2 H), 7.36 - 7.47 (m, 2 H), 7.49 (s, 1 H), 7.84 (ddd, J=13.2, 7.5, 2.2 Hz, 1 H), 8.23 (s, 1 H), 9.51 (s, 1 H); Method B; Rt: 0.94 min. m/z : 384 (M+H)+ Exact mass: 383.1.
Compound 20 : (3R)-N-(3 ,4-difluorophenyl)-3 -ethyl-7-methyl- 1 , 1 -dioxo-3 ,4-dihydro-
2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide.
Figure imgf000074_0002
Compound 20 (36.6 mg) was prepared similarly as described for compound 14, using (R)-(-)-2-amino-l-butanol instead of DL-alaninol. 1H NMR (400 MHz, DMSO-^) δ ppm 0.98 (t, J=7.4 Hz, 3 H), 1.37 - 1.55 (m, 2 H), 3.47 - 3.59 (m, 1 H), 3.82 (s, 3 H), 3.83 - 3.89 (m, 1 H), 4.56 - 4.62 (m, 1 H), 7.36 - 7.49 (m, 3 H), 7.54 (br d, J=8.4 Hz, 1 H), 7.85 (ddd, J=13.2, 7.5, 2.4 Hz, 1 H), 9.43 (s, 1 H); Method B; Rt: 0.99 min. m/z 386 (M+H)+ Exact mass: 385.1.
Compound 21 : N-(3 ,4-difiuorophenyl)-3 , 8 -dimethyl- 1 , 1 -dioxo -2,3,4,5 -tetrahydro - p rrolo[3,4-bl[l,4,51oxathiazocine-7-carboxamide.
Figure imgf000074_0003
Compound 21 (137.3 mg) was prepared similarly as described for compound 14, using 3-aminobutan-l-ol instead of DL-alaninol. 1H NMR (400 MHz, DMSO-^) δ ppm 1.04 (d, J=5.9 Hz, 3 H), 1.21 (d, J=6.6 Hz, 3 H), 1.66 - 1.76 (m, 1 H), 1.97 - 2.05 (m, 1 H), 3.78 - 3.85 (m, 4 H), 4.21 (ddd, J=l 1.8, 8.4, 3.2 Hz, 1 H), 4.31 - 4.38 (m, 1 H),
7.36 - 7.48 (m, 3 H), 7.63 (d, J=9.2 Hz, 1 H), 7.86 (ddd, J=13.3, 7.4, 2.4 Hz, 1 H), 9.54 (s, 1 H); Method B; Rt: 0.96 min. m/z : 386 (M+H)+ Exact mass: 385.1. Compound 22 : (3 S)-N-(3 ,4-difluorophenyl)-3 -isopropy 1-7 -methyl- 1 , 1 -dioxo- 3,4-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide.
Figure imgf000075_0001
Compound 22 (46.5 mg) was prepared similarly as described for compound 14, using (S)-(+)-2-amino-3 -methyl- 1-butanol instead of DL-alaninol. 1H NMR (400 MHz, DMSO- ¾ δ ppm 0.94 (d, J=6.8 Hz, 3 H), 0.97 (d, J=6.6 Hz, 3 H), 1.85 (dq, J=13.4, 6.8 Hz, 1 H), 3.46 (br s, 1 H), 3.83 (s, 3 H), 3.94 (dd, J=12.7, 9.1 Hz, 1 H), 4.70 (dd, J=12.5, 1.5 Hz, 1 H), 7.36 - 7.55 (m, 4 H), 7.86 (ddd, J=13.1, 7.4, 2.5 Hz, 1 H), 9.42 (s, 1 H); Method B; Rt: 1.05 min. m/z : 400 (M+H)+ Exact mass: 399.1.
Compound 23: (3S)-N-(3,4-difluorophenyl)-7-methyl-3-[(l S)-l-methylpropyll- lJ-dioxo-3,4-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide.
Figure imgf000075_0002
Compound 23 (30.8 mg) was prepared similarly as described for compound 14, using L-isoleucinol instead of DL-alaninol. 1H NMR (400 MHz, OMSO-d6) δ ppm 0.87 (t, J=7.4 Hz, 3 H), 0.94 (d, J=6.8 Hz, 3 H), 1.22 - 1.33 (m, 1 H), 1.46 - 1.56 (m, 1 H), 1.56 - 1.65 (m, 1 H), 3.53 (br s, 1 H), 3.83 (s, 3 H), 3.94 (dd, J=12.8, 9.0 Hz, 1 H), 4.71 (d, J=11.0 Hz, 1 H), 7.36 - 7.45 (m, 1 H), 7.45 - 7.52 (m, 2 H), 7.56 (br s, 1 H), 7.86 (ddd, J=13.2, 7.4, 2.5 Hz, 1 H), 9.42 (s, 1 H); Method B; Rt: 1.10 min. m/z : 414 (M+H)+ Exact mass : 413.1. Compound 24 : N-(3 ,4-difluorophenyl)-7-methyl- 1 , 1 -dioxo-spiro[2,4-dihydropyrrolo- [3 4-bl[l ,4,51oxathiazepine-3,3'-oxetanel-6-carboxamide.
Figure imgf000076_0001
Compound 24 (51.6 mg) was prepared similarly as described for compound 14, using (3-aminooxetan-3-yl)methanol instead of DL-alaninol. 1H NMR (400 MHz, OMSO-d6) δ ppm 3.82 (s, 3 H), 4.47 (d, J=6.8 Hz, 2 H), 4.65 (d, J=6.8 Hz, 2 H), 4.76 (s, 2 H), 7.38 - 7.46 (m, 1 H), 7.49 (s, 1 H), 7.50 - 7.54 (m, 1 H), 7.89 (ddd, J= 13.1 , 7.4, 2.5 Hz, 1 H), 8.47 (s, 1 H), 9.46 (s, 1 H); Method B; Rt: 0.88 min. m/z : 400 (M+H)+ Exact mass: 399.1.
Compound 25 : (3R)-N-(3 ,4-difluorophenyl)-7-methyl- 1 , 1 -dioxo-3-phenyl-3 ,4-dihydro- 2H-pyrrolo[3,4-bl[l ,4,51oxathiazepine-6-carboxamide.
Figure imgf000076_0002
Compound 25 (5 mg) was prepared similarly as described for compound 14, using (D)-beta-aminophenethyl alcohol instead of DL-alaninol. 1H NMR (400 MHz,
DMSO- ¾ δ ppm 3.86 (br s, 3 H), 4.15 - 4.26 (m, 1 H), 4.74 (br d, J= l 1.7 Hz, 1 H), 4.92 (br d, J=9.2 Hz, 1 H), 7.28 - 7.44 (m, 4 H), 7.48 (br s, 3 H), 7.58 (s, 1 H), 7.85 (br s, 1 H), 9.43 (br s, 1 H); Method B; Rt: 1.07 min. m/z : 432 (M-H)~ Exact mass: 433.1.
Compound 26 : (3 S)-N-(3 ,4-difluorophenyl)-7-methyl- 1 , 1 -dioxo-3-phenyl-3 ,4-dihydro-
2H-pyrrolo[3,4-bl[l ,4,51oxathiazepine-6-carboxamide.
Figure imgf000076_0003
Compound 26 (8.8 mg) was prepared similarly as described for compound 14, using (S)-(+)-2-phenylglycinol instead instead of DL-alaninol. 1H NMR (400 MHz,
DMSO- ¾ δ ppm 3.86 (s, 3 H), 4.20 (dd, J=12.8, 9.7 Hz, 1 H), 4.74 (dd, J=12.8, 2.0 Hz, 1 H), 4.92 (br d, J=8.1 Hz, 1 H), 7.31 - 7.44 (m, 4 H), 7.44 - 7.51 (m, 3 H), 7.56 (s, 1 H), 7.85 (ddd, J=13.2, 7.5, 2.4 Hz, 1 H), 8.24 (br s, 1 H), 9.43 (br s, 1 H); Method B; Rt: 1.07 min. m/z : 432 (M-H)~ Exact mass: 433.1.
Compound 27: (3R)-N-(3,4-difluorophenyl)-3-isopropyl-7-methyl-l,l-dioxo-
3,4-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide.
Figure imgf000077_0001
Compound 27 (22.7 mg) was prepared similarly as described for compound 14,
D-valinol instead of DL-alaninol. 1H NMR (400 MHz, OMSO-d6) δ ppm 0.96 (dd, J=12.1, 6.8 Hz, 6 H), 1.85 (dq, J=13.3, 6.7 Hz, 1 H), 3.46 (br d, J=6.8 Hz, 1 H), 3.83 (s, 3 H), 3.94 (dd, J=12.8, 9.2 Hz, 1 H), 4.69 (dd, J=12.8, 1.5 Hz, 1 H), 7.36 - 7.54 (m, 4 H), 7.86 (ddd, J=13.2, 7.4, 2.5 Hz, 1 H), 9.42 (s, 1 H); Method D; Rt: 2.00 min. m/z : 400 (M+H)+ Exact mass: 399.1.
Compound 28 : N-(3 ,4-difluorophenyl)-3 ,4,7-trimethyl- 1 , 1 -dioxo-3 ,4-dihydro-2H- pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide.
Figure imgf000077_0002
Compound 28 (18.1 mg) was prepared similarly as described for compound 14, using 3-amino-2-butanol instead of DL-alaninol. Method B; Rt: 0.94 min. m/z : 384 (M+H) Exact mass: 383.1. Compound 29 : (* S)-3 ,7-dimethyl- 1 , 1 -dioxo-N-(3 ,4,5 -trifluorophenyO-2,3 -dihydro- pyrrolo[3,4-f|thiazepine-6-carboxamide.
Figure imgf000078_0001
3-chloro-l-butene (88.1 g, 973 mmol) was added to an overhead stirred suspension of potassium phthalimide (157 g, 848 mmol) and K2CO3 (23.5 g, 170 mmol) in DMF (1.3 L). The reaction mixture was heated to 120°C for 5 hours. The reaction mixture was allowed to cool to room temperature and stirred overnight at room temperature. The reaction mixture was quenched in ice cold water (6 L) and filtered. The filter cake was washed with cold water (300 mL) and dried on the air for one hour and then in the vacuum oven for 3 days yielding 2-(l-methylallyl)isoindoline-l,3-dione (148g) as a white powder. 1H NMR (400 MHz, DMSO-^) δ ppm 1.51 (d, J=7.0 Hz, 3 H), 4.79 - 4.87 (m, 1 H), 5.10 - 5.20 (m, 2 H), 6.11 (ddd, J=17.3, 10.5, 5.7 Hz, 1 H), 7.82 - 7.89 (m, 4 H). This racemic mixture was seperated in enantiomers (*R)-2-(l- methylallyl)isoindoline-l,3-dione (43.6 g) and (*S)-2-(l-methylallyl)isoindoline-l,3- dione (48 g) by preparative Chiral HPLC (Stationary phase: Chiralpak Diacel AD 20 microhm 2000 gr, Mobile phase: Isocratic 100% MeOH), where *R means first eluting enantiomer and *S means second eluting enantiomer.
To a solution of (*S)-2-(l-methylallyl)isoindoline-l,3-dione (5.03 g, 25 mmol) in EtOH (10 mL) was added ethanolamine (6.34 mL, 1.01 g/mL, 105 mmol). The mixture was heated at 45°C for 20h and allowed to reach room temperature and then at 90°C for
5 hours. The flask was equiped with a short path distillation apparatus and the ethanol and free amine was distilled as an azeotrope at atmospheric pressure. The pot temperature was 120°C and the boiling point of the ethanol + amine distillate was 80 °C. To the distillate (6.8 mol% in ethanol) was added a solution of methyl 3-bromo- 4-chlorosulfonyl-l -methyl -pyrrole -2-carboxylate (5.00 g, 15.8 mmol) in DCM
(100 mL) and Hunig's base (5.44 mL, 0.75 g/mL, 31.6 mmol). The reaction mixture was stirred at room temperature for 18 h. The reaction mixture was concentrated to dryness and the residue was dissolved in DCM (100 mL) and washed with saturated aqueous ammonium chloride solution. The organic layer was separated and dried (Na2S04), filtered and concentrated to dryness. The residue was purified using silica gel column chromatography (EtOAc in heptane from 0 to 100%) to afford methyl 3-bromo-l-methyl-4-[[(l !i:S)-l-methylallyl]sulfamoyl]pyrrole-2-carboxylate (4.08 g) as a white powder. Compound 29 (139 mg) was prepared similarly as described for compound 8, using methyl 3 -bromo- 1 -methy 1-4- [[( 1 * S)- 1 -methylallyl] sulfamoyl]pyrrole-2-carboxylate instead of methyl 3-bromo-l-methyl-4-[l-(trifluoromethyl)allylsulfamoyl]pyrrole- 2-carboxylate and heating 5 minutes instead of 30 minutes, using 3,4,5-trifluoroaniline instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO-^) δ ppm 1.31 (d, J=7.3 Hz, 3 H), 3.71 (s, 3 H), 4.20 - 4.33 (m, 1 H), 5.59 (dd, J=12.6, 2.4 Hz, 1 H), 6.43 (dd, J=12.6, 2.6 Hz, 1 H), 7.48 - 7.68 (m, 4 H), 10.86 (s, 1 H); Method B; Rt: 0.97 min. m/z : 384 (M-H)" Exact mass: 385.1. Compound 30: (*S)-N-[4-fluoro-3-(trifluoromethyl)phenyll-3,7-dimethyl-l,l-dioxo-
2,3-dihydropyrrolo[3,4-f|thiazepine-6-carboxamide.
Figure imgf000079_0001
Compound 30 (126 mg) was prepared similarly as described for compound 29, using 4-fluoro-3-(trifluoromethyl)aniline instead of 3,4,5-trifluoroaniline. 1H NMR
(400 MHz, DMSO- ¾ δ ppm 1.31 (d, J=7.3 Hz, 3 H), 3.72 (s, 3 H), 4.22 - 4.32
(m, 1 H), 5.58 (dd, J=12.6, 2.4 Hz, 1 H), 6.48 (dd, J=12.6, 2.6 Hz, 1 H), 7.48 - 7.61 (m, 3 H), 7.92 - 8.00 (m, 1 H), 8.20 (dd, J=6.5, 2.7 Hz, 1 H), 10.84 (br s, 1 H); Method B; Rt: 1.00 min. m/z : 416 (M-H)" Exact mass: 417.1.
Compound 31 : (* S)-N-(4-fluoro-3-methyl-phenyl)-3 ,7-dimethyl- 1 , 1 -dioxo-2,3-dihydro- rrolo[3,4-f|thiazepine-6-carboxamide.
Figure imgf000079_0002
Compound 31 (106 mg) was prepared similarly as described for compound 29, using 4-fluoro-3-methylaniline instead of 3,4,5-trifluoroaniline. 1H NMR (400 MHz, DMSO- ¾ δ ppm 1.31 (d, J=7.3 Hz, 3 H), 2.19 - 2.26 (m, 3 H), 3.70 (s, 3 H),
4.22 - 4.31 (m, 1 H), 5.55 (dd, J=12.5, 2.4 Hz, 1 H), 6.43 (dd, J=12.6, 2.6 Hz, 1 H), 7.11 (t, J=9.2 Hz, 1 H), 7.37 - 7.79 (m, 4 H), 10.50 (br s, 1 H); Method B; Rt: 0.92 min. m/z : 362 (M-H)" Exact mass: 363.1. Compound 32 : (* S)-N-(3-cyano-4-fluoro-phenyl)-3 ,7-dimethyl- 1 , 1 -dioxo-2,3 -dihydro- pyrrolo[3,4-f|thiazepine-6-carboxamide.
Figure imgf000080_0001
Compound 32 (78 mg) was prepared similarly as described for compound 29, using 5 -amino-2-fluorobenzonitrile instead of 3,4,5-trifluoroaniline. 1H NMR (400 MHz, DMSO- ¾ δ ppm 1.31 (d, J=7.5 Hz, 3 H), 3.72 (s, 3 H), 4.23 - 4.32 (m, 1 H), 5.58 (dd, J= 12.6, 2.4 Hz, 1 H), 6.47 (dd, J=12.6, 2.6 Hz, 1 H), 7.51 - 7.60 (m, 3 H), 7.97 (ddd, J=9.2, 4.9, 2.7 Hz, 1 H), 8.19 (dd, J=5.8, 2.7 Hz, 1 H), 10.86 (br s, 1 H); Method B; Rt: 0.84 min. m/z : 373 (M-H)~ Exact mass: 374.1.
Compound 33 : (3R -N-(3 ,4-difiuorophenyiy 3 - IY1R 1 -hydroxyethyll -7-methyl- 1,1- dioxo-3,4-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide.
Figure imgf000080_0002
Compound 33 (44.1 mg) was prepared similarly as described for compound 14, using L-threoninol instead of DL-alaninol. 1H NMR (400 MHz, DMSO- d6) δ ppm 1.10 (d, J=6.4 Hz, 3 H), 3.60 - 3.70 (m, 1 H), 3.83 (s, 3 H), 3.85 - 4.00 (m, 2 H), 4.74 (d, J= 11.4 Hz, 1 H), 4.96 (d, J=4.6 Hz, 1 H), 7.35 - 7.44 (m, 2 H), 7.44 - 7.50 (m, 2 H), 7.87 (ddd, J=13.2, 7.5, 2.4 Hz, 1 H), 9.44 (s, 1 H); Method B; Rt: 0.87 min. m/z :
402 (M+H)+ Exact mass: 401.1.
Compound 34 : (3 S N-(3 ,4-difluorophenvn-3 -IY 1 R 1 -hydroxyethyll -7-methyl- 1,1- dioxo-3,4-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide.
Figure imgf000080_0003
Compound 34 (93.6 mg) was prepared similarly as described for compound 14, using D-allo-threoninol instead of DL-alaninol. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.21 (d, J=6.2 Hz, 3 H), 3.38 - 3.45 (m, 1 H), 3.56 - 3.64 (m, 1 H), 3.82 (s, 3 H), 3.97 (dd, J=12.5, 9.0 Hz, 1 H), 4.89 (dd, J=12.8, 2.0 Hz, 1 H), 5.05 (d, J=5.9 Hz, 1 H), 7.36 - 7.44 (m, 1 H), 7.44 - 7.49 (m, 2 H), 7.61 (d, J=9.7 Hz, 1 H), 7.87 (ddd, J=13.2, 7.5, 2.4 Hz, 1 H), 9.42 (s, 1 H); Method B; Rt: 0.86 min. m/z : 402 (M+H)+ Exact mass: 401.1.
Compound 35 : (3R)-N-(3 ,4-difluorophenyiy 3 - IT 1 S 1 -hydroxyethyll -7-methyl- 1.1- dioxo-3,4-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide.
Figure imgf000081_0001
Compound 35 (68.5 mg) was prepared similarly as described for compound 14, using L-allo-threoninol instead of DL-alaninol. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.21 (d, J=6.2 Hz, 3 H), 3.35 - 3.44 (m, 1 H), 3.60 (dt, J=8.1, 6.1 Hz, 1 H), 3.82 (s, 3 H), 3.97 (dd, J= 12.8, 9.0 Hz, 1 H), 4.89 (dd, J=12.7, 1.9 Hz, 1 H), 5.04 (d, J=5.9 Hz, 1 H), 7.36 - 7.44 (m, 1 H), 7.44 - 7.49 (m, 2 H), 7.61 (d, J=9.7 Hz, 1 H), 7.87 (ddd, J=13.1, 7.5, 2.4 Hz, 1 H), 9.42 (s, 1 H); Method B; Rt: 0.86 min. m/z : 402 (M+H)+ Exact mass: 401.1.
Compound 36: (3R)-N-(3,4-difluorophenyl)-3-[(R)-hydroxy(phenyl)methyll-7-methyl- l,l-dioxo-3,4-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide.
Figure imgf000081_0002
Compound 36 (81.4 mg) was prepared similarly as described for compound 14, using (lR,2R)-(-)-2-amino-l-phenyl-l,3-propanediol instead of DL-alaninol. Method B; Rt: 1.00 min. m/z : 464 (M+H)+ Exact mass: 463.1. Compound 37: (3S)-N-(3.4-difluorophenyl)-3-r(l S) -hvdroxyethyl1-7-methyl-l.l- dioxo-3,4-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide.
Figure imgf000082_0001
Compound 37 (105.5 mg) was prepared similarly as described for compound 14, using D-threoninol instead of DL-alaninol. 1H NMR (400 MHz, DMSO- d6) δ ppm 1.10 (d, J=6.4 Hz, 3 H), 3.61 - 3.70 (m, 1 H), 3.82 (s, 3 H), 3.85 - 3.99 (m, 2 H), 4.74 (d, J= 11.4 Hz, 1 H), 4.96 (d, J=4.6 Hz, 1 H), 7.36 - 7.44 (m, 2 H), 7.44 - 7.50 (m, 2 H), 7.87 (ddd, J=13.2, 7.5, 2.6 Hz, 1 H), 9.44 (s, 1 H); Method B; Rt: 0.87 min. m/z :
402 (M+H)+ Exact mass: 401.1.
Compound 38 : (3 S)-N-(3 ,4-difluorophenyl)-7-methyl- 1 , 1 -dioxo-3 -(3 -pyridylmethyl)-
3,4-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide.
Figure imgf000082_0002
Compound 38 (7.1 mg) was prepared similarly as described for compound 14, using (2S)-2-amino-3-(3-pyridyl)propan- 1 -ol instead of DL-alaninol. 1H NMR (400 MHz, CHLOROFORM -(i) δ ppm 2.86 - 3.10 (m, 2 H), 3.94 (s, 3 H), 4.13 (br s, 1 H), 4.36 (dd, J=13.0, 9.0 Hz, 1 H), 4.66 (dd, J=12.9, 3.0 Hz, 1 H), 5.35 (br s, 1 H), 7.03 (s, 1 H), 7.06 - 7.16 (m, 2 H), 7.27 - 7.34 (m, 1 H), 7.61 - 7.70 (m, 2 H), 8.45 (d, J=1.5 Hz, 1 H), 8.51 (dd, J=4.8, 1.5 Hz, 1 H), 8.66 (s, 1 H); Method B; Rt: 0.91 min. m/z : 449 (M+H)+ Exact mass: 448.1. Compound 39 : (3 * SV3.7-dimethyl- 1.1 -dioxo-N-(3.4,5 -trifluorophenyl)-2.3.4,5 -tetra- hydropyrrolo[3,4-f|thiazepine-6-carboxamide.
Figure imgf000083_0001
Compound 39 (41 mg) was prepared similarly as described for compound 10, using compound 29 instead of compound 7. 1H NMR (400 MHz, DMSO- d6) δ ppm 1.13 (d, J=6.8 Hz, 3 H), 1.34 (q, J=12.2 Hz, 1 H), 1.84 (br dd, J=14.0, 6.4 Hz, 1 H), 2.78 - 2.99 (m, 1 H), 3.57 - 3.66 (m, 1 H), 3.69 (s, 3 H), 7.03 (d, J=9.6 Hz, 1 H), 7.44 (s, 1 H), 7.54 - 7.66 (m, 1 H), 10.59 (s, 1 H); Method B; Rt: 0.91 min. m/z : 386 (M-H)~ Exact mass: 387.1.
Compound 40 : (3 * S)-N- [4-fluoro-3 -(trifluoromethyl)phenyll -3 ,7-dimethyl- 1 , 1 -dioxo- 2,3,4,5-tetrah dropyrrolo[3,4-f|thiazepine-6-carboxamide.
Figure imgf000083_0002
Compound 40 (49 mg) was prepared similarly as described for compound 10, using compound 30 instead of compound 7. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.13 (d, J=6.8 Hz, 3 H), 1.27 - 1.41 (m, 1 H), 1.81 - 1.88 (m, 1 H), 2.80 - 2.89 (m, 1 H), 2.94 - 3.02 (m, 1 H), 3.59 - 3.67 (m, 1 H), 3.69 (s, 3 H), 7.02 (d, J=9.6 Hz, 1 H), 7.43 (s, 1 H), 7.51 (t, J=9.8 Hz, 1 H), 7.91 - 7.96 (m, 1 H), 8.20 (dd, J=6.6, 2.7 Hz, 1 H), 10.58 (s, 1 H); Method B; Rt: 1.01 min. m/z : 418 (M-H)" Exact mass: 419.1.
Compound 41: (3*S)-N-(4-fluoro-3-methyl-phenyl)-3J-dimethyl-l .l-dioxo-2.3.4.5- tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide.
Figure imgf000084_0001
Compound 41 (52 mg) was prepared similarly as described for compound 10, using compound 31 instead of compound 7. 1H NMR (400 MHz, DMSO- 6) δ ppm 1.13 (d, J=6.8 Hz, 3 H), 1.35 (q, J=12.3 Hz, 1 H), 1.84 (br dd, J=14.0, 6.4 Hz, 1 H), 2.20 - 2.24 (m, 3 H), 2.78 - 2.98 (m, 2 H), 3.59 - 3.73 (m, 4 H), 7.00 (d, J=9.5 Hz, 1 H), 7.10 (t, J=9.2 Hz, 1 H), 7.39 (s, 1 H), 7.45 - 7.52 (m, 1 H), 7.62 (dd, J=7.1, 2.7 Hz, 1 H), 10.23 (s, 1 H); Method B; Rt: 0.92 min. m/z : 364 (M-H)~ Exact mass: 365.1.
Compound 42: (3*S)-3,7-dimethyl-lJ-dioxo-N-[2-(trifluoromethyl)-4-pyridyll-2,3- dihydropyrrolo[3,4-f|tliiazepine-6-carboxamide.
Figure imgf000084_0002
Compound 42 (115 mg) was prepared similarly as described for compound 29, using 4-amino-2-trifluoromethylpyridine instead of 3,4,5-trifluoroaniline. 1H NMR
(400 MHz, DMSO-dtf) δ ppm 1.32 (d, J=7.3 Hz, 3 H), 3.74 (s, 3 H), 4.22 - 4.34
(m, 1 H), 5.61 (dd, J=12.6, 2.4 Hz, 1 H), 6.49 (dd, J=12.6, 2.6 Hz, 1 H), 7.56 - 7.63 (m, 2 H), 7.89 (dd, J=5.5, 2.0 Hz, 1 H), 8.20 (d, J=2.0 Hz, 1 H), 8.67 (d, J=5.5 Hz, 1 H), 11.21 (br s, 1 H); Method B; Rt: 0.86 min. m/z : 401 (M+H)+ Exact mass: 400.1.
Compound 43: N-(3,4-difluorophenyl)-7-methyl-3-(l-methylpyrazol-4-yl)-l,l-dioxo- 3,4-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide.
Figure imgf000084_0003
Compound 43 (53.6 mg) was prepared similarly as described for compound 14, using 2-amino-2-(l -methyl- lh-pyrazol-4-yl)ethan-l-ol instead of DL-alaninol. The ring closure was obtained after heating overnight at 140 °C in DMA and compound 43 was purified using a heptane to EtOAc:EtOH 3:1 gradient. 1H NMR (400 MHz, DMSO- 6) δ ppm 3.81 (s, 3 H), 3.84 (s, 3 H), 3.98 - 4.11 (m, 1 H), 4.72 (dd, J=12.5, 2.2 Hz, 1 H), 4.86 (td, J=9.6, 1.9 Hz, 1 H), 7.36 - 7.44 (m, 1 H), 7.44 - 7.51 (m, 2 H), 7.53 (s, 1 H), 7.72 (s, 1 H), 7.82 - 7.89 (m, 1 H), 8.02 (d, J=9.7 Hz, 1 H), 9.46 (s, 1 H); Method B; Rt: 0.90 min. m/z : 438 (M+H)+ Exact mass: 437.1. Compound 44: (3 S)-N-(3 ,4-difluorophenyl)-7-fluoro-3 -isopropyl- 1 , 1 -dioxo-
3 ,4-dihydro-2H-5 , 1 6,2-benzoxathiazepine-6-carboxamide.
Figure imgf000085_0001
Compound 44 (11.5 mg) was prepared similarly as described for compound 12, using L-valinol instead of DL-alaninol. 1H NMR (400 MHz, DMSO-d6) δ ppm 0.94
(dd, J=6.71, 1.65 Hz, 6 H) 1.80 (dq, J=13.70, 6.80 Hz, 1 H) 3.43 - 3.56 (m, 1 H) 3.80 (dd, J=12.43, 10.01 Hz, 1 H) 4.55 (dd, J=12.54, 2.20 Hz, 1 H) 7.31 (t, J=8.69 Hz, 1 H) 7.35 - 7.51 (m, 2 H) 7.70 (br d, J=8.58 Hz, 1 H) 7.80 - 7.92 (m, 2 H) 10.98 (s, 1 H); Method B; Rt: 1.03 min. m/z : 413 (M-H)~ Exact mass: 414.1.
Compound 45: (3S)-N-(3-cyano-4-fluoro-phenyl)-7-fluoro-3-isopropyl-l,l-dioxo- 3 ,4-dihydro-2H-5 , 1 6,2-benzoxathiazepine-6-carboxamide.
Figure imgf000085_0002
Compound 45 (378.5 mg) was prepared similarly as described for compound 44, using
5-amino-2-fluorobenzonitrile instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO-de) δ ppm 0.94 (dd, J=6.82, 2.20 Hz, 6 H) 1.80 (dq, J=13.78, 6.78 Hz, 1 H) 3.48 (br s, 1 H) 3.80 (dd, J=12.54, 10.12 Hz, 1 H) 4.56 (dd, J=12.54, 2.20 Hz, 1 H) 7.33 (t, J=8.69 Hz, 1 H) 7.56 (t, J=9.13 Hz, 1 H) 7.70 (br s, 1 H) 7.85 - 7.98 (m, 2 H) 8.20 (dd, J=5.72, 2.64 Hz, 1 H) 11.14 (s, 1 H); Method B; Rt: 0.98 min. m/z : 420 (M-H)~ Exact mass: 421.1.
Compound 46: (3R)-7-fluoro-N-(3-fluoro-4-methyl-phenyl)-3-isopropyl-l,l-dioxo-3,4- dihydro-2H-5 , 1 6,2-benzoxathiazepine-6-carboxamide.
Figure imgf000086_0001
Compound 46 (155.1 mg) was prepared similarly as described for compound 44, using 4-fluoro-3-methylaniline instead of 3,4-difluoroaniline. 1H NMR (400 MHz,
DMSC /e) δ ppm 0.94 (dd, J=6.82, 1.98 Hz, 6 H) 1.80 (dq, J=13.78, 6.78 Hz, 1 H) 2.24 (d, J=1.54 Hz, 3 H) 3.41 - 3.60 (m, 1 H) 3.80 (dd, J=12.32, 9.90 Hz, 1 H) 4.53 (dd, J=12.54, 2.20 Hz, 1 H) 7.13 (t, J=9.24 Hz, 1 H) 7.29 (t, J=8.58 Hz, 1 H) 7.40 - 7.52 (m, 1 H) 7.63 (dd, J=6.93, 2.53 Hz, 1 H) 7.68 (br d, J=7.48 Hz, 1 H) 7.87 (dd, J=8.80, 6.38 Hz, 1 H) 10.70 (s, 1 H); Method B; Rt: 1.04 min. m/z : 409 (M-H)" Exact mass: 410.1.
Compound 47: N-(3 ,4-difluorophenyl)-7-methyl- 1 , 1 -dioxo-3-(trifluoromethyl)- 2,3,4,5-tetrah dropyrrolo[3,4-f|thiazepine-6-carboxamide.
Figure imgf000086_0002
l,l,l-trifluorobut-3-en-2-ylamine (306 mg, 1.90 mmol) was dissolved in pyridine (5 mL). Methyl 3-bromo-4-chlorosulfonyl-l-methyl-pyrrole-2-carboxylate (500 mg, 1.58 mmol) was added and the mixture stirred at room temperature for 16 hours. The reaction mixture was filtered and the filtrate was evaporated to dryness. The residue was purified by column chromatography using a gradient from 0 till 50% EtOAc in heptane over 15 column volumes. The product fractions were concentrated in vacuum to yield methyl 3-bromo-l-methyl-4-[l-(trifluoromethyl)allylsulfamoyl]pyrrole-2- carboxylate (385 mg) as a white powder. Method D; Rt: 1.74 min. m/z : 405 (M+H)+ Exact mass: 404.0.
Methyl 3-bromo-l -methyl -4-[l-(trifluoromethyl)allylsulfamoyl]pyrrole-2-carboxylate (385 mg), bis(tri-tert-butylphosphine)palladium(0) (211 mg, 0.41 mmol) and
trimethylamine (286 μί, 2.07 mmol) were dissolved in DMF (5 mL). The reaction mixture was heated in the microwave oven for 30 minutes at 120 °C. The volatiles were removed under reduced pressure and the residue was purified by column
chromatography using a gradient from 0 till 50% EtOAc in heptane over 15 column volumes. The product fractions were concentrated in vacuo to yield methyl 7-methyl- l,l-dioxo-3-(trifluoromethyl)-2,3-dihydropyrrolo[3,4-f]thiazepine-6-carboxylate (152 mg) as a white solid. Method D; Rt: 1.64 min. m/z : 405 (M+H)+ Exact mass: 404.0.
Methyl 7-methyl-l,l-dioxo-3-(trifluoromethyl)-2,3-dihydropyrrolo[3,4-f]thiazepine-6- carboxylate (152 mg) and Pd/C (10%) (50 mg, 0.047 mmol) were dispensed in MeOH (50 mL). The reaction mixture was set under a hydrogen atmosphere and stirred for 2 hours. The reaction mixture was filtered and the volatiles were removed under reduced pressure yielding methyl 7 -methyl- l,l-dioxo-3-(trifluoromethyl)-2, 3,4,5- tetrahydropyrrolo[3,4-f]thiazepine-6-carboxylate (153 mg) as a white powder.
Methyl 7-methyl-l,l-dioxo-3-(trifluoromethyl)-2,3,4,5-tetrahydropyrrolo- [3,4-fJthiazepine-6-carboxylate (153 mg) and 3,4-difluoroaniline (57 μί, 0.56 mmol) were dissolved in THF (10 mL). Lithium bis(trimethylsilyl)amide (1.41 mL, 1 M in THF, 1.41 mmol) was added and the reaction mixture was stirred 4 hours at room temperature. NH4C1 (sat., aq., 5 mL) was added and the organic layer was removed. The aqueous layer was extracted with DCM (2 X 5 mL) and the combined organic layers were evaporated to dryness. The residue was purified via prep. HPLC
(Stationary phase: RP XBridge Prep C18 ΟΒϋ-10μιη, 30x150mm, mobile phase:
0.25%) NH4HCC"3 solution in water, MeOH) compound 47 (73 mg) as a white powder. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.58 - 1.69 (m, 1 H), 2.11 (br dd, J=13.8, 6.3 Hz, 1 H), 2.84 - 2.95 (m, 1 H), 3.12 (br dd, J=15.6, 6.2 Hz, 1 H), 3.70 (s, 3 H), 4.18 - 4.31 (m, 1 H), 7.37 - 7.50 (m, 2 H), 7.54 (s, 1 H), 7.79 - 7.88 (m, 1 H), 8.04 (d, J=10.4 Hz, 1 H), 10.54 (s, 1 H); Method D; Rt: 1.82 min. m/z : 422 (M-H)~ Exact mass: 423.1. Compound 48: (3R)-N-(3 ,4-difluorophenyl)-7-fluoro-3-isopropyl- 1 , 1 -dioxo- 3 ,4-dih dro-2H-5 , 1 6,2-benzoxathiazepine-6-carboxamide.
Figure imgf000088_0001
Compound 48 (75.5 mg) was prepared similarly as described for compound 12, using D-valinol instead of DL-alaninol. 1H NMR (400 MHz, DMSO- d6) δ ppm 0.94
(dd, J=6.71, 1.87 Hz, 6 H) 1.66 - 1.94 (m, 1 H) 3.48 (br t, J=7.59 Hz, 1 H) 3.80 (dd, J=12.43, 10.01 Hz, 1 H) 4.55 (dd, J=12.54, 2.20 Hz, 1 H) 7.23 - 7.35 (m, 1 H) 7.36 - 7.51 (m, 2 H) 7.70 (s, 1 H) 7.79 - 7.94 (m, 2 H) 10.97 (s, 1 H); Method B; Rt: 1.02 min. m/z : 413 (M-H)~ Exact mass: 414.1.
Compound 49: (3R)-N-(3-cyano-4-fluoro-phenyl)-7-fluoro-3-isopropyl-l,l-dioxo- 3 ,4-dihydro-2H-5 , 1 6,2-benzoxathiazepine-6-carboxamide.
Figure imgf000088_0002
Compound 49 (39.7 mg) was prepared similarly as described for compound 48, using 5-amino-2-fluorobenzonitrile instead of 3,4-difluoroaniline. 1H NMR (400 MHz,
DMSO-de) δ ppm 0.94 (dd, J=6.82, 2.20 Hz, 6 H) 1.80 (dq, J=13.64, 6.82 Hz, 1 H) 3.43 - 3.54 (m, 1 H) 3.81 (dd, J=12.43, 10.01 Hz, 1 H) 4.56 (dd, J=12.54, 2.20 Hz, 1 H) 7.32 (t, J=8.58 Hz, 1 H) 7.56 (t, J=9.13 Hz, 1 H) 7.71 (br s, 1 H) 7.84 - 8.04 (m, 2 H) 8.20 (dd, J=5.61, 2.75 Hz, 1 H) 11.15 (br s, 1 H); Method B; Rt: 0.97 min. m/z : 420 (M-H)" Exact mass : 421.1. Compound 50: (3 * S)-N-(2-bromo-4-pyridyl)-3 ,7-dimethyl- 1 , 1 -dioxo-2,3-dihydro- pyrrolo[3,4-f|thiazepine-6-carboxamide.
Figure imgf000089_0001
Compound 50 (42 mg) was prepared similarly as described for compound 29, using
4-amino-2-bromopyridine instead of 3,4,5-trifluoroaniline. 1H NMR (400 MHz, DMSO- ¾ δ ppm 1.31 (d, J=7.5 Hz, 3 H), 3.72 (s, 3 H), 4.19 - 4.33 (m, 1 H), 5.61 (dd, J=12.5, 2.4 Hz, 1 H), 6.45 (dd, J=12.8, 2.6 Hz, 1 H), 7.55 - 7.60 (m, 2 H), 7.63 (dd, J=5.6, 1.9 Hz, 1 H), 7.96 (d, J=1.8 Hz, 1 H), 8.29 (d, J=5.6 Hz, 1 H), 1 1.05 (s, 1 Method D; Rt: 1.52 min. m/z : 41 1 (M+H)+ Exact mass: 410.0.
Compound 51 : (3 * S)-N-[3-(difluoromethyl)-4-fluoro-phenyll-3 ,7-dimethyl- 1 , 1 -dioxo- 2,3-dihydropyrrolo[3,4-f|thiazepine-6-carboxamide.
Figure imgf000089_0002
Compound 51 (46 mg) was prepared similarly as described for compound 29, using 3 -(difluoromethyl)-4-fluoro-aniline instead of 3,4,5-trifluoroaniline. 1H NMR
(400 MHz, DMSO-dtf) δ ppm 1.31 (d, J=7.5 Hz, 3 H), 3.71 (s, 3 H), 4.20 - 4.33 (m, 1 H), 5.57 (dd, J=12.5, 2.4 Hz, 1 H), 6.46 (dd, J=12.6, 2.6 Hz, 1 H), 7.23 (br t, J=54.4 Hz, 1 H), 7.38 (t, J=9.6 Hz, 1 H), 7.51 - 7.58 (m, 2 H), 7.77 - 7.87 (m, 1 H), 8.06 (dd, J=6.3, 2.7 Hz, 1 H), 10.75 (s, 1 H); Method B; Rt: 0.90 min. m/z : 398 (M-H)~ Exact mass: 399.1.
Compound 52: (3 * S)-N-(3-chloro-2,4-difluoro-phenyl)-3 ,7-dimethyl- 1 , 1 -dioxo- 2,3-dihydropyrrolo[3,4-f|thiazepine-6-carboxamide.
Figure imgf000089_0003
Compound 52 (40 mg) was prepared similarly as described for compound 29, using 3-chloro-2,4-difluoroaniline instead of 3,4,5-trifluoroaniline. 1H NMR (400 MHz, DMSO- ¾ δ ppm 1.31 (d, J=7.5 Hz, 3 H), 3.73 (s, 3 H), 4.20 - 4.33 (m, 1 H), 5.60 (dd, J=12.5, 2.4 Hz, 1 H), 6.58 (dd, J=12.7, 2.5 Hz, 1 H), 7.36 (td, J=9.0, 2.0 Hz, 1 H), 7.55 (s, 1 H), 7.57 (d, J=9.3 Hz, 1 H), 7.64 (td, J=8.7, 5.8 Hz, 1 H), 10.45 (br s, 1 H); Method B; Rt: 0.93 min. m/z : 400 (M-H)~ Exact mass: 401.0.
Compound 53: (3 * S)-3 ,7-dimethyl- 1 , 1 -dioxo-N-[2-(trifluoromethyl)-4-pyridyll-
2,3,4,5-tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide.
Figure imgf000090_0001
To a solution of methyl 3-bromo-l-methyl-4-[[(l !i:S)-l-methylallyl]sulfamoyl]pyrrole- 2-carboxylate (3.5 g, 10 mmol) in DMA (200 mL), in a pressure tube, purged with nitrogen, was added Hunig's base (1.89 mL, 0.75 g/mL, 11.0 mmol) and bis(tri-tert- butylphosphine)palladium(O) (0.76 g, 1.49 mmol). The reaction mixture was heated for 10 minutes at 140 °C. The reaction mixture was poured into HCL (aq., 0.5 M, 150 mL). The resulting suspension was extracted with ethyl acetate (3 X 100 mL). The combined organic layers were dried (Na2S04), concentrated and the residue (8 g) was purified using silica gel column chromatography (ethyl acetate in heptane from 0 to 40%). The desired fractions were combined and concentrated. This was purified via preparative HPLC (Stationary phase: RP XBridge Prep C18 OBD-ΙΟμιη, 30x150mm, Mobile phase: 0.25% NH4HC03 solution in water, MeOH) yielding methyl (3*S)-3,7-dimethyl- l,l-dioxo-2,3-dihydropyrrolo[3,4-f]thiazepine-6-carboxylate (640 mg) as a white powder. Method B; Rt: 0.74 min. m/z : 269 (M-H)" Exact mass: 270.1. Methyl (3 * S)-3 ,7-dimethyl- 1 , 1 -dioxo-2,3-dihydropyrrolo[3 ,4-f]thiazepine-
6-carboxylate (400 mg, 1.48 mmol) was dissolved in MeOH (40 mL). Under a nitrogen atmosphere Pd/C (10%>) (157 mg, 0.15 mmol) was added. The reaction mixture was hydrogenated for 30 minutes. The reaction mixture was filtered over decalite. The filtrate was evaporated to dryness to afford methyl (3S)-3,7-dimethyl-l,l-dioxo- 2,3,4,5-tetrahydropyrrolo[3,4-fJthiazepine-6-carboxylate (360 mg) as a white powder.
To a solution of methyl (3S)-3,7-dimethyl-l,l-dioxo-2,3,4,5-tetrahydropyrrolo- [3,4-fJthiazepine-6-carboxylate (72 mg) and 4-amino-2-trifluoromethylpyridine (51 mg, 0.32 mmol in THF (5 mL) was added lithium bis(trimethylsilyl)amide (1.06 mL, 1 M in THF, 1.06 mmol) and the reaction mixture was stirred 1 hour at room temperature. NH4C1 (sat., aq., 5 mL) was added and the organic layer was separated. The aqueous layer was extracted with DCM (2 X 5 mL) and the combined organic layers were evaporated to dryness. The residue was purified via prep. HPLC (Stationary phase: RP XBridge Prep C 18 OBD-ΙΟμιη, 30x150mm, Mobile phase: 0.25% NH4HCO3 solution in water, ACN) yielding compound 53 (60 mg) as a white powder. 1H NMR (400 MHz, DMSO- ¾ δ ppm 1.13 (d, J=6.8 Hz, 3 H), 1.29 - 1.42 (m, 1 H), 1.79 - 1.89 (m, 1 H), 2.80 - 2.91 (m, 1 H), 2.94 - 3.05 (m, 1 H), 3.56 - 3.67 (m, 1 H), 3.71 (s, 3 H), 7.04 (d, J=9.6 Hz, 1 H), 7.47 (s, 1 H), 7.86 (dd, J=5.6, 2.0 Hz, 1 H), 8.19 (d, J=2.0 Hz, 1 H), 8.64 (d, J=5.5 Hz, 1 H), 10.94 (br s, 1 H); Method D; Rt: 1.63 min. m/z : 403 (M+H)+ Exact mass: 402.1.
Compound 54: (3 * S)-N-(3-chloro-2,4-difluoro-phenyl)-3 ,7-dimethyl- 1 , 1 -dioxo-
2,3,4,5-tetrah dropyrrolo[3,4-f|thiazepine-6-carboxamide.
Figure imgf000091_0001
Compound 54 (24 mg) was prepared similarly as described for compound 53, using 3-chloro-2,4-difluoroaniline instead of 4-amino-2-trifluoromethylpyridine. 1H NMR (400 MHz, DMSO- ¾ δ ppm 1.14 (d, J=6.8 Hz, 3 H), 1.38 (q, J=12.4 Hz, 1 H), 1.87 (br dd, J=14.1 , 6.6 Hz, 1 H), 2.76 - 2.89 (m, 1 H), 3.12 (br dd, J=15.5, 6.6 Hz, 1 H),
3.56 - 3.68 (m, 1 H), 3.69 (s, 3 H), 7.02 (d, J=9.6 Hz, 1 H), 7.35 (td, J=9.0, 2.0 Hz, 1 H), 7.42 (s, 1 H), 7.65 (td, J=8.8, 5.8 Hz, 1 H), 10.18 (br s, 1 H); Method B; Rt: 0.94 min. m/z : 402 (M-H)~ Exact mass: 403.1. Compound 55: (3 * S)-N-[3-(difluoromethyl)-4-fluoro-phenyll-3 ,7-dimethyl- 1 , 1 -dioxo-
2,3,4,5-tetrah dropyrrolo[3,4-f|thiazepine-6-carboxamide.
Figure imgf000091_0002
Compound 55 (55 mg) was prepared similarly as described for compound 53, using
3-(difluoromethyl)-4-fluoro-aniline instead of 4-amino-2-trifluoromethylpyridine.
1H NMR (400 MHz, DMSO-^) δ ppm 1.13 (d, J=6.8 Hz, 3 H), 1.36 (q, J=12.3 Hz, 1 H), 1.85 (br dd, J=13.9, 6.4 Hz, 1 H), 2.76 - 2.90 (m, 1 H), 2.92 - 3.02 (m, 1 H), 3.57 - 3.74 (m, 4 H), 7.01 (d, J=9.6 Hz, 1 H), 7.22 (t, J=54.4 Hz, 1 H), 7.33 - 7.40 (m, 1 H), 7.41 (s, 1 H), 7.74 - 7.86 (m, 1 H), 8.06 (dd, J=6.4, 2.7 Hz, 1 H), 10.48 (s, 1 H); Method B; Rt: 0.91 min. m/z : 400 (M-H)" Exact mass: 401.1.
Compound 56: (3 * S)-N-(3 -cyano-4-fluoro-phenyl)-3 ,7-dimethyl- 1 , 1 -dioxo-
2,3,4,5-tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide.
Figure imgf000092_0001
Compound 56 (53 mg) was prepared similarly as described for compound 53, using 5-amino-2-fluorobenzonitrile instead of 4-amino-2-trifluoromethylpyridine. 1H NMR (400 MHz, DMSO- ¾ δ ppm 1.13 (d, J=6.8 Hz, 3 H), 1.35 (br q, J=12.5 Hz, 1 H), 1.84 (br dd, J=14.1 , 6.4 Hz, 1 H), 2.78 - 2.89 (m, 1 H), 2.92 - 3.02 (m, 1 H), 3.56 - 3.66 (m, 1 H), 3.69 (s, 3 H), 7.02 (d, J=9.5 Hz, 1 H), 7.43 (s, 1 H), 7.53 (t, J=9.1 Hz, 1 H), 7.95 (ddd, J=9.2, 4.9, 2.7 Hz, 1 H), 8.19 (dd, J=5.8, 2.7 Hz, 1 H), 10.59 (s, 1 H); Method B; Rt: 0.84 min. m/z : 375 (M-H)" Exact mass: 376.1.
Compound 57: (3 * S)-N-(2-bromo-4-pyridyl)-3 ,7-dimethyl- 1 , 1 -dioxo-2,3 ,4,5-tetra- hydropyrrolo[3,4-f|thiazepine-6-carboxamide.
Figure imgf000092_0002
Compound 57 (25 mg) was prepared similarly as described for compound 53, using 4-amino-2-bromopyridine instead of 4-amino-2-trifluoromethylpyridine. 1H NMR (400 MHz, DMSO-dtf) δ ppm 1.13 (d, J=6.8 Hz, 3 H), 1.35 (q, J=12.3 Hz, 1 H),
1.79 - 1.91 (m, 1 H), 2.79 - 2.89 (m, 1 H), 2.91 - 3.00 (m, 1 H), 3.55 - 3.67 (m, 1 H), 3.70 (s, 3 H), 7.04 (d, J=9.6 Hz, 1 H), 7.46 (s, 1 H), 7.61 (dd, J=5.6, 1.9 Hz, 1 H), 7.95 (d, J=1.8 Hz, 1 H), 8.27 (d, J=5.6 Hz, 1 H), 10.78 (s, 1 H); Method B; Rt: 0.84 min. m/z : 41 1 (M-H)" Exact mass: 412.0. Compound 58: 7-methyl- 1 , 1 -dioxo-3-(trifluoromethyl)-N-[2-(trifluoromethyl)- 4-pyridyll-2,3-dihydropyrrolo[3,4-f|thiazepine-6-carboxamide.
Figure imgf000093_0001
Methyl 7-methyl-l , l-dioxo-3-(trifluoromethyl)-2,3-dihydropyrrolo[3,4-f]thiazepine- 6-carboxylate (200 mg) and 4-amino-2-trifluoromethylpyridine (102 mg, 0.62 mmol) were dissolved in THF (4 mL). Lithium bis(trimethylsilyl)amide (1.85 mL, 1 M in THF, 1.85 mmol) was added dropwise to the reaction mixture and stirred at room temperature for 2 hours. The reaction was quenched with NH4C1 (sat., aq., 5 mL) and the organic layer was separated, dried (MgS04), filtered and concentrated in vacuum. The residue was purified via prep. HPLC (Stationary phase: RP XBridge Prep CI 8 OBD-ΙΟμιη, 30x150mm, Mobile phase: 0.25% NH4HC03 solution in water, ACN) yielding compound 58 (10 mg). 1H NMR (400 MHz, DMSO-^) δ ppm 3.78 (s, 3 H), 4.89 (br dd, J=l l . l , 8.2 Hz, 1 H), 5.82 (dd, J=12.2, 3.0 Hz, 1 H), 6.86 (dd, J=12.2, 2.7 Hz, 1 H), 7.79 (s, 1 H), 7.89 (dd, J=5.5, 2.0 Hz, 1 H), 8.20 (d, J=1.9 Hz, 1 H), 8.67 (d, J=5.2 Hz, 1 H), 8.69 (s, 1 H), 1 1.27 - 1 1.32 (m, 1 H); Method D; Rt: 1.76 min. m/z : 455 (M+H)+ Exact mass: 454.1.
Compound 59: 7-methyl- 1 , 1 -dioxo-3-(trifluoromethyl)-N-[2-(trifluoromethyl)- 4-pyridyll-2,3,4,5-tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide.
Figure imgf000093_0002
Compound 59 (118 mg) was prepared similarly as described for compound 47, using 4-amino-2-trifluoromethylpyridine instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.64 (q, J=12.2 Hz, 1 H), 2.06 - 2.15 (m, 1 H), 2.87 - 2.98 (m, 1 H), 3.13 - 3.29 (m, 1 H), 3.68 - 3.80 (m, 3 H), 4.20 - 4.32 (m, 1 H), 7.61 (s, 1 H), 7.87 (dd, J=5.5, 2.0 Hz, 1 H), 8.07 (br d, J=9.9 Hz, 1 H), 8.19 (d, J=2.0 Hz, 1 H), 8.66 (d, J=5.5 Hz, 1 H), 1 1.03 (s, 1 H); Method D; Rt: 1.75 min. m/z : 457 (M+H)+ Exact mass: 456.1. This racemic mixture was seperated in enantiomers 59a and 59b by preparative SFC (Stationary phase: Chiralpak Diacel AD 20 x 250 mm, Mobile phase: C02, EtOH with 0.4% iPrNH2). Method H; Rt : 59a: 1.65 min, 59b: 2.36 min.
Compound 60: N-(3-cyano-4-fluoro-phenyl)-7-methyl- 1 , 1 -dioxo-3-(trifluoromethyl)- 2,3,4,5-tetrah dropyrrolo[3,4-f|thiazepine-6-carboxamide.
Figure imgf000094_0001
Compound 60 (139 mg) was prepared similarly as described for compound 47, using 5-amino-2-fluorobenzonitrile instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.59 - 1.70 (m, 1 H), 2.06 - 2.16 (m, 1 H), 2.84 - 2.96 (m, 1 H), 3.10 - 3.21 (m, 1 H), 3.66 - 3.78 (m, 3 H), 4.19 - 4.32 (m, 1 H), 7.51 - 7.58 (m, 2 H), 7.96 (ddd, J=9.2, 4.8, 2.6 Hz, 1 H), 8.05 (d, J=10.3 Hz, 1 H), 8.19 (dd, J=5.8, 2.7 Hz, 1 H), 10.61 - 10.71 (m, 1 H); Method D; Rt: 1.73 min. m/z : 429 (M-H)~ Exact mass: 430.1. This racemic mixture was seperated in enantiomers 60a and 60b by preparative SFC (Stationary phase: Chiralpak Diacel AD 20 x 250 mm, Mobile phase: C02, EtOH with 0.4% iPrNH2). Method I; Rt : 60a: 1.16 min, 60b: 1.61 min.
Compound 61: (3 S)-N-(3 ,4-difluorophenyl)-7-methyl- 1 , 1 -dioxo-3 -(trifluoromethyl)-
3,4-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide.
Figure imgf000094_0002
Ethyl 4-chlorosulfonyl-3-fluoro-l-methyl-pyrrole-2-carboxylate (250 mg) and
(2S)-2-amino-3,3,3-trifluoropropan-l-ol hydrochloride (153 mg, 0.93 mmol) were dissolved in pyridine (2 mL) and stirred overnight at room temperature. The volatiles were removed under reduced pressure and the residue was purified on silica using a heptane to EtOAc gradient yielding ethyl 3-fluoro-l-methyl-4-[[(l S)-2,2,2-trifluoro- l-(hydroxymethyl)ethyl]sulfamoyl]pyrrole-2-carboxylate (254 mg). Ethyl 3-fluoro- 1 -methyl-4-[[(l S)-2,2,2-trifluoro- 1 -(hydroxymethyl)ethyl]sulfamoyl]- pyrrole-2-carboxylate (254 mg) and 3,4-difluoroaniline (0.071 mL, 0.7 mmol) were dissolved in THF (5 mL). Lithium bis(trimethylsilyl)amide (2.8 mL, 1 M in THF, 2.8 mmol) was added and the reaction mixture was stirred overnight at room
temperature. NH4C1 (sat., aq., 50 mL) was added and the organic layer was removed. The aqueous layer was extracted with DCM (2 X 5 mL) and the combined organic layers were evaporated to dryness. The residue was purified on silica using a heptane to EtOAc:EtOH 3:1 gradient yielding N-(3,4-difluorophenyl)-3-fluoro-l-methyl-4-[[(l S)- 2,2,2-trifluoro-l-(hydroxymethyl)ethyl]sulfamoyl]pyrrole-2-carboxamide (198 mg). Method B; Rt: 0.91 min. m/z : 446 (M+H)+ Exact mass: 445.1.
N-(3 ,4-difluorophenyl)-3-fluoro- 1 -methyl-4-[[( 1 S)-2,2,2-trifluoro- 1 -(hydroxymethyl)- ethyl]sulfamoyl]pyrrole-2-carboxamide (198 mg) and cesium fluoride (173 mg, 1.14 mmol) were dissolved in DMF (5 mL) and heated overnight at 100 °C. The reaction mixture was purified via prep. HPLC (Stationary phase: RP XBridge Prep
C18 OBD-ΙΟμιη, 30x150mm, Mobile phase: 0.25% NH4HC03 solution in water, ACN) yielding compound 61 as a white powder. 1H NMR (400 MHz, DMSO-de) δ ppm 3.83 (s, 3 H), 4.29 (dd, J=12.7, 9.4 Hz, 1 H), 4.49 - 4.62 (m, 1 H), 4.91 (dd, J=13.0, 2.0 Hz, 1 H), 7.37 - 7.46 (m, 1 H), 7.46 - 7.52 (m, 1 H), 7.58 (s, 1 H), 7.86 (ddd, J=13.2, 7.5, 2.4 Hz, 1 H), 8.75 (br s, 1 H), 9.47 (s, 1 H); Method B; Rt: 0.99 min. m/z : 426 (M+H)+ Exact mass: 425.1.
Compound 62: (3R)-N-(3,4-difluorophenyl)-3-[(lR)-l-methoxyethyll-7-methyl- lJ-dioxo-3,4-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide.
Figure imgf000095_0001
Ethyl 4-chlorosulfonyl-3-f uoro-l-methyl-pyrrole-2-carboxylate (250 mg), O-methyl-L- threonine (119 mg, 0.89 mmol) and Hunig's base (0.46 mL, 2.68 mmol) were dissolved in DCM (5 mL) and stirred overnight at room temperature. The reaction mixture was directly loaded on a silica cartridge and a gradient from heptane to EtOAc:EtOH:AcOH 3:1 :0.1 was applied yielding (2S,3R)-2-[(5-ethoxycarbonyl-4-fluoro-l-methyl-pyrrol- 3-yl)sulfonylamino]-3-methoxy-butanoic acid as an off-white powder (310 mg). (2S ,3R)-2- [(5 -ethoxycarbonyl-4-fluoro- 1 -methyl-pyrrol-3 -yl)sulfonylamino] - 3 -methoxy-butanoic acid (310 mg) and 3,4-difluoroaniline (86 μί, 0.85 mmol) were dissolved in THF (5 mL). Lithium bis(trimethylsilyl)amide (4.23 mL, 1 M in THF, 4.23 mmol) was added and the reaction mixture was stirred 2 hours at room
temperature. NH4C1 (sat., aq., 50 mL) was added and the organic layer was removed. The aqueous layer was extracted with DCM (2 X 5 mL) and the combined organic layers were evaporated to dryness. The residue was purified on silica using a gradient from heptane to EtOAc:EtOH:AcOH 3: 1 :0.1 yielding (2S,3R)-2-[[5-[(3,4-difluoro- phenyl)carbamoyl] -4-fluoro- 1 -methyl-pyrrol-3 -yl] sulfonylamino] -3 -methoxy-butanoic acid as an off-white powder (324 mg).
(2S,3R)-2-[[5-[(3,4-difluorophenyl)carbamoyl]-4-fluoro-l-methyl-pyrrol-3-yl]- sulfonylamino] -3 -methoxy-butanoic acid was dissolved in THF (10 mL) and lithium aluminum hydride solution (1.44 mL, 1 M in THF, 1.44 mmol) was added dropwise and the reaction mixture was stirred overnight at room temperature. Sodium sulfate decahydrate (348 mg, 1.08 mmol) was added followed by Na2S04. The reaction mixture was filtered and evaporated to dryness. The residue was purified using a heptane to EtOAc:EtOH 3: 1 gradient yielding N-(3,4-difluorophenyl)-3-fluoro-4- [[(1 R,2R)- 1 -(hydroxymethyl)-2-methoxy-propyl]sulfamoyl]- 1 -methyl-pyrrole- 2-carboxamide (50 mg).
N-(3 ,4-difluorophenyl)-3 -f uoro-4- [[( 1 R,2R)- 1 -(hydro xymethyl)-2-methoxy-propyl] - sulfamoyl]-l-methyl-pyrrole-2-carboxamide (50 mg) was dissolved in DMF (5 mL). Cesium fluoride (70 mg, 0.46 mmol) was added and the reaction mixture was heated overnight at 100 °C. The reaction mixture was directly loaded on a silica cartridge and a gradient from heptane to EtOAc was applied yielding compound 62 (23.9 mg) as an off-white powder. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.13 (d, J=6.4 Hz, 3 H), 3.28 (s, 3 H), 3.55 - 3.65 (m, 1 H), 3.77 (br dd, J=7.9, 3.3 Hz, 1 H), 3.82 (s, 3 H), 4.00 (dd, J=12.5, 9.0 Hz, 1 H), 4.70 (dd, J=12.7, 1.2 Hz, 1 H), 7.36 - 7.44 (m, 1 H), 7.44 - 7.51 (m, 2 H), 7.51 - 7.62 (m, 1 H), 7.86 (ddd, J=13.3, 7.5, 2.5 Hz, 1 H), 9.42 (s, 1 H); Method B; Rt: 0.99 min. m/z : 416 (M+H)+ Exact mass: 415.1. Compound 63: (3 S)-N-(3 ,4-difluorophenyl)-3 - [(S)-hydroxy(phenyOmethyl] -7-methyl - l J-dioxo-3,4-dihydro-2H-pyrrolo[3,4-bl[l ,4,51oxathiazepine-6-carboxamide.
Figure imgf000097_0001
Compound 63 (32.7 mg) was prepared similarly as described for compound 14, using (l S,2S)-(+)-2-amino-l-phenyl-l ,3-propanediol instead of DL-alaninol. The ring closure was obtained after heating overnight at 100°C in DMF and compound 63 was purified via prep. HPLC (Stationary phase: RP XBridge Prep C18 OBD-ΙΟμιη, 30xl50mm, Mobile phase: 0.25% NH4HCO3 solution in water, ACN). 1H NMR (400 MHz, DMSO-d6) δ ppm 3.80 (s, 3 H), 3.85 - 3.96 (m, 1 H), 4.01 (dd, J=12.4, 9.1 Hz, 1 H), 4.72 (br d, J=1 1.9 Hz, 1 H), 4.86 (t, J=4.3 Hz, 1 H), 5.67 (d, J=4.6 Hz, 1 H), 7.25 - 7.31 (m, 1 H), 7.31 - 7.48 (m, 8 H), 7.79 - 7.90 (m, 1 H), 9.44 (s, 1 H); Method B; Rt: 0.98 min. m/z : 462 (M-H)~ Exact mass: 463.1.
Compound 64: (3R)-N-[3-(difluoromethyl)-4-fluoro-phenyll-3-[(l S)- 1 -hy droxy ethyl] - 7-methyl-l , l-dioxo-3,4-dihydro-2H-pyrrolo[3,4-bl[l ,4,51oxathiazepine-6-carboxamide.
Figure imgf000097_0002
Compound 64 (124.8 mg) was prepared similarly as described for compound 35, using 3-(difluoromethyl)-4-fluoro-aniline instead of 3,4-difluoroaniline and heating overnight at 100°C. 1H NMR (400 MHz, DMSO-^) δ ppm 1.22 (d, J=6.2 Hz, 3 H), 3.35 - 3.46 (m, 1 H), 3.55 - 3.67 (m, 1 H), 3.83 (s, 3 H), 3.99 (dd, J=12.8, 9.0 Hz, 1 H), 4.89 (dd, J=12.8, 1.8 Hz, 1 H), 5.05 (br s, 1 H), 7.21 (t, J=54.4 Hz, 1 H), 7.35 (t, J=9.5 Hz, 1 H), 7.47 (s, 1 H), 7.61 (br s, 1 H), 7.82 (dt, J=8.1 , 4.1 Hz, 1 H), 8.04 (dd, J=6.3, 2.5 Hz, 1 H), 9.41 - 9.51 (m, 1 H); Method B; Rt: 0.87 min. m/z : 432 (M-H)" Exact mass: 433.1. Compound 65: (3R)-N-(3-cyano-4-fluoro-phenyl)-3-[(l S)- 1 -hydroxyethyl] -7-methyl - l J-dioxo-3,4-dihydro-2H-pyrrolo[3,4-bl[l ,4,51oxathiazepine-6-carboxamide.
Figure imgf000098_0001
Compound 65 (29.2 mg) was prepared similarly as described for compound 64, using 5-amino-2-fluorobenzonitrile instead of 3-(difluoromethyl)-4-fluoro-aniline. 1H NMR (400 MHz, DMSO-dtf) δ ppm 1.21 (d, J=6.2 Hz, 3 H), 3.41 (br t, J=8.0 Hz, 1 H), 3.61 (br s, 1 H), 3.83 (s, 3 H), 3.97 (dd, J=12.9, 9.1 Hz, 1 H), 4.88 - 4.96 (m, 1 H), 5.06 (br s, 1 H), 7.49 (s, 1 H), 7.51 (t, J=9.2 Hz, 1 H), 7.64 (br s, 1 H), 8.05 (ddd, J=9.2, 4.9, 2.9 Hz, 1 H), 8.20 (dd, J=5.7, 2.6 Hz, 1 H), 9.51 (s, 1 H); Method B; Rt: 0.81 min. m/z : 407 (M-H)~ Exact mass: 408.1.
Compound 66: (3R)-N-(2-bromo-4-pyridyl)-3-[(l S)-l-hydroxyethyll-7-methyl- l J-dioxo-3,4-dihydro-2H-pyrrolo[3,4-bl[l ,4,51oxathiazepine-6-carboxamide.
Figure imgf000098_0002
Compound 66 (82.9 mg) was prepared similarly as described for compound 64, using 4-amino-2-bromopyridine instead of 3-(difluoromethyl)-4-fluoro-aniline. 1H NMR
(400 MHz, DMSO-< ) δ ppm 1.21 (d, J=6.2 Hz, 3 H), 3.34 - 3.46 (m, 1 H), 3.56 - 3.66 (m, 1 H), 3.83 (s, 3 H), 4.01 (dd, J=12.8, 9.0 Hz, 1 H), 4.92 (dd, J=12.7, 1.9 Hz, 1 H), 5.07 (d, J=5.5 Hz, 1 H), 7.54 (s, 1 H), 7.61 - 7.70 (m, 1 H), 7.72 (dd, J=5.6, 1.9 Hz, 1 H), 8.02 (d, J=1.8 Hz, 1 H), 8.24 (d, J=5.5 Hz, 1 H), 9.65 (br s, 1 H); Method B; Rt: 0.75 min. m/z : 443 (M-H)" Exact mass: 444.0. Compound 67: N-(3 ,4-difluorophenyl)-3 ,7-dimethyl- 1 , 1 -dioxo-2,3 ,4,5-tetrahydro- pyrrolo[3,4-f|[l,2,51thiadiazepine-6-carboxamide.
Figure imgf000099_0001
Carbamic acid, n-(2-aminopropyl)-, 1,1-dimethylethyl ester (850 mg, 4.64 mmol) was dissolved in DCM (20 mL. Hunig's base (1.92 mL, 11.1 mmol) was added and then Ethyl 4-chlorosulfonyl-3 -fluoro- l-methyl-pyrrole-2-carboxyl ate (1 g) was added. The mixture was stirred at room temperature for 2 hours. The mixture was washed with water and the organic layer was separated, dried (MgS04), filtered and concentrated in vacuo. The residue was purified by column chromatography using a gradient from 0 till 50% EtOAc in heptane over 15 column volumes. The product fractions were concentrated in vacuum to yield ethyl 4-[[2-(tert-butoxycarbonylamino)-l-methyl- ethyl]sulfamoyl]-3-fluoro-l-methyl-pyrrole-2-carboxylate (1.3 g) as a white powder.
Ethyl 4-[[2-(fert-butoxycarbonylamino)- 1 -methyl-ethyljsulfamoyl] -3 -fluoro- 1 -methyl- pyrrole -2-carboxylate (1.3 g) was dissolved in 1,4-dioxane (15 mL). HC1 (8 mL, 4 M in dioxane, 31.9 mmol) was added and the mixture was stirred at room temperature for 16 hours. The precipitated product was filtered off and dried under vacuum to yield ethyl 4-[(2-amino-l-methyl-ethyl)sulfamoyl]-3-fluoro-l-methyl-pyrrole-2-carboxylate hydrochloride (1 g) as a white solid. Method B; Rt: 0.50 min. m/z : 208 (M+H)+ Exact mass: 307.1.
Ethyl 4- [(2-amino- 1 -methyl-ethyl)sulfamoyl] -3 -fluoro- 1 -methyl-pyrrole-2-carboxylate hydrochloride (539 mg) and 3,4-difluoroaniline (0.19 mL, 1.88 mmol) were dissolved in THF (20 mL). Lithium bis(trimethylsilyl)amide (7.8 mL, (1M in THF), 7.8 mmol) was added dropwise to the reaction mixture. The mixture was stirred at room temperature for 1 hour. The mixture was quenched with NH4C1 (sat., aq., 15 mL). The reaction mixture was diluted with 2-MeTHF and the organic layer was separated, dried
(MgS04), filtered and concntrated in vacuum. The residue was triturated in DIPE, filtered off and dried under vacuum to yield 4-[(2-amino-l-methyl-ethyl)sulfamoyl]-N- (3,4-difluorophenyl)-3-fluoro-l-methyl-pyrrole-2-carboxamide (500 mg) as a pale brown solid. A microwave vial was charged with 4-[(2-amino-l-methyl-ethyl)sulfamoyl]-N- (3,4-difluorophenyl)-3-fluoro-l-methyl-pyrrole-2-carboxamide (200 mg), water (15 mL) and 1,4-dioxane (3 mL). The vial was capped and the mixture was irradiated at 150 °C for 6 hours. The mixture was neutralized with HCl (aq., 1M). The mixture was extracted with DCM and the organic phase was separated, dried (MgS04), filtered and concentrated in vacuo. The residue was purified via prep. HPLC (Stationary phase: RP XBridge Prep C18 OBD-ΙΟμιη, 30x150mm, Mobile phase: 0.25% NH4HCO3 solution in water, MeOH) yielding compound 67 (16 mg). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.12 (d, J=6.9 Hz, 3 H), 2.80 (dd, J=14.1, 8.5 Hz, 1 H), 3.39 (dd, J=13.7, 1.6 Hz, 1 H), 3.48 - 3.60 (m, 1 H), 3.78 (s, 3 H), 5.45 (br s, 1 H), 7.26 - 7.31 (m, 1 H),
7.31 - 7.35 (m, 1 H), 7.35 (s, 1 H), 7.36 - 7.43 (m, 1 H), 7.78 (ddd, J=13.4, 7.4, 2.2 Hz, 1 H), 10.45 (br s, 1 H); Method B; Rt: 0.91 min. m/z : 369 (M-H)~ Exact mass: 370.1.
Compound 68: N-(3 ,4-difluorophenyl)-4-hydroxy-7-methyl- 1 , 1 -dioxo-2,3 ,4,5-tetra- hydropyrrolo[3,4-f|thiazepine-6-carboxamide.
Figure imgf000100_0001
l-penten-4-yne (6.2 g) and ethyl isocyanoacetate (35.3 g, 297 mmol) dissolved in dioxane (100 mL) was added dropwise to a suspension of silver carbonate (3.88 g, 14.1 mmol) in dioxane (200 mL) between 80 and 90°C during 45 minutes. The reaction mixture was stirred 2 hours at 80°C. The reaction mixture was filtered and
concentrated. The residue was subjected to column chromatography using a gradient from 10 till 100% EtOAc in heptane over 10 column volumes yielding ethyl 3-allyl-lH- pyrrole-2-carboxylate (15.7 g) as an oil. 1H NMR (400 MHz, DMSO-^) δ ppm 1.28 (t, j=7.2 Hz, 3 H), 3.48 (d, J=6.6 Hz, 2 H), 4.22 (q, j=7.2 Hz, 2 H), 4.93 - 4.98 (m, 1 H), 4.98 - 5.06 (m, 1 H), 5.93 (ddt, j=16.9, 10.1, 6.6, 6.6 Hz, 1 H), 6.01 (t, j=2.4 Hz, 1 H), 6.88 (t, j=2.9 Hz, 1 H), 11.51 (br s, 1 H); Method D; Rt: 1.83 min. m/z : 180 (M+H)+ Exact mass: 179.1.
Ethyl 3-allyl-lH-pyrrole-2-carboxylate (15.7 g) and methyl iodide (14.3 g, 100 mmol) were dissolved in DMF (150 mL) and stirred in an ice bath. NaH (4.37 g, 60%> dispersion in mineral oil, 109 mmol) was added portionwise during 10 minutes and the reaction mixture was stirred 1 hour. Another amount of NaH (2.27 g, 60% dispersion in mineral oil, 56.8 mmol) was added portionwise followed by methyl iodide (7.19 g, 50.6 mmol) and the reaction mixture was stirred 1 hour in an ice bath. The reaction mixture was quenched with ethanol (lOmL) and diluted with water (500 mL). The mixture was extracted with EtOAc (3 X 200 mL). The combined organic layers were dried (MgS04), filtered and concentrated. The residue was subjected to column chromatography using a gradient from 0 till 100% EtOAc in heptane over 10 column volumes yielding ethyl 3-allyl-l -methyl-pyrrole-2-carboxylate (13.2 g) as a light yellow oil. 1H NMR (400 MHz, DMSO-^) δ ppm 1.28 (t, J=7.2 Hz, 3 H), 3.45 (d, J=6.6 Hz, 2 H), 3.80 (s, 3 H), 4.21 (q, J=7.1 Hz, 2 H), 4.93 - 5.04 (m, 2 H), 5.86 - 5.97 (m, 2 H), 6.97 (d, J=2.4 Hz, 1 H); Method D; Rt: 2.07 min. m/z : 194 (M+H)+ Exact mass: 193.1.
Osmium tetroxide (2.43 g, 2.5 % in t-butanol, 0.239 mmol) was added to ethyl 3-allyl- 1 -methyl-pyrrole -2-carboxylate (1 156 mg, 5.982 mmol) in ACN (50 mL) and stirred 10 minutes. Water (10 mL) was added followed by benzyloxycarbonylamino
4-chlorobenzoate (1.83 g, 5.98 mmol). The reaction mixture was stirred 2 hours and then quenched with K2S2O5 (aq., sat., lOmL), diluted with water (100 mL) and extracted with EtOAc (2 X 100 mL). The combined organic layers were washed with saturated NaHC03 solution, dried (MgS04), filtered and concentrated. The residue was subjected to column chromatography using a gradient from 10 till 100% EtOAc in heptane over 10 column volumes yielding ethyl 3-[3-(benzyloxycarbonylamino)-2-hydroxy-propyl]-
1- methyl-pyrrole-2-carboxylate (1.25 g) as a clear oil. 1H NMR (400 MHz, OMSO-d6) δ ppm 1.27 (t, J=7.2 Hz, 3 H), 2.67 (dd, J=14.0, 7.2 Hz, 1 H), 2.81 - 2.96 (m, 2 H), 3.00 - 3.08 (m, 1 H), 3.60 - 3.75 (m, 1 H), 3.78 (s, 3 H), 4.19 (q, J=7.0 Hz, 2 H), 4.57 (d, J=5.5 Hz, 1 H), 5.00 (s, 2 H), 6.01 (d, J=2.4 Hz, 1 H), 6.94 (d, J=2.4 Hz, 1 H), 7.06 (br t, J=5.6 Hz, 1 H), 7.28 - 7.39 (m, 5 H); Method D; Rt: 1.76 min. m/z : 361 (M+H)+ Exact mass: 360.1.
Ethyl 3-[3-(benzyloxycarbonylamino)-2-hydroxy-propyl]-l-methyl-pyrrole-
2- carboxylate (920 mg) was dissolved in EtOH (100 mL). Under a nitrogen atmosphere Pd/C (10%)) (100 mg, 0.094 mmol) was added. The reaction mixture was hydrogenated for 3 hours. The reaction mixture was filtered over decalite. The filtrate was evaporated to dryness to afford ethyl 3-(3-amino-2-hydroxy-propyl)-l-methyl-pyrrole- 2-carboxylate (549 mg) as an oil. Method D; Rt: 1.00 min. m/z : 227 (M+H)+ Exact mass: 226.1.
Chlorosulfonic acid (2.06 g, 17.7 mmol) dissolved in dichloromethane (10 mL) was added to ethyl 3-(3-amino-2-hydroxy-propyl)-l-methyl-pyrrole -2-carboxylate (500 mg) in DCM (25 mL) in an ice bath and stirred for 1 hour. ACN (150 mL) was added and the reaction mixture was stirred 1 hour. Na2C03 (2.58 g, 24.3 mmol) was added and the reaction mixture was stirred 1 hour. Na2C03 (2.58 g, 24.3 mmol) was added and the reaction mixture was stirred for another 2 hours. 5g Na2C03 was added and the reaction mixture was stirred over weekend. The reaction mixture was filtered and concentrated. The residue was dissolved in DMF (5mL), filtered and subjected as such to column chromatography using a gradient from 10 till 100% EtOAc in heptane over 10 column volumes yielding ethyl 4-hydroxy-7-methyl-l , l-dioxo-2,3,4,5-tetrahydropyrrolo- [3,4-fJthiazepine-6-carboxylate (51 mg) as a clear resin. Lithium bis(trimethylsilyl)amide (1.4 mL, 1 M in THF, 1.4 mmol) was added to a solution of ethyl 4-hydroxy-7-methyl-l ,l-dioxo-2,3,4,5-tetrahydropyrrolo- [3,4-fJthiazepine-6-carboxylate (51 mg) and 3,4-difluoroaniline (40 mg, 0.31 mmol) in THF (10 mL) and stirred for 1 hour. The reaction mixture was quenched with NH4C1 (sat., aq., 25 mL) and extracted with EtOAc (50mL). The organic layer was dried (Na2S04), filtered and concentrated. The residue was subjected to column
chromatography using a gradient from 10 til 100% EtOAc in heptane. The product fractions were concentrated and the residue was dissolved in methanol (5mL), water was added until the product crystallized. Compound 68 (15.5 mg) was filtered off as beige crystals and dried in vacuo at 50°C. 1H NMR (400 MHz, OMSO-d6) δ ppm 2.92 - 3.09 (m, 2 H), 3.21 - 3.27 (m, 2 H), 3.49 - 3.59 (m, 1 H), 3.68 (s, 3 H), 5.06
(d, J=4.4 Hz, 1 H), 7.34 (br t, J=6.7 Hz, 1 H), 7.38 - 7.47 (m, 3 H), 7.82 - 7.90 (m, 1 H), 10.48 (s, 1 H); Method D; Rt: 1.76 min. m/z : 372 (M+H)+ Exact mass: 371.1 ; MP: 229.0 °C. Compound 69 : (3R)-N-(3.4-difluorophenyl)-3 - IT 1 R) - 1 -hydroxyethyll -7-methyl- 1.1- dioxo-2,3-dihydropyrrolo[3,4-f|thiazepine-6-carboxamide.
Figure imgf000102_0001
To a solution of N-(fert-butoxycarbonyl)-L-threonine methyl ester (10 g, 42.9 mmol) in CH2C12 (100 mL) was added 2-methoxypropene (8.22 mL, 85.7 mmol)) and
camphorsulfonic acid (100 mg, 0.43 mmol)) at 0 °C under a nitrogen atmosphere. The resulting solution was stirred at room temperature for 2 hours. The reaction was then quenched with Et3N (5 mL) and the organic solvents were removed in vacuo.
Purification of the residue via flash chromatography (silica gel, 0 to 15% EtOAc in heptanes) afforded 03-tert-butyl 04-methyl (4S,5R)-2,2,5-trimethyloxazolidine- 3,4-dicarboxylate (10.5 g) as a colorless oil. 1H NMR (400 MHz, DMSO- ¾ δ
1.25 - 1.54 (m, 18 H), 3.66 - 3.72 (m, 3 H), 3.86 - 3.91 (m, 1 H), 4.06 - 4.13 (m, 1 H) (rotamers).
To a stirred solution of methyltriphenylphosphonium bromide (27.4 g, 76.7 mmol) in THF (77 mL) at 0 °C was added KOtBu (8.39 g, 74.8 mmol) in one portion. The resulting mixture was stirred for one additional hour at the same temperature prior to use. To a stirred solution of 03-tert-butyl 04-methyl (4S,5R)-2,2,5-trimethyl- oxazolidine-3,4-dicarboxylate (10.5 g, 38.42 mmol) in CH2CI2 (125 mL) was added DIBAL-H (1 M in hexanes, 77 mL) dropwise over 1 hour at -78 °C under a nitrogen atmosphere. After an additional 2 hours at the same temperature, the ylide THF suspension was added dropwise over 40 minutes. After an additional 15 minutes, the reaction mixture was warmed to room temperature, and after an additional 3 hours at the same temperature, the reaction mixture was warmed to 50 °C. After an additional
14 hours at the same temperature, the reaction mixture was cooled to room temperature, diluted with H20 (50 mL), then aqueous HC1 (aq., 1 M, 150 mL), and the layers were separated. The aqueous residue was extracted with EtOAc (4 X 100 mL). The combined organic layers were washed with brine (1 X 250 mL), dried (Na2S04), filtered, and concentrated under reduced pressure. The resulting residue was purified by flash chromatography (1 to 23% EtOAc in heptane) on silica gel to yield tert-butyl (4R,5R)-2,2,5-trimethyl-4-vinyl-oxazolidine-3-carboxylate (4.5 g). 1H NMR
(400 MHz, CHLOROFORM- ) δ ppm 1.28 (d, J=6.0 Hz, 3 H), 1.36 - 1.49 (m, 9 H), 1.49 - 1.53 (m, 3 H), 1.57 - 1.63 (m, 3 H), 3.72 (br s, 1 H), 3.78 - 3.89 (m, 1 H), 5.08 - 5.29 (m, 2 H), 5.44 - 5.92 (m, 1 H).
7¾rt-butyl (4R,5R)-2,2,5-trimethyl-4-vinyl-oxazolidine-3-carboxylate (4.5 g) was dissolved in diethyl ether (150 mL) and HC1 (47 mL, 4 M in dioxane, 186 mmol) was added. The reaction mixture was stirred at room temperature overnight and
concentrated to dryness. The residue was triturated in diethyl ether and concentrated to dryness. To this residue was added a pre-mixed solution of 4.7 mL H20 in 47 mL 4 M HC1 in dioxane cooled to 0 °C using an ice/water bath and the resulting mixture was stirred for 2 hours allowing to warm to room temperature. The mixture was then diluted with toluene (50 mL) and concentrated to dryness under reduced pressure. The residue was then azeotroped with toluene (3 X 50 mL) to remove all traces of water to afford (2R,3R)-3-aminopent-4-en-2-ol hydrochloride (3.35 g). 1H NMR (400 MHz,
DMSO- ¾ δ ppm 1.09 (d, J=6.3 Hz, 3 H), 3.32 - 3.48 (m, 1 H), 3.62 - 3.78 (m, 1 H), 5.22 - 5.50 (m, 2 H), 5.80 (ddd, J=17.3, 10.5, 7.9 Hz, 1 H), 8.16 (br s, 3 H). Methyl 3-bromo-4-chlorosulfonyl-l-methyl-pyrrole-2-carboxylate (2.12 g) was dissolved in DCM (200 mL) and (2R,3R)-3-aminopent-4-en-2-ol (3.35 g, 32.1 mmol) and Hunig's base (13.9 mL, 80.4 mmol) were added. The reaction mixture was stirred at room temperature for 1 hour. The reaction was quenched with NH4C1 (sat., aq., 40 mL). The layers were separated and the organics were dried (Na2S04), filtered and concentrated to afford a brown residue which was purified using silica gel column chromatography (ethyl acetate in heptane from 0 to 100 %) to afford methyl 3-bromo- 4 [[(1R)-1-[(1R)-1 -hydroxyethyl] allyljsulfamoyl] - 1 -methyl-pyrrole-2-carboxylate (2.60 g) as an off white powder. 1H NMR (400 MHz, DMSO-^) δ ppm 0.96 (d, J=6.0 Hz, 3 H), 3.55 - 3.67 (m, 2 H), 3.82 (s, 3 H), 3.86 (s, 3 H), 4.57 - 4.77 (m, 1 H), 4.97 - 5.10 (m, 2 H), 5.71 (ddd, J=17.3, 10.5, 5.7 Hz, 1 H), 7.35 (br s, 1 H), 7.70 (s, 1 H); Method B; Rt: 0.70 min. m/z : 379 (M-H)~ Exact mass: 380.0. To a solution of methyl 3-bromo-4-[[(lR)-l-[(lR)-l-hydroxyethyl]allyl]sulfamoyl]- 1 -methyl-pyrrole -2-carboxylate (600 mg) in DMA (5 mL) purged with nitrogen was added Hunig's base (0.3 mL, 1.73 mmol) and bis(tri-tert-butylphosphine)palladium(0) (0.16 g, 0.31 mmol). The reaction mixture was heated in the microwave for 5 minutes at 140°C. The reaction mixture was diluted with methanol (60 mL) and purified via prep. HPLC (Stationary phase: RP XBridge Prep C18 ODB- 5μιη, 30x250mm,
Mobile phase: 0.25% NH4HC03 solution in water, ACN) yielding methyl (3R)-3-[(lR)- l-hydroxyethyl]-7-methyl-l,l-dioxo-2,3-dihydropyrrolo[3,4-f]thiazepine-6-carboxylate (160 mg). 1H NMR (400 MHz, DMSO- ¾ δ ppm 1.09 (d, J=6.4 Hz, 3 H) 3.73 - 3.87 (m, 6 H) 3.87 - 3.93 (m, 1 H) 4.09 (br s, 1 H) 4.94 (br d, J=4.0 Hz, 1 H) 5.93 (dd, J=12.8, 2.6 Hz, 1 H) 7.17 (dd, J=12.9, 2.8 Hz, 1 H) 7.31 (br s, 1 H) 7.69 (s, 1 H);
Method B; Rt: 0.60 min. m/z : 299 (M-H)" Exact mass: 300.1.
Methyl (3R)-3-[(lR)-l-hydroxyethyl]-7-methyl-l,l-dioxo-2,3-dihydropyrrolo[3,4-fJ- thiazepine-6-carboxylate (160 mg) and 3,4-difluoroaniline (76 mg, 0.59 mmol) were dissolved in THF (5 mL). Lithium bis(trimethylsilyl)amide (2.4 mL, 1 M in THF, 2.4 mmol) was added and the reaction mixture was stirred 60 minutes at room temperature. 3,4-difluoroaniline (21 mg, 0.16 mmol) was added followed by lithium bis(trimethylsilyl)amide (1 mL, 1 M in THF, 1 mmol). The reaction mixture was stirred at room temperature for 30 minutes. NH4C1 (sat., aq., 5 mL) was added and the organic layer was separated. The aqueous layer was extracted with DCM (2 X 5 mL) and the combined organic layers were evaporated to dryness. The residue was purified using silica gel column chromatography twice (ethyl acetate in heptane from 0 to 100 %) and then by prep. HPLC (Hypersyl CI 8 BDS^m,100 x 4.6 mm) Mobile phase (NH4HC03 0.2% in water, ACN) to yield compound 69 (68 mg). 1H NMR (400 MHz, DMSO-^) δ ppm 1.10 (d, J=6.4 Hz, 3 H), 3.71 (s, 3 H), 3.85 - 3.94 (m, 1 H), 4.11 (br s, 1 H), 4.92 (br s, 1 H), 5.81 (dd, J=12.7, 2.5 Hz, 1 H), 6.59 (dd, J=12.5, 2.6 Hz, 1 H), 7.22 (br s, 1 H), 7.39 - 7.47 (m, 2 H), 7.57 (s, 1 H), 7.82 - 7.88 (m, 1 H), 10.74 (br s, 1 H); Method B; Rt: 0.79 min. m/z : 396 (M-H)~ Exact mass: 397.1.
Compound 70 : (3R)-N-(3.4-difluorophenyl)-3 - Γ( 1 R) - 1 -hydroxyethyll -7-methyl-
1 J-dioxo-2,3,4,5-tetrah dropyrrolo[3,4-f|thiazepine-6-carboxamide.
Figure imgf000105_0001
Compound 69 (32 mg) was dissolved in MeOH (40 mL). Under a nitrogen atmosphere Pd/C (10%) (24 mg, 0.022 mmol) was added. The reaction mixture was hydrogenated for 60 minutes. The reaction mixture was filtered over decalite and the filtrate was evaporated to dryness to afford a white residue which was purified using silica gel column chromatography (ethyl acetate in heptane from 0 to 100%) to yield compound 70 (23 mg) as a white powder. 1H NMR (400 MHz, DMSO-^) δ ppm 1.04 (d,
J=6.2 Hz, 3 H), 1.44 (q, J=12.1 Hz, 1 H), 1.90 (br dd, J=14.1, 6.6 Hz, 1 H), 2.78 (br t, J=13.2 Hz, 1 H), 3.02 (br dd, J=15.3, 5.4 Hz, 1 H), 3.38 - 3.48 (m, 1 H), 3.63 - 3.73 (m, 4 H), 4.61 (br d, J=3.7 Hz, 1 H), 6.69 (br d, J=8.6 Hz, 1 H), 7.38 - 7.47 (m, 3 H), 7.81 - 7.89 (m, 1 H), 10.48 (br s, 1 H); Method B; Rt: 0.79 min. m/z : 398 (M-H)" Exact mass: 399.1
Compound 71: (3S)-N-(3-cyano-4-fluoro-phenyl)-7-methyl- 1 , 1 -dioxo-3-(3-pyridyl- methyl)-3,4-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide.
Figure imgf000105_0002
Compound 71 (11.2 mg) was prepared similarly as described for compound 38, using 5-amino-2-fluorobenzonitrile instead of 3,4-difluoroaniline. 1H NMR (400 MHz,
DMSC i) δ ppm 2.66 - 2.76 (m, 1 H) 2.88 (dd, J=14.1, 4.8 Hz, 1 H) 3.82 (s, 3 H) 3.86 - 3.98 (m, 1 H) 4.03 (dd, J=12.7, 9.1 Hz, 1 H) 4.67 (br d, J=12.3 Hz, 1 H) 7.37 (dd, J=7.7, 4.8 Hz, 1 H) 7.48 - 7.55 (m, 2 H) 7.68 - 7.81 (m, 2 H) 7.99 - 8.04 (m, 1 H) 8.18 (dd, J=5.7, 2.6 Hz, 1 H) 8.45 - 8.50 (m, 2 H) 9.55 (s, 1 H); Method B; Rt: 0.85 min. m/z : 456 (M+H)+ Exact mass: 455.1.
Compound 72: fert-butyl 4-[6-[(3,4-difluorophenyl)carbamoyll-7-methyl- 1 , 1 -dioxo- 3^-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepin-3-yllpiperidine-l-carboxylate.
Figure imgf000106_0001
To a cooled (-78°C) solution of tert-butyl 4-(l-amino-2-methoxy-2-oxoethyl)piperidine-
1- carboxylate (1 g) in THF (50 mL) was added drop wise lithium aluminium hydride (3.56 mL, 1 M in THF, 3.562 mmol) at -78 °C. The mixture was stirred at -78 °C for 3 hours and the mixture was allowed to rise to room temperature. The mixture was further stirred at room temperature for 16 hours. Sodium sulfate decahydrate (1.72 g, 5.34 mmol) was carefully added and the mixture was stirred at room temperature for 10 minutes. Na2S04 was added and the mixture was filtered. The filtrate was concentrated in vacuum and the residue was purified by column chromatography using a gradient from 0 till 100% MeOH/NH3 (90/10) in DCM over 10 column volumes. The product fractions were concentrated in vacuum to yield tert-butyl 4-(l-amino-
2- hydroxy-ethyl)piperidine-l-carboxylate (513 mg) as an oil.
Compound 72 (127 mg) was prepared similarly as described for compound 14, using tert-butyl 4-(l-amino-2-hydroxy-ethyl)piperidine-l-carboxylate instead of DL-alaninol and heating 6 hours at 110 °C instead of 2 hours at 140 °C. 1H NMR (400 MHz, DMSC /6) 5 ppm 1.12 - 1.27 (m, 2 H), 1.40 (s, 9 H), 1.71 (br t, J=12.7 Hz, 3 H), 2.67 (br s, 2 H), 3.47 - 3.55 (m, 1 H), 3.82 (s, 3 H), 3.90 - 4.05 (m, 2 H), 3.96 - 4.01 (m, 1 H), 4.71 (d, J=10.9 Hz, 1 H), 7.35 - 7.45 (m, 1 H), 7.45 - 7.51 (m, 2 H), 7.62 (d, J=9.7 Hz, 1 H), 7.85 (ddd, J=13.2, 7.4, 2.4 Hz, 1 H), 9.42 (s, 1 H); Method B; Rt: 1.13 min. m/z : 539 (M-H)~ Exact mass: 540.2.
Compound 73: N-(3 ,4-difluorophenyl)-7-methyl- 1 , 1 -dioxo-3-(4-piperidyl)-3 ,4-dihydro- 2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide.
Figure imgf000107_0001
Compound 72 (1 19 mg) was suspended in DCM (5 mL). TFA (0.25 mL, 3.30 mmol) was added and the mixture was stirred at room temperature for 1 hour. The mixture was washed with sat. NaHC03 solution. The organic layer was separated, dried (MgS04), filtered and concentrated in vacuo. The residue was purified via prep. HPLC
(Stationary phase: RP XBridge Prep C18 OBD-ΙΟμιη, 30x150mm, Mobile phase:
0.25% NH4HC03 solution in water, ACN). The product fractions were collected to yield compound 73 (21 mg) as a white solid. 1H NMR (400 MHz, DMSO- 6) δ ppm 1.10 - 1.25 (m, 2 H), 1.51 - 1.71 (m, 3 H), 1.75 (s, 1 H), 2.34 - 2.45 (m, 2 H), 2.89 - 2.97 (m, 2 H), 3.39 - 3.49 (m, 1 H), 3.80 - 3.85 (m, 3 H), 3.95 (dd, J=12.8, 9.0 Hz, 1 H), 4.72 (dd, J=12.9, 1.9 Hz, 1 H), 7.36 - 7.57 (m, 4 H), 7.86 (ddd, J=13.2, 7.5, 2.5 Hz, 1 H), 9.34 - 9.48 (m, 1 H); Method B; Rt: 0.72 min. m/z : 441 (M+H)+ Exact mass: 440.1.
Compound 74: (3S)-N-(4-fluoro-3-methyl-phenyl)-7-methyl- 1 , 1 -dioxo-3-(3-pyridyl- methyl)-3,4-dihydro-2H-pyrrolo[3,4-bl[l ,4,51oxathiazepine-6-carboxamide.
Figure imgf000107_0002
Compound 74 (29 mg) was prepared similarly as described for compound 38, using 4-fluoro-3-methylaniline instead of 3,4-difluoroaniline. 1H NMR (400 MHz,
DMSO- ¾ δ ppm 2.23 (d, J=1.5 Hz, 3 H), 2.66 - 2.75 (m, 1 H), 2.85 - 2.92 (m, 1 H), 3.82 (s, 3 H), 3.93 (br s, 1 H), 3.99 - 4.1 1 (m, 1 H), 4.67 (dd, J=12.5, 2.0 Hz, 1 H), 7.10 (t, J=9.1 Hz, 1 H), 7.37 (dd, J=7.7, 5.1 Hz, 1 H), 7.45 (s, 1 H), 7.49 (br d, J=4.6 Hz, 1 H), 7.53 - 7.58 (m, 1 H), 7.70 - 7.80 (m, 2 H), 8.46 (d, J=5.1 Hz, 1 H), 8.49 (s, 1 H), 9.24 (s, 1 H); Method B; Rt: 0.91 min. m/z : 445 (M+H)+ Exact mass: 444.1. Compound 75: (3S)-N-[3-(difluoromethyl)-4-fluoro-phenyll-7-methyl- 1 , 1 -dioxo-3-
(3-pyridylmethyl)-3^-dihydro-2H-pyrrolo[3,4-bl[l ,4,51oxathiazepine-6-carboxamide.
Figure imgf000108_0001
Compound 75 (5 mg) was prepared similarly as described for compound 38, using 3-(difluoromethyl)-4-fluoro-aniline instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO- ¾ δ ppm 2.65 - 2.76 (m, 1 H), 2.87 (br dd, J=14.3, 4.8 Hz, 1 H), 3.83 (s, 3 H), 3.93 (br s, 1 H), 4.00 - 4.08 (m, 1 H), 4.65 (dd, J=12.8, 2.2 Hz, 1 H), 7.20 (t, J=48.0 Hz, 1 H), 7.35 - 7.40 (m, 2 H), 7.47 (s, 1 H), 7.70 - 7.83 (m, 3 H), 8.02 (dd, J=6.3, 2.5 Hz, 1 H), 8.46 (dd, J=4.8, 1.5 Hz, 1 H), 8.49 (d, J=2.0 Hz, 1 H), 9.49 (s, 1 H); Method B; Rt: 0.90 min. m/z : 481 (M+H)+ Exact mass: 480.1. Compound 76: N-(3,4-difluorophenyl)-7-methyl-3-(l-methyl-4-piperidyl)-l,l-dioxo-
3,4-dih dro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000108_0002
Compound 73 (109 mg) was dissolved in MeOH (1 mL) and DCE (2 mL). The mixture was cooled on a ice bath and formaldehyde (22 μΐ,, 1.09 g/mL, 0.297 mmol) was added followed by sodium cyanoborohydride (33 mg, 0.50 mmol). The mixture was stirred at room temperature for 16 hours. The solvent was evaporated and the residue was partioned between NaOH (aq., 1M) and Me-THF. The organic layer was separated, dried (MgS04), filtered and evaporated. The residue was purified by column chromatography using a gradient from 0 till 100% DCM/NH3 sol. in MeOH (90/10) in DCM over 10 column volumes. The product fractions were concentrated in vacuo. The product was crystallized from water:MeOH to yield compound 76 (51 mg) as a white solid. 1H NMR (400 MHz, DMSO-^) δ ppm 1.24 - 1.47 (m, 3 H), 1.64 - 1.83 (m, 4 H), 2.09 - 2.16 (m, 3 H), 2.71 - 2.84 (m, 2 H), 3.39 - 3.53 (m, 1 H), 3.82 (s, 3 H), 3.95 (dd, J=12.9, 9.1 Hz, 1 H), 4.73 (dd, J=13.0, 2.0 Hz, 1 H), 7.36 - 7.53 (m, 3 H), 7.58 (d, J=9.7 Hz, 1 H), 7.86 (ddd, J=13.2, 7.4, 2.5 Hz, 1 H), 9.38 - 9.43 (m, 1 H); Method B; Rt: 0.75 min. m/z : 455 (M+H)+ Exact mass: 454.1. Compound 77 : (3RVN- r2-(difluoromethvn-4-pyridyll -3 - IT 1 S 1 -hydroxyethyll -7- methyl- 1 , 1 -dioxo-3 ,4-dihydro-2H-pyrrolo[3 ,4-b] [ 1 A51oxathiazepine-6-carboxamide
Figure imgf000109_0001
Compound 77 (72.7 mg) was prepared similarly as described for compound 64, using 2-(difluoromethyl)pyridin-4-amine instead of 3-(difluoromethyl)-4-fluoro-aniline. 1H NMR (400 MHz, DMSO-^) δ ppm 1.43 (d, J=6.4 Hz, 3 H), 2.12 (s, 1 H), 3.85
(tdd, J=9.2, 9.2, 4.8, 2.4 Hz, 1 H), 3.96 (s, 3 H), 4.19 (quin, J=6.1 Hz, 1 H), 4.35 (dd, J=13.0, 8.8 Hz, 1 H), 4.90 (dd, J=13.0, 2.4 Hz, 1 H), 5.18 (d, J=9.5 Hz, 1 H), 6.62 (t, J=55.5 Hz, 1 H), 7.10 (s, 1 H), 7.71 - 7.73 (m, 1 H), 7.74 - 7.75 (m, 1 H), 8.53 (d, J=5.5 Hz, 1 H), 9.05 (s, 1 H); Method B; Rt: 0.71 min. m/z: 415 (M-H)~ Exact mass: 416.1.
Compound 78 : N-(3 ,4-difluorophenyl)-7-methyl- 1 , 1 -dioxo-3-[ 1 -(2,2,2-trifluoroethyl)-4- piperidyll-3,4-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000109_0002
A microwave vial was charged with compound 73 (50 mg, 0.11 mmol), 2,2,2-trifluoroethyl trichloromethanesulfonate (34 mg, 0.11 mmol), K2CO3 (19 mg, 0.14 mmol) in acetone (1 mL). The vial was capped and the mixture was stirred at 60 °C for 16 hours. The mixture was concentrated and the residue was purified by column chromatography using a gradient from 0 till 100% EtOAc in Heptane over 10 column volumes. The product fractions were concentrated in vacuo. The product was triturated in DIPE, filtered off and dried under vacuum to give compound 78 (38 mg) as a white solid. 1H NMR (400 MHz, DMSO-^) δ ppm 1.28 - 1.44 (m, 2 H), 1.44 - 1.54 (m, 1 H), 1.64 - 1.76 (m, 2 H), 2.20 - 2.36 (m, 2 H), 2.89 - 2.98 (m, 2 H), 3.05 - 3.20 (m, 2 H), 3.42 - 3.56 (m, 1 H), 3.82 (s, 3 H), 3.92 - 4.04 (m, 1 H), 4.68 - 4.76 (m, 1 H),
7.36 - 7.51 (m, 3 H), 7.59 (d, J=9.8 Hz, 1 H), 7.86 (ddd, J=13.2, 7.5, 2.5 Hz, 1 H), 9.38 - 9.43 (m, 1 H); Method D; Rt: 2.06 min. m/z: 521 (M+H)+ Exact mass: 522.1. Compound 79 : N-(3 ,4-difluorophenyl)-3 -isopropyl-7-methyl- 1 , 1 -dioxo-2,3-dihydro- pyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000110_0001
Methyl 3-bromo-4-chlorosulfonyl-l-methyl-pyrrole-2-carboxylate (2 g, 6.32 mmol) was dissolved in DCM (100 mL). To this was added Hunig's base (4.36 mL, 25.3 mmol). To this was added 4-methyl-l-penten-3 -amine (1.71 g, 12.6 mmol) in DCM (100 mL). The resulting mixture was stirred overnight and concentrated in vacuo and the residue was purified using silica gel column chromatography (gradient elution: EtOAc:heptane 0:100 to 100:0) yielding methyl 3-bromo-4-(l-isopropylallylsulfamoyl)-l-methyl- pyrrole -2-carboxylate (1.88 g) as a beige powder which was used as such. Method B; Rt: 0.98 min. m/z: 379 (M+H)+ Exact mass: 378.0.
Methyl 3-bromo-4-(l-isopropylallylsulfamoyl)-l -methyl-pyrrole -2-carboxylate (1.70 g, 4.48 mmol) and TEA (0.62 mL, 0.73 g/mL, 4.48 mmol) in DMF (10 mL) was stirred and purged with nitrogen for 5 minutes. Then bis(tri-tert-butylphosphine)palladium(0) (458 mg, 0.90 mmol) was added and stirring and purging was continued for 5 more minutes. The mixture was heated under microwave irradiation to 100°C for 75 minutes. The reaction mixture was cooled to room temperature and filtered through a pad of dicalite and rinsed with 150 mL of EtOAc. Then the filtrate was concentrated in vacuo and purified using silica gel column chromatography (gradient elution: EtOAc:heptane 0:100 to 100:0) yielding a mixture of 2 isomers. This mixture was purified via preparative HPLC (Stationary phase: RP XBridge Prep C18 OBD-ΙΟμιη, 30x150mm, Mobile phase: 0.25% NH4HCO3 solution in water, ACN) yielding methyl 3-isopropyl- 7-methyl-l,l-dioxo-2,3-dihydropyrrolo[3,4-f]thiazepine-6-carboxylate (203 mg).
Method B; Rt: 0.88 min. m/z: 299 (M+H)+ Exact mass: 298.1.
A mixture of methyl 3-isopropyl-7-methyl-l,l-dioxo-2,3-dihydropyrrolo[3,4-f]- thiazepine-6-carboxylate (101 mg, 0.34 mmol) and 3,4-difluoroaniline (49 mg,
0.37 mmol) in THF (5 mL) was treated with LiHMDS (0.64 mL, 1.06 M in THF, 0.68 mmol) and this was stirred for 2 hours at room temperature. The resulting mixture was quenched with NH4CI (aq. sat., 5 mL). Then brine (5 mL) was added and the layers were separated. The water layer was extracted using EtOAc (2 X 10 mL). The combined extracts were concentrated in vacuo and the obtained crude was purified using silica gel column chromatography (gradient elution: EtOAc:heptane 0: 100 to 100:0). The desired fractions were concentrated in vacuo and the obtained residue was purified via Prep HPLC (Stationary phase: RP XBridge Prep CI 8 ΟΒϋ-10μηι,
30x150mm, Mobile phase: 0.25% NH4HCO3 solution in water, ACN) yielding compound 79 as a bright white solid (60.3 mg). 1H NMR (400 MHz, DMSO-^) δ ppm 1.47 - 1.51 (m, 3 H) 1.51 - 1.56 (m, 3 H) 3.20 - 3.24 (m, 1 H) 3.20 - 3.24 (m, 2 H) 4.30 (s, 2 H) 4.53 - 4.63 (m, 1 H) 6.21 (dd, J=12.32, 2.86 Hz, 1 H) 6.49 (d, J=10.56 Hz, 1 H) 7.15 (dd, J=12.32, 2.64 Hz, 1 H) 7.76 - 7.89 (m, 2 H) 7.95 - 8.05 (m, 1 H) 8.43 (ddd, J=12.87, 7.37, 2.64 Hz, 1 H) 10.23 (br s, 1 H); Method D; Rt: 1.90 min. m/z: 396 (M+H)+ Exact mass: 395.1. This racemic mixture was separated in its enantiomers via preparative SFC (Stationary phase: Chiralpak Diacel AD 20 x 250 mm, Mobile phase: C02, EtOH + 0.4 iPrNH2) yielding compound 79a and 79b. Method E; Rt : 79a: 1.22 min, 79b: 2.09 min.
Compound 80 : N-(3 ,4-difluorophenyl)-3 -( 1 -methoxy- 1 -methyl-ethyl)-7-methyl- 1,1- dioxo-3,4-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000111_0001
Ethyl 4-chlorosulfonyl-3-fluoro-l-methyl-pyrrole-2-carboxylate (250 mg, 0.89 mmol), 2-amino-3-methoxy-3-methylbutanoic acid (131 mg, 0.89 mmol) and Hunig's base (0.46 mL, 0.75 g/mL, 2.68 mmol) were dissolved in DCM (5 mL) and stirred overnight at room temperature. The reaction mixture was directly loaded on a silica cartridge and a gradient from heptane to EtOAc:EtOH:AcOH 3: 1 :0.02 was applied yielding
2-[(5 -ethoxycarbonyl-4-fluoro- 1 -methyl -pyrrol-3 -yl)sulfonylamino] -3 -methoxy-3 - methyl-butanoic acid (143 mg). 2-[(5 -ethoxycarbonyl-4-fluoro- 1 -methyl -pyrrol-3 -yl)sulfonylamino] -3 -methoxy-3 - methyl-butanoic acid (143 mg, 0.38 mmol) and 3,4-difluoroaniline (38 μί, 1.29 g/mL, 0.38 mmol) were dissolved in THF (5 mL). Lithium bis(trimethylsilyl)amide (1.88 mL, 1 M in THF, 1.88 mmol) was added and the reaction mixture was stirred overnight at room temperature. NH4CI (sat., aq., 5 mL) was added and the organic layer was removed. The aqueous layer was extracted with DCM (2 X 5 mL) and the combined organic layers were evaporated to dryness. The residue was purified on silica using a heptane to EtOAc:EtOH:AcOH 3: 1 :0.02 gradient yielding 2-[[5-[(3,4-difluorophenyl)- carbamoyl] -4-fluoro- 1 -methyl-pyrrol-3 -yljsulfonylamino] -3 -methoxy-3 -methyl- butanoic acid (123 mg). 2-[ [5 - [(3 ,4-difiuorophenyl)carbamoyl] -4-fiuoro- 1 -methyl-pyrrol-3 -yljsulfonylamino] -3 - methoxy-3 -methyl -butanoic acid (123 mg, 0.27 mmol) was dissolved in THF (10 mL) and LAH (0.27 mL, 1 M in THF, 0.27 mmol) was added drop wise. The reaction mixture was stirred overnight at room temperature. LAH (0.27 mL, 1 M in THF,
0.27 mmol) was added and stirring was continued for 24 hours. The reaction mixture was quenched with sodium sulfate decahydrate (128 mg, 0.4 mmol) followed by addition of Na2S04. After filtration and evaporation an oily residue was obtained which was purified on silica using a heptane to EtOAc:EtOH 3: 1 gradient yielding N- (3,4-difluorophenyl)-3-fluoro-4-[[l-(hydroxymethyl)-2-methoxy-2-methyl-propyl]- sulfamoyl] - 1 -methyl-pyrrole-2-carboxamide (17 mg) .
N-(3,4-difluorophenyl)-3-fluoro-4-[[l-(hydroxymethyl)-2-methoxy-2-methyl- propyl]sulfamoyl]-l-methyl-pyrrole-2-carboxamide (17 mg, 0.038 mmol) and cesium fluoride (23 mg, 0.15 mmol) were dispensed in DMF (5 mL) and heated to 100°C for 4 hours. The reaction mixture was directly purified via prep. HPLC (Stationary phase: RP XBridge Prep C18 OBD-ΙΟμιη, 30x150mm, Mobile phase: 0.25% NH4HCO3 solution in water, ACN) yielding compound 80 (6.3 mg) as a white powder. 1H NMR (400 MHz, DMSO- ¾ δ ppm 1.31 - 1.43 (m, 6 H), 3.19 (s, 3 H), 3.85 (br s, 1 H), 3.95 (s, 3 H), 4.04 (dd, J=12.8, 8.8 Hz, 1 H), 4.82 - 4.93 (m, 2 H), 7.05 (s, 1 H), 7.08 - 7.14 (m, 2 H), 7.62 - 7.69 (m, 1 H), 8.81 (s, 1 H); Method B; Rt: 1.04 min. m/z: 428 (M-H)~ Exact mass: 429.1.
Compound 81 : N-(3 ,4-difluorophenyl)-3 -isopropyl-7-methyl- 1 , 1 -dioxo-2,3 ,4,5- tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000112_0001
A hydrogenation flask was flushed with nitrogen and then charged with Pd/C (10%) (10 mg, 0.0094 mmol). To this was added under nitrogen compound 79 (50 mg, 0.13 mmol) in MeOH (30 mL). The resulting suspension was then stirred under a hydrogen atmosphere at room temperature for 90 minutes. Then the mixture was filtered over a pad of dicalite under a constant nitrogen flow and this pad was rinsed with MeOH (50 mL). The filtrate was concentrated in vacuo and the obtained residue was purified using silica gel column chromatography (gradient elution: EtOAc:heptane 0:100 to 100:0). The desired fractions were concentrated in vacuo and dried in a vacuum oven at 55°C yielding compound 81 (36 mg) as a bright white powder.
1H NMR (400 MHz, DMSO-^) δ ppm 0.88 (d, J=3.74 Hz, 3 H) 0.90 (d, J=3.52 Hz, 3 H) 1.31 - 1.48 (m, 1 H) 1.68 (dq, J=12.90, 6.56 Hz, 1 H) 1.79 - 1.95 (m, 1 H)
2.72 - 2.86 (m, 1 H) 2.94 - 3.07 (m, 1 H) 3.18 - 3.29 (m, 1 H) 3.68 (s, 3 H) 6.90
(d, J=10.12 Hz, 1 H) 7.35 - 7.49 (m, 3 H) 7.78 - 7.92 (m, 1 H) 10.48 (s, 1 H); Method B; Rt: 1.03 min. m/z: 396 (M-H)" Exact mass: 397.1.
Compound 82: N-[3-(difluoromethyl)-4-fluoro-phenyll-3-isopropyl-7-methyl-l,l- dioxo-2,3-dihydropyrrolo[3,4-f1thiazepine-6-carboxamide
Figure imgf000113_0001
Compound 82 (70.9 mg) was prepared similarly as described for compound 79, using 3-(difluoromethyl)-4-fluoro-aniline instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO-dtf) δ ppm 0.95 (d, J=6.82 Hz, 3 H) 0.98 (d, J=6.60 Hz, 3 H) 1.85 - 2.01
(m, 1 H) 3.72 (s, 3 H) 3.91 - 3.98 (m, 1 H) 5.70 (dd, J=12.43, 2.75 Hz, 1 H) 6.57 (dd, J=12.43, 2.75 Hz, 1 H) 7.06 - 7.43 (m, 3 H) 7.58 (s, 1 H) 7.78 - 7.87 (m, 1 H) 8.06 (dd, J=6.27, 2.53 Hz, 1 H) 10.75 (s, 1 H); Method B; Rt: 1.02 min. m/z: 426 (M-H)" Exact mass: 427.1.
Compound 83 : N-(3 ,4-difluorophenyl)-3 -(hydroxymethyl)-7-methyl- 1 , 1 -dioxo-3 ,4- dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000113_0002
Compound 83 (216 mg) was prepared similarly as described for compound 14, using 2-amino-l,3-propanediol instead of DL-alaninol. The ring closure was obtained after heating overnight at 100°C in DMF and compound 83 was purified on silica using a gradient from heptane to EtOAc:EtOH 3: 1. 1H NMR (400 MHz, DMSO-d6) δ ppm 3.35 - 3.42 (m, 1 H), 3.56 (dt, j=10.8, 5.2 Hz, 1 H), 3.63 - 3.73 (m, 1 H), 3.82 (s, 3 H), 3.94 (dd, J=12.8, 8.8 Hz, 1 H), 4.74 (dd, J=12.7, 1.9 Hz, 1 H), 5.10 (dd, J=6.5, 5.0 Hz, 1 H), 7.36 - 7.50 (m, 3 H), 7.61 (d, J=9.7 Hz, 1 H), 7.87 (ddd, J=13.2, 7.5, 2.6 Hz, 1 H), 9.44 (s, 1 H); Method B; Rt: 0.81 min. m/z: 386 (M-H)" Exact mass: 387.1. Compound 84 : (3R)-N-(3.4-difluorophenyl)-3 -IT 1 S 1 -hydroxyethyll -7-methyl- 1.1- dioxo-2,3-dihydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000114_0001
Methyl 3-bromo-4-chlorosulfonyl-l-methyl-pyrrole-2-carboxylate (10.8 g, 34.1 mmol) was dissolved in ACN (200 mL) and (2S,3R)-3-aminopent-4-en-2-ol hydrochloride (4.99 g, 36.2 mmol) and Hunig's base (14.7 mL, 0.75 g/mL, 85.3 mmol) were added. The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated and the residue was purified using silica gel column chromatography (EtOAc in heptane from 0 to 100 %) to afford methyl 3-bromo-4-[[(lR)-l-[(l S)-l- hydroxyethyl]allyl]sulfamoyl]-l-methyl-pyrrole-2-carboxylate (1 1.4 g) as an off white powder. 1H NMR (400 MHz, DMSO-d6) δ ppm 0.99 (d, J=6.4 Hz, 3 H), 3.41 - 3.50 (m, 1 H), 3.53 - 3.63 (m, 1 H), 3.81 (s, 3 H), 3.85 (s, 3 H), 4.62 (br d, J=5.1 Hz, 1 H), 4.91 - 4.95 (m, 1 H), 4.97 (d, J=0.7 Hz, 1 H), 5.63 - 5.74 (m, 1 H), 7.33 (br s, 1 H), 7.69 (s, 1 H); Method B; Rt: 0.68 min. m/z: 379 (M-H)~ Exact mass: 380.0.
To a solution of methyl 3-bromo-4-[[(lR)-l-[(l S)-l-hydroxyethyl]allyl]sulfamoyl]-l- methyl-pyrrole-2-carboxylate (1.10 g, 2.89 mmol) in DMF (5 mL) purged with nitrogen was added Hunig's base (0.55 mL, 0.75 g/mL, 3.17 mmol) and bis(tri-tert- butylphosphine)palladium(O) (147 mg, 0.29 mmol). The reaction mixture was heated in the microwave for 10 minutes at 130°C. The reaction mixture was purified via preparative HPLC (Stationary phase: RP XBridge Prep C 18 OBD-ΙΟμιη, 50x150mm, Mobile phase: 0.25% NH4HCO3 solution in water, ACN) yielding methyl (3R)-3-[(l S)- l-hydroxyethyl]-7-methyl-l , l-dioxo-2,3-dihydropyrrolo[3,4-fJthiazepine-6-carboxylate (380 mg). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.19 (d, J=6.2 Hz, 3 H), 3.62 - 3.72 (m, 1 H), 3.76 - 3.88 (m, 7 H), 4.98 (br d, J=3.7 Hz, 1 H), 6.07 (dd, J=12.9, 2.8 Hz, 1 H), 7.12 (dd, J=12.8, 2.6 Hz, 1 H), 7.49 (br s, 1 H), 7.69 (s, 1 H); Method B; Rt: 0.59 min. m/z: 299 (M-H)~ Exact mass: 300.1 and methyl 3-acetyl-7-methyl-l ,l-dioxo- 2,3,4,5-tetrahydropyrrolo[3,4-fJthiazepine-6-carboxylate. 1H NMR (400 MHz, DMSO- d6) ppm 1.46 - 1.59 (m, 1 H), 2.12 - 2.20 (m, 1 H), 2.22 (s, 3 H), 2.77 - 2.87 (m, 1 H),
3.58 (br dd, J=15.7, 7.7 Hz, 1 H), 3.80 (s, 3 H), 3.79 (s, 3 H), 4.19 (br t, J=9.5 Hz, 1 H),
7.59 (s, 1 H), 7.68 (br d, J=9.3 Hz, 1 H); Method B; Rt: 0.67 min. m/z: 299 (M-H)~ Exact mass: 300.1 Methyl (3R)-3-[(l S)-l-hydroxyethyl]-7-methyl-l,l-dioxo-2,3-dihydropyrrolo[3,4-f]- thiazepine-6-carboxylate (95 mg, 0.32 mmol) and 3,4-difluoroaniline (53 mg,
0.41 mmol) were dissolved in THF (5 mL). Lithium bis(trimethylsilyl)amide
(2 mL, 1 M in THF, 2 mmol) was added and the reaction mixture was stirred at room temperature. The reaction was quenched after 1 hour with NH4C1 (sat., aq., 5 mL) and the organic layer was separated. The aqueous layer was extracted with DCM (2 X 4 mL) and the combined organic layers were dried (Na2S04) and evaporated to dryness. The residue was purified via preparative HPLC (Stationary phase: RP XBridge Prep C18 OBD-ΙΟμιη, 50x150mm, Mobile phase: 0.25% NH4HC03 solution in water, ACN). The obtained product was purified using silica gel column chromatography (EtOAc in heptane from 0 to 100 %) to afford compound 84 (62 mg). 1H NMR
(400 MHz, DMSO-d6) δ ppm 1.20 (d, J=6.2 Hz, 3 H), 3.60 - 3.77 (m, 4 H), 3.77 - 3.87 (m, 1 H), 4.97 (br d, J=5.7 Hz, 1 H), 5.96 (dd, J=12.5, 2.6 Hz, 1 H), 6.54 (dd, J=12.5, 2.6 Hz, 1 H), 7.35 - 7.52 (m, 3 H), 7.57 (s, 1 H), 7.81 - 7.89 (m, 1 H), 10.73 (br s, 1 H); Method B; Rt: 0.78 min. m/z: 396 (M-H)~ Exact mass: 397.1.
Compound 85: N-(3-cyano-4-fluoro-phenyl)-3-isopropyl-7-methyl-l,l-dioxo-2,3,4,5- tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000115_0001
Methyl 3-bromo-l-methyl-pyrrole-2-carboxylate (2.44 g, 11.1 mmol), tert-butyl N-(l- isopropylallyl)carbamate (2.65 g, 13.3 mmol) and TEA (3 mL, 0.73 g/mL, 22.2 mmol) in DMF (5 mL) was stirred and purged with nitrogen for 5 minutes. Then bis(tri-tert- butylphosphine)palladium(O) (1.13 g, 2.22 mmol) was added and stirring and purging was continued for 5 more minutes. The mixture was heated under microwave irradiation to 100°C for 60 minutes. The reaction mixture was cooled to room temperature and filtered through a pad of dicalite and rinsed with EtOAc (150 mL). Then the filtrate was concentrated in vacuo and purified using silica gel column chromatography (gradient elution: EtOAc:heptane 0: 100 to 100:0) yielding methyl 3-[(E)-3-(tert-butoxycarbonylamino)-4-methyl-pent-l-enyl]-l -methyl -pyrrole -2- carboxylate (3.31 g) as an oil. Method B; Rt: 1.18 min. m/z: 335 (M-H)" Exact mass: 336.2.
A hydrogenation flask was flushed with nitrogen and then charged with Pd/C (10%) (733 mg, 0.69 mmol). To this was added under nitrogen methyl 3-[(E)-3-(tert- butoxycarbonylamino)-4-methyl-pent-l-enyl]-l -methyl-pyrrole -2-carboxylate (2.20 g, 6.54 mmol) in MeOH (35 mL). The resulting suspension was then stirred under a hydrogen atmosphere at room temperature for 90 minutes. Then the mixture was filtered over a pad of dicalite under a constant nitrogen flow and this pad was rinsed with MeOH (150 mL). The filtrate was concentrated in vacuo and the obtained residue was purified using silica gel column chromatography (gradient elution: EtOAc:heptane 0:100 to 100:0). The desired fractions were concentrated in vacuo yielding methyl 3-[3-(tert-butoxycarbonylamino)-4-methyl-pentyl]-l -methyl -pyrrole-2-carboxylate (2.16 g) as a bright white powder.
Methyl 3 - [3 -(tert-butoxycarbonylamino)-4-methyl-pentyl] - 1 -methyl-pyrrole-2- carboxylate (250 mg, 0.74 mmol) in DCM (10 mL) was treated with chlorosulfonic acid (246 μί, 1.75 g/mL, 3.69 mmol) in DCM (5 mL) at 0°C. Then it was allowed to reach room temperature and the stirred for another hour. The mixture was added dropwise to ice-water (20 mL) and this was extracted with 2-MeTHF (2 X 20 mL). The combined extracts were dried on Na2S04, filtered and concentrated in vacuo yielding methyl 3-isopropyl-7-methyl-l,l-dioxo-2,3,4,5-tetrahydropyrrolo[3,4-fJthiazepine-6- carboxylate (80mg). Methyl 3-isopropyl-7-methyl-l,l-dioxo-2,3,4,5-tetrahydropyrrolo[3,4-fJthiazepine-6- carboxylate (80 mg, 0.27 mmol) and 5-amino-2-fluoro-benzonitrile (36 mg, 0.27 mmol) in dry THF (5 mL) was treated with lithium bis(trimethylsilyl)amide (1.3 mL, 1 M in THF, 1.3 mmol) and this was stirred for 2 hours at room temperature. The resulting mixture was quenched with NH4C1 (aq. sat., 5 mL). Then brine (5 mL) was added and the layers were separated. The water layer was extracted using EtOAc (2 X 20 mL). The combined extracts were concentrated in vacuo and the obtained crude was purified using silica gel column chromatography (gradient elution: EtOAc:heptane 0: 100 to 100:0). The desired fractions were concentrated in vacuo and the obtained residue was purified via preparative HPLC (Stationary phase: RP XBridge Prep CI 8 OBD-ΙΟμιη, 30x150mm, Mobile phase: 0.25% NH4HC03 solution in water, ACN) yielding compound 85 (17 mg) as a bright white solid. 1H NMR (400 MHz, DMSO- 6) δ ppm 0.88 (d, J=3.30 Hz, 3 H) 0.90 (d, J=3.08 Hz, 3 H) 1.32 - 1.47 (m, 1 H) 1.69
(dq, J=12.96, 6.54 Hz, 1 H) 1.79 - 1.93 (m, 1 H) 2.72 - 2.85 (m, 1 H) 2.98 - 3.11 (m, 1 H) 3.19 - 3.28 (m, 1 H) 3.69 (s, 3 H) 6.91 (d, J=10.34 Hz, 1 H) 7.44 (s, 1 H) 7.54 (t, J=9.13 Hz, 1 H) 7.95 (ddd, J=9.24, 4.84, 2.64 Hz, 1 H) 8.18 (dd, J=5.83, 2.75 Hz, 1 H) 10.59 (s, 1 H); Method B; Rt: 0.97 min. m/z: 403 (M-H)~ Exact mass: 404.1. Compound 86: N-[3-(difluoromethyl)-4-fluoro-phenyll-3-isopropyl-7-methyl-l , l- dioxo-23^,5-tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000117_0001
Compound 86 (17 mg) was prepared similarly as described for compound 81, using compound 82 instead of compound 79. 1H NMR (400 MHz, DMSO-^) δ ppm 0.88 (d, J=3.30 Hz, 3 H) 0.90 (d, J=3.30 Hz, 3 H) 1.32 - 1.46 (m, 1 H) 1.69 (dq, J=13.04, 6.73 Hz, 1 H) 1.79 - 1.95 (m, 1 H) 2.71 - 2.88 (m, 1 H) 2.95 - 3.1 1 (m, 1 H) 3.19 - 3.28 (m, 1 H) 3.69 (s, 3 H) 6.89 (d, J=10.34 Hz, 1 H) 7.22 (t, J=54.36 Hz, 1 H) 7.36 (t, J=9.46 Hz, 1 H) 7.42 (s, 1 H) 7.76 - 7.85 (m, 1 H) 8.02 - 8.08 (m, 1 H) 10.49 (s, 1 H); Method B; Rt: 1.02 min. m/z: 428 (M-H)~ Exact mass: 429.1.
Compound 87: (3R)-N-(3-cyano-4-fluoro-phenyl)-3-|Yl S)-l-hydroxyethyll-7-methyl- J-dioxo-2,3-dihydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000117_0002
Compound 87 (55 mg) was prepared similarly as described for compound 84, using 5-amino-2-fluoro-benzonitrile instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO-dtf) δ ppm 1.20 (d, J=6.2 Hz, 3 H), 3.60 - 3.77 (m, 4 H), 3.77 - 3.87 (m, 1 H), 4.97 (d, J=5.7 Hz, 1 H), 5.97 (dd, J=12.5, 2.6 Hz, 1 H), 6.57 (dd, J=12.5, 2.4 Hz, 1 H), 7.40 (br d, J=9.5 Hz, 1 H), 7.55 (t, J=9.1 Hz, 1 H), 7.59 (s, 1 H), 7.98 (ddd, J=9.2, 4.8, 2.8 Hz, 1 H), 8.20 (dd, J=5.7, 2.6 Hz, 1 H), 10.85 (br s, 1 H); Method B; Rt: 0.74 min. m/z: 403 (M-H)" Exact mass: 404.1.
Compound 88 : (3R -N-(3 ,4-difluorophenvn-3 -IY 1 S 1 -hydroxyethyll -7-methyl- 1.1- dioxo-2,3,4,5-tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000117_0003
Methyl (3R)-3-[(l S)-l-hydroxyethyl]-7-methyl-l , l-dioxo-2,3-dihydropyrrolo[3,4-f]- thiazepine-6-carboxylate (200 mg, 0.67 mmol) was dissolved in MeOH (30 mL). Under a nitrogen atmosphere Pd/C (10%) (71 mg, 0.067 mmol) was added. The reaction mixture was set under a hydrogen atmosphere for 60 minutes. The reaction mixture was filtered over decalite and the solids were washed with methanol (4 x 100 mL) and THF (4 x 100 mL). The filtrate was evaporated to dryness to afford methyl (3R)-3-[(l S)-l- hydroxyethyl]-7-methyl-l,l-dioxo-2,3,4,5-tetrahydropyrrolo[3,4-fJthiazepine-6- carboxylate (180 mg) as a white powder. Method B; Rt: 0.59 min. m/z: 301 (M-H)~ Exact mass: 302.1.
Methyl (3R)-3-[(l S)-l-hydroxyethyl]-7-methyl-l,l-dioxo-2,3,4,5- tetrahydropyrrolo[3,4-f]thiazepine-6-carboxylate (90 mg, 0.24 mmol) and 3,4-difluoro- aniline (40 mg, 0.31 mmol) were dissolved in THF (5 mL). Lithium bis(trimethylsilyl)- amide (1.6 mL, 1 M in THF, 1.6 mmol) was added and the reaction mixture was stirred 1 hour at room temperature. The reaction was quenched with NH4C1 (sat., aq., 5 mL) and the organic layer was separated. The aqueous layer was extracted with DCM (2 X 4 mL) and the combined organic layers were dried (Na2S04) and evaporated to dryness. The residue was purified via preparative HPLC (Stationary phase: RP XBridge Prep C18 OBD-ΙΟμιη, 50x150mm, Mobile phase: 0.25% NH4HC03 solution in water, ACN). The obtained product was purified using silica gel column chromatography (ethyl acetate in heptane from 0 to 100 %) yielding compound 88 (35 mg). 1H NMR
(400 MHz, OMSO-de) δ ppm 1.13 (d, J=6.2 Hz, 3 H), 1.20 - 1.35 (m, 1 H), 2.18 (br dd, J=14.3, 6.8 Hz, 1 H), 2.67 - 2.80 (m, 1 H), 3.02 (br dd, J=14.9, 6.5 Hz, 1 H), 3.14 - 3.27 (m, 1 H), 3.43 - 3.51 (m, 1 H), 3.68 (s, 3 H), 4.67 (d, J=5.9 Hz, 1 H), 6.89 (d, J=10.1 Hz, 1 H), 7.38 - 7.46 (m, 3 H), 7.81 - 7.89 (m, 1 H), 10.47 (s, 1 H); Method B; Rt: 0.78 min. m/z: 398 (M-H)~ Exact mass: 399.1.
Compound 89 : N-(3 ,4-difluorophenyl)-7-methyl- 1 , 1 -dioxo-3-tetrahydropyran-4-yl-3 ,4- dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000118_0001
Compound 89 (320 mg) was prepared similarly as described for compound 14, using 2-amino-2-(oxan-4-yl)ethan-l-ol hydrochloride instead of DL-alaninol. The ring closure was obtained after heating 90 minutes at 110°C in DMF and compound 83 was purified on silica using a gradient from heptane to EtOAc. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.24 - 1.44 (m, 2 H), 1.60 - 1.79 (m, 3 H), 3.20 - 3.29 (m, 2 H), 3.42 - 3.51 (m, 1 H), 3.81 - 4.04 (m, 6 H), 4.72 (d, J=12.5 Hz, 1 H), 7.36 - 7.50 (m, 3 H), 7.62 (d, J=9.6 Hz, 1 H), 7.86 (ddd, J=13.2, 7.5, 2.5 Hz, 1 H), 9.42 (s, 1 H); Method D; Rt: 1.80 min. m/z: 440 (M-H)" Exact mass: 441.1. This racemic mixture was seperated in enantiomers 89a (101 mg) and 89b (75 mg) by preparative SFC (Stationary phase: Chiralpak Diacel AD 20 x 250 mm, Mobile phase: C02, EtOH + 0.4 iPrNH2). Method J; Rt : 89a: 1.39 min, 89b: 2.96 min.
Compound 90: (3R)-N-(3-cyano-4-fluoro-phenyl)-3-[(l S)-l-hydroxyethyll-7-methyl- lJ-dioxo-2,3,4,5-tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000119_0001
Compound 90 (38 mg) was prepared similarly as described for compound 88, using 5-amino-2-fluoro-benzonitrile instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO- ¾ δ ppm 1.13 (d, J=6.2 Hz, 3 H), 1.20 - 1.35 (m, 1 H), 2.19 (br dd, J=14.2, 6.9 Hz, 1 H), 2.71 - 2.81 (m, 1 H), 3.05 (br dd, J=15.0, 6.4 Hz, 1 H), 3.16 - 3.27
(m, 1 H), 3.47 (sxt, J=6.4 Hz, 1 H), 3.69 (s, 3 H), 4.67 (d, J=5.7 Hz, 1 H), 6.90 (d, J=10.1 Hz, 1 H), 7.44 (s, 1 H), 7.54 (t, J=9.1 Hz, 1 H), 7.96 (ddd, J=9.1, 4.8, 2.8 Hz, 1 H), 8.19 (dd, J=5.7, 2.6 Hz, 1 H), 10.59 (s, 1 H); Method B; Rt: 0.73 min. m/z:
405 (M-H)" Exact mass: 406.1.
Compound 91 : N-(3-cyano-4-fluoro-phenyl)-7-methyl- 1 , 1 -dioxo-3,4-dihydro-2H- pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000119_0002
Ethyl 3-hydroxy-l -methyl -pyrrole -2-carboxylate (200 mg, 1.0 mmol) was dissolved in
THF (8 mL) under nitrogen and NaH (60% dispersion in mineral oil) (64 mg,
1.61 mmol) was added at room temperature and stirred for 10 minutes before 2-(tert- butoxycarbonylamino)ethyl methanesulfonate (361 mg, 1.51 mmol) was added. The solution was heated overnight at 80 °C. The solution was quenched with ice water diluted with EtOAc, extracted twice with EtOAc, and the combined organics were dried with MgS04, filtered, and concentrated in vacuo. The residue was purified on silica using gradient elution (heptane/EtOAc from 100/0 to 50/50) to yield ethyl 3-[2-(tert- butoxycarbonylamino)ethoxy]-l-methyl-pyrrole-2-carboxylate (238 mg) as an oil. Ethyl 3-[2-(tert-butoxycarbonylamino)ethoxy]-l-methyl-pyrrole-2-carboxylate (235 mg, 0.68 mmol) was dissolved in DCM (4 mL) and chlorosulfonic acid (0.090 mL,
1.75 g/mL, 1.354 mmol) was added under inert atmosphere at 0 °C and stirred for 2 hours. The solution was concentrated in vacuo to give 4-(2-aminoethoxy)-5-ethoxy- carbonyl-1 -methyl -pyrrole-3-sulfonic acid (197 mg).
4-(2-aminoethoxy)-5-ethoxycarbonyl-l -methyl -pyrrole-3 -sulfonic acid (197 mg, 0.6 mmol) was dissolved in DCM (4 mL) and SOCl2 (0.218 mL, 1.64 g/mL, 2.999 mmol) was added and the solution was heated for 2 hours at 70 °C. The solution was coevaporated with toluene until dryness. The residue was redissolved in MeOH and quenched with NaHC03 (aq. sat.). The excess salts were filtered off and the residue concentrated in vacuo. The crude was then further purified on silica using a
DCM/MeOH from 100/0 to 90/10 gradient to give ethyl 7-methyl-l,l-dioxo-3,4- dihydro-2H-pyrrolo[3,4-b][l,4,5]oxathiazepine-6-carboxylate (85 mg) as a yellow solid. 1H NMR (400 MHz, CHLOROFORM- ) δ ppm 1.36 (t, J=7.2 Hz, 3 H) 3.62 - 3.70 (m, 2 H) 3.83 (s, 3 H) 4.28 - 4.36 (m, 4 H) 4.87 (br s, 1 H) 7.03 (s, 1 H).
Ethyl 7-methyl-l,l-dioxo-3,4-dihydro-2H-pyrrolo[3,4-b][l,4,5]oxathiazepine-6- carboxylate (67 mg, 0.22 mmol) was dissolved in THF (4 mL) and 5-amino-2-fluoro- benzonitrile (33 mg, 0.24 mmol) was added followed by lithium bis(trimethylsilyl)- amide (0.87 mL, 1 M in THF, 0.87 mmol) at room temperature under an inert atmosphere and stirred for 2 hours. The solution was quenched with NH4C1 (sat., aq.) and the organics were removed in vacuo, diluted with DCM, separated, dried with Na2S04, filtered off, and concentrated in vacuo. The crude was then purified via preparative HPLC to give compound 91 (15 mg). 1H NMR (400 MHz,
CHLOROFORM- ) δ ppm 3.77 - 3.83 (m, 2 H), 3.97 (s, 3 H), 4.43 - 4.47 (m, 2 H), 4.72 (t, J=6.9 Hz, 1 H), 7.11 (s, 1 H), 7.18 - 7.22 (m, 1 H), 7.72 (ddd, J=9.1, 4.5, 2.8 Hz, 1 H), 7.96 (dd, J=5.4, 2.8 Hz, 1 H), 8.86 (s, 1 H); Method B; Rt: 0.82 min. m/z:
363 (M-H)~ Exact mass: 364.1.
Compound 92 : (3 S)-3 -[cyclopropyl(hydroxy)methyl] -N-(3 -difluorophenyl)- 7-meτhyl- l -dioxo-3^-dihydro-2H-pyrrolo[3^-bl[l A51oxathiazep
O H To a cooled solution of (S)-(-)-3-boc-2,2-dimethyloxazolidine-4-carboxaldehyde in dry THF (20 mL) at -78°C was added cyclopropylmagnesium bromide (4.83 mL, 1M in THF, 4.83 mmol). The reaction mixture was warmed slowly to room temperature and stirred for 4 hours. The reaction mixture was quenched with water (20 ml) and then EtOAc was added (10 ml) to extract the product (some NaCl was added to get all THF out of the water layer). The water layer was extracted once more with EtOAc. The combined organic layers were dried over Na2S04, filtered and evaporated to dryness and the crude oil was purified on silica (from 0% to 40% EtOAc in heptane). All pure fractions were collected and evaporated to get tert-butyl (4S)-4- [cyclopropyl(hydroxy)methyl]-2,2-dimethyl-oxazolidine-3-carboxylate (679 mg) as a clear yellow oil. 1H NMR (400 MHz, CHLOROFORM-;/) δ ppm 0.20 - 0.65 (m, 4 H), 0.75 - 0.99 (m, 1 H), 1.38 - 1.78 (m, 15 H), 2.98 - 3.57 (m, 2 H), 3.87 - 4.35 (m, 3 H).
HC1 (2.35 mL, 4 M in dioxane, 9.41 mmol) was added to a solution of tert-butyl (4S)-4- [cyclopropyl(hydroxy)methyl]-2,2-dimethyl-oxazolidine-3-carboxylate (679 mg, 2.35 mmol) in 1,4-dioxane (10 mL). The reaction mixture was stirred at rt for 150 minutes. The reaction mixture was concentrated under reduced pressure to yield (2S)-2- amino-l-cyclopropyl -propane- 1, 3 -diol hydrochloride (308 mg) which was used as such. Ethyl 4-chlorosulfonyl-3-fluoro-l-methyl-pyrrole-2-carboxylate (667 mg, 2.47 mmol) was added to a solution of (2S)-2-amino-l-cyclopropyl-propane-l,3-diol hydrochloride (308.26 mg, 2.35 mmol) and Hunig's base (2.56 mL, 0.75 g/mL, 14.8 mmol) in DCM (15 mL) at room temperature under nitrogen atmosphere. The reaction mixture was stirred at room temperature overnight. A part of the DCM was concentrated and the reaction mixture was directly purified on silica (heptane/ethyl acetate 100/0 to 0/100) to afford ethyl 4-[[(l S)-2-cyclopropyl-2-hydroxy-l-(hydroxymethyl)ethyl]sulfamoyl]-3- fluoro-l-methyl-pyrrole-2-carboxylate (756 mg). Method B; Rt: 0.66 min. m/z: 363 (M-H)~ Exact mass: 364.1. Lithium bis(trimethylsilyl)amide (5.5 mL, 1 M in THF, 5.5 mmol) was added dropwise to a solution of ethyl 4-[[(l S)-2-cyclopropyl-2-hydroxy-l-
(hydroxymethyl)ethyl]sulfamoyl]-3-fluoro- 1 -methyl-pyrrole-2-carboxylate (400 mg, 1.1 mmol) and 3,4-difluoroaniline (0.13 mL, 1.29 g/mL, 1.32 mmol) in THF (15 mL). The reaction mixture was stirred at room temperature for 30 min. The reaction mixture was quenched by adding water and diluted in ethyl acetate. The aqueous layer was extracted twice with ethyl acetate. The combined organic layers were dried over Na2S04, filtered off and concentrated under reduced pressure. The residue was purified on silica (heptane/ethyl acetate 100/0 to 0/100) to afford 4-[[(l S)-2-cyclopropyl-2- hydroxy- 1 -(hydroxymethyl)ethyl] sulfamoyl] -N-(3 ,4-difluorophenyl)-3 -fluoro- 1 -methyl- pyrrole -2-carboxamide (250 mg).
Cesium fluoride (272 mg, 1.79 mmol) was added to a solution of 4-[[(l S)-2-cyclo- propyl-2-hydroxy-l-(hydroxymethyl)ethyl]sulfamoyl]-N-(3,4-difluorophenyl)-3-fluoro- 1 -methyl-pyrrole -2-carboxamide (200 mg, 0.45 mmol) in DMF (5 mL). The reaction mixture was stirred at 110°C for 7 hours. The reaction mixture was concentrated and purified on silica (heptane/ethyl acetate 100/0 to 0/100). The obtained product was purified via preparative SFC (Stationary phase: Chiralpak Diacel AD 20 x 250 mm, Mobile phase: C02, EtOH-iPrOH (50-50) + 0.4% iPrNH2) to yield compound 92a
(34 mg); 1H NMR (400 MHz, DMSO- ¾ δ ppm 0.25 - 0.50 (m, 4 H), 0.98 - 1.10 (m, 1 H), 3.03 - 3.14 (m, 1 H), 3.56 - 3.67 (m, 1 H), 3.83 (s, 3 H), 4.00 (dd, J=12.8, 9.2 Hz, 1 H), 4.91 (dd, J=12.8, 1.8 Hz, 1 H), 5.00 (d, J=5.7 Hz, 1 H), 7.35 - 7.50 (m, 3 H), 7.60 (d, J=9.9 Hz, 1 H), 7.87 (ddd, J=13.3, 7.5, 2.5 Hz, 1 H), 9.43 (s, 1 H); Method D; Rt: 1.78 min. m/z: 426 (M-H)~ Exact mass: 427.1, and 92b (11 mg); 1H NMR
(400 MHz, DMSO- ¾ δ ppm 0.17 - 0.47 (m, 4 H), 0.95 - 1.08 (m, 1 H), 3.04 - 3.18 (m, 1 H), 3.82 (s, 4 H), 3.93 - 4.10 (m, 1 H), 4.74 (dd, J=12.7, 1.4 Hz, 1 H), 5.00 (d, J=5.1 Hz, 1 H), 7.34 - 7.49 (m, 4 H), 7.86 (ddd, J=13.2, 7.5, 2.4 Hz, 1 H), 9.35 - 9.48
(m, 1 H); Method D; Rt: 1.77 min. m/z: 426 (M-H)~ Exact mass: 427.1 being the 2 epimers of compound 92. Method P; Rt : 92a: 1.88 min, 92b: 2.27 min.
Compound 93 : (3R)-N-(3 ,4-difluorophenyl)-3 -( 1 -hydroxy- 1 -methyl-ethyl)-7-methyl- lJ-dioxo-3,4-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000122_0001
Methylmagnesium bromide (12.7 mL, 3 M, 38.2 mmol) was added to a solution of (R)-3 -tert-butyl 4-methyl 2,2-dimethyloxazolidine-3,4-dicarboxylate (3 g, 1.08 g/mL, 11.6 mmol) in THF (100 mL) at -20°C under a nitrogen atmosphere. The reaction mixture was stirred at 0°C for 4h and then the reaction mixture was quenched with NH4C1 (sat., aq.) and dilluted in EtOAc. The two layers were separated and the aqueous layer was extracted with EtOAc (twice). The combined organic layers were dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified on silica (heptane/EtOAc 100/0 to 70/30 to afford tert-butyl (4R)-4-(l -hydroxy- 1-methyl- ethyl)-2,2-dimethyl-oxazolidine-3-carboxylate (2.11 g) as a light yellow oil. Compound 93 (188 mg) was prepared similarly as described for compound 92, using tert-butyl (4R)-4-(l -hydroxy-1 -methyl-ethyl)-2,2-dimethyl-oxazolidine-3-carboxylate instead of tert-butyl (4S)-4-[cyclopropyl(hydroxy)methyl]-2,2-dimethyl-oxazolidine-3- carboxylate. 1H NMR (400 MHz, DMSO-^) δ ppm 1.13 (d, J=6.2 Hz, 3 H), 1.20 - 1.35 (m, 1 H), 2.19 (br dd, J=14.2, 6.9 Hz, 1 H), 2.71 - 2.81 (m, 1 H), 3.05 (br dd, J=15.0, 6.4 Hz, 1 H), 3.16 - 3.27 (m, 1 H), 3.47 (sxt, J=6.4 Hz, 1 H), 3.69 (s, 3 H), 4.67
(d, J=5.7 Hz, 1 H), 6.90 (d, J=10.1 Hz, 1 H), 7.44 (s, 1 H), 7.54 (t, J=9.1 Hz, 1 H), 7.96 (ddd, J=9.1 , 4.8, 2.8 Hz, 1 H), 8.19 (dd, J=5.7, 2.6 Hz, 1 H), 10.59 (s, 1 H); Method B; Rt: 0.73 min. m/z: 405 (M-H)~ Exact mass: 406.1.
Compound 94 : (3 S)-N-(3 ,4-difluorophenyl)-3 -( 1 -hydroxy- 1 -methyl-ethyl)-7-methyl- l J-dioxo-3,4-dihydro-2H-pyrrolo[3,4-bl[l ,4,51oxathiazepine-6-carboxamide
Figure imgf000123_0001
Compound 94 (300 mg) was prepared similarly as described for compound 93, using (S)-(-)-3-tert-butoxycarbonyl-4-methoxycarbonyl-2,2-dimethyl-l ,3-oxazolidine instead of (R)-3 -tert-butyl 4-methyl 2,2-dimethyloxazolidine-3,4-dicarboxylate. 1H NMR (400 MHz, DMSO-< ) δ ppm 1.06 (s, 3 H), 1.25 (s, 3 H), 3.55 (t, J=9.4 Hz, 1 H), 3.83 (s, 3 H), 3.92 (dd, J=12.5, 9.0 Hz, 1 H), 4.85 (s, 1 H), 4.96 (d, J=1 1.4 Hz, 1 H),
7.33 - 7.54 (m, 4 H), 7.87 (ddd, J=13.2, 7.5, 2.4 Hz, 1 H), 9.43 (s, 1 H); Method B; Rt: 0.88 min. m/z: 414 (M-H)" Exact mass: 415.1. MP: 234.1 °C.
Compound 95 : N-(3 ,4-difluorophenyl)-3 -|"hydroxy(3 -pyridyDmethyl] -7-methyl- 1 ,1 - dioxo-3,4-dihydro-2H-pyrrolo[3,4-bl[l ,4,51oxathiazepine-6-carboxamide
Figure imgf000123_0002
To a solution of KOH (2.48 g, 44.2 mmol) in EtOH (100 mL) at 0°C was added
3-pyridinecarboxaldehyde (4.66 mL, 1.14 g/mL, 48.6 mmol) and ethyl isocyanoacetate (4.85 mL, 1.03 g/mL, 44.2 mmol). The reaction mixture was stirred for 3 hours and then concentrated to yield an oil. This was redissolved in HC1 (37% in H20, 50 mL) and heated at 60°C for 2 hours. The formed precipitate was filtered off to give 2-amino- 3-hydroxy-3-(3-pyridyl)propanoic acid (8.3 g). In a 250 mL flask 2-amino-3-hydroxy-3-(3-pyridyl)propanoic acid (8.3 g, 32.5 mmol) was dissolved in dry MeOH (50 mL) and cooled till 5°C. SOCl2 (11.8 mL, 1.64 g/mL, 163 mmol) was added dropwise and after addition the reaction was heated at reflux for 3 hours. The reaction mixture was concentrated to dryness and partitioned between DCM and NaHC03 (sat., aq.). The organic layer was dried over MgS04 and evaporated to dryness yielding methyl 2-amino-3-hydroxy-3-(3-pyridyl)propanoate (8.76 g) as a light yellow oil.
Methyl 2-amino-3-hydroxy-3-(3-pyridyl)propanoate (8.76 g, 32.5 mmol), BOC- anhydride (7.32 g, 32.5 mmol) and Et3N (22.6 mL, 0.73 g/mL, 163 mmol) were dissolved in THF (150 mL) and stirred 3 hours at room temperature. The volatiles were removed under reduced pressure and the residue was separated between water and 2- MeTHF. The organic layer was removed and concentrated under reduced pressure. The residue was purified on silica using a heptane to EtOAc:EtOH 3: 1 gradient yielding methyl 2-(tert-butoxycarbonylamino)-3-hydroxy-3-(3-pyridyl)propanoate (3.3 g).
Method B; Rt: 0.65 min. m/z: 295 (M-H)~ Exact mass: 296.1.
Methyl 2-(tert-butoxycarbonylamino)-3-hydroxy-3-(3-pyridyl)propanoate (3.3 g,
11.1 mmol) was dispensed in dioxane (100 mL). LAH (12 mL, 1 M in THF, 12 mmol) was added and the reaction mixture was stirred overnight at 80 °C. The reaction mixture was quenched with sodium sulfate decahydrate (550 mg, 1.7 mmol) and then dried with MgS04. The solids were filtered off and the filtrate was evaporated to dryness. The residue was purified on silica using a heptane to EtOAc:EtOH 3 : 1 gradient yielding tert-butyl N-[2-hydroxy-l-(hydroxymethyl)-2-(3-pyridyl)ethyl]- carbamate (763 mg) as a white powder. tert-butyl N-[2-hydroxy-l-(hydroxymethyl)-2-(3-pyridyl)ethyl]carbamate (350 mg, 1.3 mmol) was dissolved in DCM (10 mL). TFA (300 μί, 1.49 g/mL, 3.91 mmol) was added and the reaction mixture was stirred overnight. TFA (300 μί, 1.49 g/mL, 3.91 mmol) was added and the reaction mixture was stirred for 2 days at 40 °C. Hunig's base (2.25 mL, 0.75 g/mL, 13.04 mmol) was added and this reaction mixture was used as such in the further synthesis.
Compound 95 (15.2 mg) was prepared similarly as described for compound 63, using the previously described reaction mixture instead of (lS,2S)-(+)-2-amino-l-phenyl-l,3- propanediol. 1H NMR (400 MHz, DMSO- ¾ δ ppm 3.80 (s, 3 H), 3.91 - 3.97 (m, 1 H), 3.97 - 4.06 (m, 1 H), 4.82 (d, J=11.7 Hz, 1 H), 4.99 (d, J=3.3 Hz, 1 H), 5.91 (br s, 1 H), 7.36 - 7.50 (m, 4 H), 7.53 (br s, 1 H), 7.78 (dt, J=7.7, 1.8 Hz, 1 H), 7.82 - 7.90 (m, 1 H), 8.48 (dd, J=4.8, 1.5 Hz, 1 H), 8.59 (d, J=1.8 Hz, 1 H), 9.49 (s, 1 H); Method B; Rt: 0.84 min. m/z: 463 (M-H)" Exact mass: 464.1.
Compound 96: (3R)-N-[3-(difluoromethyl)-4-fluoro-phenyll-3-[(l S)-l-hydroxy ethyl] - 7-methyl-l,l-dioxo-2,3-dihydropyrrolo[3,4-f1thiazepine-6-carboxamide
Figure imgf000125_0001
Compound 96 (177 mg) was prepared similarly as described for compound 84, using 3-(difluoromethyl)-4-fluoro-aniline instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO-dtf) δ ppm 1.20 (d, J=6.2 Hz, 3 H), 3.64 - 3.76 (m, 4 H), 3.76 - 3.88 (m, 1 H), 4.96 (d, J=5.9 Hz, 1 H), 5.96 (dd, J=12.5, 2.9 Hz, 1 H), 6.56 (dd, J=12.5, 2.6 Hz, 1 H), 7.23 (t, J=54.4 Hz, 1 H), 7.32 - 7.44 (m, 2 H), 7.57 (s, 1 H), 7.80 - 7.85 (m, 1 H), 8.07 (dd, J=6.4, 2.4 Hz, 1 H), 10.75 (br s, 1 H); Method B; Rt: 0.81 min. m/z: 428 (M-H)" Exact mass: 429.1. MP: 182.3 °C. Compound 97: (3R)-JV-(2-bromo-4-pyridyl)-3-r(l S)-l -hydroxyethyll-7-methyl- 1.1- dioxo-2,3-dihydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000125_0002
Compound 97 (134 mg) was prepared similarly as described for compound 84,
4-amino-2-bromopyridine instead of 3,4-difluoroaniline. 1H NMR (400 MHz,
OMSO-d6) δ ppm 1.21 (d, J=6.2 Hz, 3 H), 3.64 - 3.91 (m, 5 H), 4.98 (d, J=5.7 Hz, 1 H), 5.99 (dd, J=12.5, 2.9 Hz, 1 H), 6.56 (dd, J=12.5, 2.6 Hz, 1 H), 7.42 (d, J=10.3 Hz, 1 H), 7.59 - 7.67 (m, 2 H), 7.97 (d, J=1.8 Hz, 1 H), 8.29 (d, J=5.7 Hz, 1 H), 11.04 (s, 1 H); Method B; Rt: 0.69 min. m/z: 439 (M-H)" Exact mass: 440.0. Compound 98: (3R -3-r(l S -l-hvdroxyethyll-7-methyl-l , l-dioxo-N-(3,4,5-trifluoro- phenyl)-2,3-dihydropyrrolo[3,4-f1thiazepine-6-carboxamide
Figure imgf000126_0001
Compound 98 (146 mg) was prepared similarly as described for compound 84, using 3,4,5-trifluoroaniline instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO-^) δ ppm 1.21 (d, J=6.2 Hz, 3 H), 3.54 - 3.74 (m, 4 H), 3.76 - 3.90 (m, 1 H), 4.98
(d, J=5.7 Hz, 1 H), 5.98 (dd, J=12.5, 2.6 Hz, 1 H), 6.54 (dd, J=12.5, 2.4 Hz, 1 H), 7.40 (br d, J=10.1 Hz, 1 H), 7.54 - 7.66 (m, 3 H), 10.85 (br s, 1 H); Method B; Rt: 0.86 min. m/z: 414 (M-H)~ Exact mass: 415.1. MP: 244.0 °C.
Compound 99 : (3R)-JV-(4-fluoro-3 -methyl-phenyl)-3 - IT 1 S) - 1 -hydroxyethyll -7-methyl- l J-dioxo-2,3-dihydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000126_0002
Compound 99 (134 mg) was prepared similarly as described for compound 84, using 4-fluoro-3-methylaniline instead of 3,4-difluoroaniline. 1H NMR (400 MHz,
DMSO-dtf) δ ppm 1.20 (d, J=6.2 Hz, 3 H), 2.23 (d, J=1.5 Hz, 3 H), 3.64 - 3.76 (m, 4 H), 3.76 - 3.88 (m, 1 H), 4.96 (br d, J=5.5 Hz, 1 H), 5.94 (dd, J=12.5, 2.6 Hz, 1 H), 6.53 (dd, J=12.5, 2.6 Hz, 1 H), 7.12 (t, J=9.2 Hz, 1 H), 7.37 (br d, J=8.1 Hz, 1 H), 7.48 - 7.53 (m, 1 H), 7.54 (s, 1 H), 7.63 (dd, J=6.9, 2.3 Hz, 1 H), 10.49 (s, 1 H); Method B; Rt: 0.80 min. m/z: 392 (M-H)~ Exact mass: 393.1.
Compound 100: (3 R)-N-[3-(difluoromethyl)-4-fluoro-phenyll-3-(l -hydroxy- 1 -methyl - ethyl)-7-methyl-l ,l-dioxo-3,4-dihydro-2H-pyrrolo[3,4-bl[l ,4,51oxathiazepine-6- carboxamide
Figure imgf000126_0003
Compound 100 (216 mg) was prepared similarly as described for compound 93, using 3-(difluoromethyl)-4-fluoro-aniline instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO- ¾ δ ppm 1.06 (s, 3 H), 1.25 (s, 3 H), 3.55 (br t, J=9.5 Hz, 1 H), 3.83 (s, 3 H), 3.94 (dd, J=12.5, 8.8 Hz, 1 H), 4.86 (s, 1 H), 4.95 (d, J=1 1.4 Hz, 1 H), 7.06 - 7.37 (m, 2 H), 7.47 - 7.53 (m, 2 H), 7.77 - 7.85 (m, 1 H), 8.04 (dd, J=6.3, 2.5 Hz, 1 H), 9.47 (s, 1 H); Method B; Rt: 0.90 min. m/z: 446 (M-H)~ Exact mass: 447.1.
Compound 101 : (3 S)-N-[3 -(difluoromethyl)-4-fluoro-phenyll -3 -( 1 -hydroxy- 1 -methyl- ethyl)-7-methyl-l ,l-dioxo-3,4-dihydro-2H-pyrrolo[3,4-bl[l ,4,51oxathiazepine-6- carboxamide
Figure imgf000127_0001
Compound 101 (132.8 mg) was prepared similarly as described for compound 94, using 3-(difluoromethyl)-4-fluoro-aniline instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO-dtf) δ ppm 1.06 (s, 3 H), 1.25 (s, 3 H), 3.55 (t, J=9.4 Hz, 1 H), 3.83 (s, 3 H), 3.93 (dd, J=12.5, 9.0 Hz, 1 H), 4.86 (s, 1 H), 4.95 (d, J= 1 1.4 Hz, 1 H), 7.05 - 7.39 (m, 2 H), 7.45 - 7.55 (m, 2 H), 7.77 - 7.85 (m, 1 H), 8.04 (dd, J=6.3, 2.5 Hz, 1 H), 9.47 (s, 1 H); Method B; Rt: 0.89 min. m/z: 446 (M-H)" Exact mass: 447.1. MP:
214.4 °C.
Compound 102 : (3R)-N-(3 ,4-difluorophenyl)-3 -( 1 -hydroxy- 1 -methyl-ethyl)-7-methyl- l J-dioxo-2,3,4,5-tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000127_0002
A solution of tert-butyl (2R)-2-(benzyloxycarbonylamino)hex-5-ynoate (5.03 g, 15.8 mmol) and ethyl isocyanoacetate (5.10 g, 42.8 mmol) in dioxane (15 mL) was added dropwise at 90 °C during 45 minutes to a solution of ethyl isocyanoacetate
(1.50 g, 12.6 mmol) in dioxane (20 mL) wherein silver carbonate (947 mg, 3.44 mmol) was suspended. The reaction mixture was heated and stirred further at this temperature during 3 hours. The reaction mixture was filtered while still hot and concentrated. The residue was subjected to silica column chromatography using a gradient from 10 till 100% EtOAc in heptane resulting in ethyl 3-[(3R)-3-(benzyloxycarbonylamino)-4-tert- butoxy-4-oxo-butyl]-lH-pyrrole-2-carboxylate (1.98 g) as a clear oil.
TFA (5.3 mL, 1.49 g/mL, 69 mmol) was added to ethyl 3-[(3R)-3-(benzyloxycarbonyl- amino)-4-tert-butoxy-4-oxo-butyl]-lH-pyrrole-2-carboxylate (1.98 g, 4.6 mmol) in DCM (50 mL) and stirred for 3 hours. The reaction mixture was concentrated and redissolved in DMF (50 mL). Mel (6.24 mL, 2.28 g/mL, 100 mmol) and Cs2C03 (13 g, 40 mmol) were added and the reaction mixture was stirred overnight. The reaction mixture was filtered and directly loaded on a silica cartridge. A gradient from 0 till 100% EtOAc in heptane was applied yielding ethyl 3-[(3R)-3-(benzyloxycarbonyl- amino)-4-methoxy-4-oxo-butyl]-l-methyl-pyrrole-2-carboxylate (1.70 g). 1H NMR (400 MHz, DMSO- ¾ δ ppm 1.26 (t, J=7.2 Hz, 3 H), 1.76 - 1.87 (m, 1 H), 1.87 - 2.00 (m, 1 H), 2.67 - 2.78 (m, 2 H), 3.62 (s, 3 H), 3.78 (s, 3 H), 3.94 - 4.06 (m, 1 H), 4.19 (q, J=7.0 Hz, 2 H), 5.05 (s, 2 H), 5.93 (d, J=2.4 Hz, 1 H), 6.96 (d, J=2.4 Hz, 1 H), 7.27 - 7.42 (m, 5 H), 7.77 (d, J=7.7 Hz, 1 H); Method D; Rt: 2.07 min. m/z: 401 (M-H)" Exact mass: 402.2.
Chlorosulfonic acid (112 mg, 0.96 mmol) was added to a solution of ethyl 3-[(3R)-3- (benzyloxycarbonylamino)-4-methoxy-4-oxo-butyl] - 1 -methyl-pyrrole-2-carboxylate (193 mg, 0.48 mmol) in DCM (20 mL) and stirred for 1 hour. Thionyl chloride (285 mg, 2.4 mmol) was added and the reaction mixture was stirred and refluxed 2 hours and then cooled in an icebath and quenched with methanol (ImL). The mixture was poured in NaHC03 (aq. sat., lOOmL). The mixture was extracted with DCM (2 X 50mL) and the combined organic layers were dried over magnesium sulfate, filtered and
concentrated. The residue was purified by column chromatography using a gradient from 0 till 100% EtOAc in heptane yielding 06-ethyl 03 -methyl (3R)-7-methyl- l,l-dioxo-2,3,4,5-tetrahydropyrrolo[3,4-fJthiazepine-3,6-dicarboxylate (58.8 mg) as a white powder. 1H NMR (400 MHz, DMSO- ¾ δ ppm 1.29 (t, J=7.0 Hz, 3 H),
1.61 - 1.74 (m, 1 H), 2.16 - 2.26 (m, 1 H), 2.81 (br dd, J=14.1, 12.1 Hz, 1 H), 3.62 - 3.72 (m, 4 H), 3.80 (s, 3 H), 4.22 - 4.30 (m, 3 H), 7.56 (s, 1 H), 7.74 (d, J=9.9 Hz, 1 H); Method D; Rt: 1.60 min. m/z: 329 (M-H)" Exact mass: 330.1.
Methylmagnesium chloride (0.12 mL, 3 M, 0.35 mmol) was added to 06-ethyl
03 -methyl (3R)-7-methyl- 1 , 1 -dioxo-2,3 ,4,5-tetrahydropyrrolo[3 ,4-f]thiazepine-3 ,6- dicarboxylate (58.8 mg, 0.168 mmol) in THF (10 mL) at -78 °C. The reaction mixture was allowed immediately to reach room temperature. Another equal amount methylmagnesium chloride (0.12 mL, 3 M, 0.35 mmol) was added at -78 °C and the reaction mixture allowed to reach room temperature. Methylmagnesium chloride (0.04 mL, 3 M, 0.12 mmol) was added at 20 °C and the reaction mixture was stirred for 15 minutes. The reaction mixture was quenched with HCl (aq., 1M, 30mL) diluted with brine (50mL) and extracted with EtOAc (3 X 50 mL). The combined organic layers were dried over MgS04, filtered and concentrated. The residue was subjected to silica gel column chromatography using a gradient from 0 till 100% EtOAc in heptane yielding ethyl (3R)-3 -( 1 -hydroxy- 1 -methyl-ethyl)-7-methyl- 1 , 1 -dioxo-2,3 ,4,5-tetra- hydropyrrolo[3,4-f]thiazepine-6-carboxylate (26 mg) as a clear oil. Method D; Rt: 1.46 min. m/z: 329 (M-H)~ Exact mass: 330.1.
Lithium bis(trimethylsilyl)amide (0.32 mL, 1 M in THF, 0.32 mmol) was added to a solution of ethyl (3R)-3-(l-hydroxy-l-methyl-ethyl)-7-methyl-l,l-dioxo-2,3,4,5-tetra- hydropyrrolo[3,4-f]thiazepine-6-carboxylate (26 mg, 0.0787 mmol) and 3,4-difluoro- aniline (21 mg, 0.16 mmol) in THF (2 mL) and stirred for 30 minutes. Another 3 times this amount of 3,4-difluoroaniline (21 mg, 0.16 mmol) and lithium bis(trimethylsilyl)- amide (0.32 mL, 1 M in THF, 0.32 mmol) were added and the reaction mixture was stirred for 1 hour. The reaction mixture was quenched with NH4C1 solution (aq. sat., 10 mL), diluted with brine (10 mL) and extracted with EtOAc (50 mL). The organic layer was dried over MgS04, filtered and concentrated. The residue was subjected to silica gel column chromatography using a gradient from 0 till 100% EtOAc in heptane. The product fractions were concentrated and the residue subjected to silica gel column chromatography using a gradient from 5 till 30% iPrOH in heptane yielding compound
102 (12 mg) as a beige resin. 1H NMR (400 MHz, DMSO-^) δ ppm 1.20 - 1.31 (m, 6 H), 1.47 - 1.59 (m, 1 H), 1.70 (br s, 1 H), 2.09 - 2.18 (m, 1 H), 2.89 - 2.99 (m, 1 H), 3.17 (td, J=7.7, 5.5 Hz, 1 H), 3.39 - 3.51 (m, 1 H), 3.74 (s, 3 H), 4.67 (d, J=10.3 Hz, 1 H), 7.09 - 7.18 (m, 2 H), 7.19 - 7.25 (m, 1 H), 7.70 (ddd, J=12.0, 7.2, 2.4 Hz, 1 H), 8.20 (s, 1 H); Method D; Rt: 1.58 min. m/z: 412 (M-H)" Exact mass: 413.1; MP: 218.2 °C.
Compound 103: (3R)-JV-r3-(difluoromethyl)-4-fluoro-phenvn-3-r(l S -l-hydroxyethyll-
7-methyl-l J-dioxo-2,3,4,5-tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000129_0001
Compound 96 (109 mg, 0.25 mmol) was dissolved in MeOH (30 mL). Under a nitrogen atmosphere Pd/C (10%>) (27 mg, 0.025 mmol) was added. The reaction mixture was hydrogenated for 60 minutes. The reaction mixture was filtered over decalite and the solids were washed with THF (4 x 80 mL). The filtrate was evaporated to dryness and the residue was purified using silica gel column chromatography (EtOAc in heptane from 0 to 100%) to afford compound 103 (70 mg) as a white powder.
1H NMR (400 MHz, DMSO-^) δ ppm 1.13 (d, J=6.2 Hz, 3 H), 1.19 - 1.37 (m, 1 H), 2.19 (br dd, J=14.3, 6.8 Hz, 1 H), 2.71 - 2.81 (m, 1 H), 3.05 (br dd, J=15.3, 6.1 Hz, 1 H), 3.16 - 3.29 (m, 1 H), 3.40 - 3.54 (m, 1 H), 3.69 (s, 3 H), 4.67 (d, J=5.7 Hz, 1 H), 6.89 (d, J=10.1 Hz, 1 H), 7.22 (t, J=54.2 Hz, 1 H), 7.37 (t, J=9.6 Hz, 1 H), 7.42 (s, 1 H), 7.78 - 7.84 (m, 1 H), 8.04 - 8.09 (m, 1 H), 10.48 (s, 1 H); Method B; Rt: 0.80 min. m/z: 430 (M-H)~ Exact mass: 431.1. MP: 274.7 °C.
Compound 104: (3R -3-r(lS -l-hydroxyethyll-7-methyl-l ,l-dioxo-N-(3,4,5-trifiuoro- phenyl)-2,3,4,5-tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000130_0001
Compound 98 (75 mg, 0.18 mmol) was dissolved in MeOH (30 mL). Under a nitrogen atmosphere Pd/C (10%) (19 mg, 0.018 mmol) was added. The reaction mixture was hydrogenated for 60 minutes. The reaction mixture was filtered over decalite and the solids were washed with THF (4 x 80 mL). The filtrate was evaporated to dryness and the residue was purified using silica gel column chromatography (EtOAc in heptane from 0 to 100%) to afford compound 104 (37 mg) as a white powder. 1H NMR
(400 MHz, DMSO-dtf) δ ppm 1.13 (d, J=6.4 Hz, 3 H), 1.19 - 1.36 (m, 1 H), 2.18 (br dd, J=14.2, 7.2 Hz, 1 H), 2.71 - 2.80 (m, 1 H), 3.02 (br dd, J=15.4, 5.9 Hz, 1 H), 3.16 - 3.28 (m, 1 H), 3.33 - 3.54 (m, 1 H), 3.68 (s, 3 H), 4.67 (d, J=5.9 Hz, 1 H), 6.90 (d, J=10.3 Hz, 1 H), 7.44 (s, 1 H), 7.56 - 7.64 (m, 2 H), 10.58 (s, 1 H); Method B; Rt: 0.85 min. m/z: 416 (M-H)" Exact mass: 417.1.
Compound 105: (3R)-3-[cyclopropyl(hydroxy)methyll-N-(3,4-difluorophenyl)-7- methyl- 1 , 1 -dioxo-3 ,4-dihydro-2H-pyrrolo[3 ,4-b [ 1 A51oxathiazepine-6-carboxamide
Figure imgf000130_0002
Compound 105 (310 mg) was prepared similarly as described for compound 92, using (R)-(-)-3-boc-2,2-dimethyloxazolidine-4-carboxaldehyde instead of (S)-(-)-3-boc-2,2- dimethyloxazolidine-4-carboxaldehyde. The obtained product was purified via preparative SFC (Stationary phase: Chiralpak Diacel AD 20 x 250 mm, Mobile phase: C02, EtOH + 0.4% iPrNH2) to yield compound 105a (60 mg); 1H NMR (400 MHz, DMSO- ¾ δ ppm 0.16 - 0.27 (m, 1 H), 0.27 - 0.36 (m, 1 H), 0.36 - 0.48 (m, 2 H), 0.94 - 1.09 (m, 1 H), 3.13 (dt, J=7.5, 4.0 Hz, 1 H), 3.72 - 3.80 (m, 1 H), 3.83 (s, 3 H), 4.04 (dd, J=12.8, 9.2 Hz, 1 H), 4.75 (dd, J=12.7, 1.4 Hz, 1 H), 5.01 (d, J=4.8 Hz, 1 H), 7.33 - 7.52 (m, 4 H), 7.86 (ddd, J=13.2, 7.5, 2.4 Hz, 1 H), 9.45 (s, 1 H); Method D; Rt: 1.77 min. m/z: 426 (M-H)" Exact mass: 427.1 ; MP: 243.0 °C, and 105b (203 mg); 1H NMR (400 MHz, DMSO-^) δ ppm 0.22 - 0.41 (m, 3 H), 0.41 - 0.53 (m, 1 H),
0.98 - 1.1 1 (m, 1 H), 3.03 - 3.14 (m, 1 H), 3.56 - 3.70 (m, 1 H), 3.83 (s, 3 H), 4.00 (dd, J=12.8, 9.2 Hz, 1 H), 4.91 (dd, J=12.8, 1.8 Hz, 1 H), 5.01 (d, J=5.5 Hz, 1 H), 7.34 - 7.51 (m, 3 H), 7.61 (d, J=9.7 Hz, 1 H), 7.87 (ddd, J=13.2, 7.5, 2.4 Hz, 1 H), 9.43 (s, 1 H); Method D; Rt: 1.77 min. m/z: 426 (M-H)" Exact mass: 427.1 ; MP: 244.8 °C, being the 2 epimers of compound 105. Method K; Rt : 105a: 1.98 min, 105b: 1.68 min.
Compound 106: (3R)-N-(3 -cyano-4-fluoro-phenyl)- 3 -( 1 -hydroxy- 1 -methyl-ethyl)-7- methyl- 1 , 1 -dioxo-3 ,4-dihydro-2H-pyrrolo[3 ,4-b [ 1 A51oxathiazepine-6-carboxamide
Figure imgf000131_0001
Compound 106 (134 mg) was prepared similarly as described for compound 93, using
5-amino-2-fluoro-benzonitrile instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO-dtf) δ ppm 1.06 (s, 3 H), 1.25 (s, 3 H), 3.55 (br t, J=9.5 Hz, 1 H), 3.84 (s, 3 H), 3.93 (dd, J=12.5, 9.0 Hz, 1 H), 4.86 (s, 1 H), 4.99 (d, J=1 1.4 Hz, 1 H), 7.46 - 7.56 (m, 3 H), 8.06 (ddd, J=9.2, 4.8, 2.9 Hz, 1 H), 8.21 (dd, J=5.7, 2.9 Hz, 1 H), 9.52 (s, 1 H); Method B; Rt: 0.83 min. m/z: 421 (M-H)" Exact mass: 422.1 ; MP: 260.1 °C.
Compound 107: (3 S)-N-(3-cyano-4-fluoro-phenyl)-3-(l -hydroxy- l-methyl-ethyl)-7- methyl- 1 , 1 -dioxo-3 ,4-dihydro-2H-pyrrolo[3 ,4-b] [ 1 A51oxathiazepine-6-carboxamide
Figure imgf000131_0002
Compound 107 (1 1 1.4 mg) was prepared similarly as described for compound 94, using 5-amino-2-fluoro-benzonitrile instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO- ¾ δ ppm 1.06 (s, 3 H), 1.25 (s, 3 H), 3.55 (br t, J=7.6 Hz, 1 H), 3.84 (s, 3 H), 3.93 (dd, J=12.4, 8.9 Hz, 1 H), 4.86 (s, 1 H), 4.99 (d, J=1 1.4 Hz, 1 H), 7.46 - 7.56 (m, 3 H), 8.06 (ddd, J=9.2, 4.9, 2.9 Hz, 1 H), 8.21 (dd, J=5.7, 2.9 Hz, 1 H), 9.52 (s, 1 H); Method B; Rt: 0.85 min. m/z: 421 (M-H)" Exact mass: 422.1. MP: 259.8 °C.
Compound 108: N-[2-(difluoromethyl)-4-pyridyll-3-isopropyl-7-methyl- 1 , 1 -dioxo- 2,3,4,5-tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000132_0001
Compound 108 (10.8 mg) was prepared similarly as described for compound 85, using 2-(difluoromethyl)pyridin-4-amine instead of 5-amino-2-fluoro-benzonitrile. 1H NMR (400 MHz, DMSO- i) δ ppm 0.86 - 0.89 (m, 3 H) 0.89 - 0.92 (m, 3 H) 1.32 - 1.47 (m, 1 H) 1.62 - 1.74 (m, 1 H) 1.82 - 1.93 (m, 1 H) 2.74 - 2.88 (m, 1 H) 2.99 - 3.10 (m, 1 H) 3.19 - 3.27 (m, 1 H) 3.71 (s, 3 H) 6.73 - 7.08 (m, 2 H) 7.47 (s, 1 H) 7.70 - 7.82 (m, 1 H) 8.03 (d, J=1.76 Hz, 1 H) 8.56 (d, J=5.72 Hz, 1 H) 10.85 (s, 1 H); Method B; Rt: 0.88 min. m/z: 41 1 (M-H)" Exact mass: 412.1.
Compound 109: N-(4-fluoro-3-methyl-phenyl)-3-isopropyl-7-methyl-l , l-dioxo-2,3,4,5- tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000132_0002
Compound 109 (16.1 mg) was prepared similarly as described for compound 85, using 4-fluoro-3-methylaniline instead of 5 -amino- 2-fluoro-benzonitrile. 1H NMR (400 MHz, DMSO- i) δ ppm 0.89 (dd, J=6.82, 3.52 Hz, 6 H) 1.38 (q, J=1 1.88 Hz, 1 H) 1.62 - 1.74 (m, 1 H) 1.86 (br dd, J=13.97, 6.71 Hz, 1 H) 2.22 (d, J=1.32 Hz, 3 H) 2.73 - 2.84 (m, 1 H) 2.95 - 3.06 (m, 1 H) 3.18 - 3.28 (m, 1 H) 3.68 (s, 3 H) 6.87 (br d, J=10.12 Hz, 1 H) 7.10 (t, J=9.13 Hz, 1 H) 7.39 (s, 1 H) 7.45 - 7.54 (m, 1 H) 7.58 - 7.66 (m, 1 H) 10.23 (s, 1 H); Method B; Rt: 1.03 min. m/z: 392 (M-H)" Exact mass: 393.1. Compound 110 : N-(3 ,4-difluorophenyl)-3 -(dimethylaminomethyl)-7-methyl- 1 , 1 -dioxo- 3^-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000133_0001
Compound 83 (105 mg, 0.27 mmol), MsCl (31 μί, 1.48 g/mL, 0.41 mmol) and TEA (150 μί, 0.73 g/mL, 1.08 mmol) were dissolved in DCM (10 mL) and stirred for 2 hours. Water was added and a precipitate appeared. This was filtered off, triturated with DIPE and dried to yield [6-[(3,4-difluorophenyl)carbamoyl]-7-methyl-l,l-dioxo- 3,4-dihydro-2H-pyrrolo[3,4-b][l,4,5]oxathiazepin-3-yl]methyl methanesulfonate (64 mg) as a white powder.
[6-[(3,4-difluorophenyl)carbamoyl]-7-methyl-l,l-dioxo-3,4-dihydro-2H-pyrrolo[3,4-b]- [l,4,5]oxathiazepin-3-yl]methyl methanesulfonate (10 mg, 0.021 mmol) was dissolved in dimethylamine (3 mL, 2M in THF) and stirred for 4 hours at room temperature. The volatiles were removed under reduced pressure and the residue was purified on silica using a heptane to EtO Ac gradient yielding compound 110 (2 mg). 1H NMR
(400 MHz, DMSO- ¾ δ ppm 2.32 (s, 6 H), 2.42 (dd, J=12.2, 5.8 Hz, 1 H), 2.66
(dd, J=12.2, 9.6 Hz, 1 H), 3.62 - 3.79 (m, 1 H), 3.86 - 3.97 (m, 4 H), 4.14 (dd, J=13.0, 5.7 Hz, 1 H), 4.85 (dd, J=13.0, 2.4 Hz, 1 H), 7.05 (s, 1 H), 7.07 - 7.15 (m, 2 H), 7.61 - 7.67 (m, 1 H), 8.72 (s, 1 H); Method B; Rt: 0.86 min. m/z: 413 (M-H)~ Exact mass: 414.1.
Compound 111: (3R)-JV-(2-bromo-4-pyridyl)-3 - IT 1 S) - 1 -hydroxyethyll -7-methyl- 1.1- dioxo-2,3,4,5-tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000133_0002
Compound 111 (20.5 mg) was prepared similarly as described for compound 90, using 4-amino-2-bromopyridine instead of 5-amino-2-fluoro-benzonitrile. 1H NMR
(400 MHz, DMSO- ¾ δ ppm 1.13 (d, J=6.2 Hz, 3 H), 1.22 - 1.34 (m, 1 H), 2.18 (br dd, J=14.2, 6.7 Hz, 1 H), 2.72 - 2.81 (m, 1 H), 3.03 (br dd, J=14.7, 6.4 Hz, 1 H), 3.16 - 3.28 (m, 1 H), 3.47 (sxt, J=6.2 Hz, 1 H), 3.70 (s, 3 H), 4.68 (d, J=5.9 Hz, 1 H), 6.92 (d, J=10.3 Hz, 1 H), 7.47 (s, 1 H), 7.62 (dd, J=5.6, 1.9 Hz, 1 H), 7.96 (d, J=1.8 Hz, 1 H), 8.27 (d, J=5.5 Hz, 1 H), 10.78 (s, 1 H); Method B; Rt: 0.67 min. m/z: 441 (M-H)~ Exact mass: 442.0.
Compound 112: (3R)-N-(4-fluoro-3-methyl-phenyl)-3-[(l S)-l-hydroxyethyll-7-methyl- 1 J-dioxo-2,3,4,5-tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000134_0001
Compound 112 (56 mg) was prepared similarly as described for compound 90, using 4-fluoro-3-methylaniline instead of 5 -amino- 2-fluoro-benzonitrile. 1H NMR (400 MHz, DMSO- ¾ δ ppm 1.13 (d, J=6.2 Hz, 3 H), 1.29 (q, J=1 1.9 Hz, 1 H), 2.13 - 2.24
(m, 4 H), 2.70 - 2.79 (m, 1 H), 3.02 (br dd, J=14.9, 6.5 Hz, 1 H), 3.16 - 3.25 (m, 1 H), 3.47 (sxt, J=6.2 Hz, 1 H), 3.67 (s, 3 H), 4.66 (d, J=5.7 Hz, 1 H), 6.87 (d, J=10.1 Hz, 1 H), 7.10 (t, J=9.2 Hz, 1 H), 7.39 (s, 1 H), 7.47 - 7.52 (m, 1 H), 7.62 (dd, J=7.0, 2.2 Hz, 1 H), 10.23 (s, 1 H); Method B; Rt: 0.79 min. m/z: 394 (M-H)~ Exact mass: 395.1. MP: 287.3 °C.
Compound 113: (3 S)-N-(3 ,4-difluorophenyl)-3 -( 1 -hydroxy- 1 -methyl-ethyl)-7-methyl- l J-dioxo-2,3,4,5-tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000134_0002
To a solution of methyl 3-acetyl-7-methyl-l , l-dioxo-2,3,4,5-tetrahydropyrrolo[3,4-f]- thiazepine-6-carboxylate (1000 mg, 3.33 mmol) in THF (15 mL) under nitrogen atmosphere at -78°C was added methylmagnesium bromide (2.55 mL, 3 M in diethyl ether, 7.66 mmol). The reaction mixture was stirred 90 minutes at -78 °C.
methylmagnesium bromide (2.55 mL, 3 M in diethyl ether, 7.66 mmol) was added to the reaction mixture and the reaction was quenched with NH4C1 (sat., aq., 4 mL) and allowed to reach room temperature. The reaction mixture was filtered and the solids were washed with THF (3 x 100 mL). The filtrate was washed with brine and dried (Na2S04), and concentrated to afford a white foam. The residue was purified using silica gel column chromatography (EtOAc in heptane from 0 to 100%) to afford methyl 3-( 1 -hydroxy- 1 -methyl-ethyl)-7-methyl- 1 , 1 -dioxo-2,3 ,4,5-tetrahydropyrrolo[3 ,4-f]- thiazepine-6-carboxylate (910 mg) as a white powder. Methyl 3 -( 1 -hydroxy- 1 -methyl-ethyl)-7-methyl- 1 , 1 -dioxo-2,3 ,4,5 - tetrahydropyrrolo[3,4-f]thiazepine-6-carboxylate (220 mg, 0.63 mmol) and 3,4-difluoro- aniline (106 mg, 0.82 mmol) were dissolved in THF (5 mL). Lithium
bis-(trimethylsilyl)amide (4.11 mL, 1 M in THF, 4.11 mmol) was added and the reaction mixture was stirred 4 hours at room temperature. The reaction was quenched with NH4C1 (sat., aq., 5 mL) and the organic layer was separated. The aqueous layer was extracted with 2-MeTHF (2 X 4 mL) and the combined organic layers were evaporated to dryness. The residue was purified using preparative HPLC (Stationary phase: RP XBridge Prep C18 OBD-ΙΟμιη, 50x150mm, Mobile phase: 0.25% NH4HCO3 solution in water, ACN). The obtained product (222 mg) was separated into its enantiomers via preparative SFC (Stationary phase: Chiralpak Diacel AD 20 x 250 mm, Mobile phase: C02, EtOH + 0.4 iPrNH2) yielding compound 113 (105 mg), 1H NMR (400 MHz, DMSO- ¾ δ ppm 1.03 (s, 3 H), 1.17 (s, 3 H), 1.24 - 1.39 (m, 1 H), 2.16 (br dd, J=13.9, 6.8 Hz, 1 H), 2.66 - 2.78 (m, 1 H), 3.03 (br dd, J=14.6, 6.1 Hz, 1 H),
3.22 - 3.35 (m, 1 H), 3.69 (s, 3 H), 4.39 (s, 1 H), 6.83 (br d, J=10.1 Hz, 1 H), 7.38 - 7.46 (m, 3 H), 7.81 - 7.88 (m, 1 H), 10.47 (br s, 1 H); Method D; Rt: 1.60 min. m/z: 412 (M-H)~ Exact mass: 413.1; MP: 217.7 °C and compound 102 (105 mg). Method F; Rt : 113: 1.15 min, 102: 1.85 min.
Compound 114: N-(3 ,4-difluorophenyl)-3-( 1 -hydro xy-2-methyl-propyl)-7-methyl- 1,1- dioxo-3,4-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000135_0001
To a cooled solution (-78 °C) of ethyl 2-(dibenzylamino)acetate (2.0 g, 7.1 mmol) in dry THF was added dropwise lithium bis(trimethylsilyl)amide (24.7 mL, 1 M in THF,
24.7 mmol) while keeping the temperature below -50°C. The solution was stirred for 30 min at -78 °C. The isobutyraldehyde (2.32 mL, 0.79 g/mL, 24.7 mmol) was added slowly keeping the temperature below -50°C and the reaction mixture was stirred for 3 hours. The reaction mixture was warmed to 0°C and then it was quenched with NH4CI (sat., aq.). Then EtOAc was added to extract the product. The combined organic layers were dried over Na2S04, filtered and evaporated. The residue was purified and separated into its 2 diastereoisomers by silica gel column chromatography (0% to 50% EtOAc in heptane) yielding diastereoisomer 1 (492 mg); 1H NMR (400 MHz,
CHLOROFORM- ) δ ppm 0.60 (d, J=6.8 Hz, 3 H), 0.87 - 1.02 (m, 3 H), 1.39 (t, J=7.2 Hz, 3 H), 1.50 - 1.62 (m, 1 H), 3.27 (d, J=9.9 Hz, 1 H), 3.41 (d, J=13.2 Hz, 2 H), 3.84 (dd, J=9.9, 3.1 Hz, 1 H), 4.04 (d, J=13.2 Hz, 2 H), 4.21 - 4.40 (m, 2 H), 7.18 - 7.39 (m, 10 H); Method D; Rt: 2.54 min. m/z: 356 (M+H)+ Exact mass: 355.2 and
diastereoisomer 2 (1.45 g); 1H NMR (400 MHz, CHLOROFORM-;/) δ ppm 0.35 (d, J=6.8 Hz, 3 H), 0.92 (d, J=7.0 Hz, 3 H), 1.43 (t, J=7.2 Hz, 3 H), 2.08 - 2.20 (m, 2 H), 3.32 (d, J=9.2 Hz, 1 H), 3.44 (d, J=13.4 Hz, 2 H), 3.83 - 3.87 (m, 1 H), 3.90 (d, J=13.6 Hz, 2 H), 4.23 - 4.45 (m, 2 H), 7.20 - 7.28 (m, 2 H), 7.29 - 7.38 (m, 8 H); Method D; Rt: 2.47 min. m/z: 356 (M+H)+ Exact mass: 355.2 To a solution of diastereoisomer 2 (1.35 g, 3.81 mmol) in dry THF (30 mL) was added LAH (2.29 mL, 1 M in THF, 4.57 mmol) at -70°C. The reaction mixture was warmed slowly to room temperature and stirred overnight. LAH (0.20 mL, 1 M in THF, 0.20 mmol) was added and the reaction mixture was stirred 4.5 hours. The reaction mixture was quenched carefully with EtOAc (30 mL) and it was stirred for 5 minutes. Then Na2SO4.10H2O was added and this was again stirred for 15 min. Then anhydrous Na2S04 was added. The solids were filtered off and the filtrate was evaporated to dryness. The residue was purified on silica (0% to 50% EtOAc in DCM) yielding 2-(dibenzylamino)-4-methyl-pentane-l,3-diol (1.19 g) as a clear oil. 1H NMR
(400 MHz, CHLOROFORM- ) δ ppm 0.65 (d, J=6.8 Hz, 3 H), 0.89 (d, J=6.8 Hz, 3 H), 1.44 - 1.73 (m, 2 H), 1.99 (dtd, J=13.6, 6.8, 6.8, 4.8 Hz, 1 H), 2.79 (q, J=5.9 Hz, 1 H), 3.61 - 3.86 (m, 6 H), 3.96 (dd, J=l l .l, 6.3 Hz, 1 H), 7.14 - 7.45 (m, 10 H); Method D; Rt: 2.19 min. m/z: 314 (M+H)+ Exact mass: 313.2.
Pd(OH)2/C (50% w/w with respect to A) was added to a solution of 2-(dibenzylamino)- 4-methyl-pentane- 1 ,3-diol in degassed MeOH and the resulting suspension was stirred 1 hour at room temperature under a hydrogen atmosphere. The reaction mixture was filtered through a pad of dicalite and concentrated in vacuo to yield 2-amino-4-methyl- pentane-l,3-diol (485 mg) 1H NMR (400 MHz, CHLOROFORM-^) δ ppm 0.93 (d, J=6.6 Hz, 3 H), 1.00 (d, J=6.6 Hz, 3 H), 1.79 (dq, J=13.5, 6.8 Hz, 1 H), 2.44 (br s, 4 H), 3.00 (q, J=4.7 Hz, 1 H), 3.28 (dd, J=7.2, 5.0 Hz, 1 H), 3.65 - 3.81 (m, 2 H).
2-amino-4-methyl-pentane-l,3-diol (485 mg, 3.64 mmol) was suspended in DCM (20 mL) and DIPEA (1.26 mL, 0.75 g/mL, 7.28 mmol) was added. The reaction mixture was stirred for 5 minutes. Ethyl 4-chlorosulfonyl-3-fluoro-l -methyl-pyrrole -2- carboxylate (982 mg, 3.64 mmol) was added. The suspension was stirred at room temperature for 5 hours. The reaction mixture was diluted with some DCM and then quenched with NaHC03(aq. sat.). The water layer was extracted two times more with DCM. The combined organic layers were evaporated to dryness and the residue was purified by silica gel chromatography (0% to 100% EtOAc in DCM) yielding ethyl 3 -fluoro-4-[ [2-hydroxy- 1 -(hydroxymethyl)-3 -methyl-butyl] sulfamoyl] - 1 -methyl- pyrrole-2-carboxylate (870 mg) as a white sticky solid. 1H NMR (400 MHz, OMSO-d6) δ ppm 0.68 (d, J=6.6 Hz, 3 H), 0.83 (d, J=6.8 Hz, 3 H), 1.28 (t, J=7.0 Hz, 3 H),
1.74 - 1.84 (m, 1 H), 3.05 - 3.17 (m, 1 H), 3.17 - 3.25 (m, 1 H), 3.41 - 3.51 (m, 2 H), 3.81 (s, 3 H), 4.27 (q, J=7.0 Hz, 2 H), 4.33 (t, J=5.5 Hz, 1 H), 4.53 (d, J=5.7 Hz, 1 H), 7.28 (br d, J=8.1 Hz, 1 H), 7.52 (d, J=4.8 Hz, 1 H); Method D; Rt: 1.45 min. m/z:
367 (M+H)+ Exact mass: 366.1. To a solution of ethyl 3-fluoro-4-[[2-hydroxy-l-(hydroxymethyl)-3-methyl-butyl]- sulfamoyl]-l-methyl-pyrrole-2-carboxylate (410 mg, 1.06 mmol) and 3,4-difluoro- aniline (0.13 mL, 1.29 g/mL, 1.28 mmol) in dry THF (10 mL) was added drop wise lithium bis(trimethylsilyl)amide (5.3 mL, 1 M in THF, 5.3 mmol) at room temperature under a nitrogen atmosphere. The reaction mixture was stirred at room temperature for 30 min. The reaction mixture was quenched with NH4C1 (aq. sat.) and then diluted with EtOAc. The aqueous layer was extracted twice with EtOAc. The combined organic layers were dried over Na2S04, filtered and concentrated under reduced pressure. The residue was triturated with diethylether to form N-(3,4-difluorophenyl)-3-fluoro-4- [[2-hydroxy- 1 -(hydroxymethyl)-3 -methyl-butyl] sulfamoyl]- 1 -methyl-pyrrole-2- carboxamide (253 mg) as a white solid.
N-(3 ,4-difluorophenyl)-3 -fluoro-4- [[2-hydroxy- 1 -(hydro xymethyl)-3 -methyl -butyl] - sulfamoyl]- l-methyl-pyrrole-2-carboxamide (253 mg, 0.55 mmol) and cesium fluoride (335 mg, 2.21 mmol) were dissolved in dry DMF and heated overnight at 1 10°C. The reaction mixture was added slowly into an ice/water mixture. When the suspension had reached room temperature, the formed yellow solid was filtered off. The water layer was extracted with ether. The solid and the ether-crude were redissolved in MeOH and evaporated together with dicalite to be purified by silica gel chromatography (0% to 75% EtOAc in DCM) yielding compound 114. This racemic mixture was separated in enantiomers 114a (69 mg); 1H NMR (400 MHz, DMSO- ¾ δ ppm 0.83 (d, J=6.8 Hz, 3 H), 0.92 (d, J=6.8 Hz, 3 H), 2.01 (quind, J=6.8, 6.8, 6.8, 6.8, 3.0 Hz, 1 H), 3.21 - 3.29 (m, 1 H), 3.47 - 3.62 (m, 1 H), 3.82 (s, 3 H), 3.97 (dd, J=12.7, 8.9 Hz, 1 H), 4.89 (dd, J=12.7, 1.9 Hz, 1 H), 4.95 (d, J=6.4 Hz, 1 H), 7.31 - 7.68 (m, 4 H), 7.87 (ddd, J=13.1 , 7.4, 2.5 Hz, 1 H), 9.43 (s, 1 H); Method D; Rt: 1.83 min. m/z: 430 (M+H)+ Exact mass: 429.1 ; MP: 245.7 °C and 114b (62 mg) 1H NMR (400 MHz, DMSO-^) δ ppm 0.83 (d, J=6.8 Hz, 3 H), 0.92 (d, J=7.0 Hz, 3 H), 2.01 (quind, J=6.8, 6.8, 6.8, 6.8, 3.1 Hz, 1 H), 3.23 - 3.30 (m, 1 H), 3.49 - 3.62 (m, 1 H), 3.82 (s, 3 H), 3.97 (dd, J=12.7, 8.9 Hz, 1 H), 4.89 (dd, J=12.5, 1.8 Hz, 1 H), 4.95 (d, J=6.6 Hz, 1 H), 7.33 - 7.51 (m, 3 H), 7.52 - 7.65 (m, 1 H), 7.87 (ddd, J=13.2, 7.5, 2.4 Hz, 1 H), 9.43 (s, 1 H); Method D; Rt: 1.84 min. m/z: 430 (M+H)+ Exact mass: 429.1; MP: 247.3 °C, by preparative SFC (Stationary phase: Chiralpak Diacel AD 20 x 250 mm, Mobile phase: C02, EtOH with 0.4% iPrNH2). Method K; Rt : 114a:1.18 min, 114b: 1.79 min.
Compound 115: (3R)-3-[cyclopropyl(hydroxy)methyll-N-[3-(difluoromethyl)-4-fluoro- phenyll-7-methyl-l,l-dioxo-3,4-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6- carboxamide
Figure imgf000138_0001
Compound 115 (541 mg) was prepared similarly as described for compound 105, using 3-(difluoromethyl)-4-fluoro-aniline instead of 3,4-difluoroaniline. This racemic mixture was separated in its epimers via preparative SFC (Stationary phase: Chiralpak Diacel AD 20 x 250 mm, Mobile phase: C02, EtOH + 0.4 iPrNH2) yielding 115a (130 mg) 1H NMR (400 MHz, DMSO-^) δ ppm 0.20 - 0.55 (m, 4 H), 0.98 - 1.12 (m, 1 H),
3.02 - 3.16 (m, 1 H), 3.55 - 3.70 (m, 1 H), 3.83 (s, 3 H), 4.02 (dd, J=12.9, 9.1 Hz, 1 H), 4.90 (dd, J=12.8, 1.8 Hz, 1 H), 5.01 (br d, J=4.6 Hz, 1 H), 7.02 - 7.40 (m, 2 H), 7.47 (s, 1 H), 7.60 (br s, 1 H), 7.76 - 7.89 (m, 1 H), 8.05 (dd, J=6.3, 2.5 Hz, 1 H), 9.47 (s, 1 H); Method D; Rt: 1.76 min. m/z: 458 (M-H)~ Exact mass: 459.1 and 115b (44 mg) 1H NMR (400 MHz, DMSO-^) δ ppm 0.16 - 0.27 (m, 1 H), 0.27 - 0.36 (m, 1 H), 0.37 - 0.50 (m, 2 H), 0.95 - 1.09 (m, 1 H), 3.05 - 3.19 (m, 1 H), 3.71 - 3.81 (m, 1 H), 3.83 (s, 3 H), 4.06 (dd, J=12.8, 9.2 Hz, 1 H), 4.74 (dd, J=12.8, 1.3 Hz, 1 H), 5.00 (br d, J=4.2 Hz, 1 H), 7.02 - 7.57 (m, 4 H), 7.75 - 7.86 (m, 1 H), 8.03 (dd, J=6.4, 2.6 Hz, 1 H), 9.48 (s, 1 H); Method D; Rt: 1.76 min. m/z: 458 (M-H)" Exact mass: 459.1; MP:
240.7 °C. Method N; Rt : 115a: 1.75 min, 115b: 2.01 min.
Compound 116: N-(3 -cyano-4-fluoro-phenyl)-3 -( 1 -hydroxy- 1 -methyl-ethyl)-7-methyl- lJ-dioxo-2,3,4,5-tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000138_0002
Compound 116 (200 mg) was prepared similarly as described for compound 113, using 5-amino-2-fluoro-benzonitrile instead of 3,4-difluoroaniline. This racemic mixture was separated in its enantiomers via preparative SFC (Stationary phase: Chiralpak Diacel AD 20 x 250 mm, Mobile phase: C02, EtOH + 0.4 iPrNH2) yielding 116a (54 mg); 1H NMR (400 MHz, DMSO-^) δ ppm 1.03 (s, 3 H), 1.17 (s, 3 H), 1.28 - 1.39 (m, 1 H), 2.17 (br dd, J=14.0, 6.5 Hz, 1 H), 2.66 - 2.79 (m, 1 H), 3.06 (br dd, J=14.9, 6.3 Hz, 1 H), 3.22 - 3.29 (m, 1 H), 3.69 (s, 3 H), 4.39 (s, 1 H), 6.84 (br d, J=10.6 Hz, 1 H), 7.45
(s, 1 H), 7.54 (t, J=9.1 Hz, 1 H), 7.96 (ddd, J=9.2, 4.9, 2.6 Hz, 1 H), 8.19 (dd, J=5.9, 2.6 Hz, 1 H), 10.59 (s, 1 H); Method D; Rt: 1.49 min. m/z: 419 (M-H)" Exact mass: 420.1 and 116b (52 mg); 1H NMR (400 MHz, DMSO-^) δ ppm 1.03 (s, 3 H), 1.17 (s, 3 H), 1.34 (q, J=l 1.5 Hz, 1 H), 2.17 (br dd, J=13.9, 6.8 Hz, 1 H), 2.68 - 2.78 (m, 1 H), 3.06 (br dd, J=14.5, 6.2 Hz, 1 H), 3.23 - 3.29 (m, 1 H), 3.69 (s, 3 H), 4.39 (s, 1 H), 6.84 (br d, J=10.6 Hz, 1 H), 7.45 (s, 1 H), 7.54 (t, J=9.1 Hz, 1 H), 7.96 (ddd, J=9.1, 4.8, 2.8 Hz, 1 H), 8.19 (dd, J=5.7, 2.6 Hz, 1 H), 10.59 (s, 1 H); Method D; Rt: 1.49 min. m/z: 419 (M-H)" Exact mass: 420.1. Method F; Rt : 116a:1.29 min, 116b: 2.03 min. Compound 117: N-(3-cyano-4-fluoro-phenyl)-7-methyl- 1 , 1 -dioxo-3-(2,2,2-trifluoro- 1 - hydroxy- l-methyl-ethyl)-2,3,4,5-tetrahydropyrrolo[3,4-f1thiazepine-6-carboxamide
Figure imgf000139_0001
A DMF (5 ml) solution of methyl 3-acetyl-7-methyl-l,l-dioxo-2,3,4,5-tetrahydro- pyrrolo[3,4-fJthiazepine-6-carboxylate (156 mg, 0.52 mmol), (trifluoromethyl)- trimethylsilane (220 mg, 1.55 mmol) and TBAF (13.5 mg, 0.052 mmol) was stirred at 100 °C for 2 hours. (Trifluoromethyl)trimethylsilane (220 mg, 1.55 mmol) and CsF (79 mg. 0.52 mmol) were added to the reaction mixture. The reaction mixture was heated at 100°C for 1 hour. Then the mixture was cooled to room temperature and HCl (aq., 1M. 2 ml) was added. After 18 hours, the mixture was quenched with NaHC03 (aq. sat., 20 mL), and the product was extracted with EtOAc (4 x 6 mL). The combined organic layers were dried over Na2S04, evaporation and purification through silica gel column chromatography (EtOAc in heptane from 0 to 100%) yielded methyl 7-methyl- 1 , 1 -dioxo-3-(2,2,2-trifluoro- 1 -hydroxy- 1 -methyl-ethyl)-2,3 ,4,5-tetrahydropyrrolo[3 ,4- fJthiazepine-6-carboxylate (36 mg) as a yellow powder. Method B; Rt: 0.76 min. m z: 369 (M-H)" Exact mass: 370.1.
Methyl 7-methyl- 1 , 1 -dioxo-3-(2,2,2-trifluoro- 1 -hydroxy- 1 -methyl-ethyl)-2,3 ,4,5-tetra- hydropyrrolo[3,4-f]thiazepine-6-carboxylate (36 mg, 0.097 mmol) and 5-amino-2- fluoro-benzonitrile (17 mg, 0.13 mmol) were dissolved in THF (5 mL). Lithium bis(trimethylsilyl)amide (0.63 mL, 1 M in THF, 0.63 mmol) was added and the reaction mixture was stirred at room temperature for 1 hour. The reaction was quenched with NH4C1 (sat., aq., 5 mL) and the organic layer was separated. The aqueous layer was extracted with EtOAc (2 X 10 mL) and the combined organic layers were evaporated to dryness. The residue was purified using preparative HPLC (Stationary phase: RP
XBridge Prep C18 OBD-ΙΟμιη, 50x150mm, Mobile phase: 0.25% NH4HCO3 solution in water, ACN). The obtained product was purified using silica gel column
chromatography (EtOAc in heptane from 0 to 100%) to afford compound 117 (18 mg) as a white powder. 1H NMR (600 MHz, DMSO-d6) δ ppm 1.20 (s, 3 H), 1.38 - 1.46 (m, 1 H), 2.13 (br dd, J=13.8, 7.0 Hz, 1 H), 2.75 - 2.80 (m, 1 H), 3.07 - 3.15 (m, 1 H), 3.70 (s, 3 H), 3.78 (br t, J=10.8 Hz, 1 H), 6.16 (s, 1 H), 7.23 (d, J=11.2 Hz, 1 H), 7.49 (s, 1 H), 7.55 (t, J=9.1 Hz, 1 H), 7.96 (ddd, J=9.2, 4.8, 2.7 Hz, 1 H), 8.19
(dd, J=5.7, 2.6 Hz, 1 H), 10.63 (s, 1 H); Method B; Rt: 0.86 min. m/z: 473 (M-H)~ Exact mass: 474.1.
Compound 118: N-(3-cyano-4-fluoro-phenyl)-3-(l , 1 -difluoroethyl)-7-methyl- 1 , 1 -dioxo-
2,3,4,5-tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000140_0001
At room temperature to a solution of methyl 3-acetyl-7-methyl-l,l-dioxo-2,3,4,5- tetrahydropyrrolo[3,4-f]thiazepine-6-carboxylate (518 mg, 1.72 mmol) in DCM (7 mL) was added DAST (0.69 mL, 1.32 g/mL, 5.7 mmol). The reaction mixture was stirred for 18 hours. DAST (0.69 mL, 1.32 g/mL, 5.7 mmol) was added and the reaction mixture was stirred for 18 hours, cooled to 0°C and quenched by addition of NaCl (aq. sat., 2 mL). The aqueous phase was separated and extracted with DCM (3 X 8 mL). The combined organic layers were dried over Na2S04, filtered and concentrated. The residue was purified by silica gel column chromatography (EtOAc in heptane 0-50%>) to give methyl 3 -( 1 , 1 -difluoroethyl)-7-methyl- 1 , 1 -dioxo-2,3 ,4,5 -tetrahydropyrrolo [3 ,4-f] - thiazepine-6-carboxylate (56 mg). Method B; Rt: 0.84 min. m/z: 321 (M-H)" Exact mass: 322.1.
Methyl 3-(l,l-difluoroethyl)-7-methyl-l,l-dioxo-2,3,4,5-tetrahydropyrrolo[3,4-f]- thiazepine-6-carboxylate (56 mg, 0.15 mmol) and 5-amino-2-fluoro-benzonitrile (26 mg, 0.19 mmol) were dissolved in THF (3 mL). Lithium bis(trimethylsilyl)amide (1 mL, 1 M in THF, 1 mmol) was added and the reaction mixture was stirred at room temperature for 1 hour. The reaction was quenched with NH4C1 (sat., aq., 5 mL) and the organic layer was separated. The aqueous layer was extracted with EtOAc
(2 X 10 mL) and the combined organic layers were evaporated to dryness. The residue was purified using silica gel column chromatography (EtOAc in heptane from 0 to 100%). The obtained product was purified via HPLC (Stationary phase: RP XBridge Prep C18 OBD-ΙΟμιη, 50x150mm, Mobile phase: 0.25% NH4HCO3 solution in water, ACN) to yield compound 118 (21 mg). 1H NMR (600 MHz, DMSO-d6) δ ppm
1.48 - 1.59 (m, 1 H), 1.64 (t, J=19.3 Hz, 3 H), 2.04 - 2.11 (m, 1 H), 2.77 - 2.88 (m, 1 H), 3.09 - 3.19 (m, 1 H), 3.69 - 3.86 (m, 4 H), 7.50 - 7.70 (m, 3 H), 7.96 (ddd, J=9.2, 4.8, 2.6 Hz, 1 H), 8.19 (dd, J=5.8, 2.8 Hz, 1 H), 10.64 (br s, 1 H); Method B; Rt: 0.93 min. m/z: 425 (M-H)" Exact mass: 426.1.
Compound 119: N-(3 -cyano-4-fluoro-phenyl)-3 -( 1 -hydroxy-2-methyl-propyl)-7- methyl- 1 , 1 -dioxo-3 ,4-dihydro-2H-pyrrolo[3 ,4-b [ 1 A51oxathiazepine-6-carboxamide
Figure imgf000141_0001
Compound 119 (165 mg) was prepared similarly as described for compound 114, using 5-amino-2-fluoro-benzonitrile instead of 3,4-difluoroaniline. This racemic mixture was separated in its epimers via preparative SFC (Stationary phase: Chiralpak Diacel AD 20 x 250 mm, Mobile phase: C02, EtOH + 0.4 iPrNH2) yielding 119a (49 mg); 1H NMR (400 MHz, DMSO-^) δ ppm 0.83 (d, J=6.8 Hz, 3 H), 0.92 (d, J=6.8 Hz, 3 H), 1.95 - 2.08 (m, 1 H), 3.23 - 3.30 (m, 1 H), 3.48 - 3.62 (m, 1 H), 3.83 (s, 3 H), 3.97 (dd, J=12.8, 9.0 Hz, 1 H), 4.87 - 4.99 (m, 2 H), 7.46 - 7.55 (m, 2 H), 7.60 (d, J=9.9 Hz, 1 H), 8.05 (ddd, J=9.1, 4.8, 2.8 Hz, 1 H), 8.21 (dd, J=5.7, 2.6 Hz, 1 H), 9.52 (s, 1 H); Method D; Rt: 1.75 min. m/z: 435 (M-H)" Exact mass: 436.1; MP: 213.7 °C and 119b (44 mg); 1H NMR (400 MHz, DMSO- ¾ δ ppm 0.84 (d, J=6.8 Hz, 3 H), 0.92 (d, J=7.0 Hz, 3 H), 2.02 (quind, J=6.8, 6.8, 6.8, 6.8, 3.0 Hz, 1 H), 3.24 - 3.30 (m, 1 H), 3.56 (qd, J=9.4, 1.7 Hz, 1 H), 3.83 (s, 3 H), 3.97 (dd, J=12.8, 9.0 Hz, 1 H), 4.86 - 5.01 (m, 2 H), 7.45 - 7.55 (m, 2 H), 7.60 (d, J=9.9 Hz, 1 H), 8.05 (ddd, J=9.2, 4.9, 2.6 Hz, 1 H), 8.21 (dd, J=5.8, 2.8 Hz, 1 H), 9.52 (s, 1 H); Method D; Rt: 1.75 min. m/z:
435 (M-H)" Exact mass: 436.1; MP: 213.7 °C. Method N; Rt : 119a:1.50 min, 119b: 2.78 min. Compound 120: (3R)-N-(3-cyano-4-fluoro-phenyl)-3-[cyclopropyl(hydroxy)methyll-7- methyl- 1 , 1 -dioxo-3 ,4-dihydro-2H-pyrrolo[3 ,4-b [ 1 A51oxathiazepine-6-carboxamide
Figure imgf000142_0001
Compound 120 (225 mg) was prepared similarly as described for compound 105, using 5-amino-2-fluoro-benzonitrile instead of 3,4-difluoroaniline. This racemic mixture was separated in its epimers via preparative SFC (Stationary phase: Chiralpak Diacel AD 20 x 250 mm, Mobile phase: C02, EtOH + 0.4 iPrNH2) yielding 120a (84 mg) 1H NMR (400 MHz, DMSO-dtf) δ ppm 0.23 - 0.52 (m, 4 H), 0.98 - 1.1 1 (m, 1 H), 3.03 - 3.14 (m, 1 H), 3.57 - 3.69 (m, 1 H), 3.83 (s, 3 H), 4.01 (dd, J=12.8, 9.2 Hz, 1 H), 4.94 (dd, J=12.8, 1.8 Hz, 1 H), 5.01 (d, J=5.5 Hz, 1 H), 7.45 - 7.55 (m, 2 H), 7.62 (d, J=9.9 Hz, 1 H), 8.06 (ddd, J=9.2, 4.8, 2.9 Hz, 1 H), 8.21 (dd, J=5.8, 2.8 Hz, 1 H), 9.52 (s, 1 H) ; Method D; Rt: 1.69 min. m/z: 433 (M-H)~ Exact mass: 434.1 and 120b (36 mg) 1H NMR (400 MHz, DMSO-^) δ ppm 0.15 - 0.28 (m, 1 H), 0.28 - 0.36 (m, 1 H),
0.36 - 0.49 (m, 2 H), 0.95 - 1.08 (m, 1 H), 3.09 - 3.16 (m, 1 H), 3.73 - 3.81 (m, 1 H), 3.83 (s, 3 H), 4.05 (dd, J=12.8, 9.2 Hz, 1 H), 4.77 (dd, J=12.5, 1.3 Hz, 1 H), 5.02 (d, J=5.1 Hz, 1 H), 7.41 - 7.58 (m, 3 H), 8.04 (ddd, J=9.2, 4.8, 2.9 Hz, 1 H), 8.19 (dd, J=5.7, 2.6 Hz, 1 H), 9.54 (s, 1 H); Method D; Rt: 1.69 min. m/z: 433 (M-H)" Exact mass: 434.1 ; MP: 233.9 °C. Method O; Rt : 120a: 1.81 min, 120b: 2.77 min.
Compound 121 : (3 S)-N-(3 ,4-difluorophenyl)-3 -( 1 -fluoro- 1 -methyl-ethyl)-7-methyl- 1 , 1- dioxo-3,4-dihydro-2H-pyrrolo[3,4-bl[l ,4,51oxathiazepine-6-carboxamide
Figure imgf000142_0002
Diethylaminosulfur trifluoride (90 μί, 1 M, 0.09 mmol) was added dropwise to a solution of compound 94 (25 mg, 0.06 mmol) in DCM (0.46 mL, 1.33 g/mL, 7.2 mmol) at 0 °C under a nitrogen atmosphere. The reaction mixture was stirred at 0°C for 15 minutes. The reaction mixture was allowed to reach room temperature and concentrated under reduced pressure. The residue was purified via preparative HPLC (Stationary phase: RP Vydac Denali C18 - ΙΟμιη, 200g, 5cm, Mobile phase: 0.25% NH4HCO3 solution in water, MeOH). The obtained product was purified by preparative SFC (Stationary phase: Chiralpak Diacel AD 20 microhm 2000 gr, Mobile phase: C02, EtOH + 0.4 iPrNH2) yielding compound 121 (46.9 mg). 1H NMR (400 MHz, DMSO- ¾ δ ppm 1.41 (dd, J=39.2, 22.2 Hz, 6 H), 3.72 - 3.81 (m, 1 H), 3.83 (s, 3 H), 4.01 (dd, J=12.4, 9.1 Hz, 1 H), 4.88 (d, J=1 1.4 Hz, 1 H), 7.34 - 7.54 (m, 3 H),
7.82 - 7.93 (m, 2 H), 9.43 (s, 1 H); 19F NMR (377 MHz, DMSO-^) δ ppm 144.56 (d, J=23.1 Hz, 1 F), -141.28 (s, 1 F), -137.61 (d, J=23.1 Hz, 1 F); Method D; Rt: 1.96 min. m/z: 416 (M-H)" Exact mass: 417.1 ; MP: 239.8 °C.
Compound 122: (3R)-N-(3-cyano-4-fluoro-phenyl)-3-(l-hydroxypropyl)-7-methyl-l , l- dioxo-3,4-dihydro-2H-pyrrolo[3,4-bl[l ,4,51oxathiazepine-6-carboxamide
Figure imgf000143_0001
Compound 122 (262 mg) was prepared similarly as described for compound 105, using ethylmagnesium bromide instead of cyclopropylmagnesium bromide and 5-amino-2- fluoro-benzonitrile instead of 3,4-difluoroaniline. The racemic mixture was separated in its epimers via preparative SFC (Stationary phase: Kromasil (R,R) Whelk-0 1 10/100, Mobile phase: C02, EtOH + 0.4% iPrNH2) to yield compound 122a (1 13 mg); 1H NMR (400 MHz, DMSO- ¾ δ ppm 0.92 (t, J=7.4 Hz, 3 H), 1.44 (dquin, J=14.2, 7.2, 7.2, 7.2, 7.2 Hz, 1 H), 1.65 - 1.79 (m, 1 H), 3.35 - 3.44 (m, 1 H), 3.44 - 3.56 (m, 1 H), 3.83 (s, 3 H), 3.98 (dd, J=12.7, 8.9 Hz, 1 H), 4.93 (dd, J=12.8, 1.8 Hz, 1 H), 4.98 (br d, J=5.9 Hz, 1 H), 7.44 - 7.55 (m, 2 H), 7.61 (br d, J=9.0 Hz, 1 H), 8.05 (ddd, J=9.2, 5.0, 2.8 Hz, 1 H), 8.21 (dd, J=5.7, 2.6 Hz, 1 H), 9.51 (s, 1 H); Method D; Rt: 1.67 min. m/z: 421 (M-H)" Exact mass: 422.1 ; MP: 222.3 °C, and 122b (102 mg); 1H NMR (400 MHz, DMSO-< ) δ ppm 0.88 (t, J=7.4 Hz, 3 H), 1.28 - 1.44 (m, 1 H), 1.50 - 1.63 (m, 1 H), 3.54 - 3.66 (m, 1 H), 3.66 - 3.76 (m, 1 H), 3.83 (s, 3 H), 3.99 (dd, J=12.7, 9.1 Hz, 1 H), 4.74 (dd, J=12.7, 1.0 Hz, 1 H), 4.87 (d, J=5.3 Hz, 1 H), 7.37 (br s, 1 H), 7.49 (s, 1 H), 7.52 (t, J=9.1 Hz, 1 H), 8.05 (ddd, J=9.3, 4.9, 2.8 Hz, 1 H), 8.19 (dd, J=5.7, 2.6 Hz, 1 H), 9.54 (s, 1 H); Method D; Rt: 1.69 min. m/z: 421 (M-H)" Exact mass: 422.1 ; MP: 252.2 °C. Method L; Rt : 122a: 2.81 min, 122b: 3.50 min.
Compound 123 : (3 S)-N-(3 ,4-difluorophenyl)-7-methyl- 1 , 1 -dioxo-3-(2,2,2-trifluoro- 1 - hydroxy-ethyl)-3,4-dihydro-2H-pyrrolo[3,4-bl[l ,4,51oxathiazepine-6-carboxamide
Figure imgf000143_0002
(Trifluoromethyl)trimethylsilane (0.82 mL, 0.96 g/mL, 5.6 mmol) was added to a solution of tert-butyl (4S)-4-formyl-2,2-dimethyl-oxazolidine-3-carboxylate (1.06 g, 4.62 mmol) and TBAF (0.11 mL, 1 M in THF, 0.11 mmol) in THF (28 mL) at room temperature under a nitrogen atmosphere. The reaction mixture was stirred overnight at room temperature. Tetrabutylammonium fluoride (9.25 mL, 1 M, 9.25 mmol) was added to the reaction mixture and stirring was continued overnight. The reaction mixture was quenched with NaHCC"3 (aq. sat.), and extracted with EtOAc (3 times). The combined organic layers were dried over Na2S04, filtered and concentrated under reduced pressure.
The residue was purified by silica gel column chromatography (heptane/ethyl acetate 100/0 to 0/100) to afford tert-butyl (4S)-2,2-dimethyl-4-(2,2,2-trifluoro-l-hydroxy- ethyl)oxazolidine-3-carboxylate (1.42 g) as an oil.
HC1 (4.6 mL, 4 M in dioxane, 18 mmol) was added dropwise to a solution of tert-butyl (4S)-2,2-dimethyl-4-(2,2,2-trifluoro-l-hydroxy-ethyl)oxazolidine-3-carboxylate (1.38 g, 4.62 mmol) in 1,4-dioxane (40 mL). The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure to yield (2S)-2-amino-4,4,4-trifluoro-butane-l,3-diol (735 mg). Ethyl 4-chlorosulfonyl-3-fluoro-l-methyl-pyrrole-2-carboxylate (1.06 g, 3.93 mmol) was added portion wise to a solution of (2S)-2-amino-4,4,4-trifluoro-butane-l,3-diol (735 mg, 4.62 mmol) and DIPEA (4.78 mL, 0.75 g/mL, 27.7 mmol) in DCM (30 mL). The reaction mixture was stirred overnight at room temperature. The reaction mixture was quenched with NH4C1 (sat., aq.) and diluted in DCM. The two layers were separated and the aqueous layer was extracted with DCM twice. The combined organic layers were dried over Na2S04, filtered off and concentrated under reduced pressure and the residue was purified by silica gel column chromatography (heptane/ethyl acetate 100/0 to 0/100) to afford ethyl 3-fiuoro-l-methyl-4-[[3,3,3-trifluoro-2-hydroxy-l- (hydroxymethyl)propyl]sulfamoyl]pyrrole-2-carboxylate (610 mg) as a beige solid. 1H NMR (400 MHz, DMSO-^) δ ppm 1.28 (s, 3 H), 3.33 - 3.42 (m, 1 H), 3.36 (s, 1 H),
3.43 - 3.58 (m, 2 H), 3.81 (s, 3 H), 4.04 (dt, J=7.0, 3.7 Hz, 1 H), 4.27 (d, J=7.0 Hz, 2 H), 4.56 (br t, J=5.2 Hz, 1 H), 6.51 (br d, J=6.6 Hz, 1 H), 7.52 (d, J=4.6 Hz, 1 H), 7.75 (br s, 1 H); Method B; Rt: 0.73 min. m/z: 391 (M-H)~ Exact mass: 392.1. Lithium bis(trimethylsilyl)amide (7.8 mL, 1 M in THF, 7.8 mmol) was added dropwise to a solution of ethyl 3-fluoro-l-methyl-4-[[3,3,3-trifluoro-2-hydroxy-l-(hydroxyl- methyl)propyl]sulfamoyl]pyrrole-2-carboxylate (610 mg, 1.55 mmol) and
3,4-difluoroaniline (0.19 mL, 1.29 g/mL, 1.9 mmol) in THF (20 mL). The reaction mixture was stirred overnight at room temperature. Lithium bis(trimethylsilyl)amide (4.7 mL, 1 M in THF, 4.7 mmol) was added and the reaction mixture was stirred for 30 additionnal minutes. The reaction mixture was quenched with NH4C1 (sat., aq.), and diluted with EtOAc. The two layers were separated and the aqueous layer was extracted with EtOAc twice. The combined organic layers were dried over Na2S04, filtered and concentrated under reduced pressure. The residue was precipitated in DCM (small amount) and diethyl ether to afford N-(3,4-difluorophenyl)-3-fluoro-l-methyl-4-[[3,3, 3- trifluoro-2-hydroxy- 1 -(hydro xymethyl)propyl] sulfamoyl]pyrrole-2-carboxamide (300 mg) as a beige solid. A second crop (280 mg) was obtained after purification of the filtrate via silica gel column chromatography (heptane/ethyl acetate 100/0 to 0/100).
Cesium fluoride (741 mg, 4.88 mmol) was added to a solution of N-(3,4- difluorophenyl)-3-fluoro- 1 -methyl-4-[[3,3,3-trifluoro-2-hydroxy- 1 -(hydroxyl- methyl)propyl]sulfamoyl]pyrrole-2-carboxamide (580 mg, 1.22 mmol) in DMF
(13 mL). The reaction mixture was heated overnight at 105 °C. The reaction mixture was concentrated under reduced pressure and the residue was purified via silica gel column chromatography (heptane/ethyl acetate 100/0 to 0/100). The obtained product was purified via preparative SFC (Stationary phase: Chiralpak Diacel AS 20 x 250 mm, Mobile phase: C02, iPrOH + 0.4 iPrNH2) yielding 1 epimer of compound 123
(30.7 mg). 1H NMR (400 MHz, DMSO-d6) δ ppm 3.82 (s, 3 H), 3.83 - 3.88 (m, 1 H), 4.08 (br s, 1 H), 4.18 (dd, J=13.0, 9.5 Hz, 1 H), 4.86 (dd, J=12.9, 2.5 Hz, 1 H), 6.93 (br d, J=6.1 Hz, 1 H), 7.35 - 7.44 (m, 1 H), 7.44 - 7.50 (m, 1 H), 7.50 (s, 1 H), 7.87 (ddd, J=13.3, 7.5, 2.5 Hz, 1 H), 8.00 (br s, 1 H), 9.43 (s, 1 H); Method D; Rt: 1.82 min. m/z: 454 (M-H)~ Exact mass: 455.1.
Compound 124: (3R)-N-[3-(difluoromethyl)-4-fluoro-phenyll-3-(l-hydroxypropyl)-7- methyl- 1 , 1 -dioxo-3 ,4-dihydro-2H-pyrrolo[3 ,4-b [ 1 A51oxathiazepine-6-carboxamide
Figure imgf000145_0001
Compound 124 (445 mg) was prepared similarly as described for compound 122, using 3-(difluoromethyl)-4-fluoro-aniline instead of 5-amino-2-fluoro-benzonitrile. The racemic mixture was separated in its epimers via preparative SFC (Stationary phase:
Kromasil (R,R) Whelk-0 1 10/100, Mobile phase: C02, EtOH + 0.4% iPrNH2) to yield compound 124a (209 mg); 1H NMR (400 MHz, DMSO- ¾ δ ppm 0.92 (t, j=7.3 Hz, 3 H), 1.44 (dquin, j=14.2, 7.3, 7.3, 7.3, 7.3 Hz, 1 H), 1.72 (dqd, J=14.1, 7.2, 7.2, 7.2, 3.1 Hz, 1 H), 3.26 - 3.44 (m, 1 H), 3.49 (br t, J=7.9 Hz, 1 H), 3.83 (s, 3 H), 3.99 (dd, J=12.7, 8.9 Hz, 1 H), 4.89 (dd, J=12.7, 1.9 Hz, 1 H), 4.98 (d, J=6.2 Hz, 1 H), 7.03 - 7.40
(m, 2 H), 7.47 (s, 1 H), 7.58 (br s, 1 H), 7.76 - 7.88 (m, 1 H), 8.04 (dd, J=6.4, 2.6 Hz, 1 H), 9.47 (s, 1 H); Method D; Rt: 1.74 min. m/z: 446 (M-H)" Exact mass: 447.1 , and 124b (159 mg); 1H NMR (400 MHz, DMSO-^) δ ppm 0.88 (t, J=7.4 Hz, 3 H),
1.29 - 1.44 (m, 1 H), 1.49 - 1.64 (m, 1 H), 3.55 - 3.65 (m, 1 H), 3.66 - 3.77 (m, 1 H), 3.83 (s, 3 H), 4.00 (dd, J=12.7, 9.1 Hz, 1 H), 4.62 - 4.76 (m, 1 H), 4.86 (br d, J=4.8 Hz, 1 H), 7.04 - 7.41 (m, 3 H), 7.46 (s, 1 H), 7.77 - 7.87 (m, 1 H), 8.03 (dd, J=6.3, 2.5 Hz, 1 H), 9.49 (s, 1 H); Method D; Rt: 1.77 min. m/z: 446 (M-H)" Exact mass: 447.1 ; MP: 224.5 °C. Method M; Rt : 124a: 2.53 min, 124b: 3.56 min.
Compound 125 : N-(3 ,4-difluorophenyl)-3 ,7-dimethyl- 1 , 1 -dioxo-3-phenyl-2,4-dihydro- pyrrolo[3,4-bl[l ,4,51oxathiazepine-6-carboxamide
Figure imgf000146_0001
Compound 125 (85 mg) was prepared similarly as described for compound 14, using 2-amino-2-phenylpropan-l-ol hydrochloride instead of DL-alaninol and DCM instead of THF as a solvent in the first step. The ring closure was obtained after heating 90 minutes at 1 10°C in DMF and compound 125 was purified on silica using a gradient from heptane to EtOAc. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.60 (s, 3 H), 3.82 (s, 3 H), 4.89 - 5.00 (m, 2 H), 7.25 - 7.49 (m, 6 H), 7.58 (d, J=7.6 Hz, 2 H), 7.82 - 7.89 (m, 1 H), 8.35 (s, 1 H), 9.43 (s, 1 H); Method D; Rt: 2.05 min. m/z: 446 (M-H)" Exact mass: 447.1 ; MP: 256.6 °C.
Compound 126 : (3R)-N-(3 ,4-difluorophenyl)-3 ,7-dimethyl- 1 , 1 -dioxo-3-(2-pyridyl)-2,4- dihydropyrrolo[3,4-bl[l ,4,51oxathiazepine-6-carboxamide
Figure imgf000146_0002
Compound 126 (1 15 mg) was prepared similarly as described for compound 125, using (2R)-2-amino-2-(2-pyridyl)propan-l-ol instead of 2-amino-2-phenylpropan-l-ol hydrochloride. The ring closure was obtained after heating 3 hours and compound 126 was purified on silica using a gradient from heptane to EtOAc:EtOH 3 : 1. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.59 (s, 3 H), 3.82 (s, 3 H), 4.99 (d, J=13.3 Hz, 1 H), 5.21 (d, J=13.3 Hz, 1 H), 7.29 - 7.51 (m, 4 H), 7.78 - 7.92 (m, 3 H), 8.46 - 8.54 (m, 2 H), 9.39 (s, 1 H); Method D; Rt: 1.97 min. m/z: 447 (M-H)" Exact mass: 448.1 ; MP: 270.5
Compound 127: (3SVN-(3.4-difluorophenylV3 J-dimethyl-1 , l-dioxo-3-(2-pyridvn-2,4- dihydropyrrolo[3,4-bl[l ,4,51oxathiazepine-6-carboxamide
Figure imgf000147_0001
Compound 127 (145 mg) was prepared similarly as described for compound 126, using (2S)-2-amino-2-(2-pyridyl)propan-l-ol instead of (2R)-2-amino-2-(2-pyridyl)propan-l- ol hydrochloride. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.55 - 1.62 (m, 3 H), 3.82 (s, 3 H), 4.99 (d, J=13.3 Hz, 1 H), 5.21 (d, J=13.3 Hz, 1 H), 7.29 - 7.50 (m, 4 H), 7.79 - 7.92 (m, 3 H), 8.47 - 8.53 (m, 2 H), 9.39 (s, 1 H); Method D; Rt: 1.98 min. m/z: 447 (M-H)" Exact mass: 448.1 ; MP: 270.8 °C.
Compound 128 : (3 S)-N-(3 -cyano-4-fluoro-phenyl)-3 J-dimethyl- 1 , 1 -dioxo-3 -(2- pyridyl)-2,4-dihydropyrrolo[3,4-bl[l ,4,51oxathiazepine-6-carboxamide
Figure imgf000147_0002
Compound 128 (55 mg) was prepared similarly as described for compound 127, using 5-amino-2-fluoro-benzonitrile instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO-de) δ ppm 1.59 (s, 3 H), 3.83 (s, 3 H), 4.99 (d, J=13.3 Hz, 1 H), 5.25 (d, J=13.3 Hz, 1 H), 7.31 (ddd, J=7.4, 4.8, 1.2 Hz, 1 H), 7.48 - 7.55 (m, 2 H), 7.78 - 7.84 (m, 1 H), 7.84 - 7.90 (m, 1 H), 8.08 (ddd, J=9.2, 4.9, 2.7 Hz, 1 H), 8.21 (dd, J=5.7, 2.7 Hz, 1 H), 8.47 - 8.51 (m, 1 H), 8.53 (s, 1 H), 9.47 (s, 1 H); Method D; Rt: 1.89 min. m/z: 454 (M-H)" Exact mass: 455.1 ; MP: 235.0 °C Compound 129: N-(3^-difluorophenyl)-3-[methoxymethox^
methyl-l ,l-dioxo-3,4-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide.
Figure imgf000148_0001
To a cooled solution of ethyl 2-(dibenzylamino)acetate (2.0 g, 7.1 mmol) in dry THF (40 mL) was added dropwise lithium bis(trimethylsilyl)amide (24.7 mL, 1 M in THF, 24.7 mmol) at -70°C. The solution was slowly warmed to -5 °C and it was stirred for 3 hours. Then the reaction mixture was cooled to -70 °C again and
2-pyridinecarboxaldehyde (2.36 mL, 24.7 mmol) was added slowly and it was stirred at -70°C for 45 minutes. The reaction mixture was warmed slowly to room temperature and quenched with NH4C1 (aq., sat., 50 mL). This was extracted with EtOAc (3 X
75 mL). The combined organic layers were dried over Na2S04, filtered and evaporated to dryness. The residue was purified and separated into its 2 diastereoisomers by silica gel column chromatography (0% to 20% EtOAc in heptane) yielding diastereoisomer 1 (827 mg); Method B; Rt: 1.23 min. m/z: 391 (M+H)+ Exact mass: 390.2 and
diastereoisomer 2 (813 mg); Method B; Rt: 1.19 min. m/z: 391 (M+H)+ Exact mass: 390.2.
To a solution of diastereoisomer 1 (827 mg, 0.72 mmol) in dry DCM (5 mL) was added DIPEA (1.12 mL, 6.48 mmol) followed by chloromethyl methyl ether (0.49 mL, 6.48 mmol) and the reaction mixtue was stirred at room temperature for 3 days. DIPEA (1.12 mL, 6.48 mmol) and chloromethyl methyl ether (0.49 mL, 6.48 mmol) were added and the reaction mixture was stirred again for 3 days. The reaction mixture was quenched with NaHC03 (aq., sat., 25 mL) and extracted with EtOAc (3 X 25 mL). The combined organic layers were dried over Na2S04, filtered and evaporated to dryness. The residue was purified on silica using a heptane to EtOAc gradient yielding ethyl 2-(dibenzylamino)-3-(methoxymethoxy)-3-(2-pyridyl)propanoate (418 mg) as a clear oil. Method B; Rt: 1.35 min. m/z: 435 (M+H)+ Exact mass: 434.2.
To a solution of ethyl 2-(dibenzylamino)-3-(methoxymethoxy)-3-(2-pyridyl)propanoate (418 mg, 0.96 mmol) in dry THF was added LAH (0.72 mL, 2M in THF, 1.44 mmol) at -70°C. After addition the reaction mixture was slowly warmed to room temperature and stirred 4.5 hours. The reaction mixture was quenched carefully with EtOAc and the mixture was stirred for 5 min. Then Na2S04.10H2O was added and this was again stirred for 15 min. Then anhydrous Na2S04 was added. The solids were filtered off and the filtrate was evaporated to dryness. The residue was purified on silica using a DCM to EtOAc gradient yielding 2-(dibenzylamino)-3-(methoxymethoxy)-3-(2-pyridyl)- propan-l-ol (316 mg) as a clear yellow oil.
Pd(OH)2/C (150 mg) was added to a solution of 2-(dibenzylamino)-3-(methoxy- methoxy)-3-(2-pyridyl)propan-l-ol (316 mg, 0.81 mmol) in degassed MeOH and the resulting suspension was stirred under H2 at room temperature overnight. The reaction mixture was filtered through a pad of dicalite and concentrated in vacuo yielding 2-amino-3-(methoxymethoxy)-3-(2-pyridyl)propan- 1 -ol (119 mg).
2-amino-3-(methoxymethoxy)-3-(2-pyridyl)propan-l-ol (119 mg, 0.56 mmol) was dissolved in DCM (4 mL) and Hunig's base (0.193 mL, 1.12 mmol) was added followed by ethyl 4-chlorosulfonyl-3-fluoro-l -methyl -pyrrole -2-carboxylate (151 mg, 0.56 mmol). After 4 hours, the reaction mixture was diluted with DCM (5 mL) and then quenched with NaHC03 (aq., sat., 5 mL). The water layer was extracted with DCM (2 X 5 mL). The combined organic layers were evaporated to get a yellow foam. The crude was recrystalized/triturated in DCM and it was stirred for 3 days. The formed white solid was filtered off and washed with some DIPE to obtain ethyl 3-fluoro-4-[[l- (hydroxymethyl)-2-(methoxymethoxy)-2-(2-pyridyl)ethyl]sulfamoyl]- 1 -methyl-pyrrole- 2-carboxylate (140 mg).
To a solution of ethyl 3-fluoro-4-[[l-(hydroxymethyl)-2-(methoxymethoxy)-2-(2- pyridyl)ethyl]sulfamoyl]-l -methyl-pyrrole -2-carboxylate (98 mg, 0.22 mmol) and 3,4- difluoroaniline (0.027 mL, 0.26 mmol) in dry THF (3 mL) was added dropwise lithium bis(trimethylsilyl)amide (0.88 mL, 1 M in THF, 0.88 mmol) in a nitrogen atmosphere and it was stirred at room temperature for 2.5 hours. Then the reaction mixture was quenched with NH4C1 (aq., sat., 3 mL) and extracted with EtOAc (3 X 3 mL). The combined organic layers were dried over Na2S04, filtered and evaporated to dryness. The residue was purified on silica using a DCM to EtOAc gradient yielding N-(3,4- difluorophenyl)-3-fluoro-4-[[l-(hydroxymethyl)-2-(methoxymethoxy)-2-(2- pyridyl)ethyl]sulfamoyl]-l -methyl-pyrrole -2-carboxamide (128 mg) as a brown solid.
N-(3,4-difluorophenyl)-3-fluoro-4-[[l-(hydroxymethyl)-2-(methoxymethoxy)-2-(2- pyridyl)ethyl]sulfamoyl]-l -methyl-pyrrole -2-carboxamide (128 mg, 0.24 mmol) and cesium fluoride (216 mg, 1.42 mmol) were dissolved in dry DMF (3 mL) and heated at 110°C instandly. The mixture was stirred at 110°C for 7 hours. The reaction mixture was quenched with water (3 mL) and the product was extracted with EtOAc (3 X 3 mL). The combined org layers were evaporated and the residue was purified on silica using a DCM to EtOAc gradient. The crude was purified via Prep HPLC (Stationary phase: RP XBridge Prep C18 OBD-ΙΟμιη, 30xl50mm, Mobile phase: 0.25% NH4HCO3 solution in water, ACN) yielding crude compound 129 and crude compound 141. The obtained crude compound 129 was purified on silica using a DCM to EtOAc gradient to obtain compound 129 (14 mg) as a beige solid. 1H NMR (400 MHz, CHLOROFORM- d) δ ppm 3.47 (s, 3 H), 3.85 - 4.03 (m, 4 H), 4.37 - 4.48 (m, 1 H), 4.74 (dd, J=12.8, 2.0 Hz, 1 H), 4.78 - 4.96 (m, 2 H), 5.10 (d, J=4.0 Hz, 1 H), 6.58 - 6.89 (m, 1 H), 6.97 - 7.16 (m, 3 H), 7.19 - 7.26 (m, 1 H), 7.52 - 7.64 (m, 2 H), 7.74 (td, J=7.7, 1.8 Hz, 1 H), 8.42 - 8.53 (m, 1 H), 8.64 (s, 1 H); Method D; Rt: 1.88 min. m/z: 509 (M+H)+ Exact mass: 508.1.
Compound 130 : (3R)-N-(3 ,4-difluorophenyl)-3-(l -hydroxypropyl)-7-methyl- 1 , 1 -dioxo-
3,4-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000150_0001
Compound 130 (414 mg) was prepared similarly as described for compound 122, using 3,4-difluoroaniline instead of 5-amino-2-fluoro-benzonitrile. The racemic mixture was separated in its epimers via preparative SFC (Stationary phase: Kromasil (R,R)
Whelk-0 1 10/100, Mobile phase: C02, EtOH-iPrOH (50-50) + 0.4% iPrNH2) to yield compound 130a (130 mg); 1H NMR (400 MHz, DMSO^) δ ppm 0.91 (t, J=7.4 Hz, 3 H), 1.43 (dquin, J=14.2, 7.3, 7.3, 7.3, 7.3 Hz, 1 H), 1.62 - 1.82 (m, 1 H), 3.34 - 3.44 (m, 1 H), 3.44 - 3.56 (m, 1 H), 3.82 (s, 3 H), 3.98 (dd, J=12.8, 9.0 Hz, 1 H), 4.90 (dd, J=12.7, 1.9 Hz, 1 H), 4.98 (d, J=6.4 Hz, 1 H), 7.34 - 7.44 (m, 1 H), 7.44 - 7.51 (m, 2 H), 7.60 (d, J=9.7 Hz, 1 H), 7.87 (ddd, J=13.3, 7.5, 2.5 Hz, 1 H), 9.42 (s, 1 H);
Method D; Rt: 1.76 min. m/z: 414 (M-H)~ Exact mass: 415.1; MP: 217.4 °C, and 130b (104 mg); 1H NMR (400 MHz, DMSO-^) δ ppm 0.88 (t, J=7.4 Hz, 3 H), 1.29 - 1.44 (m, 1 H), 1.49 - 1.65 (m, 1 H), 3.54 - 3.66 (m, 1 H), 3.66 - 3.77 (m, 1 H), 3.83 (s, 3 H), 3.99 (dd, J=12.8, 9.0 Hz, 1 H), 4.63 - 4.79 (m, 1 H), 4.86 (d, J=5.3 Hz, 1 H), 7.25 - 7.55 (m, 4 H), 7.86 (ddd, J=13.1, 7.4, 2.5 Hz, 1 H), 9.45 (s, 1 H); Method D; Rt: 1.78 min. m/z: 414 (M-H)" Exact mass: 415.1; MP: 214.6 °C. Method S; Rt : 130a: 2.65 min, 130b: 3.46 min. Compound 131: N-(3^-difluorophenyl)-7-methyl-lJ-dioxo-spiro[4,5-dihydro-2H- pyrrolo[3,4-f1thiazepine-3,3'-oxetanel-6-carboxamide
Figure imgf000151_0001
Methyl 7-methyl-l,l-dioxo-spiro[2H-pyrrolo[3,4-fJthiazepine-3,3'-oxetane]-6- carboxylate (450 mg, 1.51 mmol) was dissolved in methanol (200 mL). Under a nitrogen atmosphere Et3N (420 μί, 0.73 g/mL, 3 mmol) and Pd/C (10%) (161 mg, 0.15 mmol) were added. The reaction mixture was hydrogenated for 1 hour and then filtered over decalite and the solids were washed with THF (4 x 80 mL). The filtrate was evaporated to dryness to afford methyl 7-methyl- 1 , 1 -dioxo-spiro[4,5-dihydro-2H- pyrrolo[3,4-fJthiazepine-3,3'-oxetane]-6-carboxylate (430 mg) as a white powder.
Methyl 7-methyl-l,l-dioxo-spiro[4,5-dihydro-2H-pyrrolo[3,4-f]thiazepine-3,3'- oxetane]-6-carboxylate (107 mg, 0.36 mmol) and 3,4-difluoroaniline (51 mg, 0.39 mmol) were dissolved in THF (3 mL). Lithium bis(trimethylsilyl)amide (2.1 mL, 1 M in THF, 2.1 mmol) was added and the reaction mixture was stirred at room temperature for 30 minutes. The reaction was quenched with NH4C1 (sat., aq., 5 mL) and the organic layer was separated. The aqueous layer was extracted with EtOAc (2 X 5 mL) and the combined organic layers were concentrated to dryness. The residue was purified using Prep HPLC (Stationary phase: RP XBridge Prep C 18 OBD- 1 Ομιη, 50x150mm, Mobile phase: 0.25% NH4HC03 solution in water, ACN) yielding compound 131 (80 mg) after recrystallization from DCM as a white powder. 1H NMR (400 MHz, DMSO-dtf) δ ppm 2.13 - 2.25 (m, 2 H), 2.84 - 2.99 (m, 2 H), 3.69 (s, 3 H), 4.29 (d, J=6.4 Hz, 2 H), 4.64 (d, J=6.2 Hz, 2 H), 7.39 - 7.46 (m, 3 H), 7.78 - 7.89 (m, 2 H), 10.49 (br s, 1 H); Method B; Rt: 0.81 min. m/z: 396 (M-H)~ Exact mass: 397.1.
Compound 132: N-(3,4-difluorophenyl)-7-methyl-l,l-dioxo-spiro[2H-pyrrolo[3,4-f|- thiazepine-3,3'-oxetanel-6-carboxamide
Figure imgf000151_0002
Compound 132 (84 mg) was prepared similarly as described for compound 84, using 3-vinyloxetan-3-amine hydrochloride instead of (2S,3R)-3-aminopent-4-en-2-ol hydrochloride. 1H NMR (400 MHz, DMSO-^) δ ppm 3.70 (s, 3 H), 4.50 (d, J=6.4 Hz, 2 H), 4.78 (d, J=6.2 Hz, 2 H), 6.27 (d, J=12.8 Hz, 1 H), 6.50 (d, J=12.8 Hz, 1 H), 7.40 - 7.47 (m, 2 H), 7.52 (s, 1 H), 7.82 - 7.88 (m, 1 H), 8.44 (br s, 1 H), 10.76
(br s, 1 H); Method B; Rt: 0.82 min. m/z: 394 (M-H)" Exact mass: 395.1.
Compound 133 : N-(3 ,4-difiuorophenyl)- 3 ,3 ,7-trimethyl- 1 , 1 -dioxo-2,4-dihydropyrrolo-
[3 ,4-b [ 1 ,4,51oxathiazepine-6-carboxamide
Figure imgf000152_0001
Compound 133 (111 mg) was prepared similarly as described for compound 83, using 2-amino-2-methyl-l-propanol instead of 2-amino- 1,3 -propanediol and ACN instead of THF in the first step. The ring closure was obtained after heating 2 hours at 110°C in DMF and compound 133 was purified on silica using a gradient from heptane to EtOAc 1H NMR (400 MHz, DMSO-d6) δ ppm 1.29 (s, 6 H), 3.81 (s, 3 H), 4.40 (s, 2 H),
7.37 - 7.45 (m, 3 H), 7.76 - 7.88 (m, 2 H), 9.38 (s, 1 H); Method B; Rt: 1.01 min. m/z: 384 (M-H)" Exact mass: 385.1.
Compound 134 : N-(3 ,4-difluorophenyl)-3-ethyl-3 ,7-dimethyl- 1 , 1 -dioxo-2,4-dihydro- pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000152_0002
Compound 134 (121 mg) was prepared similarly as described for compound 133, using
2-amino-2-methylbutan- 1 -ol instead of 2-amino-2 -methyl- 1 -propanol. 1H NMR
(400 MHz, DMSO-de) δ ppm 0.92 (t, J=7.4 Hz, 3 H), 1.22 (s, 3 H), 1.41 - 1.50 (m, 1 H), 1.71 - 1.80 (m, 1 H), 3.81 (s, 3 H), 4.31 - 4.53 (m, 2 H), 7.37 - 7.44 (m, 3 H), 7.64
(s, 1 H), 7.81 - 7.88 (m, 1 H), 9.35 (s, 1 H); Method B; Rt: 1.07 min. m/z: 398 (M-H)" Exact mass: 399.1. This racemic mixture was separated in enantiomers 134a (49 mg) and 134b (52 mg) by preparative SFC (Stationary phase: Chiralpak Diacel AS 20 x 250 mm, Mobile phase: C02, EtOH with 0.4% iPrNH2). Method T; Rt : 134a:
2.75 min, 134b: 2.92 min. Compound 135 : N-(3-cyano-4-fluoro-phenyl)-3 ,3 ,7-trimethyl- 1 , 1 -dioxo-2,4-dihydro- pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000153_0001
Compound 135 (39 mg) was prepared similarly as described for compound 133, using
5-amino-2-fluoro-benzonitrile instead of 3,4-difluoroaniline. 1H NMR (400 MHz,
DMSO-de) δ ppm 1.30 (s, 6 H), 3.82 (s, 3 H), 4.41 (s, 2 H), 7.45 (s, 1 H), 7.53
(t, J=9.1 Hz, 1 H), 7.80 (s, 1 H), 8.03 (ddd, J=9.2, 4.8, 2.9 Hz, 1 H), 8.16 (dd, J=5.7,
2.6 Hz, 1 H), 9.46 (s, 1 H); Method B; Rt: 0.94 min. m/z: 391 (M-H)~ Exact mass:
392.1.
Compound 136 : 7-methyl- 1 , 1 -dioxo-N-(3 ,4,5-trifluorophenyl)spiro[4,5 -dihydro-2H- pyrrolo[3,4-f|thiazepine-3,3'-oxetanel-6-carboxamide
Figure imgf000153_0002
Compound 136 (41 mg) was prepared similarly as described for compound 131, using 3,4,5-trifluoroaniline instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO-d6) δ ppm 2.10 - 2.25 (m, 2 H), 2.85 - 2.97 (m, 2 H), 3.69 (s, 3 H), 4.29 (d, J=6.4 Hz, 2 H), 4.64 (d, J=6.2 Hz, 2 H), 7.47 (s, 1 H), 7.54 - 7.65 (m, 2 H), 7.84 (s, 1 H), 10.61 (s, 1 H); Method D; Rt: 1.67 min. m/z: 414 (M-H)" Exact mass: 415.1.
Compound 137: N-[3-(difluoromethyl)-4-fluoro-phenyll-7-methyl-l,l-dioxo-spiro[4,5- dihydro-2H-pyrrolo[3,4-f|thiazepine-3,3'-oxetanel-6-carboxamide
Figure imgf000153_0003
Compound 137 (64 mg) was prepared similarly as described for compound 131, using 3-(difluoromethyl)-4-fluoro-aniline instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO-d6) δ ppm 2.10 - 2.33 (m, 2 H), 2.86 - 3.00 (m, 2 H), 3.70 (s, 3 H), 4.29 (d,
J=6.4 Hz, 2 H), 4.65 (d, J=6.2 Hz, 2 H), 7.23 (br t, J=54.2 Hz, 1 H), 7.37 (t, J=9.5 Hz, 1 H), 7.45 (s, 1 H), 7.77 - 7.89 (m, 2 H), 8.06 (dd, J=6.2, 2.4 Hz, 1 H), 10.51 (s, 1 H); Method D; Rt: 1.59 min. m/z: 428 (M-H)" Exact mass: 429.1.
Compound 138: N-(3-cyano-4-fluoro-phenyl)-7-methyl-l,l-dioxo-spiro[4,5-dihydro- 2H-pyrrolo[3,4-f1thiazepine-3,3'-oxetanel-6-carboxamide
Figure imgf000154_0001
Compound 138 (23 mg) was prepared similarly as described for compound 131, using 5-amino-2-fluoro-benzonitrile instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO-de) δ ppm 2.14 - 2.27 (m, 2 H), 2.87 - 2.99 (m, 2 H), 3.70 (s, 3 H), 4.29
(d, J=6.4 Hz, 2 H), 4.64 (d, J=6.2 Hz, 2 H), 7.46 (s, 1 H), 7.55 (t, J=9.1 Hz, 1 H), 7.84 (s, 1 H), 7.97 (ddd, J=9.2, 4.8, 2.9 Hz, 1 H), 8.19 (dd, J=5.8, 2.8 Hz, 1 H), 10.61 (s, 1 H); Method D; Rt: 1.48 min. m/z: 403 (M-H)" Exact mass: 404.1.
Compound 139: N-[3-(difluoromethyl)-4-fluoro-phenyll-7-methyl-l,l-dioxo-spiro[2H- pyrrolo[3,4-f|thiazepine-3,3'-oxetanel-6-carboxamide
Figure imgf000154_0002
Compound 139 (108 mg) was prepared similarly as described for compound 132, using 3-(difluoromethyl)-4-fluoro-aniline instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO-de) δ ppm 3.71 (s, 3 H), 4.50 (d, J=6.2 Hz, 2 H), 4.79 (d, J=6.4 Hz, 2 H), 6.27 (d, J=12.8 Hz, 1 H), 6.53 (d, J=12.8 Hz, 1 H), 7.23 (t, J=54.2 Hz, 1 H), 7.39 (t, J=9.6 Hz, 1 H), 7.52 (s, 1 H), 7.81 - 7.86 (m, 1 H), 8.06 (dd, J=6.2, 2.4 Hz, 1 H), 8.45 (br s, 1 H), 10.78 (br s, 1 H); Method B; Rt: 0.83 min. m/z: 426 (M-H)" Exact mass: 427.1.
Compound 140: N-(3-cyano-4-fluoro-phenyl)-7-methyl-l,l-dioxo-spiro[2H-pyrrolo- [3,4-f|thiazepine-3,3'-oxetanel-6-carboxamide
Figure imgf000154_0003
Compound 140 (23 mg) was prepared similarly as described for compound 132, using 5-amino-2-fluoro-benzonitrile instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO-d6) δ ppm 3.71 (s, 3 H), 4.51 (d, J=6.4 Hz, 2 H), 4.79 (d, J=6.4 Hz, 2 H), 6.28 (d, J=12.8 Hz, 1 H), 6.54 (d, J=12.8 Hz, 1 H), 7.53 - 7.58 (m, 2 H), 7.98 (ddd, J=9.2, 4.9, 2.6 Hz, 1 H), 8.19 (dd, J=5.8, 2.8 Hz, 1 H), 8.46 (br s, 1 H), 10.88 (br s, 1 H); Method D; Rt: 1.48 min. m/z: 401 (M-H)~ Exact mass: 402.1.
Compound 141 : N-(3 ,4-difluorophenyl)-3 - [hydroxy(2-pyridyl)methyl] -7-methyl- 1,1- dioxo-3,4-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000155_0001
The crude compound 141 obtained in the synthesis of compound 129 was purified on silica eluting with a DCM to EtOAc gradient to obtain compound 141a (3 mg) as a beige solid. 1H NMR (400 MHz, CHLOROFORM- ) δ ppm 3.87 - 4.04 (m, 3 H), 4.25 (dd, J=12.8, 9.0 Hz, 1 H), 4.40 - 4.53 (m, 1 H), 4.82 - 4.97 (m, 1 H), 5.00 - 5.12 (m, 1 H), 6.96 - 7.21 (m, 3 H), 7.27 - 7.37 (m, 1 H), 7.42 - 7.49 (m, 1 H), 7.58 - 7.73 (m, 1 H), 7.76 - 7.88 (m, 1 H), 8.49 - 8.60 (m, 1 H), 8.80 (s, 1 H); Method B; Rt:
0.91 min. m/z: 465 (M+H)+ Exact mass: 464.1.
Alternatively this compound can be synthesized as described in compound 129 using 6-bromopyridine-2-carbaldehyde instead of 2-pyridinecarboxaldehyde. During the synthesis diastereomers were separated in the final step using preparative HPLC
(Stationary phase: RP XBridge Prep C18 ΟΒΟ-10μιη, 30x150mm, Mobile phase:
0.25% NH4HCO3 solution in water, MeOH) yielding compound 141a (5 mg); 1H NMR (400 MHz, DMSO-d6) δ ppm 3.87 - 4.04 (m, 3 H), 4.25 (dd, J=12.8, 9.0 Hz, 1 H), 4.40 - 4.53 (m, 1 H), 4.82 - 4.97 (m, 1 H), 5.00 - 5.12 (m, 1 H), 6.96 - 7.21 (m, 3 H), 7.27 - 7.37 (m, 1 H), 7.42 - 7.49 (m, 1 H), 7.58 - 7.73 (m, 1 H), 7.76 - 7.88 (m, 1 H), 8.49 - 8.60 (m, 1 H), 8.80 (s, 1 H); Method D; Rt: 1.76 min. m/z: 465 (M+H)+ Exact mass: 464.1 and compound 141b (14 mg); 1H NMR (400 MHz, DMSO-d6) δ ppm 3.81 (s, 3 H), 4.03 (dd, J=12.6, 9.3 Hz, 1 H), 4.13 - 4.21 (m, 1 H), 4.82 (dd, J=12.3, 1.1 Hz, 1 H), 4.90 (d, J=3.3 Hz, 1 H), 5.91 (br s, 1 H), 7.26 - 7.32 (m, 1 H), 7.32 - 7.49 (m, 4 H), 7.54 (d, J=7.7 Hz, 1 H), 7.77 - 7.96 (m, 2 H), 8.50 - 8.56 (m, 1 H), 9.45
(s, 1 H); Method D; Rt: 1.74 min. m/z: 465 (M+H)+ Exact mass: 464.1. Method AD; Rt : 141a: 5.75 min and 6.63 min, 141b: 5.13 min and 6.00 min. Compound 142 : N-(3 ,4-difluorophenyl)-3-( 1 -hydro xypropyl)-7-methyl- 1 , 1 -dioxo-3 ,4- dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000156_0001
Compound 142 (387 mg) was prepared similarly as described for compound 92, using ethylmagnesium bromide instead of cyclopropylmagnesium bromide. The racemic mixture was separated in its epimers via preparative SFC (Stationary phase: Chiralpak Daicel ID 20 x 250 mm, Mobile phase: C02, EtOH + 0.4 iPrNH2) to yield compound 142a (141 mg); 1H NMR (400 MHz, DMSO-^) δ ppm 0.91 (t, J=7.4 Hz, 3 H), 1.44 (dquin, J=14.3, 7.3, 7.3, 7.3, 7.3 Hz, 1 H), 1.64 - 1.79 (m, 1 H), 3.34 - 3.44 (m, 1 H), 3.44 - 3.55 (m, 1 H), 3.82 (s, 3 H), 3.98 (dd, J=12.8, 8.8 Hz, 1 H), 4.90 (dd, J=12.5, 1.8 Hz, 1 H), 4.98 (d, J=6.2 Hz, 1 H), 7.34 - 7.44 (m, 1 H), 7.44 - 7.51 (m, 2 H), 7.60 (d, J=9.7 Hz, 1 H), 7.87 (ddd, J=13.3, 7.5, 2.5 Hz, 1 H), 9.42 (s, 1 H); Method D; Rt: 1.75 min. m/z: 414 (M-H)~ Exact mass: 415.1; MP: 218.6 °C, and 142b (136 mg); 1H NMR (400 MHz, DMSO^) δ ppm 0.88 (t, J=7.4 Hz, 3 H), 1.29 - 1.43 (m, 1 H), 1.49 - 1.63 (m, 1 H), 3.55 - 3.64 (m, 1 H), 3.66 - 3.75 (m, 1 H), 3.82 (s, 3 H), 3.99 (dd, J=12.7, 9.1 Hz, 1 H), 4.68 - 4.75 (m, 1 H), 4.86 ( br d, J=4.2 Hz, 1 H), 7.26 - 7.52 (m, 4 H), 7.86 (ddd, J=13.2, 7.5, 2.4 Hz, 1 H), 9.45 (s, 1 H); Method D; Rt: 1.77 min. m/z: 414 (M-H)~ Exact mass: 415.1; MP: 212.6 °C. Method U; Rt : 142a: 3.06 min, 142b: 3.64 min.
Compound 143: 7-methyl-l,l-dioxo-N-(3,4,5-trifluorophenyl)spiro[2H-pyrrolo[3,4- f|thiazepine-3,3'-oxetanel-6-carboxamide
Figure imgf000156_0002
Compound 143 (28 mg) was prepared similarly as described for compound 132, using 3,4,5-trifluoroaniline instead of 3,4-difhioroaniline. 1H NMR (400 MHz, DMSO-d6) δ ppm 3.70 (s, 3 H), 4.51 (d, J=6.4 Hz, 2 H), 4.78 (d, J=6.2 Hz, 2 H), 6.28 (d, J=12.8 Hz, 1 H), 6.50 (d, J=12.8 Hz, 1 H), 7.54 (s, 1 H), 7.56 - 7.66 (m, 2 H), 8.45 (br s, 1 H), 10.88 (br s, 1 H); Method B; Rt: 0.88 min. m/z: 412 (M-H)~ Exact mass: 413.1. Compound 144: N-[3-(difluoromethyl)-4-fluoro-phenyll-3-(l -hydroxypropyl)-7- methyl- 1 , 1 -dioxo-3 ,4-dihydro-2H-pyrrolo[3 ,4-b [ 1 A51oxathiazepine-6-carboxamide
Figure imgf000157_0001
Compound 144 (420 mg) was prepared similarly as described for compound 142, using 3-(difluoromethyl)-4-fluoro-aniline instead of 3,4-difluoroaniline. The racemic mixture was separated in its epimers via preparative SFC (Stationary phase: Chiralpak Daicel ID 20 x 250 mm, Mobile phase: C02, EtOH + 0.4 iPrNH2) to yield compound 144a
(176 mg); 1H NMR (400 MHz, DMSO- ¾ δ ppm 0.92 (t, J=7.3 Hz, 3 H), 1.44 (dquin, J=14.2, 7.1, 7.1, 7.1, 7.1 Hz, 1 H), 1.64 - 1.79 (m, 1 H), 3.35 - 3.44 (m, 1 H), 3.44 - 3.56 (m, 1 H), 3.83 (s, 3 H), 3.99 (dd, J=12.7, 8.9 Hz, 1 H), 4.89 (dd, J=12.8, 1.8 Hz, 1 H), 4.98 (d, J=6.4 Hz, 1 H), 7.03 - 7.41 (m, 2 H), 7.47 (s, 1 H), 7.59 (br s, 1 H), 7.73 - 7.89 (m, 1 H), 8.04 (dd, J=6.3, 2.5 Hz, 1 H), 9.47 (s, 1 H); Method D; Rt: 1.75 min. m/z: 446 (M-H)~ Exact mass: 447.1, and 144b (156 mg); 1H NMR (400 MHz, DMSO-^) δ ppm 0.88 (t, J=7.4 Hz, 3 H), 1.30 - 1.43 (m, 1 H), 1.49 - 1.63 (m, 1 H), 3.56 - 3.64 (m, 1 H), 3.66 - 3.76 (m, 1 H), 3.83 (s, 3 H), 4.00 (dd, J=12.7, 9.1 Hz, 1 H), 4.64 - 4.77 (m, 1 H), 4.86 (d, J=5.5 Hz, 1 H), 7.02 - 7.42 (m, 3 H), 7.46 (s, 1 H), 7.76 - 7.88 (m, 1 H), 8.03 (dd, J=6.3, 2.5 Hz, 1 H), 9.49 (s, 1 H); Method D; Rt: 1.78 min. m/z: 446 (M-H)" Exact mass: 447.1; MP: 224.6 °C. Method U; Rt : 144a: 2.92 min, 144b: 3.49 min. Synthesis of 2-amino-2-pyrazin-2-yl-propan-l-ol.
A 100 ml flask was charged with acetylpyrazine (2.00 g, 16.4 mmol), N¾ (33 mL, 7 M in MeOH, 229 mmol) and ammonium chloride (2.63 g, 49.1 mmol). Trimethylsilyl cyanide (6.2 mL, 0.793 g/mL, 49 mmol) was added and the mixture was stirred at room temperature for 16 hours. The mixture was concentrated in vacuo. The residue was was taken up in DCM and the precipitate was filtered off. The filtrate was concentrated in vacuo and the residue was purified by column chromatography using a gradient from 0 till 100% EtOAc-EtOH (3-1) in heptane. The product fractions were concentrated in vacuo to yield 2-amino-2-pyrazin-2-yl-propanenitrile (1.9 g) as a pale yellow oil. 2-amino-2-pyrazin-2-yl-propanenitrile (1.9 g, 12.8 mmol) was dissolved in acetic acid (6.3 mL). Hydrobromic acid in acetic acid (30 mL) was added carefully and the mixture was stirred at 80 °C for 1 hour. The mixture was cooled and poured out in EtOAc (400 mL). The precipitate was filtered off and washed with EtOAc and ACN and dried under vacuum to yield 2-amino-2-pyrazin-2-yl-propanamide trihydrobromide (5.2 g) as a yellow solid.
2-amino-2-pyrazin-2-yl-propanamide trihydrobromide (5.2 g, 12.7 mmol) was dissolved in MeOH (50 mL). H2SO4 (5 mL) was carefully added (exotherm) and the mixture was heated at reflux for 16 hours. The mixture was cooled and concentrated in vacuo. The residue was dissolved in water (50 mL) and washed with EtOAc. The water fraction was neutralized with Na2C03, and extracted with Me-THF (2 X 50 mL). The combined organic layers were dried (MgS04), filtered and concentrated in vacuo. The residue was purified by column chromatography using a gradient from 0 till 100%
EtOAc-EtOH(3-l) in heptane. The product fractions were concentrated in vacuo to yield methyl 2-amino-2-pyrazin-2-yl-propanoate (371 mg) as a yellow oil.
Methyl 2-amino-2-pyrazin-2-yl-propanoate (371 mg, 2.05 mmol) was dissolved in MeOH (10 mL) under N2 atmosphere. Sodium borohydride (155 mg, 4.10 mmol) was added and the mixture was stirred at room temperature for 16 hours. The mixture was concentrated in vacuo. The residue was dissolved in Me-THF, dried (MgS04), filtered and concentrated in vacuo yielding 2-amino-2-pyrazin-2-yl-propan-l-ol (285 mg).
Compound 145 : N-(3 ,4-difluorophenyl)-3 ,7-dimethyl- 1 , 1 -dioxo-3-pyrazin-2-yl-2,4- dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000158_0001
Compound 145 (221 mg) was prepared similarly as described for compound 125, using 2-amino-2-pyrazin-2-yl-propan-l-ol instead of 2-amino-2-phenylpropan-l-ol hydrochloride. The ring closure was obtained after heating 3 hours and compound 145 was crystallized from ACN. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.63 (s, 3 H), 3.82 (s, 3 H), 4.98 - 5.14 (m, 2 H), 7.38 - 7.52 (m, 3 H), 7.88 (ddd, J=13.2, 7.5, 2.5 Hz, 1 H), 8.56 - 8.60 (m, 2 H), 8.68 (s, 1 H), 9.03 (d, J=l .l Hz, 1 H), 9.43 (s, 1 H); Method B; Rt: 0.96 min. m/z: 448 (M-H)" Exact mass: 449.1. The racemic mixture was separated in its epimers via preparative SFC (Stationary phase: Chiralpak Daicel AS 20 x 250 mm,
Mobile phase: C02, EtOH + 0.4 iPrNH2) to yield compound 145a (89 mg); Method D; Rt: 1.83 min. m/z: 448 (M-H)" Exact mass: 449.1, MP: 199.4 °C, and 145b (156 mg); Method D; Rt: 1.83 min. m/z: 448 (M-H)~ Exact mass: 449.1; MP: 199.4 °C. Method T; Rt : 145a: 3.51 min, 145b: 4.34 min.
Compound 146: (3R)-N-(2-chloro-4-pyridyl)-3-(l-hydroxy-l-methyl-ethyl)-7-methyl- lJ-dioxo-3,4-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000159_0001
Compound 146 (214 mg) was prepared similarly as described for compound 93, using 4-amino-2-chloropyridine instead of 3,4-difluoroaniline. 1H NMR (400 MHz,
DMSC /e) δ ppm 1.07 (s, 3 H), 1.25 (s, 3 H), 3.50 - 3.61 (m, 1 H), 3.84 (s, 3 H), 3.96 (dd, J=12.5, 8.8 Hz, 1 H), 4.87 (s, 1 H), 4.98 (dd, J=12.4, 1.0 Hz, 1 H), 7.47 - 7.61
(m, 2 H), 7.69 (dd, J=5.6, 1.9 Hz, 1 H), 7.88 (d, J=1.8 Hz, 1 H), 8.27 (d, J=5.7 Hz, 1 H), 9.69 (s, 1 H); Method D; Rt: 1.53 min. m/z: 413 (M-H)" Exact mass: 414.1, MP: 246.6 °C. Compound 147: (3R -3-( 1 -hydroxy- 1 -methyl-ethyl)- 7-methyl- 1.1 -dioxo-N-(3.4.5- trifluorophenyl)-3,4-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000159_0002
Compound 147 (259 mg) was prepared similarly as described for compound 93, using 3,4,5-trifluoroaniline instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.07 (s, 3 H), 1.25 (s, 3 H), 3.50 - 3.60 (m, 1 H), 3.83 (s, 3 H), 3.92 (dd, J=12.4, 8.9 Hz, 1 H), 4.86 (s, 1 H), 4.95 - 5.04 (m, 1 H), 7.43 - 7.59 (m, 2 H), 7.65 - 7.79 (m, 2 H), 9.49 (s, 1 H); Method D; Rt: 1.84 min. m/z: 432 (M-H)" Exact mass: 433.1.
Compound 148 : N-(3 ,4-difluorophenyl)-4,4-difluoro-7-methyl- 1 , 1 -dioxo-3 ,5-dihydro-
2H-pyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000159_0003
2- iodoxybenzoic acid (3.71 g, 13.3 mmol) was added to a solution of ethyl
3- [3-(benzyloxycarbonylamino)-2-hydroxy-propyl]-l-methyl-pyrrole-2-carboxylate (2.12 g, 5.89 mmol) in EtOAc (50 mL) and stirred at reflux temperature for 5 hours and 30 minutes. The reaction mixture was filtered while still hot. The precipitate was washed with EtOAc (150mL). The organic layer was washed with NaHC03 (aq., sat., 200 mL), dried over magnesium sulfate, filtered and concentrated. The residue was purified on silica using a gradient from 0 till 100% EtOAc in heptane yielding ethyl 3-[3-(benzyloxycarbonylamino)-2-oxo-propyl]-l-methyl-pyrrole-2-carboxylate (1.49 g) as a clear oil. 1H NMR (400 MHz, DMSO- 6) δ ppm 1.24 (t, J=7.0 Hz, 3 H),
3.76 - 3.93 (m, 7 H), 4.16 (q, J=7.2 Hz, 2 H), 5.03 (s, 2 H), 6.00 (d, J=2.4 Hz, 1 H),
7.01 (d, J=2.4 Hz, 1 H), 7.27 - 7.50 (m, 6 H); Method D; Rt: 1.90 min. m/z: 357 (M-H)" Exact mass: 358.2.
Diethylaminosulfur trifluoride (3.35 g, 20.8 mmol) was added to a solution of ethyl 3-[3-(benzyloxycarbonylamino)-2-oxo-propyl]-l-methyl-pyrrole-2-carboxylate (1.49 g, 4.16 mmol) in DCM (100 mL) and stirred overnight at room temperature. The reaction mixture was quenched by pouring in NaHC03 (aq., sat., 300 mL). The organic layer was dried over sodium sulfate, filtered and concentrated. The residue was purified on silica using a gradient from 0 till 100% EtOAc in heptane yielding ethyl 3-[3- (benzyloxycarbonylamino)-2,2-difluoro-propyl]- 1 -methyl-pyrrole -2-carboxylate (371 mg) as a clear oil. 1H NMR (400 MHz, DMSO- 6) δ ppm 1.27 (t, J=7.0 Hz, 3 H), 3.32 - 3.49 (m, 4 H), 3.80 (s, 3 H), 4.20 (q, J=7.0 Hz, 2 H), 5.04 (s, 2 H), 6.08 (d, J=2.2 Hz, 1 H), 7.01 (d, J=2.6 Hz, 1 H), 7.27 - 7.40 (m, 5 H), 7.68 (br t, J=6.2 Hz, 1 H);
Method D; Rt: 2.07 min. m/z: 379 (M-H)" Exact mass: 380.2.
Chlorosulfonic acid (7.8 g, 67 mmol) was added to a solution of ethyl 3-[3- (benzyloxycarbonylamino)-2,2-difluoro-propyl]-l -methyl-pyrrole -2-carboxylate (365 mg, 0.96 mmol) in DCM (50 mL) and the reaction mixture was stirred for 20 minutes. The reaction mixture was poured in water (300mL) and the organic layer was washed with NaHC03 (aq., sat., 250 mL), dried over magnesium sulfate, filtered and concentrated. The residue was purified on silica using a gradient from 0 till 100% EtOAc in heptane yielding ethyl 4,4-difluoro-7-methyl-l ,l-dioxo-3,5-dihydro-2H- pyrrolo[3,4-fJthiazepine-6-carboxylate (17 mg) as white crystals. 1H NMR (400 MHz, DMSO- 6) δ ppm 1.31 (t, J=7.2 Hz, 3 H), 3.66 (td, J=1 1.6, 7.2 Hz, 2 H), 3.76 - 3.89 (m, 5 H), 4.30 (q, J=7.1 Hz, 2 H), 7.65 (s, 1 H), 8.18 (t, J=6.8 Hz, 1 H); Method D; Rt: 1.65 min. m/z: 307 (M-H)" Exact mass: 308.1. Lithium bis(trimethylsilyl)amide (0.33 mL, 1 M in THF, 0.33 mmol) was added to a solution of ethyl 4,4-difluoro-7-methyl-l,l-dioxo-3,5-dihydro-2H-pyrrolo[3,4- fJthiazepine-6-carboxylate (17 mg, 0.055 mmol) and 3,4-difluoroaniline (22 mg, 0.17 mmol) in THF (3 mL) and stirred for 30 minutes. The reaction mixture was quenched with NH4CI solution (aq., sat., lOmL) and extracted with EtOAc (50mL). The organic layer was dried over magnesium sulfate, filtered and concentrated. The residue was purified on silica using a gradient from 10 till 100% EtOAc in heptane yielding compound 148 (9.8 mg). 1H NMR (400 MHz, DMSO-d6) δ ppm 3.39 - 3.50 (m, 2 H), 3.61 - 3.70 (m, 2 H), 3.72 (s, 3 H), 7.39 - 7.49 (m, 2 H), 7.55 (s, 1 H), 7.81 - 7.88 (m, 1 H), 8.14 (t, J=6.9 Hz, 1 H), 10.62 (s, 1 H); Method D; Rt: 1.72 min. m/z:
390 (M-H)" Exact mass: 391.1.
Compound 149 : 3-( 1 -hydroxy- 1 -methyl-ethyl)-7-methyl- 1 , 1 -dioxo-N-(3 ,4,5 - trifluorophenyl)-2,3,4,5-tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000161_0001
Compound 149 (140 mg) was prepared similarly as described for compound 113, using 3,4,5-trifluoroaniline instead of 3,4-difluoroaniline. The racemic mixture was separated in its enantiomers via preparative SFC (Stationary phase: Chiralpak Daicel AD 20 x 250 mm, Mobile phase: C02, EtOH + 0.4 iPrNH2) to yield compound 149a (66 mg);
1H NMR (400 MHz, DMSC /6) δ ppm 1.03 (s, 3 H), 1.17 (s, 3 H), 1.33 (br q, J=l 1.5 Hz, 1 H), 2.17 (br dd, J=14.0, 6.9 Hz, 1 H), 2.67 - 2.78 (m, 1 H), 2.98 - 3.08 (m, 1 H), 3.21 - 3.29 (m, 1 H), 3.69 (s, 3 H), 4.39 (s, 1 H), 6.85 (d, J=10.8 Hz, 1 H), 7.45 (s, 1 H), 7.56 - 7.64 (m, 2 H), 10.59 (s, 1 H); Method D; Rt: 1.70 min. m/z: 430 (M-H)" Exact mass: 431.1, and 149b (63 mg); 1H NMR (400 MHz, DMSO-d6) δ ppm 1.03 (s, 3 H), 1.17 (s, 3 H), 1.27 - 1.38 (m, 1 H), 2.17 (br dd, J=14.0, 6.9 Hz, 1 H), 2.67 - 2.78
(m, 1 H), 2.98 - 3.08 (m, 1 H), 3.23 - 3.30 (m, 1 H), 3.69 (s, 3 H), 4.39 (s, 1 H), 6.85 (d, J=10.6 Hz, 1 H), 7.45 (s, 1 H), 7.56 - 7.64 (m, 2 H), 10.59 (s, 1 H); Method D; Rt: 1.70 min. m/z: 430 (M-H)" Exact mass: 431.1. Method R; Rt : 149a: 2.83 min, 149b: 3.64 min. Compound 150: N-[3-(difluoromethyl)-4-fluoro-phenyll-3-(l -hydroxy-1 -methyl-ethyl)- 7-methyl-l J-dioxo-23^,5-tetrahydropyrrolo[3,4-f1thiazepine-6-carboxamide
Figure imgf000162_0001
Compound 150 (45 mg) was prepared similarly as described for compound 113, using 3-(difluoromethyl)-4-fluoro-aniline instead of 3,4-difluoroaniline. The racemic mixture was separated in its enantiomers via preparative SFC (Stationary phase: Chiralpak Daicel AD 20 x 250 mm, Mobile phase: C02, EtOH + 0.4 iPrNH2) to yield compound 150a (23 mg); 1H NMR (400 MHz, DMSO-d6) δ ppm 1.03 (s, 3 H), 1.17 (s, 3 H), 1.34 (q, J=11.6 Hz, 1 H), 2.17 (br dd, J=14.1, 6.8 Hz, 1 H), 2.66 - 2.79 (m, 1 H), 3.06 (br dd, J=14.4, 6.5 Hz, 1 H), 3.21 - 3.30 (m, 1 H), 3.69 (s, 3 H), 4.39 (s, 1 H), 6.83
(d, J=10.8 Hz, 1 H), 7.22 (t, J=54.2 Hz, 1 H), 7.37 (t, J=9.6 Hz, 1 H), 7.43 (s, 1 H), 7.78 - 7.84 (m, 1 H), 8.06 (dd, J=6.3, 2.3 Hz, 1 H), 10.49 (s, 1 H); Method D; Rt: 1.61 min. m/z: 444 (M-H)~ Exact mass: 445.1, and 150b (22 mg); 1H NMR (400 MHz, DMSO-d6) δ ppm 1.03 (s, 3 H), 1.17 (s, 3 H), 1.34 (br q, J=12.0 Hz, 1 H), 2.17 (br dd, J=13.9, 6.8 Hz, 1 H), 2.68 - 2.79 (m, 1 H), 3.01 - 3.11 (m, 1 H), 3.19 - 3.30 (m, 1 H), 3.69 (s, 3 H), 4.39 (s, 1 H), 6.83 (br d, J=10.6 Hz, 1 H), 7.22 (t, J=54.2 Hz, 1 H), 7.37 (t, J=9.6 Hz, 1 H), 7.43 (s, 1 H), 7.78 - 7.84 (m, 1 H), 8.06 (dd, J=6.2, 2.4 Hz, 1 H), 10.49 (s, 1 H); Method D; Rt: 1.61 min. m/z: 444 (M-H)~ Exact mass: 445.1. Method R; Rt : 150a: 2.92 min, 150b: 3.74 min.
Compound 151: (3 R)-N- [2 -(difluoromethyl)-4 -pyridy 1] -3 - ( 1 -hydroxy- 1 -methyl-ethyl)- 7-methyl-l ,l-dioxo-3,4-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000162_0002
Compound 151 (359 mg) was prepared similarly as described for compound 93, using 2-(difluoromethyl)pyridin-4-amine instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.06 (s, 3 H), 1.25 (s, 3 H), 3.49 - 3.61 (m, 1 H), 3.85 (s, 3 H), 3.97 (dd, J=12.5, 8.9 Hz, 1 H), 4.88 (s, 1 H), 4.97 (dd, J=12.9, 0.5 Hz, 1 H), 6.91 (t, J=55.0 Hz, 1 H), 7.48 - 7.61 (m, 2 H), 7.77 - 7.85 (m, 1 H), 8.09 (d, J=2.1 Hz, 1 H), 8.53 (d, J=5.6 Hz, 1 H), 9.75 (s, 1 H); Method B; Rt: 0.73 min. m/z: 429 (M-H)" Exact mass: 430.1. Compound 152 : (3 S)-N-(3.4-difluorophenyl)-3.7.8-trimethyl- 1.1 -dioxo-2.3.4.5 - tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000163_0001
Methyl (3S)-3,7-dimethyl-l,l-dioxo-2,3,4,5-tetrahydropyrrolo[3,4-fJthiazepine-6- carboxylate (200 mg, 0.73 mmol) was dissolved in acetic acid (5 mL) and bromine (0.057 mL, 3.10 g/mL, 1.10 mmol) was added. The solution was then refluxed for 4 hours and stirred at room temperature 16 hours. The solution was then cooled to 0 °C, quenched with NaHC03 and extracted with EtOAc. The combined organics were dried with Na2S04, filtered and concentrated in vacuo. The crude was then purified on silica using heptane/EtOAc from 100/0 to 50/50 to give methyl (3S)-8-bromo-3,7-dimethyl- l,l-dioxo-2,3,4,5-tetrahydropyrrolo[3,4-fJthiazepine-6-carboxylate (202 mg).
Methyl (3S)-8-bromo-3,7-dimethyl-l,l-dioxo-2,3,4,5-tetrahydropyrrolo[3,4- fJthiazepine-6-carboxylate (202 mg, 0.58 mmol) and 3,4-difluoroaniline (0.069 mL, 1.29 g/mL, 0.69 mmol) are dissolved in THF (5 mL) and LiHMDS (1.7 mL, 1 M, 1.7 mmol) was added. After 2 hours the solution was quenched with NH4C1 (aq., sat.) and stirred for 5 min. The solution was then diluted with EtOAc, extracted and the combined organics were dried with MgS04, filtered off and concentrated in vacuo. The crude was then purified on silica using heptane/EtOAc 100/0 to 0/100 to give (3S)-8- bromo-N-(3 ,4-difluorophenyl)-3 ,7-dimethyl- 1 , 1 -dioxo-2,3 ,4,5-tetrahydropyrrolo[3 ,4- fJthiazepine-6-carboxamide (228 mg). Method B; Rt: 0.97 min. m/z: 446 (M-H)~ Exact mass: 447.0. (3S)-8-bromo-N-(3,4-difluorophenyl)-3,7-dimethyl-l,l-dioxo-2,3,4,5- tetrahydropyrrolo[3,4-f]thiazepine-6-carboxamide (54 mg, 0.12 mmol) was dissolved in DMF (2 mL). Tetramethyltin (0.025 mL, 0.18 mmol) was added and the solution was flushed with nitrogen during 5 minutes before tetrakis(triphenylphosphine)palladium(0) was added. The vial was then heated by microwave irradiation at 140 °C during 30 minutes. The solution was then filtered over dicalite and washed with EtOAc. The filtrate was concentrated in vacuo and purified on silica using heptane/EtOAc 100/0 to 80/20 and further triturated with diethylether to give compound 152 (37 mg) as a white solid. 1H NMR (400 MHz, DMSO- 6) δ ppm 1.12 (d, J=6.8 Hz, 3 H) 1.15 - 1.39 (m, 1 H) 1.83 (br dd, J=14.0, 7.2 Hz, 1 H) 2.39 - 2.45 (m, 1 H) 2.42 (s, 2 H) 2.73 - 2.84 (m, 1 H) 2.88 - 2.98 (m, 1 H) 3.53 (s, 3 H) 3.56 - 3.65 (m, 1 H) 7.07
(d, J=9.5 Hz, 1 H) 7.35 - 7.46 (m, 2 H) 7.79 - 7.91 (m, 1 H) 10.46 (s, 1 H); Method B;
Rt: 0.93 min. m/z: 382 (M-H)" Exact mass: 383.1. Compound 153 : N-(3 ,4-difluorophenyl)-3 ,7-dimethyl- 1 , 1 -dioxo-3-pyrimidin-2-yl-2,4- dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000164_0001
Compound 153 (205 mg) was prepared similarly as described for compound 125, using 2-amino-2-pyrimidin-2-yl-propan-l-ol instead of 2-amino-2-phenylpropan-l-ol hydrochloride. 2-amino-2-pyrimidin-2-yl-propan-l-ol was synthesized as described for 2-amino-2-pyrazin-2-yl-propan- 1 -ol using 2-acetylpyrimidine instead of acetylpyrazine. The ring closure was obtained after heating 3 hours and compound 153 was crystallized from ACN. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.63 (s, 3 H), 3.80 (s, 3 H),
5.07 - 5.20 (m, 2 H), 7.36 - 7.43 (m, 2 H), 7.43 - 7.48 (m, 2 H), 7.80 - 7.87 (m, 1 H), 8.30 - 8.36 (m, 1 H), 8.86 (d, J=4.9 Hz, 2 H), 9.38 (s, 1 H); Method B; Rt: 1.01 min. m/z: 448 (M-H)" Exact mass: 449.1. The racemic mixture was separated in its enantiomers via preparative SFC (Stationary phase: Chiralpak Daicel AD 20 x 250 mm, Mobile phase: C02, EtOH + 0.4 iPrNH2) to yield compound 153a (75 mg); Method D; Rt: 1.93 min. m/z: 448 (M-H)" Exact mass: 449.1, MP: 228.3 °C, and 153b (73 mg); Method D; Rt: 1.94 min. m/z: 448 (M-H)" Exact mass: 449.1; MP: 228.6 °C. Method R; Rt : 153a: 4.67 min, 153b: 5.97 min.
Synthesis of (2R)-2-amino-2-methyl-3-phenyl-propan-l-ol.
A solution of Z-L-alanine (5 g, 22.4 mmol) and benzaldehyde dimethyl acetal (5.11 g, 33.6 mmol) in diethylether (50 mL) was cooled to -78 °C. Boron trifluoride etherate (23.5 mL, 1.15 g/mL, 190 mmol) was added keeping the temperature below -70 °C. After addition the reaction mixture was allowed to warm to -15 °C and stirring was continued over weekend at this temperature. The reaction mixture was quenched in cooled NaHC03 (sat., aq., 100 mL) and stirred for 30 minutes. The organic layer was removed and evaporated under reduced pressure. The residue was purified on silica using a heptane to heptane:EtOAc 1 : 1 yielding benzyl (2S,4S)-4-methyl-5-oxo-2- phenyl-oxazolidine-3-carboxylate (6.2 g) as an oil which solidified on standing. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.52 (d, J=7.0 Hz, 3 H), 4.56 (q, J=6.9 Hz, 1 H), 5.10 (br s, 2 H), 6.58 (s, 1 H), 7.31 (br s, 4 H), 7.40 - 7.50 (m, 6 H).
A solution of benzyl (2S,4S)-4-methyl-5-oxo-2-phenyl-oxazolidine-3-carboxylate (1.5 g, 4.82 mmol) and benzyl bromide (572 μί, 1.44 g/mL, 4.82 mmol) was added dropwise to a solution of lithium bis(trimethylsilyl)amide (5.78 mL, 1 M in THF, 5.78 mmol) in THF (5 mL) and stirred for 1 hour. The reaction mixture was quenched with NH4C1 (sat., aq., 10 mL) and the organic layer was removed. The aqueous layer was extracted with DCM (2 X 5 mL) and the combined organic layers were evaporated to dryness and the residue was purified on silica using a heptane to EtOAc gradient yielding benzyl (2S,4R)-4-benzyl-4-methyl-5-oxo-2-phenyl-oxazolidine-3-carboxylate (1.01 g). Method D; Rt: 2.38 min. m/z: 402 (M+H)+ Exact mass: 401.1.
LiOH (121 mg, 5.03 mmol) dissolved in water (1 mL) was added to a solution of benzyl (2S,4R)-4-benzyl-4-methyl-5-oxo-2-phenyl-oxazolidine-3-carboxylate (1.01 g, 2.52 mmol) in MeOH (10 mL). The reaction mixture was stirred for 2 hours. HC1 (aq., 1M, 5 mL) was added and the volatiles were removed under reduced pressure. The residue was purified on silica using a heptane to EtO Ac gradient yielding methyl
(2R)-2-(benzyloxycarbonylamino)-2-methyl-3-phenyl-propanoate (691 mg). Method B; Rt: 1.13 min. m/z: 328 (M+H)+ Exact mass: 327.2.
Methyl (2R)-2-(benzyloxycarbonylamino)-2-methyl-3-phenyl-propanoate (560 mg, 1.71 mmol) was dissolved in THF (10 mL). Lithium aluminum hydride (5.13 mL, 1 M in THF, 5.13 mmol) was added and the reaction mixture was stirred for 2 hours. THF (100 mL) was added and then potassium sodium tartrate tetrahydrate (2.17 g,
7.7 mmol) dissolved in water (3 mL) was added and the reaction mixture was stirred for 15 minutes. Na2S04 was added and the reaction mixture was stirred for 15 minutes. The precipitate was removed by filtration and the filtrate was evaporated to dryness. The residue was purified on silica using a heptane to EtO Ac gradient yielding benzyl N-[(lR)-l-benzyl-2-hydroxy-l-methyl-ethyl]carbamate (186 mg).
Benzyl N-[(lR)-l-benzyl-2-hydroxy-l-methyl-ethyl]carbamate (186 mg, 0.62 mmol) and Pd/C (10%) (33 mg, 0.031 mmol) were dispensed in MeOH (40 mL) and set under a hydrogen atmosphere overnight. The reaction mixture was filtered and evaporated to dryness yielding (2R)-2-amino-2-methyl-3-phenyl-propan-l-ol which was used as such. Compound 154 : (3R)-3-benzyl-N-(3 ,4-difluorophenyl)-3 ,7-dimethyl- 1 , 1 -dioxo-2,4- dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000166_0001
Compound 154 (111 mg) was prepared similarly as described for compound 133, using (2R)-2-amino-2-methyl-3-phenyl-propan-l-ol instead of 2-amino-2-methyl-l-propanol. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.15 (s, 3 H), 2.80 (d, J=13.0 Hz, 1 H), 3.00 (d, J=13.0 Hz, 1 H), 3.82 (s, 3 H), 4.40 (d, J=13.2 Hz, 1 H), 4.57 (d, J=13.0 Hz, 1 H), 7.24 - 7.38 (m, 5 H), 7.38 - 7.46 (m, 2 H), 7.47 (s, 1 H), 7.57 - 7.80 (m, 1 H), 7.81 - 7.90 (m, 1 H), 9.40 (s, 1 H); Method B; Rt: 1.19 min. m/z: 460 (M-H)~ Exact mass: 461.1.
Compound 155: (3 S)-3 -benzyl-N-(3 ,4-difiuorophenyl)-3 ,7-dimethyl- 1 , 1 -dioxo-2,4- dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000166_0002
Compound 155 (92 mg) was prepared similarly as described for compound 133, using (2S)-2-amino-2-methyl-3 -phenyl-propan- 1 -ol instead of 2-amino-2-methyl- 1 -propanol. (2S)-2-amino-2-methyl-3-phenyl-propan-l-ol was synthesized as described for (2S)-2- amino-2-methyl-3 -phenyl-propan- l-ol using Z-D-alanine instead of Z-L-alanine.
1H NMR (400 MHz, DMSC /6) δ ppm 1.15 (s, 3 H), 2.80 (d, J=13.0 Hz, 1 H),
3.00 (d, J=13.2 Hz, 1 H), 3.82 (s, 3 H), 4.40 (d, J=13.2 Hz, 1 H), 4.57 (d, J=13.2 Hz, 1 H), 7.25 - 7.36 (m, 5 H), 7.40 - 7.46 (m, 2 H), 7.47 (s, 1 H), 7.71 - 7.89 (m, 2 H), 9.40 (s, 1 H); Method B; Rt: 1.19 min. m/z: 460 (M-H)" Exact mass: 461.1.
Compound 156: (3S)-3-benzyl-N-(3-cyano-4-fluoro-phenyl)-3,7-dimethyl-l,l-dioxo-
2,4-dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000166_0003
Compound 156 (41 mg) was prepared similarly as described for compound 155, using 5-amino-2-fluoro-benzonitrile instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.16 (s, 3 H), 2.79 (d, J=13.2 Hz, 1 H), 3.01 (d, J=13.2 Hz, 1 H), 3.83 (s, 3 H), 4.40 (d, J=13.2 Hz, 1 H), 4.59 (d, J=13.0 Hz, 1 H), 7.24 - 7.36 (m, 5 H), 7.49 (s, 1 H), 7.55 (t, J=9.1 Hz, 1 H), 7.75 (s, 1 H), 8.02 (ddd, J=9.2, 4.8, 2.9 Hz, 1 H), 8.18 (dd, J=5.7, 2.6 Hz, 1 H), 9.49 (s, 1 H); Method B; Rt: 1.13 min. m/z: 467 (M-H)~ Exact mass: 468.1.
Synthesis of (S)-2-(l-methylallyl)isoindoline-l,3-dione.
DIBAL (11 mL, 1 M in heptane, 11 mmol) was added drop wise to an anhydrous solution of methyl (2S)-2-(benzyloxycarbonylamino)propanoate (2.50 g, 10.5 mmol) in THF (50 mL) at -78 °C. After addition the solution was carefully quenched with NaF (aq., sat.) at -78°C. The resulting mixture was stirred while allowing warming to room temperature. More water was added and the reaction mixture was extracted with EtOAc (3 X 25 mL). The combined extracts were evaporated to dryness and the residue was purified on silica using a heptane to EtOAc gradient yielding benzyl N-[(l S)-l-methyl- 2-oxo-ethyl]carbamate (1.13 g) as an oil.
Methyltriphenylphosphonium bromide (3.11 g, 8.69 mmol) was suspended in toluene (50 mL) and cooled to 0 °C. Lithium bis(trimethylsilyl)amide (8.2 mL, 1 M in toluene, 8.2 mmol) was added. The reaction was stirred at 0 °C for 30 minutes, then cooled to - 78 °C and a solution of benzyl N-[(l S)-l-methyl-2-oxo-ethyl]carbamate (1.13 g, 5.43 mmol) in toluene (5 mL) was added. The solution was allowed to warm to room temperature, stirred for 30 min, then quenched with sat NH4Cl(aq., sat.) (20 mL). The layers were separated and the aqueous was washed with EtOAc (10 mL). The combined organic layers were evaporated to dryness and the residue was purified on silica using a heptane to EtOAc gradient yielding benzyl N-[(1S)-1- methylallyl] carbamate (230 mg) as an oil which solidified on standing.
Benzyl N-[(l S)-l-methylallyl]carbamate (100 mg, 0.49 mmol) was dissolved in HC1 (37% in H20, 3 mL) and heated for 30 minutes at 100°C. The volatiles were removed under reduced pressure and the residue was dissolved in THF (5 mL). Hunig's base
(0.84 mL, 0.75 g/mL, 4.9 mmol) and 1,3-isobenzofurandione (79 mg, 0.54 mmol) were added and the reaction mixture was stirred over weekend. Hunig's base (0.84 mL, 0.75 g/mL, 4.9 mmol) was added and the reaction mixture was heated at 50 °C for 2 hours. (S)-2-(l-methylallyl)isoindoline-l,3-dione formed in this reaction mixture was found identical to (*S)-2-(l-methylallyl)isoindoline-l,3-dione described in the synthesis of compound 29. Method Q; Rt: (*R)-2-(l-methylallyl)isoindoline-l,3-dione :
1.65 min, (*S)-2-(l-methylallyl)isoindoline-l,3-dione and (S)-2-(l- methylallyl)isoindoline-l,3-dione: 1.89 min. Compound 157: (3S)-N-(3-cyano-2,4-difluoro-phenyl)-3,7-dimethyl-lJ-dioxo-2,3,4,5- tetrahydropyrrolo[3,4-f1thiazepine-6-carboxamide
Figure imgf000168_0001
To methyl 3-bromo-l-methyl-pyrrole-2-carboxylate (10.0 g, 45.9 mmol) and 2-[(l S)-l- methylallyl]isoindoline-l,3-dione (10.2 g, 50.5 mmol) in DMF (50 mL) was added TEA (12.7 mL, 0.73 g/mL, 91.7 mmol) and this was stirred and purged with nitrogen for 5 minutes. Then bis(tri-tert-butylphosphine)palladium(0) (1.17 g, 2.29 mmol) was added and the mixture was stirred and heated in an oil bath at 110 °C for 90 minutes. The resulting mixture was filtered over a pad of dicalite, rinsed with EtOAc (300 mL) and concentrated in vacuo. The crude was purified on silica (gradient elution:
EtOAc:heptane 0: 100 to 100:0). The desired fractions were concentrated under reduced pressure yielding methyl 3-[(E,3S)-3-(l,3-dioxoisoindolin-2-yl)but-l-enyl]-l-methyl- pyrrole-2-carboxylate (15.1 g) as a yellow oil.
A hydrogenation flask was flushed with nitrogen and then charged with Pd/C (10%) (2.37 g, 2.22 mmol). To this was added under nitrogen methyl 3-[(E,3S)-3-(l,3- dioxoisoindolin-2-yl)but-l-enyl]-l-methyl-pyrrole-2-carboxylate (15.4 g, 44.5 mmol) in THF (200 mL). The resulting suspension was then stirred under a hydrogen atmosphere at room temperature for 2 hours. Then the mixture was filtered over a pad of dicalite under a constant nitrogen flow and this pad was rinsed with THF (250 mL). The filtrate was concentrated in vacuo to yield methyl 3-[(3S)-3-(l,3-dioxoisoindolin-2-yl)butyl]-l- methyl-pyrrole-2-carboxylate (15.0 g). Methyl 3-[(3S)-3-(l,3-dioxoisoindolin-2-yl)butyl]-l-methyl-pyrrole-2-carboxylate
(15.0 g, 44.1 mmol) was dissolved in n-butanol (150 mL). Ethylenediamine (118 mL) was added and stirred at room temperature for 5 minutes and then heated at 90 °C for 3 hours. The mixture was cooled and concentrated in vacuo. The residue was purified by column chromatography on silica using a gradient from 0 till 10% MeOH/NH3 in DCM. The product fractions were concentrated in vacuo to yield methyl 3-[(3S)-3- aminobutyl]-l-methyl-pyrrole-2-carboxylate (9.1 g) as an oil. Method B; Rt: 0.52 min. m/z : 211 (M+H)+ Exact mass: 210.1.
Chlorosulfonic acid (55 mL, 1.75 g/mL, 832 mmol) was stirred and cooled in an ice-acetone bath. A gentle nitrogen flow was maintained. To this was added drop methyl 3-[(3S)-3-aminobutyl]-l-methyl-pyrrole-2-carboxylate (3.50 g, 16.6 mmol) in DCM (65 mL). After addition the resulting mixture was added dropwise to an ice- cooled and stirring solution of Na2C03 (176 g) in ice cold water (1 L). After addition the layers were separated and the water layer was extracted with DCM (2 X 500 mL). The combined extracts were dried on Na2S04, filtered and concentrated in vacuo. The crude was purified on silica gel using gradient elution (heptane/iPrOH 100:0 to 20:80) yielding methyl (3 S)-3 ,7-dimethyl- 1 , 1 -dioxo-2,3 ,4,5-tetrahydropyrrolo[3 ,4- fJthiazepine-6-carboxylate (1.95 g) as a clear oil. Method B; Rt: 0.73 min. m/z :
271 (M-H)~ Exact mass: 272.1.
Methyl (3S)-3,7-dimethyl-l,l-dioxo-2,3,4,5-tetrahydropyrrolo[3,4-fJthiazepine-6- carboxylate (200 mg, 0.73 mmol) and 3-amino-2,6-difluoro-benzonitrile (0.16 g, 0.88 mmol) in dry THF (5 mL) was treated with lithium bis(trimethylsilyl)amide (2.2 mL, 1 M in THF, 2.2 mmol) and this was stirred overnight at room temperature. The resulting mixture was quenched with NH4C1 (aq., sat., 5 mL). Then 5 mL of brine was added and the layers were separated. The water layer was extracted using EtOAc (2 X 30 mL). The combined extracts were concentrated in vacuo and the obtained crude was purified using silica gel column chromatography (gradient elution: EtOAc:heptane 0: 100 to 100:0). The desired fractions were concentrated in vacuo and the obtained residue was purified via preparative HPLC (Stationary phase: RP XBridge Prep CI 8 OBD-ΙΟμιη, 30x150mm, Mobile phase: 0.25% NH4HC03 solution in water, ACN). The desired fractions were concentrated under reduced pressure, co-evaporated with methanol (2 X 25 mL) and dried in a vacuum oven at 55°C for 18 hours yielding compound 157 (7.6 mg). 1H NMR (400 MHz, DMSO-^) δ ppm 1.14 (d, J=6.82 Hz, 3 H) 1.31 - 1.45 (m, 1 H) 1.81 - 1.91 (m, 1 H) 2.77 - 2.89 (m, 1 H) 3.07 - 3.18 (m, 1 H) 3.58 - 3.67 (m, 1 H) 3.70 (s, 3 H) 7.03 (d, J=9.68 Hz, 1 H) 7.40 - 7.51 (m, 2 H) 8.06 (td, J=8.97, 6.05 Hz, 1 H) 10.31 (s, 1 H); Method B; Rt: 0.85 min. m/z : 393 (M-H)" Exact mass: 394.1, MP: 247.5 °C. Methyl (3S)-3,7-dimethyl-l,l-dioxo-2,3,4,5-tetrahydropyrrolo[3,4-fJthiazepine-6- carboxylate (140 mg, 0.51 mmol) and 5-amino-2-fluorobenzonitrile (77 mg, 0.57 mmol) in THF (8 mL) was treated with LiHMDS (1 mL, 1 M in THF, 1 mmol) and this was stirred for 2 hours at room temperature. The resulting mixture was quenched with NH4C1 (aq., sat., 5 mL). Then brine (5 mL) was added and the layers were separated. The water layer was extracted with EtOAc (2 X 10 mL). The combined extracts were concentrated in vacuo and the obtained crude was purified using silica gel column chromatography (EtOAc: heptane 0: 100 to 100:0). The desired fractions were concentrated in vacuo and the obtained residue was purified via preparative HPLC (Stationary phase: RP XBridge Prep C 18 OBD-ΙΟμηι, 30x150mm, Mobile phase:
0.25% NH4HCO3 solution in water, ACN) yielding (3S)-N-(3-cyano-4-fluoro-phenyl)- 3 ,7-dimethyl- 1 , 1 -dioxo-2,3 ,4,5 -tetrahydropyrrolo[3 ,4-f]thiazepine-6-carboxamide (41 mg) being identical to compound 56. 1H NMR (400 MHz, DMSO-<¾) δ ppm 1.13 (d, J=6.60 Hz, 3 H) 1.28 - 1.42 (m, 1 H) 1.77 - 1.92 (m, 1 H) 2.77 - 2.90 (m, 1 H) 2.92 - 3.04 (m, 1 H) 3.56 - 3.66 (m, 1 H) 3.69 (s, 3 H) 7.02 (d, J=9.68 Hz, 1 H) 7.43 (s, 1 H) 7.54 (t, J=9.13 Hz, 1 H) 7.95 (ddd, J=9.19, 4.90, 2.86 Hz, 1 H) 8.19 (dd, J=5.72, 2.64 Hz, 1 H) 10.59 (s, 1 H); Method B; Rt: 0.85 min. m/z : 375 (M-H)" Exact mass: 376.1.
Compound 158 : N-[2-(difluoromethyl)-4-pyridyll-3 ,3 ,7-trimethyl- 1 , 1 -dioxo-2,4- dihydropyrrolo[3,4-bl[l ,4,51oxathiazepine-6-carboxamide
Figure imgf000170_0001
Compound 158 (610 mg) was prepared similarly as described for compound 133, using 2-(difluoromethyl)pyridin-4-amine instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO-de) δ ppm 1.30 (s, 6 H), 3.82 (s, 3 H), 4.43 (s, 2 H), 6.91 (t, J=55.0 Hz, 1 H), 7.49 (s, 1 H), 7.77 - 7.81 (m, 1 H), 7.82 (s, 1 H), 8.03 (d, J=2.0 Hz, 1 H), 8.54 (d, J=5.5 Hz, 1 H), 9.69 (s, 1 H); Method B; Rt: 0.82 min. m/z: 399 (M-H)" Exact mass:
400.1 , MP: 229.9 °C.
Compound 159: (3R -N-(3-cvano-2,4-difiuoro-phenvn-3-r(l S -l-hvdroxyethyll-7- methyl-1 J-dioxo-2,3,4,5-tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000170_0002
Compound 159 (7 mg) was prepared similarly as described for compound 88, using 3-amino-2,6-difluoro-benzonitrile instead of 3,4-difluoroaniline. 1H NMR (400 MHz,
DMSO-dtf) δ ppm 1.13 (d, J=6.2 Hz, 3 H), 1.25 - 1.37 (m, 1 H), 2.17 - 2.24 (m, 1 H), 2.71 - 2.79 (m, 1 H), 3.15 - 3.24 (m, 2 H), 3.42 - 3.53 (m, 1 H), 3.70 (s, 3 H), 4.68 (d, J=5.7 Hz, 1 H), 6.91 (d, J=10.1 Hz, 1 H), 7.43 - 7.49 (m, 2 H), 8.06 (td, J=8.9, 6.2 Hz, 1 H), 10.31 (s, 1 H); Method D; Rt: 1.71 min. m/z: 423 (M-H)" Exact mass: 424.1. Compound 160: N-(3,4-difluorophenyl)-3,7-dimethyl-3-oxazol-2-yl-l J-dioxo-2,4- dihydropyrrolo[3,4-bl[l ,4,51oxathiazepine-6-carboxamide
Figure imgf000171_0001
Compound 160 (240 mg) was prepared similarly as described for compound 153, using l-(oxazol-2-yl)ethanone instead of 2-acetylpyrimidine. 1H NMR (400 MHz, DMSO-de) 5 ppm 1.63 (s, 3 H), 3.81 (s, 3 H), 4.88 (d, J=13.3 Hz, 1 H), 5.1 1 (d, J=13.3 Hz, 1 H), 7.18 (d, J=0.8 Hz, 1 H), 7.38 - 7.50 (m, 3 H), 7.87 (ddd, J=13.2, 7.5, 2.4 Hz, 1 H), 8.13 (d, J=0.8 Hz, 1 H), 8.68 (s, 1 H), 9.46 (s, 1 H); Method B; Rt: 0.93 min. m/z:
439 (M+H)+ Exact mass: 438.1. The racemic mixture was separated in its enantiomers via preparative SFC (Stationary phase: Chiralpak Daicel OD 20 x 250 mm, Mobile phase: C02, EtOH + 0.4 iPrNH2) to yield compound 160a (88 mg); MP: 239.5 °C, and 160b (80 mg); MP: 240.2 °C. Method Y; Rt : 160a: 3.43 min, 160b: 3.73 min.
Synthesis of 2-amino-3-(2,2,2-trifluoroethylamino)butan-l-ol.
Tert-butyl 4-acetyl-2,2-dimethyloxazolidine-3-carboxylate (3.0 g, 12 mmol) and 2,2,2- trifluoroethylamine (1.47 mL, 1.24 g/mL, 18.5 mmol) were dissolved in DCM (50 mL) and stirred at room temperature for 30 min. Then NaBH(OAc)3 (3.40 g, 16.0 mmol) was added and the reaction mixture was stirred overnight. The reaction mixture was diluted with DCM (40 mL) and quenched with Na2C03 (aq., sat., 60 mL). The organic layer was separated, dried over Na2S04, filtered and evaporated to dryness. The crude oil was purified on silica using a heptane to EtOAc gradient yielding tert-butyl 2,2- dimethyl-4-[l-(2,2,2-trifluoroethylamino)ethyl]oxazolidine-3-carboxylate (4.2 g) as a clear oil. 1H NMR (400 MHz, CHLOROFORM- ) δ ppm 1.04 (d, J=6.6 Hz, 3 H), 1.35 - 1.57 (m, 15 H), 3.00 - 4.21 (m, 6 H). tert-butyl 2,2-dimethyl-4-[ 1 -(2,2,2-trifluoroethylamino)ethyl]oxazolidine-3-carboxylate (3.73 g, 1 1.43 mmol) was dissolved in 1 ,4-dioxane (50 mL) and HC1 (17 mL, 4 M in 1 ,4-dioxane, 68.6 mmol) was added at room temperature. After stirring for 5 hours, the solvents were removed yielding crude 2-amino-3-(2,2,2-trifluoroethylamino)butan-l-ol hydrochloride which was used as such in the next step. Compound 161 : N-(3-cyano-4-fluoro-phenyl)-7-methyl-l , l-dioxo-3-[l -(2,2,2- trifluoroethylamino)ethyll-3,4-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6- carboxamide
Figure imgf000172_0001
A mixture of 2-amino-3-(2,2,2-trifluoroethylamino)butan-l-ol hydrochloride (2.13 g, 11.4 mmol) and Hunig's base (12.4 mL, 0.75 g/mL, 72.2 mmol) in dry DCM (75 mL) was stirred for 15 min to get a clear yellow solution. Then ethyl 4-chlorosulfonyl-3- fluoro-l-methyl-pyrrole-2-carboxylate (3.08 g, 11.43 mmol) was added and the solution was stirred at room temperature for 4 hours. The reaction mixture was quenched with NaHC03 (aq., sat., 75 mL). The water layer was extracted with DCM (2 X 50 mL). The combined organic layers were dried over Na2S04, filtered and evaporated to get a yellow oil. The crude was purified on silica using a DCM to EtOAc gradient to afford ethyl 3-fluoro-4-[[l-(hydroxymethyl)-2-(2,2,2-trifluoroethylamino)propyl]sulfamoyl]-l- methyl-pyrrole-2-carboxylate (4.55 g) as a yellow oil. 1H NMR (400 MHz, OMSO-d6) δ ppm 0.84 - 0.97 (m, 3 H), 1.28 (t, J=7.0 Hz, 3 H), 1.85 - 2.10 (m, 1 H), 2.76 - 2.91 (m, 1 H), 2.99 - 3.52 (m, 5 H), 3.82 (s, 3 H), 4.27 (q, J=7.0 Hz, 2 H), 4.54 - 4.77 (m, 1 H), 7.44 (br s, 1 H), 7.51 - 7.60 (m, 1 H); Method D; Rt: 1.64 min. m/z: 418 (M-H)~ Exact mass: 419.1. To a solution of ethyl 3-fluoro-4-[[l-(hydroxymethyl)-2-(2,2,2- trifluoroethylamino)propyl]sulfamoyl]-l-methyl-pyrrole-2-carboxylate (1.00 g, 2.38 mmol) and 5-amino-2-fluoro-benzonitrile (389 mg, 2.86 mmol) in dry THF (25 mL) was added lithium bis(trimethylsilyl)amide (1M in THF) [4039-32-1] #JNJ-70824# (12 mL, 1 M in THF, 12 mmol). The reaction mixture was stirred at room temperature for 5 hours. Then NH4C1 (aq., sat., 30 mL) was added followed by EtOAc (30 mL) and the mixture was stirred for 15 min. The two layers were separated and the aqueous layer was extracted with EtOAc (2 X 30 mL). The combined organic layers were dried over Na2S04, filtered and concentrated under reduced pressure to get a brown oil. The crude was purified on silica using a DCM to EtOAc gradient yielding N-(3-cyano-4- fluoro-phenyl)-3-fluoro-4-[[ 1 -(hydroxymethyl)-2-(2,2,2- trifluoroethylamino)propyl]sulfamoyl] - 1 -methyl-pyrrole-2-carboxamide (818 mg) .
N-(3-cyano-4-fluoro-phenyl)-3-fluoro-4-[[l-(hydroxymethyl)-2-(2,2,2- trifluoroethylamino)propyl]sulfamoyl]- 1 -methyl-pyrrole-2-carboxamide (818 mg, 1.61 mmol) and cesium fluoride (976 mg, 6.42 mmol) were dissolved in dry DMF (12 mL) and heated at 110°C for 18 hours. The reaction mixture was quenched with cold water (15 mL) and extracted with EtOAc (3 X 15 mL). The combined organic layers were evaporated and the residue was purified on silica using a DCM to EtOAc gradient to get a yellow foam. The 4 isomers were separated via Prep SFC (Stationary phase: Chiralpak Daicel AS 20 microhm 500 gr, Mobile phase: C02, EtOH + 0.4 iPrNH2) yielding compound 161a (89 mg); 1H NMR (400 MHz, DMSO-^) δ ppm 1.08 (d, J=6.4 Hz, 3 H), 2.30 - 2.43 (m, 1 H), 2.71 - 2.84 (m, 1 H), 3.12 - 3.41 (m, 2 H), 3.53 - 3.63 (m, 1 H), 3.83 (s, 3 H), 4.00 (dd, J=12.7, 8.9 Hz, 1 H), 4.84 (dd, J=12.8, 1.9 Hz, 1 H), 7.44 - 7.56 (m, 2 H), 7.60 (br s, 1 H), 8.00 (ddd, J=9.2, 4.9, 2.7 Hz, 1 H), 8.18 (dd, J=5.8, 2.7 Hz, 1 H), 9.55 (s, 1 H); Method D; Rt: 1.92 min. m/z: 488 (M-H)" Exact mass: 489.1, compound 161b (70 mg); 1H NMR (400 MHz, DMSO-^) ppm 1.08 (d, J=6.4 Hz, 3 H), 2.31 - 2.43 (m, 1 H), 2.70 - 2.85 (m, 1 H), 3.13 - 3.41 (m, 2 H), 3.53 - 3.64 (m, 1 H), 3.83 (s, 3 H), 4.00 (dd, J=12.7, 8.9 Hz, 1 H), 4.84 (dd, J=12.7, 2.0 Hz, 1 H), 7.47 - 7.57 (m, 2 H), 7.62 (br s, 1 H), 8.00 (ddd, J=9.2, 4.9, 2.8 Hz, 1 H), 8.18
(dd, J=5.8, 2.7 Hz, 1 H), 9.55 (s, 1 H); Method D; Rt: 1.92 min. m/z: 488 (M-H)" Exact mass: 489.1, compound 161c (15 mg); 1H NMR (400 MHz, DMSO-^) δ ppm 1.07 (d, J=6.5 Hz, 3 H), 2.35 (q, J=7.4 Hz, 1 H), 2.88 - 3.02 (m, 1 H), 3.12 - 3.44 (m, 2 H),
3.62 - 3.72 (m, 1 H), 3.83 (s, 3 H), 4.01 (dd, J=12.8, 9.0 Hz, 1 H), 4.72 (dd, J=12.8, 1.3 Hz, 1 H), 7.42 - 7.56 (m, 2 H), 7.59 (br s, 1 H), 8.02 (ddd, J=9.2, 4.9, 2.7 Hz, 1 H),
8.18 (dd, J=5.8, 2.7 Hz, 1 H), 9.56 (s, 1 H); Method D; Rt: 1.93 min. m/z: 488 (M-H)" Exact mass: 489.1 and compound 161d (18 mg); 1H NMR (400 MHz, DMSO-^) δ ppm 1.07 (d, J=6.5 Hz, 3 H), 2.35 (q, J=7.3 Hz, 1 H), 2.89 - 3.03 (m, 1 H), 3.13 - 3.45 (m, 2 H), 3.63 - 3.73 (m, 1 H), 3.83 (s, 3 H), 4.01 (dd, J=12.8, 9.0 Hz, 1 H), 4.72 (dd, J=13.1, 1.2 Hz, 1 H), 7.43 - 7.56 (m, 2 H), 7.60 (br s, 1 H), 8.02 (ddd, J=9.2, 4.9, 2.7 Hz, 1 H), 8.18 (dd, J=5.8, 2.7 Hz, 1 H), 9.56 (s, 1 H); Method D; Rt: 1.93 min. m/z: 488 (M-H)" Exact mass: 489.1. Method AA; Rt : 161a: 3.69 min, 161b: 3.61 min, 161c: 3.75 min, 161d: 4.02 min.
Compound 162: N-(3,4-difluorophenyl)-3,7-dimethyl-3-[(5-methylisoxazol-3- yl)methyl]-l ,l-dioxo-2,4-dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000173_0001
DL-alanine methyl ester hydrochloride (12.8 g, 91.7 mmol) was finely ground and added to DCM (250 mL). Benzophenone imine (14.4 g, 1.62 g/mL, 79.5 mmol) was added and the mixture was stirred overnight at room temperature. The mixture was filtered and the filtrate was washed with water. The organic layer was separated and concentrated in vacuo. The residue was purified on silica using a gradient from 0 till 50% EtOAc in heptane yielding methyl 2-(benzhydrylideneamino)propanoate (15.7 g) as a clear oil.
Potassium tert-butoxide (3.74 g, 33.3 mmol) was added to a cooled (-10 °C) solution of methyl 2-(benzhydrylideneamino)propanoate (7.42 g, 27.8 mmol) and 3- (chloromethyl)-5-methylisoxazole (3.77 g, 27.8 mmol) in NMP (20 mL). The reaction mixture was stirred 1 hour and HC1 (67 mL, 1 M in H20, 67 mmol) was added and the reaction mixture was stirred overnight. The reaction mixture was then diluted with EtOAc (100 mL) and washed with brine (3 X 100 mL). The combined organic layers were evaporated to dryness and the residue was purified on silica using a heptane to EtOAc gradient yielding methyl 2-(benzhydrylideneamino)-2-methyl-3-(5- methylisoxazol-3-yl)propanoate (4.44 g) as an oil. 1H NMR (400 MHz, OMSO-d6) δ ppm 1.55 (s, 3 H), 2.37 - 2.41 (m, 3 H), 3.22 (s, 2 H), 3.69 - 3.79 (m, 3 H), 6.15 (s, 1 H), 8.78 (br s, 3 H).
Methyl 2-(benzhydrylideneamino)-2-methyl-3 -(5 -methylisoxazol-3 -yl)propanoate (4.44 g, 18.9 mmol) was dissolved in MeOH (50 mL) cooled in an ice bath (-10 °C). Sodium borohydride (2.15 g, 56.8 mmol) was added and the reaction mixture was stirred overnight. Incomplete conversion was seen. The volatiles were removed under reduced pressure and the residue was redispensed in THF (100 mL) and lithium aluminum hydride (18.9 mL, 1 M in THF, 18.9 mmol) was added dropwise. The reaction mixture was stirred overnight. Sodium sulfate decahydrate (27.4 g, 85.1 mmol) was added followed by Na2S04. The reaction mixture was filtered and the volatiles were removed under reduced pressure and the residue was purified on silica using a DCM to DCM:MeOH/NH3 9: 1 gradient yielding 2-amino-2-methyl-3-(5- methylisoxazol-3-yl)propan-l-ol (1.41 g) as a clear oil. The filter cake was washed with MeOH and the volatiles were removed from the filtrate. The residue was purified on silica using a DCM to DCM:MeOH/NH3 9: 1 gradient yielding a second crop of
2-amino-2-methyl-3-(5-methylisoxazol-3-yl)propan-l-ol (455 mg) as a light yellow oil.
Both fractions (1.44 g and 455 mg, 1 1.1 mmol), ethyl 4-chlorosulfonyl-3-fluoro-l- methyl-pyrrole-2-carboxylate (2.74 g, 10.2 mmol) and Hunig's base (4.37 mL,
0.75 g/mL, 25.4 mmol) were dissolved in ACN (25 mL) and the reaction mixture was stirred overnight. The volatiles were removed under reduced pressure and the residue was purified on silica using a heptane to EtOAc gradient yielding ethyl 3-fluoro-4-[[l- (hydroxymethyl)-l-methyl-2-(5-methylisoxazol-3-yl)ethyl]sulfamoyl]-l -methyl- pyrrole -2-carboxylate (2.42 g) as a yellow oil which solidified overnight.
Ethyl 3-fluoro-4-[[ 1 -(hydroxymethyl)- 1 -methyl-2-(5-methylisoxazol-3- yl)ethyl]sulfamoyl]-l-methyl-pyrrole-2-carboxylate (484 mg, 1.20 mmol) and 3,4- difluoroaniline (0.12 mL, 1.29 g/mL, 1.2 mmol) were dispensed in THF (5 mL).
Lithium bis(trimethylsilyl)amide (6 mL, 1 M in THF, 6 mmol) was added and the reaction mixture was stirred 3 hours at room temperature. The reaction mixture was quenched with NH4C1 (sat., aq., 10 mL) and the organic layer was removed. The aqueous layer was extracted with DCM (2 X 5 mL) and the combined organic layers were evaporated to dryness and the residue was purified on silica using a heptane to EtOAc gradient yielding N-(3,4-difluorophenyl)-3-fluoro-4-[[l-(hydroxymethyl)-l- methyl-2-(5 -methylisoxazol-3 -yl)ethyl] sulfamoyl] - 1 -methyl -pyrrole-2-carboxamide (175 mg).
N-(3 ,4-difluorophenyl)-3 -fluoro-4- [[ 1 -(hydroxymethyl)- 1 -methyl-2-(5 -methylisoxazol- 3-yl)ethyl]sulfamoyl]-l-methyl-pyrrole-2-carboxamide (175 mg, 0.36 mmol) and cesium fluoride (219 mg, 1.44 mmol) were dispensed in DMF (3 mL) and heated in a microwave tube at 110 °C for 2 hours. The reaction mixture was directly loaded on a silica cartridge and a heptane to EtOAc gradient was applied yielding compound 162. This was separated into its enantiomers via preparative SFC (Stationary phase:
Chiralpak Diacel AD 20 x 250 mm, Mobile phase: C02, MeOH + 0.4 iPrNH2) yielding compound 162a (32 mg); 1H NMR (400 MHz, DMSO-^) δ ppm 1.21 (s, 3 H), 2.38 - 2.41 (m, 3 H), 2.87 (d, J=13.9 Hz, 1 H), 3.04 (d, J=13.9 Hz, 1 H), 3.82 (s, 3 H), 4.41 (d, J=13.0 Hz, 1 H), 4.60 (d, J=13.0 Hz, 1 H), 6.21 (d, J=0.9 Hz, 1 H), 7.40 - 7.44 (m, 2 H), 7.48 (s, 1 H), 7.81 - 7.93 (m, 2 H), 9.39 (s, 1 H); Method B; Rt: 1.04 min. m/z: 465 (M- H)~ Exact mass: 466.1 and compound 162b (33 mg); 1H NMR (400 MHz, DMSO-^) δ ppm 1.21 (s, 3 H), 2.37 - 2.41 (m, 3 H), 2.87 (d, J=13.9 Hz, 1 H), 3.04 (d, J=13.9 Hz, 1 H), 3.82 (s, 3 H), 4.41 (d, J=13.2 Hz, 1 H), 4.60 (d, J=13.0 Hz, 1 H), 6.21 (d, J=0.9 Hz, 1 H), 7.38 - 7.45 (m, 2 H), 7.48 (s, 1 H), 7.80 - 7.93 (m, 2 H), 9.39 (s, 1 H); Method B; Rt: 1.04 min. m/z: 465 (M-H)" Exact mass: 466.1, as white powders after crystallization from an EtOAc:DIPE mixture. Method V; Rt : 162a: 3.82 min, 162b: 4.21 min. Compound 163 : N-(3-cyano-4-fluoro-phenyl)-3-(T -hydroxypropyl)-7-methyl- 1 , 1 -dioxo- 3^-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000176_0001
Compound 163 (132 mg) was prepared similarly as described for compound 142, using 5-amino-2-fluoro-benzonitrile instead of 3,4-difluoroaniline. The racemic mixture was separated in its epimers via preparative SFC (Stationary phase: Chiralpak Daicel AD 20 x 250 mm, Mobile phase: C02, EtOH + 0.4 iPrNH2) to yield compound 163a (41 mg); 1H NMR (400 MHz, DMSO-^) δ ppm 0.92 (t, J=7.4 Hz, 3 H), 1.44 (dquin, J=14.2, 7.3, 7.3, 7.3, 7.3 Hz, 1 H), 1.65 - 1.78 (m, 1 H), 3.35 - 3.44 (m, 1 H), 3.44 - 3.57 (m, 1 H), 3.83 (s, 3 H), 3.98 (dd, J=12.6, 8.8 Hz, 1 H), 4.93 (dd, J=12.8, 2.0 Hz, 1 H), 4.99
(d, J=6.2 Hz, 1 H), 7.45 - 7.56 (m, 2 H), 7.62 (br d, J=8.6 Hz, 1 H), 8.05 (ddd, J=9.2, 4.9, 2.8 Hz, 1 H), 8.21 (dd, J=5.8, 2.7 Hz, 1 H), 9.51 (s, 1 H); Method D; Rt: 1.69 min. m/z: 421 (M-H)" Exact mass: 422.1, and 163b (21 mg); 1H NMR (400 MHz, DMSO-^) δ ppm 0.88 (t, J=7.3 Hz, 3 H), 1.29 - 1.43 (m, 1 H), 1.50 - 1.63 (m, 1 H), 3.55 - 3.64 (m, 1 H), 3.67 - 3.76 (m, 1 H), 3.83 (s, 3 H), 3.99 (dd, J=12.7, 9.1 Hz, 1 H), 4.74
(dd, J= 13.1, 0.5 Hz, 1 H), 4.88 (br d, J=5.3 Hz, 1 H), 7.35 (br s, 1 H), 7.49 (s, 1 H), 7.52 (t, J=9.1 Hz, 1 H), 8.05 (ddd, J=9.2, 4.9, 2.8 Hz, 1 H), 8.19 (dd, J=5.8, 2.7 Hz, 1 H), 9.54 (s, 1 H); Method D; Rt: 1.70 min. m/z: 421 (M-H)" Exact mass: 422.1; MP: 247.0 °C. Method R; Rt : 163a: 4.44 min, 163b: 4.60 min.
Compound 164: (3S)-N-[3-(difluoromethyl)-2,4-difluoro-phenyll-3,7-dimethyl-l,l- dioxo-2,3,4,5-tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000176_0002
Compound 164 (87 mg) was prepared similarly as described for compound 157, using 3-(difluoromethyl)-2,4-difluoro-aniline instead of 3-amino-2,6-difluoro-benzonitrile. 1H NMR (400 MHz, DMSO-^) δ ppm 1.14 (d, J=6.82 Hz, 3 H) 1.29 - 1.52 (m, 1 H) 1.79 - 1.99 (m, 1 H) 2.74 - 2.93 (m, 1 H) 3.12 (br dd, J=15.07, 6.05 Hz, 1 H) 3.55 - 3.67 (m, 1 H) 3.70 (s, 3 H) 7.02 (br d, J=9.02 Hz, 1 H) 7.17 - 7.56 (m, 3 H) 7.77 - 7.99 (m, 1 H) 10.13 (br s, 1 H); Method B; Rt: 0.89 min. m/z : 418 (M-H)" Exact mass:
419.1, MP: 227.7 °C. Compound 165: (3S)-N-r2-(difluoromethyl)-4-pyridyl1-3 J-dimethyl-1.l-dioxo-2.3.4.5- tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000177_0001
Compound 165 (84 mg) was prepared similarly as described for compound 157,
2-(difluoromethyl)pyridin-4-amine instead of 3-amino-2,6-difluoro-benzonitrile.
1H NMR (400 MHz, DMSO-^) δ ppm 1.13 (d, J=6.82 Hz, 3 H) 1.29 - 1.44 (m, 1 H) 1.79 - 1.93 (m, 1 H) 2.78 - 2.91 (m, 1 H) 2.92 - 3.03 (m, 1 H) 3.56 - 3.68 (m, 1 H) 3.71 (s, 3 H) 6.73 - 7.12 (m, 2 H) 7.47 (s, 1 H) 7.75 (dd, J=5.50, 1.76 Hz, 1 H) 8.03
(d, J=1.76 Hz, 1 H) 8.56 (d, J=5.50 Hz, 1 H) 10.84 (s, 1 H); Method B; Rt: 0.74 min. m/z : 385 (M-H)~ Exact mass: 384.1.
Compound 166: (3S)-N-(2-cMoro^-pyridyl)-3J-dimethyl-l.l-dioxo-2.3.4.5- tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000177_0002
Compound 166 (107 mg) was prepared similarly as described for compound 157, using 2-chloropyridin-4-amine instead of 3-amino-2,6-difluoro-benzonitrile. 1H NMR (400 MHz, DMSO-dtf) δ ppm 1.13 (d, J=6.82 Hz, 3 H) 1.27 - 1.47 (m, 1 H) 1.79 - 1.91 (m, 1 H) 2.78 - 2.90 (m, 1 H) 2.91 - 3.04 (m, 1 H) 3.55 - 3.67 (m, 1 H) 3.70 (s, 3 H) 7.04 (d, J=9.46 Hz, 1 H) 7.47 (s, 1 H) 7.58 (dd, J=5.72, 1.76 Hz, 1 H) 7.80 (d, J=1.76 Hz, 1 H) 8.29 (d, J=5.50 Hz, 1 H) 10.81 (br s, 1 H); Method B; Rt: 0.76 min. m/z : 367 (M-H)" Exact mass: 368.1.
Compound 167: N-(3,4-difluorophenyl)-3,7-dimethyl-3-[(l-methylpyrazol-3- yl)methyl]-l ,l-dioxo-2,4-dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000177_0003
Compound 167 (435 mg) was prepared similarly as described for compound 162, using 3 -(chloromethyl)-l -methyl- IH-pyrazole hydrochloride instead of 3-(chloromethyl)-5- methylisoxazole. The racemic mixture was separated in its enantiomers via preparative SFC (Stationary phase: Chiralpak Daicel AD 20 x 250 mm, Mobile phase: C02, MeOH + 0.4 iPrNH2) to yield compound 167a (154.1 mg); 1H NMR (400 MHz, DMSO-^) δ ppm 1.21 (s, 3 H), 2.83 (d, J=13.9 Hz, 1 H), 2.98 (d, J=13.9 Hz, 1 H), 3.80 (s, 3 H), 3.82 (s, 3 H), 4.40 (d, J=13.0 Hz, 1 H), 4.53 (d, J=13.2 Hz, 1 H), 6.14 (d, J=2.2 Hz, 1 H),
7.38 - 7.45 (m, 2 H), 7.46 (s, 1 H), 7.60 (d, J=2.0 Hz, 1 H), 7.80 (s, 1 H), 7.81 - 7.88 (m, 1 H), 9.37 (s, 1 H); Method B; Rt: 0.99 min. m/z : 464 (M-H)~ Exact mass: 465.1 , and 167b (151.4 mg); 1H NMR (400 MHz, DMSO^) δ ppm 1.21 (s, 3 H), 2.83 (d, J=13.9 Hz, 1 H), 2.98 (d, J=13.9 Hz, 1 H), 3.80 (s, 3 H), 3.82 (s, 3 H), 4.40 (d, J=13.0 Hz, 1 H), 4.53 (d, J=13.0 Hz, 1 H), 6.14 (d, J=2.0 Hz, 1 H), 7.38 - 7.45 (m, 2 H), 7.46 (s, 1 H),
7.60 (d, J=2.0 Hz, 1 H), 7.80 (s, 1 H), 7.81 - 7.87 (m, 1 H), 9.37 (s, 1 H); Method B; Rt: 0.99 min. m/z : 464 (M-H)" Exact mass: 465.1. Method V; Rt : 167a: 3.93 min, 167b: 4.50 min. Compound 168 : N-(3 ,4-difluorophenyl)-3 J-dimethyl-3 -(6-methyl-2-pyridyD- 1 ,1- dioxo-2,4-dihydropyrrolo[3,4-bl[l ,4,51oxathiazepine-6-carboxamide
Figure imgf000178_0001
Compound 168 (1 18 mg) was prepared similarly as described for compound 153, using 2-acetyl-6-methylpyridine instead of 2-acetylpyrimidine. 1H NMR (400 MHz,
DMSO-de) δ ppm 1.54 - 1.59 (m, 3 H), 2.44 - 2.47 (m, 3 H), 3.79 - 3.84 (m, 3 H), 4.97 (d, J=13.4 Hz, 1 H), 5.21 (d, J=13.3 Hz, 1 H), 7.16 (d, J=7.6 Hz, 1 H), 7.37 - 7.51 (m, 3 H), 7.60 (d, J=7.9 Hz, 1 H), 7.75 (t, J=7.8 Hz, 1 H), 7.89 (ddd, J=13.2, 7.5, 2.5 Hz, 1 H), 8.47 (s, 1 H), 9.40 (s, 1 H); Method B; Rt: 1.26 min. m/z: 463 (M+H)+ Exact mass: 462.1. The racemic mixture was separated in its enantiomers via preparative SFC (Stationary phase: Chiralpak Daicel AS 20 x 250 mm, Mobile phase: C02, EtOH + 0.4 iPrNH2) to yield compound 168a (37 mg); MP: 221.9 °C, and 168b (35 mg); MP:
221.5 °C. Method T; Rt : 168a: 3.67 min, 168b: 4.66 min. Compound 169: (3S)-N-[3-(difluoromethyl)-4-fluoro-phenyll-3 ,7-dimethyl-l,l-dioxo- 3-(2-pyridyl)-2,4-dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000179_0001
Compound 169 (131 mg) was prepared similarly as described for compound 127, using 3-(difluoromethyl)-4-fluoro-aniline instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSC /6) δ ppm 1.55 - 1.62 (m, 3 H), 3.82 (s, 3 H), 4.99 (d, J=13.4 Hz, 1 H), 5.20 (d, J=13.3 Hz, 1 H), 7.04 - 7.41 (m, 3 H), 7.47 (s, 1 H), 7.79 - 7.89 (m, 3 H), 8.05 (dd, J=6.3, 2.6 Hz, 1 H), 8.48 - 8.52 (m, 2 H), 9.44 (s, 1 H); Method B; Rt: 1.07 min. m/z: 479 (M-H)" Exact mass: 480.1; MP: 208.8 °C.
Compound 170: 3,7-dimethyl-3-[(5-methylisoxazol-3-yl)methyll-l,l-dioxo-N-(3,4,5- trifluorophenyl)-2,4-dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000179_0002
Compound 170 (102 mg) was prepared similarly as described for compound 162, using 3,4,5-trifluoroaniline instead of 3,4-difluoroaniline. This was separated into its enantiomers via preparative SFC (Stationary phase: Kromasil (R,R) Whelk-0 1 10/100, Mobile phase: C02, iPrOH + 0.4 iPrNH2) yielding compound 170a (18 mg), 1H NMR (400 MHz, DMSO- ¾ δ ppm 1.22 (s, 3 H), 2.40 (s, 3 H), 2.88 (d, J=14.1 Hz, 1 H), 3.05 (d, J=13.9 Hz, 1 H), 3.82 (s, 3 H), 4.43 (d, J=13.2 Hz, 1 H), 4.61 (d, J=13.2 Hz, 1 H), 6.22 (s, 1 H), 7.51 (s, 1 H), 7.62 - 7.75 (m, 2 H), 7.93 (s, 1 H), 9.45 (s, 1 H); Method B; Rt: 1.13 min. m/z : 483 (M-H)" Exact mass: 484.1 and compound 170b (29 mg), 1H NMR (400 MHz, DMSO-^) δ ppm 1.17 - 1.27 (m, 3 H), 2.40 (s, 3 H), 2.88 (d, J=13.9 Hz, 1 H), 3.05 (d, J=14.1 Hz, 1 H), 3.82 (s, 3 H), 4.42 (d, J=13.0 Hz, 1 H), 4.61 (d, J=13.2 Hz, 1 H), 6.21 (d, J=0.9 Hz, 1 H), 7.51 (s, 1 H), 7.62 - 7.70 (m, 2 H), 7.93 (s, 1 H), 9.45 (s, 1 H); Method B; Rt: 1.13 min. m/z : 483 (M-H)" Exact mass: 484.1. Method X; Rt : 170a: 4.81 min, 170b: 5.12 min. Compound 171 : 3-[(6-bromo-3-pyridyl)methyll-N-(3,4-difluorophenyl)-3 ,7-dimethyl- 1 J-dioxo-2^-dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000180_0001
Compound 171 (102 mg) was prepared similarly as described for compound 162, using 2-bromo-5-(bromomethyl)pyridine instead of 3-(chloromethyl)-5-methylisoxazole. 1H NMR (400 MHz, DMSO-^) δ ppm 1.13 (s, 3 H), 2.72 (d, J=13.2 Hz, 1 H), 3.04 (d, J=13.2 Hz, 1 H), 3.82 (s, 3 H), 4.41 (d, J=13.2 Hz, 1 H), 4.64 (d, J=13.2 Hz, 1 H), 7.38 - 7.47 (m, 2 H), 7.49 (s, 1 H), 7.63 - 7.67 (m, 1 H), 7.67 - 7.73 (m, 1 H), 7.76 (s, 1 H), 7.80 - 7.88 (m, 1 H), 8.31 (d, J=2.2 Hz, 1 H), 9.40 (s, 1 H); Method B; Rt: 1.11 min. m/z : 539 (M-H)" Exact mass: 540.0, MP: 259.2 °C.
Compound 172: N-(3,4-difluorophenyl)-3,7-dimethyl-3-[(6-methyl-2-pyridyl)methyll- lJ-dioxo-2,4-dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000180_0002
Compound 172 (196 mg) was prepared similarly as described for compound 162, using 2-(bromomethyl)-6-methyl-pyridine instead of 3-(chloromethyl)-5-methylisoxazole. 1H NMR (400 MHz, DMSO-^) δ ppm 1.23 (s, 3 H), 2.42 (s, 3 H), 2.99 - 3.11 (m, 2 H), 3.81 (s, 3 H), 4.49 (d, J=13.0 Hz, 1 H), 4.62 (d, J=13.2 Hz, 1 H), 7.12 (d, J=7.7 Hz, 1 H), 7.20 (d, J=7.7 Hz, 1 H), 7.38 - 7.45 (m, 2 H), 7.46 (s, 1 H), 7.62 (t, J=7.6 Hz, 1 H), 7.79 - 7.86 (m, 1 H), 8.02 (s, 1 H), 9.30 (s, 1 H); Method B; Rt: 1.13 min. m/z : 475 (M-H)" Exact mass: 476.1, MP: 206.0 °C. This was separated into its enantiomers via preparative SFC (Stationary phase: Chiralpak Diacel AD 20 x 250 mm, Mobile phase: C02, iPrOH + 0.4 iPrNH2) yielding compound 172a (65 mg) and compound 172b
(36 mg). Method W; Rt : 172a: 4.20 min, 172b: 4.40 min.
Compound 173: N-(3,4-difluorophenyl)-3,7-dimethyl-3-[(l-methylimidazol-2- yl)methyl]-l ,l-dioxo-2,4-dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000180_0003
Compound 173 (109 mg) was prepared similarly as described for compound 162, using 2-chloromethyl-l -methyl- IH-imidazole instead of 3-(chloromethyl)-5-methylisoxazole. 1H NMR (400 MHz, DMSO-^) δ ppm 1.29 - 1.36 (m, 3 H), 2.96 - 3.10 (m, 2 H), 3.64 (s, 3 H), 3.75 - 3.83 (m, 3 H), 4.51 - 4.66 (m, 2 H), 6.82 (d, J=l .l Hz, 1 H), 7.06 (d, J=l .l Hz, 1 H), 7.38 - 7.46 (m, 3 H), 7.79 - 7.87 (m, 1 H), 8.07 (br s, 1 H), 9.37 (s, 1 H); Method B; Rt: 0.92 min. m/z : 464 (M-H)" Exact mass: 465.1, MP: 297.1 °C.
Compound 174 : N-(3 ,4-difluorophenyl)-3 ,7-dimethyl-3-|Y3 -methylimidazol-4- yl)methyl]-l ,l-dioxo-2,4-dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000181_0001
Compound 174 (109 mg) was prepared similarly as described for compound 162, using 5 -chloromethyl-1 -methyl- IH-imidazole instead of 3-(chloromethyl)-5-methylisoxazole. 1H NMR (400 MHz, DMSO-^) δ ppm 1.03 - 1.24 (m, 3 H), 2.83 (d, J=15.0 Hz, 1 H), 2.97 (d, J=15.0 Hz, 1 H), 3.60 (s, 3 H), 3.81 (s, 3 H), 4.38 (d, J=13.4 Hz, 1 H), 4.65 (d, J=13.0 Hz, 1 H), 6.80 (s, 1 H), 7.38 - 7.45 (m, 2 H), 7.46 (s, 1 H), 7.53 (s, 1 H), 7.79 - 7.91 (m, 2 H), 9.39 (s, 1 H); Method B; Rt: 0.87 min. m/z : 464 (M-H)" Exact mass: 465.1, MP: 265.5 °C.
Compound 175: N-(3,4-difluorophenyl)-3-[(2,5-dimethylpyrazol-3-yl)methyll-3,7- dimethyl- 1 , 1 -dioxo-2,4-dihydropyrrolo[3 ,4-b [ 1 A51oxathiazepine-6-carboxamide
Figure imgf000181_0002
Compound 175 (182 mg) was prepared similarly as described for compound 162, using 5-(chloromethyl)-l,3-dimethyl-lH-pyrazole instead of 3-(chloromethyl)-5- methylisoxazole. 1H NMR (400 MHz, DMSO-^) δ ppm 1.22 (s, 3 H), 2.11 (s, 3 H), 2.85 (d, J=14.5 Hz, 1 H), 3.01 (d, J=14.7 Hz, 1 H), 3.72 (s, 3 H), 3.81 (s, 3 H), 4.38 (d, J=13.2 Hz, 1 H), 4.65 (d, J=13.2 Hz, 1 H), 5.96 (s, 1 H), 7.38 - 7.48 (m, 3 H),
7.81 - 7.92 (m, 2 H), 9.39 (s, 1 H); Method B; Rt: 0.98 min. m/z : 478 (M-H)" Exact mass: 479.1. This was separated into its enantiomers via preparative SFC (Stationary phase: Chiralpak Diacel AD 20 x 250 mm, Mobile phase: C02, EtOH + 0.4 iPrNH2) yielding compound 175a (74 mg) and compound 175b (63 mg). Method R; Rt : 172a: 3.88 min, 172b: 5.31 min. Compound 176 : N-[3 -(difluoromethyl)-4-fluoro-phenyll -3 - [(2,5 -dimethylpyrazol-3 - yl)methyl]-3,7-dimethyl-l ,l-dioxo-2,4-dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6- carboxamide
Figure imgf000182_0001
Compound 176 was prepared similarly as described for compound 175, using 3-
(difluoromethyl)-4-fluoro-aniline instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO-dtf) δ ppm 1.22 (s, 3 H), 2.11 (s, 3 H), 2.94 (dd, J=55.6, 14.6 Hz, 2 H), 3.72 (s, 3 H), 3.82 (s, 3 H), 4.38 (d, J=13.2 Hz, 1 H), 4.63 (d, J=13.6 Hz, 1 H), 5.96 (s, 1 H), 7.23 (t, J=54.8 Hz, 1 H), 7.32 - 7.42 (m, 1 H), 7.46 (s, 1 H), 7.76 - 7.84 (m, 1 H), 7.76 - 7.84 (m, 1 H), 7.88 (s, 1 H), 7.97 - 8.03 (m, 1 H), 9.44 (s, 1 H); Method B; Rt: 0.98 min. m/z : 510 (M-H)" Exact mass: 511.2. This was separated into its enantiomers via preparative SFC (Stationary phase: Chiralpak Diacel AD 20 x 250 mm, Mobile phase: C02, EtOH + 0.4 iPrNH2) yielding compound 176a (97 mg) and compound 176b (83 mg). Method R; Rt : 176a: 3.61 min, 176b: 5.13 min.
Compound 177: N-[3-(difluoromethyl)-4-fluoro-phenyll-3,7-dimethyl-3-(6-methyl-2- pyridyD- 1 , 1 -dioxo-2,4-dihydropyrrolo[3 ,4-b [ 1 ,4,51oxathiazepine-6-carboxamide
Figure imgf000182_0002
Compound 177 (273 mg) was prepared similarly as described for compound 168, using 3-(difluoromethyl)-4-fluoro-aniline instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.52 - 1.62 (m, 3 H), 2.44 - 2.48 (m, 3 H), 3.78 - 3.86 (m, 3 H), 4.97 (d, J=13.4 Hz, 1 H), 5.20 (d, J=13.4 Hz, 1 H), 7.04 - 7.42 (m, 2 H), 7.47 (s, 1 H), 7.60 (d, J=7.9 Hz, 1 H), 7.75 (br t, J=7.7 Hz, 1 H), 7.79 - 7.87 (m, 1 H), 8.05 (dd, J=6.4, 2.7 Hz, 1 H), 8.46 (s, 1 H), 9.41 - 9.47 (m, 1 H); Method B; Rt: 1.15 min. m/z: 493 (M-H)" Exact mass: 494.1; MP: 210.2 °C. This was separated into it's enatiomers via Prep SFC (Stationary phase: Chiralpak Diacel AS 20 x 250 mm, Mobile phase: C02, EtOH + 0.4 iPrNH2) yielding compound 177a (66 mg) and compound 177b (86 mg). Method T; Rt : 177a: 3.09 min, 177b: 3.88 min. Compound 178: (3R)-N-(3-cvano-2.4-difluoro-phenyl)-3-r(l S)-l-hvdroxyethyl1-7- methyl- 1 , 1 -dioxo-2,3-dihydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000183_0001
Compound 178 (26 mg) was prepared similarly as described for compound 84, using 3-amino-2,6-difluorobenzonitrile instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO-dtf) δ ppm 1.21 (d, J=6.2 Hz, 3 H), 3.64 - 3.78 (m, 4 H), 3.82 (ddt, J=10.1 , 7.4, 2.7, 2.7 Hz, 1 H), 4.98 (d, J=5.9 Hz, 1 H), 5.98 (dd, J=12.5, 2.9 Hz, 1 H), 6.70 (dd, J=12.5, 2.4 Hz, 1 H), 7.41 (d, J=9.9 Hz, 1 H), 7.47 (t, J=9.0 Hz, 1 H), 7.59 (s, 1 H), 8.06 (td, J=8.9, 6.2 Hz, 1 H), 10.59 (br s, 1 H); Method B; Rt: 0.73 min. m/z: 421 (M-H)~ Exact mass : 422.1.
Compound 179 : N-(3 -bromo-2,4-difluoro-phenyl)-3 -( 1 -hydroxy- 1 -methyl-ethyl)-7- methyl-1 ,l-dioxo-2,3,4,5-tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000183_0002
Compound 179 (274 mg) was prepared similarly as described for compound 113, using 3-bromo-2,4-difluoro-aniline instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO-d6) 5 ppm 1.04 (s, 3 H), 1.17 (s, 3 H), 1.37 (q, J=1 1.7 Hz, 1 H), 2.18 (br dd, J=14.2, 7.2 Hz, 1 H), 2.67 - 2.78 (m, 1 H), 3.16 - 3.30 (m, 2 H), 3.70 (s, 3 H), 4.40 (s, 1 H), 6.85 (br d, J=10.3 Hz, 1 H), 7.31 (td, J=8.6, 1.9 Hz, 1 H), 7.44 (s, 1 H), 7.70 (td, J=8.7, 5.9 Hz, 1 H), 10.15 (br s, 1 H); Method B; Rt: 0.86 min. m/z: 490 (M- H)~ Exact mass: 491.0, MP: 236.8 °C.
Compound 180: (3R)-N-(3-chloro-4-fluoro-phenyl)-3-(l-hydroxy-l-methyl-ethyl)-7- methyl- 1 , 1 -dioxo-3 ,4-dihydro-2H-pyrrolo[3 ,4-b] [ 1 ,4,51oxathiazepine-6-carboxamide
Figure imgf000183_0003
Compound 180 (289 mg) was prepared similarly as described for compound 93, using 3-chloro-4-fluoro-aniline instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO- d6) δ ppm 1.06 (s, 3 H), 1.25 (s, 3 H), 3.55 (br t, J=8.5 Hz, 1 H), 3.83 (s, 3 H), 3.93 (dd, J=12.5, 8.9 Hz, 1 H), 4.85 (s, 1 H), 4.96 (d, J=12.4 Hz, 1 H), 7.38 (t, J=9.1 Hz, 1 H), 7.45 - 7.57 (m, 2 H), 7.65 (ddd, J=9.0, 4.3, 2.6 Hz, 1 H), 8.00 (dd, J=6.8, 2.6 Hz, 1 H), 9.41 (s, 1 H); Method D; Rt: 1.82 min. m/z: 430 (M-H)~ Exact mass: 431.1 , MP: 234.1 °C.
Compound 181 : N-[3-(difluoromethyl)-4-fluoro-phenyll-3,7-dimethyl-3-(5- methylisoxazol-3-yl)-l J-dioxo-2,4-dihydropyrrolo[3,4-bl[l ,4,51oxathiazepine-6- carboxamide
Figure imgf000184_0001
Compound 181 (151 mg) was prepared similarly as described for compound 153, using l-(5-methylisoxazol-3-yl)ethanone instead of 2-acetylpyrimidine. 1H NMR (400 MHz, DMSC /e) δ ppm 1.60 (s, 3 H), 2.39 - 2.43 (m, 3 H), 3.82 (s, 3 H), 4.83 (d, J=13.3 Hz, 1 H), 4.99 (d, J=13.3 Hz, 1 H), 6.34 (d, J=l . l Hz, 1 H), 7.22 (t, J=54.2 Hz, 1 H), 7.37 (t, J=9.5 Hz, 1 H), 7.47 (s, 1 H), 7.80 - 7.85 (m, 1 H), 8.05 (dd, J=6.4, 2.7 Hz, 1 H), 8.56 (s, 1 H), 9.47 (s, 1 H); Method B; Rt: 1.03 min. m/z: 483 (M+H)+ Exact mass: 484.1. The racemic mixture was separated in its epimers via preparative SFC (Stationary phase: Chiralpak Daicel OD 20 x 250 mm, Mobile phase: C02, EtOH + 0.4 iPrNH2) to yield compound 181a (47 mg) and 181b (48 mg). Method Y; Rt : 181a: 3.07 min, 181b:
3.53 min.
Compound 182 : (3R)-N- [3 -(difluoromethyl)-2,4-difluoro-phenyll -3 -( 1 -hydroxy- 1 - methyl-ethyl)-7-methyl- 1 , 1 -dioxo-3 ,4-dihydro-2H-pyrrolo[3 ,4-b] [ 1 A5"|oxathiazepine- 6-carboxamide
Figure imgf000184_0002
Compound 182 (153 mg) was prepared similarly as described for compound 93,
3-(difluoromethyl)-2,4-difluoro-aniline instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.04 (s, 3 H), 1.25 (s, 3 H), 3.53 - 3.63 (m, 1 H), 3.87 (s, 3 H), 3.99 (dd, J=12.5, 8.8 Hz, 1 H), 4.83 - 5.03 (m, 2 H), 7.15 - 7.78 (m, 4 H), 8.17 - 8.34 (m, 1 H), 9.36 (s, 1 H); Method D; Rt: 1.79 min. m/z: 464 (M-H)~ Exact mass: 465.1, MP: 182.1 °C.
Compound 183 : N-(3 ,4-difluorophenyl)-3 - [hydroxy(4-pyridyl)methyl] -7-methyl- 1,1- dioxo-3,4-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000185_0001
To a cooled solution of ethyl 2-(dibenzylamino)acetate (10 g, 35.3 mmol) in dry THF (200 mL) was added dropwise lithium bis(trimethylsilyl)amide (100 mL, 1 M in THF, 100 mmol) at -70 °C. The solution was stirred for 1 hour. Then
4-pyridinecarboxaldehyde (6.6 mL, 1.137 g/mL, 70.6 mmol) was added slowly. After complete addition the reaction mixture was warmed to 0 °C over 1 hour. NH4CI- solution (aq., sat., 150 mL) was added and the product was extracted with EtOAc (3 X 200 mL). The combined organic layers were dried over Na2S04, filtered and evaporated. The residue was purified on silica using a DCM to EtOAc gradient yielding ethyl 2-(dibenzylamino)-3-hydroxy-3-(4-pyridyl)propanoate (8.72 g) as a yellow oil.
To a solution of ethyl 2-(dibenzylamino)-3-hydroxy-3-(4-pyridyl)propanoate (1.30 g, 2.56 mmol) in dry DCM/pyridine was added imidazole (524 mg, 7.69 mmol) followed by TBDMS-C1 (1.16 g, 7.69 mmol) and the reaction mixture was stirred at room temperature for 2 hours. More imidazole (524 mg, 7.69 mmol) and TBDMS-C1 (1.16 g, 7.69 mmol) were added and the reaction mixture was stirred overnight. More imidazole (524 mg, 7.69 mmol) and TBDMS-C1 (1.16 g, 7.69 mmol) were added and the reaction mixture was stirred overnight. Pyridine (15 mL) was added and the reaction mixture was stirred overnight. The reaction mixture was quenched with NaHC03 (aq., sat.) and the product was extracted with DCM (3 times). The combined organic layers were dried over Na2S04, filtered and evaporated to get a yellow oil, this was purified and separated into its 2 diastereoisomers by silica gel column chromatography (0% to 50%
EtOAc in heptane) yielding diastereoisomer 1 (744 mg); 1H NMR (400 MHz,
CHLOROFORM -d) δ ppm -0.30 (s, 3 H), -0.02 (s, 3 H), 0.72 (s, 9 H), 1.42 (t, J=7.1 Hz, 3 H), 3.31 (d, J=14.0 Hz, 2 H), 3.53 (d, J=9.9 Hz, 1 H), 3.91 (d, J=14.0 Hz, 2 H), 4.20 - 4.43 (m, 2 H), 4.97 (d, J=9.9 Hz, 1 H), 6.89 - 7.02 (m, 6 H), 7.15 - 7.24 (m, 6 H), 8.48 - 8.57 (m, 2 H); Method D; Rt: 3.11 min. m/z: 505 (M+H)+ Exact mass: 504.3 and diastereoisomer 2 (40 mg); 1H NMR (400 MHz, CHLOROFORM -d) δ
ppm -0.23 (s, 3 H), 0.03 (s, 3 H), 0.88 (s, 9 H), 1.32 (t, J=7.1 Hz, 3 H), 3.58 (d, J=4.5 Hz, 1 H), 3.81 (d, J=14.3 Hz, 2 H), 4.07 - 4.37 (m, 4 H), 5.30 (d, J=4.5 Hz, 1 H), 7.00 - 7.09 (m, 6 H), 7.14 - 7.25 (m, 6 H), 8.45 - 8.53 (m, 2 H); Method D; Rt: 3.29 min. m/z: 505 (M+H)+ Exact mass: 505.3.
To a cooled solution of diastereoisomer 1 (744 mg, 1.46 mmol) in dry DCM was added slowly DIBAL (3.5 mL, 1 M in heptane, 3.5 mmol) at -78 °C under nitrogen
atmosphere and continuous stirring at this temperature for 4 hours. Extra DIBAL (3.5 mL, 1 M in heptane, 3.5 mmol) was added and the reaction was stirred for another 2 hours. The reaction mixture was quenched with MeOH (6 mL) followed by potassium sodium tartrate (15 mL) at -78 °C. Then the cooling bath was removed and the reaction mixture was warmed slowly to room temperature. The product was extraced with DCM (3 X 20 mL). The combined organic layers were evaporated and purified on silica using a DCM to EtOAc gradient to yield 3-[tert- butyl(dimethyl)silyl]oxy-2-(dibenzylamino)-3-(4-pyridyl)propan-l-ol (611 mg) as a clear oil. Method B; Rt: 1.42 min. m/z: 463 (M+H)+ Exact mass: 462.3.
Palladium hydroxide on carbon (91 mg, 0.65 mmol) was added to a solution of 3-[tert- butyl(dimethyl)silyl]oxy-2-(dibenzylamino)-3-(4-pyridyl)propan-l-ol (300 mg,
0.65 mmol) in degassed MeOH (6.5 mL) and the resulting suspension was stirred at room temperature under hydrogen atmosphere. After 18 hours the reaction mixture was filtered through a pad of dicalite (eluent MeOH) and concentrated in vacuo. The crude was used as such in the next step.
To a mixture of 2-amino-3-[tert-butyl(dimethyl)silyl]oxy-3-(4-pyridyl)propan-l-ol (162 mg, 0.57 mmol) and Hunig's base (0.62 mL, 0.75 g/mL, 3.6 mmol) in dry DCM (3.9 mL) was added ethyl 4-chlorosulfonyl-3-fluoro-l-methyl-pyrrole-2-carboxylate (0.16 g, 0.57 mmol), the reaction mixture was stirred for 1 hour. The reaction mixture was quenched with NaHC03 (aq., sat., 5 mL). The 2 layers were separated. The water layer was extracted with DCM (2 X 5 mL). The combined organic layers were evaporated and the crude was purified on silica using a DCM to EtOAc gradient to afford ethyl 4-[[2-[tert-butyl(dimethyl)silyl]oxy-l -(hydroxymethyl)-2-(4- pyridyl)ethyl]sulfamoyl]-3-fluoro-l-methyl-pyrrole-2-carboxylate (120 mg) as an orange oil.
To a solution of ethyl 4-[[2-[tert-butyl(dimethyl)silyl]oxy-l-(hydroxymethyl)-2-(4- pyridyl)ethyl]sulfamoyl]-3-fluoro-l-methyl-pyrrole-2-carboxylate (120 mg, 0.23 mmol) and 3,4-difluoroaniline (0.035 mL, 1.29 g/mL, 0.35 mmol) in dry THF (2.8 mL) was added slowly lithium bis(trimethylsilyl)amide (1.4 mL, 1 M in THF, 1.4 mmol). The mixture was stirred for 3 hours at room temperature. Then it was quenched with NH4Cl-solution (aq., sat., 10 mL) and EtOAc was added (5 mL). The two layers were separated and the aqueous layer was extracted with EtOAc (2 X 10 mL). The combined organic layers were concentrated under reduced pressure. The crude was purified on silica using a DCM to EtOAc gradient to yield 4-[[2-[tert-butyl(dimethyl)silyl]oxy-l - (hydroxymethyl)-2-(4-pyridyl)ethyl]sulfamoyl]-N-(3,4-difluorophenyl)-3-fluoro-l- methyl-pyrrole-2-carboxamide (104 mg) as a brown solid.
4-[[2-[tert-butyl(dimethyl)silyl]oxy-l-(hydroxymethyl)-2-(4-pyridyl)ethyl]sulfamoyl]- N-(3,4-difluorophenyl)-3-fluoro-l-methyl-pyrrole-2-carboxamide (104 mg, 0.17 mmol) and cesium fluoride (106 mg, 0.70 mmol) were dissolved in DMF (2 mL) and heated at 1 10°C for 18 hours. The reaction mixture was quenched with cold water (5 mL) and the product was extracted with EtOAc (3 X 5 mL). The combined organic layers were evaporated and the crude was purified on silica using a DCM to DCM:MeOH 9: 1 gradient to obtain a brown foam. A second purification was performed via preparative HPLC (Stationary phase: RP XBridge Prep C18 OBD-ΙΟμιη, 30x150mm, Mobile phase: 0.25% NH4HC03 solution in water, ACN) to obtain compound 183 (8 mg) as a mixture of 2 enantiomers. 1H NMR (400 MHz, OMSO-d6) δ ppm 3.73 - 3.80 (m, 1 H),
3.81 (s, 3 H), 4.17 (dd, J=12.8, 9.2 Hz, 1 H), 4.57 (d, J=8.5 Hz, 1 H), 4.93 (dd, J=12.9, 2.3 Hz, 1 H), 6.10 (br s, 1 H), 7.33 - 7.51 (m, 5 H), 7.71 (br s, 1 H), 7.87 (ddd, J=13.2, 7.5, 2.5 Hz, 1 H), 8.53 - 8.62 (m, 2 H), 9.42 (s, 1 H); Method D; Rt: 1.62 min. m/z: 463 (M-H)~ Exact mass: 464.1.
Compound 184: (3R)-N-[3-(difluoromethyl)-4-fluoro-phenyll-3-(hydroxymethyl)-7- methyl-1 J-dioxo-2,3,4,5-tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000187_0001
Diisobutylaluminum hydride (1.5 mL, 1 M in heptane, 1.5 mmol) was added dropwise during 5 minutes to a solution of 06-ethyl 03-methyl (3R)-7-methyl-l ,l-dioxo-2, 3,4,5- tetrahydropyrrolo[3,4-f]thiazepine-3,6-dicarboxylate (239 mg, 0.70 mmol) in 2-MeTHF (25 mL, 0.86 g/mL, 250 mmol) at -78 °C and stirred 1 hour. Another amount of diisobutylaluminum hydride (3 mL, 1 M, 3 mmol) was added and the reaction mixture was stirred 15 minutes at -78 °C. The reaction mixture was allowed to reach room temperature in a water bath during 10 minutes and quenched with methanol (10 mL). The reaction mixture was diluted with HC1 (aq., 1 M, 10 mL) and extracted with EtOAc (50 mL). The organic layer was separated, dried over magnesium sulfate, filtered and concentrated. The residue was purified on silica using a gradient from 0 till 100% EtOAc in heptane yielding ethyl (3R)-3-(hydroxymethyl)-7-methyl-l,l-dioxo-2, 3,4,5- tetrahydropyrrolo[3,4-f]thiazepine-6-carboxylate (62 mg) as a white powder. Method D; Rt: 1.31 min. m/z: 301 (M-H)~ Exact mass: 302.1.
Lithium bis(trimethylsilyl)amide in THF (1 mL, 1 M in THF, 1 mmol) was added to a solution of ethyl (3R)-3-(hydroxymethyl)-7-methyl-l,l-dioxo-2,3,4,5- tetrahydropyrrolo[3,4-f]thiazepine-6-carboxylate (62 mg, 0.205 mmol) and
3-(difluoromethyl)-4-fluoro-aniline hydrochloride (51 mg, 0.26 mmol) in THF (3 mL) and stirred 3 hours. More 3-(difluoromethyl)-4-fluoro-aniline hydrochloride (102 mg, 0.52 mmol) and lithium bis(trimethylsilyl)amide in THF (2 mL, 1 M in THF, 2 mmol) were added and stirred 1 hour. The reaction mixture was quenched with NH4C1 (aq., sat.), diluted with brine and extracted with EtOAc. The organic layer was dried over magnesium sulfate, filtered and concentrated. The residue was purified on silica using a gradient from 10 till 100% EtOAc in heptane and further via preparative HPLC
(Stationary phase: RP XBridge Prep C18 OBD-ΙΟμιη, 30x150mm, Mobile phase:
0.25% NH4HC03 solution in water, ACN) yielding compound 184 (11 mg). 1H NMR (400 MHz, DMSO- ¾ δ ppm 1.22 - 1.36 (m, 1 H), 2.02 (br dd, J=14.3, 6.6 Hz, 1 H),
2.75 - 2.85 (m, 1 H), 2.99 - 3.09 (m, 1 H), 3.26 (dt, J=10.3, 6.8 Hz, 1 H), 3.38 - 3.53 (m, 2 H), 3.69 (s, 3 H), 4.76 (t, J=5.7 Hz, 1 H), 6.91 (d, J=9.7 Hz, 1 H), 7.07 - 7.40 (m, 2 H), 7.42 (s, 1 H), 7.78 - 7.84 (m, 1 H), 8.06 (dd, J=6.2, 2.4 Hz, 1 H), 10.49 (s, 1 H); Method D; Rt: 1.50 min. m/z: 416 (M-H)" Exact mass: 417.1.
Compound 185: N-(3 -cyano-2,4-difluoro-phenyl)-3 -( 1 -hydroxy- 1 -methyl-ethyl)-7- methyl-1 J-dioxo-2,3,4,5-tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000188_0001
A microwave tube was loaded with compound 179 (248 mg, 0.5 mmol), zinc cyanide (41 mg, 0.35 mmol), and DMF (5 mL). This solution was purged with nitrogen for 10 minutes and l,l'-bis(diphenylphosphino)ferrocenedichloro palladium(II) (37 mg, 0.05 mmol) was added. The tube was closed and stirred and heated under microwave irradiation at 160°C for 30 minutes. The reaction mixture was cooled and purged with nitrogen for 10 minutes and Pd(PPh3)4 (58 mg, 0.05 mmol) was added. The tube was closed and stirred and heated under microwave irradiation at 160°C for 50 minutes. The reaction mixture was filtered over a pad of dicalite, rinsed with 10 mL of acetonitrile and concentrated in vacuo. The residue was purified using preparative HPLC
(Stationary phase: RP XBridge Prep C18 OBD-ΙΟμιη, 50x150mm, Mobile phase:
0.25% NH4HCO3 solution in water, ACN) yielding compound 185 (17 mg). 1H NMR (400 MHz, DMSO- ¾ δ ppm 1.03 (s, 3 H), 1.17 (s, 3 H), 1.31 - 1.42 (m, 1 H), 2.18 (br dd, J=13.5, 6.9 Hz, 1 H), 2.67 - 2.78 (m, 1 H), 3.15 - 3.29 (m, 2 H), 3.70 (s, 3 H), 4.40 (s, 1 H), 6.85 (d, J=10.6 Hz, 1 H), 7.42 - 7.48 (m, 2 H), 8.07 (td, J=8.9, 6.1 Hz, 1 H), 10.32 (br s, 1 H); Method B; Rt: 0.76 min. m/z: 437 (M-H)~ Exact mass: 438.1.
Compound 186: (3R -N-r3-(difluoromethvn-2,4-difiuoro-phenyll-3-r(lS -l- hydroxyethyl]-7-methyl-l ,l-dioxo-2,3-dihydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000189_0001
Compound 186 (72 mg) was prepared similarly as described for compound 84, using 3-(difluoromethyl)-2,4-difluoro-aniline instead of 3,4-difluoroaniline. 1H NMR
(400 MHz, DMSO-dtf) δ ppm 1.21 (d, J=6.2 Hz, 3 H), 3.64 - 3.74 (m, 1 H), 3.75 (s, 3 H), 3.78 - 3.85 (m, 1 H), 4.98 (d, J=5.9 Hz, 1 H), 5.98 (dd, J=12.5, 2.6 Hz, 1 H), 6.69 (dd, J=12.7, 2.5 Hz, 1 H), 7.35 (t, J=52.0 Hz, 1 H), 7.29 - 7.48 (m, 2 H), 7.58 (s, 1 H), 7.84 - 7.91 (m, 1 H), 10.41 (br s, 1 H); Method B; Rt: 0.78 min. m/z: 446 (M-H)~ Exact mass : 447.1.
Compound 187: N-[3-(difluoromethyl)-4-fluoro-phenyll-3,7-dimethyl-3-[(l- methylimidazol-2-yl)methyll-l ,l-dioxo-2,4-dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-
6-carboxamide
Figure imgf000189_0002
Compound 187 (75 mg) was prepared similarly as described for compound 173, using 3-(difluoromethyl)-4-fluoro-aniline instead of 3,4-difluoroaniline. 1H NMR (400 MHz, DMSC i) δ ppm 1.33 (s, 3 H), 3.01 - 3.06 (m, 2 H), 3.64 (s, 3 H), 3.81 (s, 3 H), 4.54 (d, J=13.2 Hz, 1 H), 4.64 (d, J=13.4 Hz, 1 H), 6.82 (d, J=l .l Hz, 1 H), 7.05 (d, J=l .l Hz, 1 H), 7.22 (t, J=54.4 Hz, 1 H), 7.36 (t, J=9.5 Hz, 1 H), 7.45 (s, 1 H), 7.76 - 7.81 (m, 1 H), 8.00 (dd, J=6.3, 2.5 Hz, 1 H), 8.08 (br s, 1 H), 9.41 (s, 1 H); Method B; Rt: 0.93 min. m/z : 496 (M-H)~ Exact mass: 497.1, MP: 282.8 °C.
Compound 188: (3R)-N-r3-(difluoromethyl)-2.4-difluon)-phenyl1-3-r(lS)-l- hydroxyethyl]-7-methyl-l J-dioxo-2,3,4,5-tetrahydropyrrolo[3,4-f|thiazepine-6- carboxamide
Figure imgf000190_0001
Compound 188 (96 mg) was prepared similarly as described for compound 88, using 3-(difluoromethyl)-2,4-difluoro-aniline instead of 3,4-difluoroaniline. 1H NMR
(400 MHz, OMSO-d6) δ ppm 1.13 (d, J=6.2 Hz, 3 H), 1.27 - 1.38 (m, 1 H), 2.21 (br dd, J=14.0, 6.9 Hz, 1 H), 2.66 - 2.80 (m, 1 H), 3.16 - 3.27 (m, 2 H), 3.44 - 3.52 (m, 1 H), 3.70 (s, 3 H), 4.67 (d, J=5.7 Hz, 1 H), 6.90 (br d, J=10.1 Hz, 1 H), 7.34 (br t, J=52.2 Hz, 1 H), 7.30 (br t, J=9.5 Hz, 1 H), 7.43 (s, 1 H), 7.85 - 7.92 (m, 1 H), 10.14 (br s, 1 H); Method B; Rt: 0.88 min. m/z: 448 (M-H)" Exact mass: 449.1, MP: 277.1 °C.
Compound 189: N-(3-cyano-4-fluoro-phenyl)-3-(difluoromethyl)-7-methyl-lJ-dioxo- 2,3-dihydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000190_0002
(S)-(-)-2-methyl-2-propanesulfinamide (21.2 g, 175 mmol) was mixed with 1-ethoxy- 2,2-difluoroethanol (20.1 g, 159 mmol). Titanium(IV)ethoxide (50 mL, 1.09 g/mL,
238 mmol) was added to form a clear, thick solution which was heated to 80 °C with a reflux condensor under nitrogen for 2 days. The mixture was cooled to room
temperature and diluted using EtOAc (500 mL). This was poured into brine (500 mL) under vigorous stirring. This biphasic mixture was filtered over a pad of dicalite which was rinsed with EtOAc (500 mL). The layers of the filtrate were separated and the organic layer was dried on Na2S04, filtered and concentrated in vacuo. The crude was purified on silica using gradient elution (EtOAc: heptane 0:100 to 100:0) yielding N-(l- ethoxy-2,2-difluoro-ethyl)-2-methyl-propane-2-sulfinamide (18.3 g). Method B; Rt: 0.69 min. m/z : 230 (M+H)+ Exact mass: 229.1. N-(l-ethoxy-2,2-difluoro-ethyl)-2-methyl-propane-2-sulfinamide (18.0 g, 78.5 mmol) in DCM (300 mL) was cooled under a nitrogen flow to -50 °C. To this was added vinylmagnesium bromide (118 mL, 1 M, 118 mmol) drop wise under nitrogen and stirring, maintaining the temperature below -47 °C. After complete addition stirring was continued for 3 hours, allowed to reach 0 °C and stirred for 2 hours. The reaction mixture was quenched with NH4C1 (aq., sat.) and diluted with EtOAc (500 mL). The layers were separated and the aqueous layer was extracted with EtOAc (2 X 250 mL). The combined organics were dried on Na2S04, filtered and concentrated in vacuo. The residue was purified on silica using a gradient from heptane to EtOAc to yield N-[l- (difluoromethyl)allyl]-2-methyl-propane-2-sulfinamide (8.86 g). Method B; Rt: 0.71 mm. m/z : 212 (M+H)+ Exact mass: 211.1.
N-[l-(difluoromethyl)allyl]-2-methyl-propane-2-sulfinamide (8.86 g, 42.0 mmol) was dissolved in MeOH (100 mL) and cooled to 0 °C. This was treated with HC1 (21 mL, 4 M in dioxane, 84 mmol). The resulting mixture was stirred for 2 hours. The mixture was concentrated in vacuo. The obtained residue was triturated with diethylether, filtered, rinsed with diethylether (100 mL) and dried in a vacuum oven to yield l,l-difluorobut-3-en-2-amine hydrochloride (5.4 g) as a white solid. Methyl 3-bromo-4-chlorosulfonyl-l-methyl-pyrrole-2-carboxylate (3.68 g, 11.6 mmol) was dissolved in pyridine (10 mL). l,l-difluorobut-3-en-2-amine hydrochloride (2 g, 13.9 mmol) was added and the mixture was stirred at room temperature for 19 hours. The resulting mixture was concentrated in vacuo and the residue was purified on silica (gradient elution: EtOAc:heptane 0: 100 to 100:0) yielding methyl 3-bromo-4-[l- (difluoromethyl)allylsulfamoyl]-l-methyl-pyrrole-2-carboxylate (1200 mg). Method B; Rt: 0.84 min. m/z : 385 (M-H)~ Exact mass: 386.0.
Methyl 3 -bromo-4- [ 1 -(difluoromethyl)allylsulfamoyl] - 1 -methyl-pyrrole-2-carboxylate (200 mg, 0.52 mmol) and 5-amino-2-fluoro-benzonitrile (84 mg, 0.62 mmol) in dry THF (5 mL) was treated with lithium bis(trimethylsilyl)amide (1.6 mL, 1 M in THF, 1.6 mmol) at room temperature. After 1 hour at room temperature, lithium
bis(trimethylsilyl)amide (1 mL, 1 M in THF, 1 mmol) was added and the mixture was stirred at room temperature for 1 hour. The mixture was quenched with NH4C1 (aq., sat., 10 mL) and brine (10 mL). The layers were separated and the water layer was extracted with EtOAc (3 X 20 mL). The combined extracts were dried on Na2S04, filtered and concentrated in vacuo. The crude was purified on silica (gradient elution: EtOAc:heptane 0: 100 to 100:0) yielding 3-bromo-N-(3-cyano-4-fluoro-phenyl)-4-[l- (difluoromethyl)allylsulfamoyl]- 1 -methyl-pyrrole-2-carboxamide (210 mg). 3 -bromo-N-(3 -cyano-4-fluoro-phenyl)-4- [ 1 -(difluoromethyl)allylsulfamoyl] - 1 -methyl- pyrrole -2-carboxamide (210 mg, 0.43 mmol) in DMF (1 mL) with TEA (0.12 mL, 0.73 g/mL, 0.85 mmol) was purged with nitrogen for 5 minutes. Then bis(tri-tert- butylphosphine)palladium(O) (11 mg, 0.021 mmol) was added and the mixture was heated under nitrogen in a sealed tube at 90 °C for 2 hours. The mixture was poured on a silica plug as such and a gradient from heptane to EtOAc was applied yielding compound 189 (86 mg). 1H NMR (400 MHz, DMSO- ¾ δ ppm 3.74 (s, 3 H)
4.38 - 4.59 (m, 1 H) 5.74 (dd, J=12.54, 2.86 Hz, 1 H) 6.07 - 6.49 (m, 1 H) 6.76
(dd, J=12.54, 2.64 Hz, 1 H) 7.56 (t, J=9.13 Hz, 1 H) 7.68 (s, 1 H) 7.98 (ddd, J=9.19, 4.90, 2.64 Hz, 1 H) 8.03 - 8.34 (m, 2 H) 10.93 (br s, 1 H); Method B; Rt: 0.88 min. m/z : 409 (M-H)~ Exact mass: 410.1.
Compound 190: 3-[(2-chloro-4-pyridyl)methyll-N-(3,4-difluorophenyl)-3,7-dimethyl- lJ-dioxo-2,4-dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000192_0001
Compound 190 (90 mg) was prepared similarly as described for compound 162, using 2-chloro-4-(chloromethyl)pyridine instead of 3-(chloromethyl)-5-methylisoxazole. 1H NMR (400 MHz, DMSO-^) δ ppm 1.37 (s, 3 H) 2.65 (d, J=12.9 Hz, 1 H) 3.35 (d, J=13.2 Hz, 1 H) 3.97 (s, 3 H) 4.38 (d, J=13.2 Hz, 1 H) 4.65 (s, 1 H) 4.98 (br d, J=13.4 Hz, 1 H) 7.07 (s, 1 H) 7.09 - 7.18 (m, 2 H) 7.26 (d, J=1.3 Hz, 1 H) 7.32 (s, 1 H)
7.61 - 7.69 (m, 1 H) 8.39 (d, J=5.1 Hz, 1 H) 8.61 (s, 1 H); Method B; Rt: 1.07 min. m/z : 495 (M-H)" Exact mass: 496.1, MP: 225.0 °C. Compound 191: N-(3^-difluorophenyl)-3,7-dimethyl-lJ-dioxo-3-(4-pyridylmethyl)-
2,4-dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000192_0002
Compound 190 (70 mg, 0.14 mmol) was dissolved in MeOH (25 mL) and Pd/C (10%) (15 mg, 0.014 mmol) was added and the reaction mixture was set under a hydrogen atmosphere. After 2 hours the solution was filtered over dicalite, concentrated in vacuo, redissolved in DCM (30 mL), neutralized with NaHC03 (aq., sat.) and the combined organics were concentrated in vacuo and purified on silica using DCM/MeOH 100/0 to 90/10 to yield compound 191 (23 mg). 1H NMR (400 MHz, DMSO-^) δ ppm 1.15 (s, 3 H) 2.74 (d, J=13.0 Hz, 1 H) 3.07 (d, J=12.8 Hz, 1 H) 3.82 (s, 3 H) 4.40 (d, J=13.2 Hz, 1 H) 4.63 (d, J=13.6 Hz, 1 H) 7.30 - 7.36 (m, 2 H) 7.40 - 7.46 (m, 2 H) 7.49 (s, 1 H) 7.78 (br s, 1 H) 7.82 - 7.90 (m, 1 H) 8.51 - 8.53 (m, 2 H) 9.41 (s, 1 H); Method B; Rt: 0.96 min. m/z : 461 (M-H)~ Exact mass: 462.1, MP: 276.0 °C.
Synthesis of 2-amino-2-(l-methylpyrazol-3-yl)propan-l-ol.
A 30ml tube was charged with ethyl N-(diphenylmethylene)glycinate (2.5 g, 9.35 mmol), 3 -bromo-1 -methyl- lh-pyrazole (1.51 g, 9.35 mmol), potassium phosphate tribasic (6 g, 27.7 mmol) in toluene (15 mL) and the mixture was purged with N2 for 5 minutes. Bis(tri-tert-butylphosphine)palladium(0) (526 mg, 1.03 mmol) was added and the vial was capped and the mixture was stirred at 100°C for 16 hours. The mixture was cooled and filtered over decalite. The filtrate was concentrated in vacuo. The residue was purified by column chromatography using a gradient from 0 till 100% EtOAc in heptane. The product fractions were concentrated in vacuo to yield ethyl
2-(benzhydrylideneamino)-2-(l-methylpyrazol-3-yl)acetate (1.95 g) as a pale yellow oil.
Ethyl 2-(benzhydrylideneamino)-2-(l-methylpyrazol-3-yl)acetate (1.95 g, 5.61 mmol) was dissolved in DMF (30 mL) under N2 atmosphere. The mixture was cooled on a ice bath and NaH (60% dispersion in mineral oil) (269 mg, 6.74 mmol) was added portionwise. The mixture was stirred at 5 °C for 30 minutes. Mel (0.42 mL, 2.28 g/mL, 6.74 mmol) was added dropwise and the mixture was stirred at 5°C for 15 minutes and was then allowed to rise to room temperature. The mixture was stirred at room temperature for 16 hours. The mixture was quenched with water and the mixture was concentrated in vacuo. The residue was partitioned between water and EtOAc and the organic layer was separated, washed with brine, dried (MgS04), filtered and
concentrated in vacuo. The residue was purified by column chromatography using a gradient from 0 till 50% EtOAc in heptane. The product fractions were concentrated in vacuo to yield ethyl 2-(benzhydrylideneamino)-2-(l-methylpyrazol-3-yl)propanoate (1.1 g) as a yellow oil.
Ethyl 2-(benzhydrylideneamino)-2-(l-methylpyrazol-3-yl)propanoate (1.1 g, 3.04 mmol) was dissolved in diethylether (20 mL). HC1 (3.7 mL, 1 M in H20, 3.7 mmol) was added and the mixture was stirred at room temperature for 3 hours. The organic layer was separated and the water layer was neutralized with NaHC03. The water layer was extracted with 2-MeTHF and the organic layer was dried (MgS04), filtered and concentrated in vacuo. The residue was purified by column chromatography using a gradient from 0 till 100% MeOH/NH3 (90/10) in DCM. The product fractions were concentrated in vacuo to yield ethyl 2-amino-2-(l-methylpyrazol-3-yl)propanoate (382 mg) as a clear oil. Method B; Rt: 0.52 min. m/z : 198 (M+H)+ Exact mass: 197.1. Ethyl 2-amino-2-(l-methylpyrazol-3-yl)propanoate (382 mg, 1.94 mmol) was dissolved in MeOH (10 mL) under N2. Sodium borohydride (147 mg, 3.87 mmol) was added and the mixture was stirred at room temperature for 16 hours. The mixture was
concentrated in vacuo. The residue was purified by column chromatography using a gradient from 0 till 100% MeOH/NH3 (90/10) in DCM. The product fractions were concentrated in vacuo to yield 2-amino-2-( 1 -methylpyrazol-3 -yl)propan- 1 -ol (230 mg) as a clear oil.
Compound 192 : N-(3 ,4-difluorophenyl)-3 ,7-dimethyl-3 -( 1 -methylpyrazol-3 -yl)- 1,1- dioxo-2,4-dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000194_0001
Compound 192 (223 mg) was prepared similarly as described for compound 125, using 2-amino-2-(l -methylpyrazol-3 -yl)propan-l-ol instead of 2-amino-2-phenylpropan-l-ol hydrochloride. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.59 (s, 3 H), 3.79 (s, 3 H), 3.82 (s, 3 H), 4.81 - 4.92 (m, 2 H), 6.33 (d, J=2.2 Hz, 1 H), 7.36 - 7.50 (m, 3 H), 7.60 (d, J=2.2 Hz, 1 H), 7.87 (ddd, J=13.2, 7.5, 2.5 Hz, 1 H), 8.16 (s, 1 H), 9.33 - 9.38 (m, 1 H); Method B; Rt: 1.05 min. m/z: 450 (M-H)" Exact mass: 451.1. The racemic mixture was separated in its enantiomers via preparative SFC (Stationary phase: Chiralpak Daicel AD 20 x 250 mm, Mobile phase: C02, EtOH + 0.4 iPrNH2) to yield compound 192a (85 mg); Method D; Rt: 1.85 min. m/z: 450 (M-H)" Exact mass: 451.1, MP: 208.7 °C, and 192b (85 mg); Method D; Rt: 1.86 min. m/z: 450 (M-H)" Exact mass: 451.1; MP: 209.2 °C. Method R; Rt : 192a: 4.17 min, 192b: 4.96 min.
Compound 193: (3R)-N-(3-chloro-4-fluoro-phenyl)-3-[(lS)-l-hydroxyethyll-7-methyl-
1 J-dioxo-2,3,4,5-tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000194_0002
Compound 193 (101 mg) was prepared similarly as described for compound 88, using 3-chloro-4-fluoro-aniline instead of 3,4-difluoroaniline. 1H NMR (400 MHz,
DMSC ) δ ppm 1.13 (d, J=6.4 Hz, 3 H), 1.21 - 1.35 (m, 1 H), 2.19 (br dd, J=14.3, 6.8 Hz, 1 H), 2.70 - 2.81 (m, 1 H), 3.03 (br dd, J=14.9, 6.5 Hz, 1 H), 3.15 - 3.26 (m, 1 H), 3.47 (sxt, J=6.3 Hz, 1 H), 3.69 (s, 3 H), 4.69 (d, J=5.7 Hz, 1 H), 6.91 (d, J=10.1 Hz, 1 H), 7.38 - 7.45 (m, 2 H), 7.61 (ddd, J=9.0, 4.4, 2.6 Hz, 1 H), 8.00 (dd, J=6.9, 2.5 Hz, 1 H), 10.46 (s, 1 H); Method B; Rt: 0.92 min. m/z: 414 (M-H)" Exact mass: 415.1 , MP: 290.8 °C. Compound 194: (3R)-N-(3-cMoro-4-fluoro-phenyl)-3-r(l S)-l-hvdroxyethyl1-7-methyl- J-dioxo-2,3-dihydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000195_0001
Compound 194 (89 mg) was prepared similarly as described for compound 84, using 3-chloro-4-fluoro-aniline instead of 3,4-difluoroaniline. 1H NMR (400 MHz,
DMSO-dtf) δ ppm 1.20 (d, J=6.2 Hz, 3 H), 3.62 - 3.74 (m, 4 H), 3.76 - 3.88 (m, 1 H), 4.96 (d, J=5.7 Hz, 1 H), 5.96 (dd, J=12.5, 2.6 Hz, 1 H), 6.55 (dd, J=12.5, 2.4 Hz, 1 H), 7.34 - 7.46 (m, 2 H), 7.57 (s, 1 H), 7.62 (ddd, J=9.0, 4.3, 2.5 Hz, 1 H), 8.00 (dd, J=6.8, 2.6 Hz, 1 H), 10.71 (s, 1 H); Method D; Rt: 1.63 min. m/z: 412 (M-H)" Exact mass: 413.1 ; MP: 21 1.3 °C.
Compound 195: (3R)-N-(4-fluoro-3 -methyl-phenyl)- 3 -( 1 -hydroxy- 1 -methyl-ethyl)-7- methyl- 1 , 1 -dioxo-3 ,4-dihydro-2H-pyrrolo[3 ,4-b] [ 1 A51oxathiazepine-6-carboxamide
Figure imgf000195_0002
Compound 195 (274 mg) was prepared similarly as described for compound 93,
4-fluoro-3 -methyl-aniline instead of 3,4-difluoroaniline. 1H NMR (400 MHz,
DMSO-d6) δ ppm 1.06 (s, 3 H), 1.25 (s, 3 H), 2.23 (d, J=2.0 Hz, 3 H), 3.47 - 3.61 (m, 1 H), 3.83 (s, 3 H), 3.93 (dd, J=12.5, 8.9 Hz, 1 H), 4.85 (s, 1 H), 4.90 - 5.00 (m, 1 H), 7.09 (t, J=9.2 Hz, 1 H), 7.46 (s, 1 H), 7.47 - 7.55 (m, 2 H), 7.57 (dd, J=7.0, 2.6 Hz, 1 H), 9.22 (s, 1 H); Method D; Rt: 1.75 min. m/z: 410 (M-H)" Exact mass: 41 1.1. Synthesis of ethyl 4-chlorosulfonyl-3 -hydroxy- 1 -methyl-pyrrole -2-carboxylate.
Chlorosulfonic acid (2 mL, 1.753 g/mL, 30 mmol) was cooled to 0 °C and to this stirring liquid was added ethyl 3 -hydroxy- 1 -methyl-pyrrole -2-carboxylate (1 g, 5.9 mmol) portion wise. After addition the mixture was allowed to reach room temperature and then stirred for another hour. The resulting mixture was added dropwise to a stirred ice-water mixture (100 mL) keeping the temperature below 5 °C. The mixture was extracted with Me-THF, dried (Na2S04), filtered and concentrated in vacuo. The obtained crude was triturated in cyclohexane, filtered and dried to yield ethyl 4-chlorosulfonyl-3-hydroxy-l-methyl-pyrrole-2-carboxylate (1.1 g).
Compound 196: (3S)-N-(3,4-difluorophenyl)-3-(l-hydroxycyclopropyl)-7-methyl-l,l- dioxo-3,4-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000196_0001
(S)-(-)-3-tert-butoxycarbonyl-4-methoxycarbonyl-2,2-dimethyl-l ,3-oxazolidine (5 g, 19. 3 mmol) was dissolved in THF (100 mL) and cooled to 0 °C before titanium(IV) isopropoxide (2.9 mL, 0.96 g/mL, 9.6 mmol) was added while stirred over 10 minutes. Then ethylmagnesium bromide (16 mL, 3 M, 48 mmol) was slowly added over 10 minutes to obtain a dark brown solution, and the solution was stirred at 0 °C and then allowed to reach room temperature. After 16 hours the solution was quenched with NH4C1 (aq., sat.) and extracted with EtOAc, dried over MgS04, filtered and
concentrated in vacuo. The obtained crude was purified on silica using heptane/EtOAc: 100/0 to 80/20 to yield tert-butyl (4S)-4-(l-hydroxycyclopropyl)-2,2-dimethyl- oxazolidine-3-carboxylate (4.0 g) as light oil. 1H NMR (400 MHz, DMSO- 6) δ ppm 0.29 - 0.73 (m, 4 H) 1.35 - 1.49 (m, 15 H) 3.74 (br d, J=81.0 Hz, 1 H) 3.93 - 4.09 (m, 2 H) 5.30 (br s, 1 H).
NaH (933 mg, 60% dispersion in mineral oil, 23.3 mmol) was dissolved in DMF (45 mL) and cooled to 0 °C before a solution of tert-butyl (4S)-4-(l- hydroxycyclopropyl)-2,2-dimethyl-oxazolidine-3-carboxylate (3.0 g, 11.7 mmol) in THF (10 mL) was added. The solution was stirred for 30 minutes and then benzyl bromide (1.5 mL, 1.44 g/mL, 13 mmol) was added. The solution was allowed to reach room temperature and stirred for 16 hours. The solution was quenched with NH4C1 (aq., sat.) and stirred for 10 minutes before being extracted with EtOAc and washed three times with brine. The combined organic layers were dried over MgS04, filtered off and concentrated in vacuo. The obtained crude was purified on silica using heptane/EtOac from 100/0 to 50/50 to yield tert-butyl (4S)-4-(l-benzyloxycyclopropyl)- 2,2-dimethyl-oxazolidine-3-carboxylate (2.8 g). tert-butyl (4S)-4-(l-benzyloxycyclopropyl)-2,2-dimethyl-oxazolidine-3-carboxylate
(2.8 g, 8.1 mmol) was dissolved in a mixture of MeOH (30 mL) and THF (65 mL). HC1 (25 mL, 1 M in H20, 24.176 mmol) was added dropwise and the solution was heated to 50 °C and stirred for 48 hours. The solution was then basified with K2C03 and concentrated in vacuo. The crude was then diluted with DCM and washed with water. The combined organic layers were concentrated in vacuo and purified on silica using a gradient from DCM to DCM/MeOH(NH3 7N) 9/1 to yield (2S)-2-amino-2-(l- benzyloxycyclopropyl)ethanol (1.2 g). Method B; Rt: 0.52 min. m/z: 208 (M+H)+ Exact mass: 207.1. (2S)-2-amino-2-(l-benzyloxycyclopropyl)ethanol (950 mg, 4.6 mmol) was dissolved in dry DCM and 2 g molecular sieves (4A) was added at room temperature under inert atmosphere. 4-methoxybenzaldehyde (0.69 mL, 1.119 g/mL, 5.5 mmol) was then added and the solution was stirred at room temperature for 16 hours. The solution was rapidly filtered, concentrated in vacuo and redissolved in MeOH (18 mL) and cooled to 0 °C before sodium borohydride (433 mg, 11.46 mmol) was added and the solution then allowed to reach room temperature. After 2 hours the solution was quenhed with water, extracted with DCM, dried over Na2S04, filtered, concentrated and purified on silica using heptane/EtOAc 100/0 to 10/90 to yield (2S)-2-(l-benzyloxycyclopropyl)-2-[(4- methoxyphenyl)methylamino]ethanol (1.38 g). 1H NMR (400 MHz, DMSO- 6) δ ppm 0.59 - 0.71 (m, 2 H) 0.87 - 1.03 (m, 2 H) 2.68 (dd, J=7.0, 4.6 Hz, 1 H) 3.56 (dd, J=10.8, 7.0 Hz, 1 H) 3.74 (dd, J=10.8, 4.6 Hz, 1 H) 3.78 - 3.84 (m, 4 H) 3.91 - 3.98 (m, 1 H) 4.47 - 4.62 (m, 2 H) 6.86 (d, J=7.7 Hz, 2 H) 7.22 - 7.34 (m, 7 H); Method B; Rt:
0.94 min. m/z: 328 (M+H)+ Exact mass: 327.2. (2S)-2-(l -benzyloxycyclopropyl)-2-[(4-methoxyphenyl)methylamino]ethanol (1.13 g, 3.451 mmol) was dissolved in ACN (20 mL) and Hunig's base (1.78 mL, 0.75 g/mL, 10.4 mmol) was added followed by ethyl 4-chlorosulfonyl-3 -hydroxy- 1-methyl-pyrrole- 2-carboxylate (924 mg, 3.45 mmol). After 16 hours, the solution was quenched with NaHC03 (aq., sat., 50 mL) and stirred for 10 minutes. The solution was then extracted with EtOAc (3 X 50 mL). The combined organics were dried over Na2S04, filtered, concentrated in vacuo and purified on silica using heptane/EtOAc 100/0 to 20/80 to yield ethyl 4-[[(lS)-l-(l-benzyloxycyclopropyl)-2-hydroxy-ethyl]-[(4- methoxyphenyl)methyl] sulfamoyl] -3 -hydroxy- 1 -methyl-pyrrole-2-carboxylate
(800 mg).
Ethyl 4-[[(lS)-l-(l-benzyloxycyclopropyl)-2-hydroxy-ethyl]-[(4- methoxyphenyl)methyl]sulfamoyl]-3-hydroxy-l-methyl-pyrrole-2-carboxylate (800 mg, 1.43 mmol) was dissolved in THF (15 mL). Triphenylphosphine (413 mg, 1.58 mmol) and di-tert-butyl azodicarboxylate (363 mg, 1.58 mmol) were added. After 16 hours, the solution was extracted with EtOAc, washed with water and the combined organics dried over MgS04, filtered and concentrated in vacuo. The crude was purified on silica using heptane/EtOAc 100/ to 0/100 to yield ethyl (3S)-3-(l-benzyloxycyclopropyl)-2- [(4-methoxyphenyl)methyl] -7-methyl- 1 , 1 -dioxo-3 ,4-dihydropyrrolo [3 ,4- b][l,4,5]oxathiazepine-6-carboxylate (774 mg).
Ethyl (3S)-3-(l -benzyloxycyclopropyl)-2-[(4-methoxyphenyl)methyl]-7-methyl- 1,1- dioxo-3,4-dihydropyrrolo[3,4-b][l,4,5]oxathiazepine-6-carboxylate (774 mg, 1.43 mmol) was dissolved in THF (20 mL) and 3,4-difluoroaniline (0.16 mL, 1.29 g/mL, 1.58 mmol) and LiHMDS (7 mL, 1 M in THF, 7 mmol) were added. After 2 hours at room temperature the solution was quenched with NH4C1 (aq., sat.) and extracted with EtOAc, the combined organic layers were dried with MgS04, filtered, concentrated in vacuo and the crude purified on silica using heptane/EtOAc: 100/0 to 0/100 gradient elution. The obtained crude was partitioned between EtOAc (50 ml), 10 mL HC1 (aq., 1M) and water (20 mL) and stirred during 10 minutes. After extraction, the combined organic layers were dried over MgS04, filtered and concentrated in vacuo to yield (3S)-3-(l-benzyloxycyclopropyl)-N-(3,4-difluorophenyl)-2-[(4- methoxyphenyl)methyl]-7-methyl-l,l-dioxo-3,4-dihydropyrrolo[3,4- b][l,4,5]oxathiazepine-6-carboxamide (621 mg) Method B; Rt: 1.41 min. m/z: 624 (M+H)+ Exact mass: 623.1.
(3S)-3-(l-benzyloxycyclopropyl)-N-(3,4-difluorophenyl)-2-[(4- methoxyphenyl)methyl] -7-methyl- 1 , 1 -dioxo-3 ,4-dihydropyrrolo [3 ,4- b][l,4,5]oxathiazepine-6-carboxamide (100 mg, 0.16 mmol) was dissolved in DCM (2 mL) and TFA (1.23 mL, 1.49 g/mL, 16.0 mmol) was added at room temperature. After 16 hours, the reaction was quenched with water and NaHC03 (aq., sat.) and extracted with DCM. The combined organic layers were dried over MgS04, filtered,
concentrated in vacuo and purified on silica yielding (3S)-3-(l-benzyloxycyclopropyl)- N-(3 ,4-difluorophenyl)-7-methyl- 1 , 1 -dioxo-3 ,4-dihydro-2H-pyrrolo[3 ,4- b][l,4,5]oxathiazepine-6-carboxamide (70 mg). Method B; Rt: 1.21 min. m/z: 504 (M+H)+ Exact mass: 503.1. (3 S)-3 -( 1 -benzyloxycyclopropyl)-N-(3 ,4-difluorophenyl)-7-methyl- 1 , 1 -dioxo-3 ,4- dihydro-2H-pyrrolo[3,4-b][l,4,5]oxathiazepine-6-carboxamide (70 mg, 0.139 mmol) was dissolved in MeOH (20 mL) and HO Ac (0.4 mL, 1.049 g/mL, 7.0 mmol) and 5 droplets 0.4% thiophene in THF were added. Pd/C (10%) (15 mg, 0.014 mmol) was added. The solution was hydrogenated at room temperature during 1 hour. The reaction mixture was filtered over dicalite, concentrated in vacuo, purified on silica using heptane/EtOAc 100/0 to 50/50 to yield compound 196 (12 mg). 1H NMR (400 MHz, DMSO-< ) δ ppm 0.57 - 0.80 (m, 4 H) 3.46 - 3.53 (m, 1 H) 3.83 (s, 3 H) 3.99 - 4.09 (m, 1 H) 4.92 (dd, J=12.5, 1.3 Hz, 1 H) 5.50 (s, 1 H) 7.36 - 7.53 (m, 4 H) 7.87 (ddd, J=13.1, 7.5, 2.4 Hz, 1 H) 9.43 (s, 1 H); Method B; Rt: 0.89 min. m/z : 412 (M-H)~ Exact mass: 413.1.
Compound 197: 3 -|Y6-chloro-3 -pyridyOmethyl] -N-(3 ,4-difluorophenyl)-3 ,7-dimethyl- lJ-dioxo-2,4-dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000199_0001
Compound 197 (331 mg) was prepared similarly as described for compound 162, using 2-chloro-5-(chloromethyl)pyridine instead of 3-(chloromethyl)-5-methylisoxazole. 1H NMR (400 MHz, DMSO-^) δ ppm 1.13 (s, 3 H), 2.75 (d, J=13.2 Hz, 1 H), 3.06 (d, J=13.2 Hz, 1 H), 3.82 (s, 3 H), 4.41 (d, J=13.0 Hz, 1 H), 4.64 (d, J=13.2 Hz, 1 H), 7.38 - 7.46 (m, 2 H), 7.49 (s, 1 H), 7.52 (d, J=8.1 Hz, 1 H), 7.74 - 7.88 (m, 3 H), 8.33 (d, J=2.2 Hz, 1 H), 9.40 (s, 1 H); Method B; Rt: 1.08 min. m/z : 495 (M-H)" Exact mass: 496.1. Compound 198: N-(3-chloro-4-fluoro-phenyl)-3-[(6-chloro-3-pyridyl)methyll-3,7- dimethyl- 1 , 1 -dioxo-2,4-dihydropyrrolo[3 ,4-b [ 1 A51oxathiazepine-6-carboxamide
Figure imgf000199_0002
Compound 198 (109 mg) was prepared similarly as described for compound 197, using 3-chloro-4-fluoro-aniline instead of 3,4-difluoroaniline. 1H NMR (400 MHz,
DMSC i) δ ppm 1.14 (s, 3 H), 2.74 (d, J=13.2 Hz, 1 H), 3.07 (d, J=13.4 Hz, 1 H), 3.82 (s, 3 H), 4.42 (d, J=13.2 Hz, 1 H), 4.64 (d, J=13.2 Hz, 1 H), 7.41 (t, J=9.0 Hz, 1 H), 7.49 (s, 1 H), 7.51 (d, J=8.5 Hz, 1 H), 7.63 (ddd, J=9.0, 4.4, 2.6 Hz, 1 H), 7.76 (s, 1 H), 7.80 (dd, J=8.4, 2.4 Hz, 1 H), 7.97 (dd, J=6.8, 2.6 Hz, 1 H), 8.33 (d, J=2.4 Hz, 1 H), 9.38 (s, 1 H); Method B; Rt: 1.13 min. m/z : 511 (M-H)" Exact mass: 512.1.
Compound 199: N-(3^-difluorophenyl)-3,7-dimethyl-l,l-dioxo-3-(3-pyridylmethyl)- 2,4-dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000200_0001
Compound 197 (389 mg, 0.78 mmol), Pd/C (10%) (42 mg, 0.039 mmol) and TEA (0.22 mL, 0.73 g/mL, 1.57 mmol) were dispensed in THF (50 mL) and set under a hydrogen atmosphere for 2 hours. The reaction mixture was filtered and the residue was triturated in DIPE yielding compound 199 as an off-white powder. This was separated into its enantiomers via preparative SFC (Stationary phase: Chiralpak Diacel AD 20 x 250 mm, Mobile phase: C02, EtOH + 0.4 iPrNH2) yielding compound 199a (141 mg), 1H NMR (400 MHz, DMSO-^) δ ppm 1.14 (s, 3 H), 2.74 (d, J=13.2 Hz, 1 H), 3.06 (d, J=13.4 Hz, 1 H), 3.82 (s, 3 H), 4.42 (d, J=13.2 Hz, 1 H), 4.63 (d, J=13.2 Hz, 1 H), 7.37 (dd, J=7.7, 5.3 Hz, 1 H), 7.40 - 7.45 (m, 2 H), 7.48 (s, 1 H), 7.71 - 7.75 (m, 1 H), 7.76 (s, 1 H), 7.82 - 7.89 (m, 1 H), 8.47 (d, J=5.0 Hz, 1 H), 8.52 (s, 1 H), 9.41 (s, 1 H); Method B; Rt: 0.94 min. m/z : 461 (M-H)" Exact mass: 462.1, MP: 267.1 °C and compound 199b (136 mg), 1H NMR (400 MHz, DMSO-^) δ ppm 1.14 (s, 3 H), 2.74 (d, J=13.2 Hz, 1 H), 3.06 (d, J=13.2 Hz, 1 H), 3.82 (s, 3 H), 4.42 (d, J=13.2 Hz, 1 H), 4.63 (d, J=13.2 Hz, 1 H), 7.37 (dd, J=7.8, 5.2 Hz, 1 H), 7.40 - 7.47 (m, 2 H), 7.49 (s, 1 H), 7.71 - 7.75 (m, 1 H), 7.76 (s, 1 H), 7.82 - 7.89 (m, 1 H), 8.46 - 8.53 (m, 2 H), 9.41 (s, 1 H); Method B; Rt: 0.94 min. m/z : 461 (M-H)" Exact mass: 462.1, MP: 268.3 °C after trituration from DIPE. Method R; Rt : 197a: 4.57 min, 197b: 5.09 min. Compound 200 : (3R -N-(4-fluoro-3 -methyl-phenylV 3 - IT 1 S 1 -hydroxyethyll -7-methyl- lJ-dioxo-3,4-dihydro-2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000200_0002
Compound 200 (241 mg) was prepared similarly as described for compound 35, using 4-fluoro-3 -methyl-aniline instead of 3,4-difluoroaniline and heating 8 hours at 110°C. The crude product was purified via preparative HPLC (Stationary phase: RP XBridge Prep C18 ODB- 5μιη, 30x250mm, Mobile phase: 0.1 % TFA solution in water + 5% ACN, ACN) yielding compound 200 (241 mg). 1H NMR (400 MHz, DMSO- ¾ δ ppm 1.21 (d, J=6.2 Hz, 3 H), 2.23 (d, J=2.0 Hz, 3 H), 3.36 - 3.46 (m, 1 H), 3.55 - 3.66 (m, 1 H), 3.83 (s, 3 H), 3.98 (dd, J=12.7, 8.9 Hz, 1 H), 4.88 (dd, J=12.7, 2.0 Hz, 1 H), 5.04 (d, J=5.9 Hz, 1 H), 7.09 (t, J=9.2 Hz, 1 H), 7.44 (s, 1 H), 7.48 - 7.55 (m, 1 H), 7.55 - 7.67 (m, 2 H), 9.21 (s, 1 H); Method Z; Rt: 7.32 min. m/z : 396 (M-H)" Exact mass: 397.1.
Compound 201 : N-(3 ,4-difluorophenyl)-3 ,3 -bis(hydroxymethyl)-7-methyl- 1 , 1 -dioxo- 4,5-dihydro-2H-pyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000201_0001
Compound 131 (55 mg, 0.14 mmol), water (0.200 ml), MeOH (3 mL), PTSA (0.57 mg, 0.003 mmol) and 2,6-ditert-butyl-4-methyl-phenol (0.5 mg, 0.002 mmol) were placed in a sealed tube. The reaction was carried out by heating and stirring for 132 hours at 80°C. The reaction mixture was purified via preparative HPLC (Stationary phase: RP XBridge Prep C18 OBD-ΙΟμιη, 50x150mm, Mobile phase: 0.25% NH4HCO3 solution in water, ACN) yielding compound 201 (10 mg); 1H NMR (400 MHz, DMSO-d6) δ ppm 1.84 - 1.96 (m, 2 H), 2.86 - 2.97 (m, 2 H), 3.40 - 3.55 (m, 4 H), 3.69 (s, 3 H), 4.91 (br s, 1 H), 7.35 - 7.46 (m, 3 H), 7.80 - 7.87 (m, 1 H); Method B; Rt: 0.71 min. m/z: 414 (M-H)" Exact mass: 415.1, and crude compound 202 (18 mg).
Compound 202 : N-(3 ,4-difluorophenyl)-3 -(hydroxymethyl)-3 -(methoxymethyl)-7- methyl- 1 , 1 -dioxo-4,5-dihydro-2H-pyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000201_0002
The crude compound 202 (18 mg) obtained in the synthesis of compound 201 was purified on silica using a heptane to EtOAc gradient to yield compound 202 (12 mg); 1H NMR (400 MHz, DMSO-d6) δ ppm 1.82 - 1.97 (m, 2 H), 2.86 - 2.98 (m, 2 H), 3.27 - 3.29 (m, 3 H), 3.35 - 3.53 (m, 4 H), 3.69 (s, 3 H), 4.72 (br s, 1 H), 6.94
(br s, 1 H), 7.37 - 7.46 (m, 3 H), 7.79 - 7.87 (m, 1 H), 10.36 (br s, 1 H); Method B; Rt: 0.81 min. m/z: 428 (M-H)" Exact mass: 429.1. Compound 203 : N-(3 ,4-difluorophenyl)-3 -(hydroxymethyl)-3 ,7-dimethyl- 1 , 1 -dioxo- 2,4-dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000202_0001
Compound 203 (196 mg) was prepared similarly as described for compound 133, using 2-amino-2-methyl-propane-l,3-diol instead of 2-amino-l,3-propanediol. This racemic mixture was separated into its enantiomers using preparative SFC (Stationary phase: Chiralpak Diacel AD 20 x 250 mm, Mobile phase: C02, EtOH with 0.4% iPrNH2) yielding compound 203a (46.6 mg); 1H NMR (400 MHz, DMSO-d6) δ ppm 1.26 (s, 3 H), 3.19 - 3.29 (m, 1 H), 3.68 (dd, J=10.9, 6.1 Hz, 1 H), 3.81 (s, 3 H), 4.47 (d,
J=13.2 Hz, 1 H), 4.56 (d, J=13.2 Hz, 1 H), 5.06 (t, J=5.8 Hz, 1 H), 7.37 - 7.45 (m, 3 H), 7.70 (s, 1 H), 7.81 - 7.88 (m, 1 H), 9.33 (s, 1 H); Method B; Rt: 0.85 min. m/z: 400 (M- H)~ Exact mass: 401.1; and compound 203b (44.7 mg); 1H NMR (400 MHz, DMSO-d6) δ ppm 1.26 (s, 3 H), 3.22 - 3.28 (m, 1 H), 3.68 (dd, J=10.7, 6.1 Hz, 1 H), 3.81 (s, 3 H), 4.44 - 4.59 (m, 2 H), 5.06 (t, J=5.8 Hz, 1 H), 7.37 - 7.45 (m, 3 H), 7.71 (s, 1 H),
7.81 - 7.88 (m, 1 H), 9.33 (s, 1 H); Method B; Rt: 0.85 min. m/z: 400 (M-H)~ Exact mass: 401.1 as white powders after crystallization from a EtOAc:DIPE mixture.
Method R; Rt : 203a: 3.86 min, 203b: 4.39 min. Compound 204 : N-(2-chloro-4-pyridyl)-3-(hydroxymethyl)-3 ,7-dimethyl- 1 , 1 -dioxo-2,4- dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000202_0002
Compound 204 (205 mg) was prepared similarly as described for compound 203, using 2-chloropyridin-4-amine instead of 3,4-difluoroaniline. The crude product was purified via preparative HPLC (Stationary phase: RP XBridge Prep C18 ODB- 5μιη,
50x150mm, Mobile phase: 0.25% NH4HCO3 solution in water, MeOH) yielding compound 204. This racemic mixture was separated into its enantiomers using preparative SFC (Stationary phase: Chiralpak Diacel AD 20 x 250 mm, Mobile phase: C02, EtOH with 0.4% iPrNH2) yielding compound 204a (44.2 mg); 1H NMR
(400 MHz, DMSO-de) δ ppm 1.27 (s, 3 H), 3.26 - 3.29 (m, 1 H), 3.68 (dd, J=10.8, 5.9 Hz, 1 H), 3.82 (s, 3 H), 4.48 - 4.61 (m, 2 H), 5.08 (t, J=5.8 Hz, 1 H), 7.50 (s, 1 H), 7.67 (dd, J=5.7, 2.0 Hz, 1 H), 7.75 (s, 1 H), 7.83 (d, J=1.5 Hz, 1 H), 8.28 (d, J=5.7 Hz, 1 H), 9.58 (s, 1 H); Method B; Rt: 0.72 min. m/z: 399 (M-H)" Exact mass: 400.1; and compound 203b (48.7 mg); 1H NMR (400 MHz, DMSO-d6) δ ppm 1.27 (s, 3 H), 3.25 - 3.29 (m, 1 H), 3.64 - 3.72 (m, 1 H), 3.82 (s, 3 H), 4.48 - 4.61 (m, 2 H), 5.03 - 5.13 (m, 1 H), 7.50 (s, 1 H), 7.67 (dd, J=5.6, 1.9 Hz, 1 H), 7.75 (br s, 1 H), 7.83 (d, J=1.8 Hz, 1 H), 8.28 (d, J=5.5 Hz, 1 H), 9.58 (br s, 1 H); Method B; Rt: 0.85 min. m/z: 399 (M-H)" Exact mass: 400.1 as white powders after crystallization from a EtOAc:DIPE mixture. Method R; Rt : 204a: 4.58 min, 204b: 5.15 min.
Compound 205 : 3-but-2-ynyl-N-(3 ,4-difluorophenyl)-7-methyl- 1 , 1 -dioxo-3 ,4-dihydro- 2H-pyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000203_0001
Compound 205 (243 mg) was prepared similarly as described for compound 14, using 2-aminohex-4-yn-l-ol instead of DL-alaninol and ACN instead of THF as a solvent in the first step. The ring closure was obtained after heating overnight at 110 °C in DMF. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.78 (t, J=2.4 Hz, 3 H), 2.32 - 2.47 (m, 2 H), 3.68 - 3.78 (m, 1 H), 3.81 (s, 3 H), 3.95 (dd, J=13.0, 9.0 Hz, 1 H), 4.67 (dd, J=12.8, 2.0 Hz, 1 H), 7.36 - 7.48 (m, 3 H), 7.77 (d, J=9.2 Hz, 1 H), 7.82 - 7.88 (m, 1 H), 9.45 (s, 1 H); Method B; Rt: 1.03 min. m/z: 408 (M-H)" Exact mass: 409.1.
Compound 206: 3-[cyclopropyl(hydroxy)methyll-N-(4-fluoro-3-methyl-phenyl)-7- methyl- 1 , 1 -dioxo-3 ,4-dihydro-2H-pyrrolo[3 ,4-b [ 1 A51oxathiazepine-6-carboxamide
Figure imgf000203_0002
Compound 206 (361 mg) was prepared similarly as described for compound 105, using 4-fluoro-3 -methyl-aniline instead of 3,4-difluoroaniline. This racemic mixture was separated in its epimers via preparative SFC (Stationary phase: Chiralpak Diacel ID 20 x 250 mm, Mobile phase: C02, EtOH + 0.4 iPrNH2) yielding 206a (163 mg); 1H NMR (400 MHz, DMSO-dtf) δ ppm 0.23 - 0.51 (m, 4 H), 1.00 - 1.12 (m, 1 H), 2.23 (d, J=2.0 Hz, 3 H), 3.09 (q, J=6.5 Hz, 1 H), 3.57 - 3.69 (m, 1 H), 3.83 (s, 3 H), 4.01 (dd, J=12.8, 9.1 Hz, 1 H), 4.90 (dd, J=12.7, 2.0 Hz, 1 H), 5.00 (d, J=5.6 Hz, 1 H), 7.09 (t, J=9.2 Hz, 1 H), 7.44 (s, 1 H), 7.47 - 7.55 (m, 1 H), 7.55 - 7.64 (m, 2 H), 9.22 (s, 1 H); Method D; Rt: 1.80 min. m/z: 422 (M-H)" Exact mass: 423.1 and 206b (32 mg); 1H NMR
(400 MHz, DMSO- ¾ δ ppm 0.17 - 0.48 (m, 4 H), 0.96 - 1.09 (m, 1 H), 2.23 (d, J=2.0 Hz, 3 H), 3.05 - 3.18 (m, 1 H), 3.71 - 3.81 (m, 1 H), 3.83 (s, 3 H), 4.05 (dd, J=12.7, 9.2 Hz, 1 H), 4.74 (dd, J=13.2, 0.7 Hz, 1 H), 4.90 - 5.08 (m, 1 H), 7.09 (t, J=9.2 Hz, 1 H), 7.35 - 7.47 (m, 2 H), 7.47 - 7.54 (m, 1 H), 7.56 (dd, J=6.9, 2.8 Hz, 1 H), 9.24 (s, 1 H); Method D; Rt: 1.81 min. m/z: 422 (M-H)" Exact mass: 423.1; MP: 234.7 °C. Method U; Rt : 206a: 4.19 min, 206b: 5.11 min. Compound 207: /V-(3-chloro-4-fluoro-phenyl)-3-[cyclopropyl(hydroxy)methyll-7- methyl- 1 , 1 -dioxo-3 ,4-dihydro-2H-pyrrolo[3 ,4-b] [ 1 A51oxathiazepine-6-carboxamide
Figure imgf000204_0001
Compound 207 (260 mg) was prepared similarly as described for compound 105, using 3-chloro-4-fluoro-aniline instead of 3,4-difluoroaniline. This racemic mixture was separated in its epimers via preparative SFC (Stationary phase: Chiralpak Diacel ID 20 x 250 mm, Mobile phase: C02, EtOH + 0.4 iPrNH2) yielding 207a (148 mg); 1H NMR (400 MHz, DMSO-^) δ ppm 0.20 - 0.55 (m, 4 H), 0.96 - 1.12 (m, 1 H), 3.09 (q, J=6.5 Hz, 1 H), 3.56 - 3.69 (m, 1 H), 3.83 (s, 3 H), 4.00 (dd, J=12.8, 9.2 Hz, 1 H), 4.91 (dd, J=12.7, 2.0 Hz, 1 H), 5.00 (d, J=5.6 Hz, 1 H), 7.38 (t, J=9.1 Hz, 1 H), 7.47 (s, 1 H), 7.60 (d, J=9.9 Hz, 1 H), 7.65 (ddd, J=9.1, 4.3, 2.6 Hz, 1 H), 8.00 (dd, J=6.8, 2.6 Hz, 1
H), 9.41 (s, 1 H); Method D; Rt: 1.88 min. m/z: 442 (M-H)" Exact mass: 443.1 and 207b (45 mg); 1H NMR (400 MHz, DMSO-^) δ ppm 0.16 - 0.49 (m, 4 H), 0.95 - 1.09 (m, 1 H), 3.08 - 3.17 (m, 1 H), 3.71 - 3.81 (m, 1 H), 3.83 (s, 3 H), 4.04 (dd, J=12.7, 9.2 Hz, 1 H), 4.75 (dd, J=12.9, 1.1 Hz, 1 H), 5.00 (d, J=4.9 Hz, 1 H), 7.39 (t, J=9.1 Hz, 1 H), 7.42 - 7.50 (m, 2 H), 7.64 (ddd, J=9.0, 4.3, 2.6 Hz, 1 H), 7.99 (dd, J=6.8, 2.6 Hz, 1 H), 9.43 (s, 1 H); Method D; Rt: 1.81 min. m/z: 442 (M-H)" Exact mass: 443.1; MP: 215.8 °C. Method U; Rt : 206a: 4.30 min, 206b: 5.41 min. Compound 208: 3-[cyclopropyl(hydroxy)methyl]-7-m
trifluorophenyl)-3^-dihydro-2H-pwoto
Figure imgf000205_0001
Compound 208 (289 mg) was prepared similarly as described for compound 105, using 3,4,5-trifluoroaniline instead of 3,4-difluoroaniline. This racemic mixture was separated in its epimers via preparative SFC (Stationary phase: Chiralpak Diacel ID 20 x 250 mm, Mobile phase: C02, EtOH + 0.4 iPrNH2) yielding 208a (124 mg);
1H NMR (400 MHz, DMSO-^) δ ppm 0.25 - 0.53 (m, 4 H), 0.99 - 1.11 (m, 1 H), 3.08 (q, J=6.5 Hz, 1 H), 3.63 (q, J=8.4 Hz, 1 H), 3.82 (s, 3 H), 3.99 (dd, J=12.8, 9.2 Hz, 1 H), 4.94 (dd, J=12.8, 1.8 Hz, 1 H), 5.02 (d, J=5.6 Hz, 1 H), 7.50 (s, 1 H), 7.62 (br d, J=9.5 Hz, 1 H), 7.66 - 7.77 (m, 2 H), 9.49 (s, 1 H); Method D; Rt: 1.91 min. m/z: 444 (M-H)" Exact mass: 445.1 and 208b (43 mg); 1H NMR (400 MHz, DMSO-^) δ ppm
0.16 - 0.50 (m, 4 H), 0.95 - 1.08 (m, 1 H), 3.08 - 3.16 (m, 1 H), 3.72 - 3.81 (m, 1 H), 3.82 (s, 3 H), 4.04 (dd, J=12.7, 9.2 Hz, 1 H), 4.77 (dd, J=12.5, 1.1 Hz, 1 H), 5.02 (d, J=4.9 Hz, 1 H), 7.41 - 7.53 (m, 2 H), 7.64 - 7.75 (m, 2 H), 9.51 (s, 1 H); Method D; Rt: 1.88 min. m/z: 444 (M-H)" Exact mass: 445.1. Method U; Rt : 208a: 3.49 min, 208b: 4.27 min.
Compound 209: N-[2-(difluoromethyl)-4-pyridyll-3,7-dimethyl-3-[(5-methylisoxazol-3- yl)methyl]-l ,l-dioxo-2,4-dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000205_0002
Compound 209 (92 mg) was prepared similarly as described for compound 162, using 2-(difluoromethyl)pyridin-4-amine instead of 3,4-difluoroaniline. This was separated into its enantiomers via preparative SFC (Stationary phase: Kromasil (R,R) Whelk-0 1 10/100, Mobile phase: C02, EtOH + 0.4 iPrNH2) yielding compound 209a (23 mg), 1H NMR (400 MHz, DMSO-^) δ ppm 1.22 (s, 3 H), 2.40 (s, 3 H), 2.89 (d, J=13.9 Hz, 1 H), 3.04 (d, J=14.1 Hz, 1 H), 3.83 (s, 3 H), 4.44 (d, J=13.2 Hz, 1 H), 4.62 (d, J=13.2 Hz, 1 H), 6.21 (d, J=0.9 Hz, 1 H), 6.91 (t, J=55.0 Hz, 1 H), 7.54 (s, 1 H), 7.79
(br d, J=5.6 Hz, 1 H), 7.95 (br s, 1 H), 8.03 (d, J=1.8 Hz, 1 H), 8.55 (d, J=5.5 Hz, 1 H), 9.71 (s, 1 H); Method B; Rt: 0.88 min. m/z : 480 (M-H)" Exact mass: 481.1 and compound 209b (19 mg), 1H NMR (400 MHz, DMSO-^) δ ppm 1.22 (s, 3 H), 2.40 (s, 3 H), 2.91 (s, 1 H), 3.04 (d, J=14.1 Hz, 1 H), 3.83 (s, 3 H), 4.44 (d, J=13.2 Hz, 1 H), 4.61 (s, 1 H), 6.21 (s, 1 H), 6.91 (t, J=55.0 Hz, 1 H), 7.54 (s, 1 H), 7.79 (d, J=5.4 Hz, 1 H), 7.95 (br s, 1 H), 8.03 (d, J=1.8 Hz, 1 H), 8.55 (d, J=5.7 Hz, 1 H), 9.71 (s, 1 H); Method B; Rt: 0.86 min. m/z : 480 (M-H)" Exact mass: 481.1. Method X; Rt : 209a: 5.56 min, 209b: 5.91 min.
Compound 210: N-(3 -cyano-4-fluoro-phenyl)-3 -(hydroxymethyl)-3 ,7-dimethyl- 1,1- dioxo-2,4-dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000206_0001
Compound 210 (354 mg) was prepared similarly as described for compound 203, using 5-amino-2-fluoro-benzonitrile instead of 3,4-difluoroaniline. This racemic mixture was separated into its enantiomers using preparative SFC (Stationary phase: Chiralpak Diacel AD 20 x 250 mm, Mobile phase: C02, EtOH with 0.4% iPrNH2) yielding compound 210a (96.6 mg); 1H NMR (400 MHz, DMSO-d6) δ ppm 1.27 (s, 3 H), 3.19 - 3.28 (m, 1 H), 3.68 (dd, J=10.6, 6.2 Hz, 1 H), 3.82 (s, 3 H), 4.49 (d, J=13.2 Hz, 1 H), 4.57 (d, J=13.0 Hz, 1 H), 5.07 (t, J=5.8 Hz, 1 H), 7.45 (s, 1 H), 7.52 (t, J=9.1 Hz, 1 H), 7.73 (s, 1 H), 8.03 (ddd, J=9.2, 5.0, 2.8 Hz, 1 H), 8.17 (dd, J=5.7, 2.6 Hz, 1 H), 9.42 (s, 1 H); Method B; Rt: 0.79 min. m/z: 407 (M-H)" Exact mass: 408.1; and compound 210b (73.4 mg); 1H NMR (400 MHz, DMSO-d6) δ ppm 1.27 (s, 3 H), 3.21 - 3.29 (m, 1 H), 3.64 - 3.71 (m, 1 H), 3.82 (s, 3 H), 4.49 (d, J=13.2 Hz, 1 H), 4.57 (d, J=13.2 Hz, 1 H), 5.07 (t, J=5.8 Hz, 1 H), 7.45 (s, 1 H), 7.52 (t, J=9.1 Hz, 1 H), 7.73 (s, 1 H), 8.01 - 8.05 (m, 1 H), 8.16 - 8.19 (m, 1 H), 9.42 (s, 1 H); Method B; Rt:
0.80 min. m/z: 407 (M-H)" Exact mass: 408.1 as white powders after crystallization from a EtOAc:DIPE mixture. Method R; Rt : 210a: 4.21 min, 210b: 4.67 min.
Compound 211: N-(3-chloro-4-fluoro-phenyl)-3,7-dimethyl- 1 , 1 -dioxo-3-(3- pyridylmethyl)-2,4-dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000206_0002
Compound 198 (252 mg, 0.49 mmol), Pd/C (10%) (26 mg, 0.025 mmol), TEA
(0.14 mL, 0.73 g/mL, 0.98 mmol) and thiofene (2.15 mL, 0.72 g/mL, 0.4% in DIPE, 0.074 mmol) were dispensed in THF (100 mL) and set under a hydrogen atmosphere 2 hours. More Pt/C (5%) (96 mg, 0.025 mmol) was added and the reaction mixture was stirred overnight under a hydrogen atmosphere. Pd/C (10%) (52 mg, 0.049 mmol) was added and the reaction mixture was stirred overnight under a hydrogen atmosphere. More Pd/C (10%) (52 mg, 0.049 mmol) was added and the reaction mixture was stirred 2 days under a hydrogen atmosphere. The reaction mixture was filtered and the residue was purified on silica using a heptane to EtOAc gradient and again via preparative HPLC (Stationary phase: RP XBridge Prep C18 OBD-ΙΟμιη, 30x150mm, Mobile phase: 0.25%> NH4HCO3 solution in water, ACN) yielding compound 211 (87 mg) as a white powder. 1H NMR (400 MHz, DMSO^) δ ppm 1.14 (s, 3 H), 2.74 (d, J=13.0 Hz, 1 H), 3.06 (d, J=13.2 Hz, 1 H), 3.82 (s, 3 H), 4.42 (d, J=13.0 Hz, 1 H), 4.63 (d, J=13.2 Hz, 1 H), 7.35 - 7.44 (m, 2 H), 7.48 (s, 1 H), 7.61 - 7.66 (m, 1 H), 7.73 (br d, J=7.7 Hz, 2 H), 7.97 (dd, J=6.8, 2.6 Hz, 1 H), 8.47 (dd, J=4.7, 1.7 Hz, 1 H), 8.52 (d, J=1.5 Hz, 1 H), 9.39 (s, 1 H); Method B; Rt: 1.00 min. m/z : 477 (M-H)~ Exact mass: 478.1, MP: 211.5 °C.
Compound 212: N-(3-chloro-4-fluoro-phenyl)-7-methyl- 1 , 1 -dioxo-spiro[2,4- dihydropyrrolo[3^-bl[l^,51oxathiazepine-33'-tetrahydrofuranl-6-carboxamide
Figure imgf000207_0001
Compound 212 (243 mg) was prepared similarly as described for compound 205, using (3-aminotetrahydrofuran-3-yl)methanol instead of 2-aminohex-4-yn-l-ol. The ring closure was obtained after heating 2 hours at 110 °C in DMF. 1H NMR (400 MHz, DMSO-de) δ ppm 1.99 - 2.19 (m, 2 H), 3.73 - 3.89 (m, 7 H), 4.40 - 4.53 (m, 2 H), 7.40 (t, J=9.1 Hz, 1 H), 7.49 (s, 1 H), 7.66 (ddd, J=9.1, 4.2, 2.5 Hz, 1 H), 7.98 (dd, J=6.8, 2.6 Hz, 1 H), 8.24 (br s, 1 H), 9.36 (s, 1 H); Method B; Rt: 0.96 min. m/z: 428 (M-H)~ Exact mass: 429.1. This was separated into its enantiomers via preparative SFC (Stationary phase: Chiralpak Diacel IC 20 x 250 mm, Mobile phase: C02, EtOH + 0.4 iPrNH2) yielding compound 212a (97 mg) and compound 212b (14 mg). Method AA; Rt : 212a: 4.78 min, 212b: 5.55 min. Compound 213: N-(2-chloro-4-pyridyl)-3,7-dimethyl-3-[(5-methylisoxazol-3- yl)methyl]-l J-dioxo-2,4-dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000208_0001
Compound 213 (92 mg) was prepared similarly as described for compound 162, using 4-amino-2-chloropyridine instead of 3,4-difluoroaniline. This was separated into its enantiomers via preparative SFC (Stationary phase: Chiralpak Diacel AD 20 x 250 mm, Mobile phase: C02, EtOH + 0.4 iPrNH2) yielding compound 213a (25 mg), 1H NMR (400 MHz, DMSO-dtf) δ ppm 1.22 (s, 3 H), 2.38 - 2.41 (m, 3 H), 2.88 (d, J=13.9 Hz, 1 H), 3.04 (d, J=13.9 Hz, 1 H), 3.82 (s, 3 H), 4.44 (d, J=13.0 Hz, 1 H), 4.62 (d, J=13.2 Hz, 1 H), 6.21 (d, J=0.9 Hz, 1 H), 7.55 (s, 1 H), 7.66 (dd, J=5.7, 1.8 Hz, 1 H), 7.82 (d, J=1.8 Hz, 1 H), 7.95 (br s, 1 H), 8.28 (d, J=5.5 Hz, 1 H), 9.65 (br s, 1 H); Method B; Rt: 0.92 min. m/z : 464 (M-H)" Exact mass: 465.1 and compound 213b (23 mg), 1H NMR (400 MHz, DMSO-dtf) δ ppm 1.19 - 1.24 (m, 3 H), 2.37 - 2.43 (m, 3 H), 2.88 (d, J=14.1 Hz, 1 H), 3.04 (d, J=14.1 Hz, 1 H), 3.82 (s, 3 H), 4.44 (d, J=13.2 Hz, 1 H), 4.62 (d, J=13.2 Hz, 1 H), 6.21 (s, 1 H), 7.55 (s, 1 H), 7.67 (dd, J=5.7, 1.8 Hz, 1 H), 7.82 (d, J=1.8 Hz, 1 H), 7.95 (br s, 1 H), 8.28 (d, J=5.7 Hz, 1 H), 9.65 (s, 1 H); Method B; Rt: 0.93 min. m/z : 464 (M-H)" Exact mass: 465.1. Method R; Rt : 213a: 4.57 min, 213b: 4.87 min.
Compound 214: 3-(hydroxymethyl)-3,7-dimethyl-lJ-dioxo-N-(3,4,5-trifluorophenyl)-
2,4-dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000208_0002
Compound 214 (474 mg) was prepared similarly as described for compound 203, using 3,4,5-trifluoroaniline instead of 3,4-difluoroaniline. This racemic mixture was separated into its enantiomers using preparative SFC (Stationary phase: Chiralpak Diacel AS 20 x 250 mm, Mobile phase: C02, iPrOH with 0.4% iPrNH2) yielding compound 214a (80 mg); 1H NMR (400 MHz, DMSO-d6) δ ppm 1.27 (s, 3 H), 3.18 - 3.28 (m, 1 H), 3.68 (dd, J=10.9, 6.3 Hz, 1 H), 3.81 (s, 3 H), 4.49 (d, J=13.2 Hz, 1 H), 4.57 (d, J=13.2 Hz, 1 H), 5.07 (t, J=5.8 Hz, 1 H), 7.46 (s, 1 H), 7.64 - 7.74
(m, 3 H), 9.39 (s, 1 H); Method B; Rt: 0.94 min. m/z: 418 (M-H)" Exact mass: 419.1; and compound 214b (75 mg); 1H NMR (400 MHz, DMSO-d6) δ ppm 1.27 (s, 3 H),
3.21 - 3.30 (m, 1 H), 3.68 (dd, J=10.8, 6.2 Hz, 1 H), 3.81 (s, 3 H), 4.47 - 4.60 (m, 2 H), 5.07 (t, J=5.8 Hz, 1 H), 7.46 (s, 1 H), 7.64 - 7.74 (m, 3 H), 9.39 (s, 1 H); Method B; Rt: 0.95 min. m/z: 418 (M-H)~ Exact mass: 419.1 as white powders after crystallization from a EtOAc:DIPE mixture. Method T; Rt : 214a: 2.90 min, 214b: 3.19 min. Compound 215: N-[2-(difluoromethyl)-4-pyridyll -3 -(hydroxymethyl)-3 ,7-dimethyl- 1,1- dioxo-2,4-dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000209_0001
Compound 215 was prepared similarly as described for compound 203, using 2- (difluoromethyl)pyridin-4-amine instead of 3,4-difluoroaniline. This racemic mixture was separated into its enantiomers using preparative SFC (Stationary phase: Chiralpak Diacel AD 20 x 250 mm, Mobile phase: C02, EtOH with 0.4% iPrNH2) yielding compound 215a (78.3 mg); 1H NMR (400 MHz, DMSO-d6) δ ppm 1.27 (s, 3 H), 3.23 - 3.29 (m, 1 H), 3.68 (dd, J=10.8, 6.2 Hz, 1 H), 3.82 (s, 3 H), 4.46 - 4.62 (m, 2 H), 5.08 (t, J=5.7 Hz, 1 H), 6.91 (t, J=55.0 Hz, 1 H), 7.50 (s, 1 H), 7.71 - 7.80 (m, 2 H), 8.05 (d, J=2.0 Hz, 1 H), 8.54 (d, J=5.5 Hz, 1 H), 9.65 (s, 1 H); Method B; Rt: 0.72 min. m/z: 415 (M-H)~ Exact mass: 416.1; and compound 215b (79.3 mg); 1H NMR (400 MHz, DMSO-de) δ ppm 1.27 (s, 3 H), 3.24 - 3.29 (m, 1 H), 3.68 (dd, J=10.7, 6.1 Hz, 1 H), 3.82 (s, 3 H), 4.46 - 4.62 (m, 2 H), 5.08 (t, J=5.8 Hz, 1 H), 6.91 (t, J=55.0 Hz, 1 H), 7.50 (s, 1 H), 7.71 - 7.81 (m, 2 H), 8.05 (d, J=2.0 Hz, 1 H), 8.54 (d, J=5.5 Hz, 1 H), 9.65 (s, 1 H); Method B; Rt: 0.72 min. m/z: 415 (M-H)" Exact mass: 416.1 as white powders after crystallization from a EtOAc:DIPE mixture. Method R; Rt : 215a: 3.83 min, 215b: 4.26 min.
Compound 216: -benzyl-N-(3,4-difluorophenyl)-7-methyl-l,l-dioxo-spiro[2,4- dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-3,3'-pyrrolidinel-6-carboxamide
Figure imgf000209_0002
Compound 216 (265 mg) was prepared similarly as described for compound 212, using
(3 -amino- 1 -benzyl-pyrrolidin-3 -yl)methanol instead of (3 -aminotetrahydrofuran-3 - yl)methanol. 1H NMR (400 MHz, DMSO-d6) ppm 1.93 - 2.05 (m, 2 H), 2.45 - 2.48 (m, 1 H), 2.54 (s, 1 H), 2.68 (br d, J=8.1 Hz, 1 H), 2.86 (br d, J=9.7 Hz, 1 H), 3.61 (q, J=13.1 Hz, 2 H), 3.81 (s, 3 H), 4.37 - 4.55 (m, 2 H), 7.25 (br d, J=4.0 Hz, 1 H), 7.32 (d, J=4.2 Hz, 4 H), 7.38 - 7.48 (m, 3 H), 7.80 - 7.88 (m, 1 H), 8.12 (s, 1 H), 9.34 (s, 1 H); Method B; Rt: 1.19 min. m/z: 501 (M-H)" Exact mass: 502.2.
Compound 217: N-[2-(difluoromethyl)-4-pyridyll -3 ,7-dimethyl-3 - |Y 1 -methylpyrazol-3 - yl)methyl]-l ,l-dioxo-2,4-dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000210_0001
Compound 217 (269 mg) was prepared similarly as described for compound 167, using 2-(difluoromethyl)pyridin-4-amine instead of 3,4-difluoroaniline. This was separated into it's enatiomers via Prep SFC (Stationary phase: Chiralpak Diacel IC 20 x 250 mm, Mobile phase: C02, EtOH + 0.4 iPrNH2) yielding compound 176a (62.2 mg); 1H NMR (400 MHz, DMSO-dtf) δ ppm 1.21 (s, 3 H), 2.83 (d, J=13.9 Hz, 1 H), 2.99 (d, J=13.9 Hz, 1 H), 3.80 (s, 3 H), 3.83 (s, 3 H), 4.42 (d, J=13.2 Hz, 1 H), 4.56 (d, J=13.4 Hz, 1 H), 6.15 (d, J=2.2 Hz, 1 H), 6.92 (t, J=55.1 Hz, 1 H), 7.52 (s, 1 H), 7.59 (s, 1 H), 7.75 - 7.87 (m, 2 H), 8.02 (d, J=2.0 Hz, 1 H), 8.55 (d, J=5.5 Hz, 1 H), 9.68 (s, 1 H); Method B; Rt: 0.85 min. m/z : 479 (M-H)" Exact mass: 480.1. and compound 176b (59.4 mg);
1H NMR (400 MHz, DMSO-^) δ ppm 1.22 (s, 3 H), 2.83 (d, J=13.9 Hz, 1 H), 2.99 (d, J=14.1 Hz, 1 H), 3.80 (s, 3 H), 3.83 (s, 3 H), 4.42 (d, J=13.2 Hz, 1 H), 4.56
(d, J=13.2 Hz, 1 H), 6.15 (d, J=2.2 Hz, 1 H), 6.92 (t, J=55.1 Hz, 1 H), 7.52 (s, 1 H), 7.59 (s, 1 H), 7.78 (br d, J=3.7 Hz, 1 H), 7.84 (s, 1 H), 8.02 (d, J=2.0 Hz, 1 H), 8.55 (d, J=5.5 Hz, 1 H), 9.68 (s, 1 H); Method B; Rt: 0.85 min. m/z : 479 (M-H)" Exact mass: 480.1. Method AA; Rt : 217a: 5.76 min, 217b: 6.29 min.
Compound 218: 7-methyl- 1 , 1 -dioxo-3 - [ 1 -(2,2,2-trifluoroethylamino)ethyl] -N-(3 ,4,5 - trifluorophenyl)-2,3,4,5-tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000210_0002
Methyl 3-acetyl-7-methyl-l,l-dioxo-2,3,4,5-tetrahydropyrrolo[3,4-fJthiazepine-6- carboxylate (550 mg, 1.83 mmol) and 2,2,2-trifluoroethylamine (7.31 mL, 1.24 g/mL, 91.6 mmol) were dissolved in methanol (70 mL) and thiophene (1 mL, 4% in DiPE) and Pd/C (10%) (390 mg, 0.37 mmol) were added succesively. The reaction mixture was hydrogenated for 38 hours. Pd/C (10%) (390 mg, 0.37 mmol) was added to the reaction mixture under a nitrogen atmosphere and was hydrogenated for 20 hours. Pd/C (10%)) (390 mg, 0.37 mmol) was added to the reaction mixture under a nitrogen atmosphere and was hydrogenated for 120 hours more. The reaction mixture was filtered over decalite and the solids were washed with THF (3 X 100 mL). The filtrate was concentrated to afford methyl 7-methyl-l,l-dioxo-3-[l-(2,2,2- trifluoroethylamino)ethyl]-2,3,4,5-tetrahydropyrrolo[3,4-f]thiazepine-6-carboxylate (1.50 g). This was separated into its 4 isomers via preparative SFC (Stationary phase: Chiralpak Diacel AS 20 x 250 mm, Mobile phase: C02, EtOH + 0.4 iPrNH2). The obtained 4 isomers were reacted with 3,4,5-trifluoroaniline using LiHMDS as a base in THF yielding compound 218a (33 mg); 1H NMR (400 MHz, DMSO^) δ ppm 1.00 (d, J=6.6 Hz, 3 H), 1.33 (br d, J=13.2 Hz, 1 H), 2.01 - 2.13 (m, 2 H), 2.53 - 2.67 (m, 1 H), 2.74 - 2.82 (m, 1 H), 3.01 (br dd, J=15.0, 6.6 Hz, 1 H), 3.16 - 3.28 (m, 2 H), 3.37 - 3.47 (m, 1 H), 3.69 (s, 3 H), 6.91 (d, J=10.3 Hz, 1 H), 7.46 (s, 1 H), 7.56 - 7.64 (m, 2 H), 10.60 (s, 1 H); Method D; Rt: 1.99 min. m/z : 497 (M-H)" Exact mass: 498.1, compound 218b (78 mg); 1H NMR (400 MHz, DMSO-^) δ ppm 0.99 (d, J=6.6 Hz, 3 H), 1.38 - 1.48 (m, 1 H), 1.92 (br dd, J=14.4, 6.5 Hz, 1 H), 2.20 - 2.30 (m, 1 H), 2.67 - 2.82 (m, 2 H), 3.00 (br dd, J=14.4, 6.1 Hz, 1 H), 3.15 - 3.36 (m, 2 H), 3.37 - 3.47 (m, 1 H), 3.69 (s, 3 H), 6.94 (d, J=10.3 Hz, 1 H), 7.47 (s, 1 H), 7.55 - 7.64 (m, 2 H), 10.61 (br s, 1 H); Method D; Rt: 2.00 min. m/z : 497 (M-H)" Exact mass: 498.1, compound 218c (38 mg); 1H NMR (400 MHz, DMSO-^) δ ppm 0.99 (d, J=6.6 Hz, 3 H), 1.38 - 1.48 (m, 1 H), 1.88 - 1.95 (m, 1 H), 2.24 (q, J=7.4 Hz, 1 H), 2.67 - 2.82 (m, 2 H), 3.01 (br dd, J=15.3, 5.8 Hz, 1 H), 3.15 - 3.35 (m, 2 H), 3.37 - 3.47 (m, 1 H), 3.69 (s, 3 H), 6.94 (d, J=10.3 Hz, 1 H), 7.47 (s, 1 H), 7.56 - 7.64 (m, 2 H), 10.61 (s, 1 H); Method D; Rt: 2.00 min. m/z : 497 (M-H)" Exact mass: 498.1; MP: 216.2 °C and compound 218d (34 mg); 1H NMR (400 MHz, DMSO-^) δ ppm 1.00 (d, J=6.6 Hz, 3 H), 1.28 - 1.38 (m, 1 H), 2.01 - 2.13 (m, 2 H), 2.54 - 2.67 (m, 1 H), 2.73 - 2.82 (m, 1 H), 3.01 (br dd, J=15.2, 5.7 Hz, 1 H), 3.16 - 3.29 (m, 2 H), 3.39 - 3.48 (m, 1 H), 3.69 (s, 3 H), 6.91 (d, J=10.3 Hz, 1 H), 7.47 (s, 1 H), 7.56 - 7.64 (m, 2 H), 10.60 (s, 1 H); Method D; Rt: 1.99 min. m/z : 497 (M-H)" Exact mass: 498.1, after purification via preparative HPLC (Stationary phase: RP XBridge Prep CI 8 OBD-ΙΟμιη,
50x150mm, Mobile phase: 0.25% NH4HCO3 solution in water, MeOH). Method AB; Rt : 218a: 3.49 min, 218b: 3.15 min, 218c: 2.09 min, 218d: 2.26 min.
Compound 219: 3 -|Y6-chloro-3 -pyridyQmethyl] -N-(3 ,4-difluorophenyl)-3 ,7-dimethyl- lJ-dioxo-2H-pyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000211_0001
2- amino-3-(6-chloro-3-pyridyl)-2-methyl-propan-l-ol (1.00 g, 4.98 mmol), methyl
3- bromo-4-chlorosulfonyl-l-methyl-pyrrole-2-carboxylate (1.58 mg, 4.98 mmol) and Hunig's base (2.58 mL, 0.75 g/mL, 15 mmol) were dissolved in ACN (20 mL) and the reaction mixture was stirred overnight. The volatiles were removed under reduced pressure and the residue was purified on silica using a heptane to EtOAc gradient yielding methyl 3-bromo-4-[[ 1 -[(6-chloro-3-pyridyl)methyl]-2-hydroxy- 1 -methyl- ethyl]sulfamoyl]-l-methyl-pyrrole-2-carboxylate (777 mg) as a white powder.
Methyl 3-bromo-4-[[ 1 -[(6-chloro-3-pyridyl)methyl]-2-hydroxy- 1 -methyl - ethyl]sulfamoyl]-l-methyl-pyrrole-2-carboxylate (777 mg, 1.62 mmol) and 3,4- difluoroaniline (162 μί, 1.29 g/mL, 1.62 mmol) were dissolved in THF (5 mL).
Lithium bis(trimethylsilyl)amide (1M in THF) (8 mL, 1 M in THF, 8 mmol) was added and the reaction mixture was stirred overnight at room temperature. The reaction mixture was quenched with NH4C1 (sat., aq., 10 mL) and the organic layer was removed. The aqueous layer was extracted with DCM (2 X 5 mL) and the combined organic layers were filtered and evaporated to dryness yielding crude 3-bromo-4-[[l- [(6-chloro-3 -pyridyl)methyl] -2-hydroxy- 1 -methyl-ethyl] sulfamoyl] -N-(3 ,4- difluorophenyl)-l -methyl -pyrrole-2-carboxamide (833 mg). 3-bromo-4-[[ 1 -[(6-chloro-3-pyridyl)methyl]-2-hydroxy- 1 -methyl-ethyl]sulfamoyl]-N- (3,4-difluorophenyl)-l-methyl-pyrrole-2-carboxamide (833 mg, 1.44 mmol) was dissolved in ACN (15 mL). 2-iodoxybenzoic acid (606 mg, 2.16 mmol) was added and the reaction mixture was heated at 80°C for 90 minutes. The reaction mixture was filtered while still hot, evaporated to dryness and the residue was purified on silica using a heptane to EtOAc gradient yielding 3-bromo-4-[[l-[(6-chloro-3-pyridyl)methyl]-l- methyl-2-oxo-ethyl]sulfamoyl]-N-(3,4-difluorophenyl)-l -methyl-pyrrole -2- carboxamide (721 mg). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.07 (s, 3 H),
2.96 - 3.04 (m, 2 H), 3.74 (s, 3 H), 7.41 - 7.49 (m, 3 H), 7.67 (s, 1 H), 7.72 (dd, J=8.1, 2.4 Hz, 1 H), 7.80 - 7.88 (m, 1 H), 8.24 (s, 1 H), 8.27 (d, J=2.2 Hz, 1 H), 9.57 (s, 1 H), 10.60 (s, 1 H).
KOtBu (73.1 mg, 0.65 mmol) was added to a stirred suspension of
methyltriphenylphosphonium bromide (233 mg, 0.65 mmol) in THF (5 mL) at 0 °C. The suspension was stirred at 0 °C for 10 min and then at room temperature for 1 hour. 3 -bromo-4- [[ 1 -[(6-chloro-3 -pyridyl)methyl] - 1 -methyl-2-oxo-ethyl] sulfamoyl] -N-(3 ,4- difluorophenyl)-l -methyl -pyrrole-2-carboxamide (150 mg, 0.26 mmol) in THF (5 mL) was added dropwise to this solution at 0 °C. The reaction mixture was allowed to warm to room temperature and stirred overnight. LCMS showed product formed. The volatiles were removed under reduced pressure and the residue was purified on silica using a heptane to EtOAc gradient yielding 3-bromo-4-[[l-[(6-chloro-3- pyridyl)methyl] - 1 -methy 1-allyl] sulfamoyl] -N-(3 ,4-difluorophenyl)- 1 -methyl -pyrrole -2- carboxamide (118 mg) as a white powder.
3-bromo-4-[[l-[(6-chloro-3-pyridyl)methyl]-l-methyl-allyl]sulfamoyl]-N-(3,4- difluorophenyl)-l -methyl -pyrrole-2-carboxamide (118 mg, 0.21 mmol), bis(tri-tert- butylphosphine)palladium(O) (5 mg, 0.01 mmol) and Hunig's base (39 μί, 0.75 g/mL, 0.23 mmol) were dissolved in DMF (1 mL) and heated in the microwave at 150 °C for 5 minutes. Bis(tri-tert-butylphosphine)palladium(0) (5 mg, 0.01 mmol) was added and the reaction mixture was and heated in the microwave at 150 °C for 5 minutes. The reaction mixture was directly loaded on a silica cartridge and a gradient from heptane to EtOAc was applied yielding compound 219 (54 mg) after crystallization from a DCM:DIPE mixture. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.13 (s, 3 H), 2.83 (d, J=13.4 Hz, 1 H), 3.42 (d, J=13.4 Hz, 1 H), 3.70 (s, 3 H), 5.61 (d, J=13.0 Hz, 1 H), 6.40 (d, J=13.0 Hz, 1 H), 7.40 - 7.55 (m, 4 H), 7.61 (s, 1 H), 7.80 - 7.88 (m, 2 H), 8.36 (d, J=2.2 Hz, 1 H), 10.70 (s, 1 H); Method B; Rt: 1.06 min. m/z: 491 (M-H)~ Exact mass: 492.1. Compound 220: N-(3-cyano-4-fluoro-phenyl)-3,7-dimethyl-3-[(5-methylisoxazol-3- yl)methyl]-l ,l-dioxo-2,4-dihydropyrrolo[3,4-bl[l,4,51oxathiazepine-6-carboxamide
Figure imgf000213_0001
Compound 220 (124 mg) was prepared similarly as described for compound 162, using 5-amino-2-fluoro-benzonitrile instead of 3,4-difluoroaniline. This was separated into its enantiomers via preparative SFC (Stationary phase: Chiralpak Diacel AS 20 x 250 mm, Mobile phase: C02, iPrOH + 0.4 iPrNH2) yielding compound 220a (28 mg), 1H NMR (400 MHz, DMSO-dtf) δ ppm 1.22 (s, 3 H), 2.40 (s, 3 H), 2.88 (d, J=13.9 Hz, 1 H), 3.05 (d, J=13.9 Hz, 1 H), 3.75 - 3.88 (m, 3 H), 4.42 (d, J=13.2 Hz, 1 H), 4.62 (d, J=13.0 Hz, 1 H), 6.22 (s, 1 H), 7.49 - 7.56 (m, 2 H), 7.93 (s, 1 H), 8.02 (ddd, J=9.2, 4.8, 2.9 Hz, 1 H), 8.16 (dd, J=5.7, 2.6 Hz, 1 H), 9.47 (s, 1 H); Method B; Rt: 1.01 min. m/z :
472 (M-H)~ Exact mass: 473.1 and compound 2210 (21 mg), 1H NMR (400 MHz, DMSO-dtf) δ ppm 1.23 (s, 3 H), 2.40 (s, 3 H), 2.88 (d, J=13.9 Hz, 1 H), 3.05 (d, J=13.9 Hz, 1 H), 3.83 (s, 3 H), 4.42 (d, J=13.0 Hz, 1 H), 4.62 (d, J=13.2 Hz, 1 H), 6.22 (d, J=0.9 Hz, 1 H), 7.49 - 7.56 (m, 2 H), 7.93 (s, 1 H), 8.02 (ddd, J=9.2, 4.8, 2.9 Hz, 1 H), 8.16 (dd, J=5.7, 2.6 Hz, 1 H), 9.47 (s, 1 H); Method B; Rt: 1.00 min. m/z : 472 (M-H)" Exact mass: 473.1. Method AC; Rt : 220a: 4.96 min, 220b: 5.40 min.
Compound 221: N-(3^-difluorophenyl)-3,7-dimethyl-l,l-dioxo-3-(3-pyridylmethyl)- 4,5-dihydro-2H-pyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000214_0001
Compound 219 (48 mg, 0.097 mmol), Pd/C (10%) (5 mg, 0.005 mmol) and TEA (0.027 mL, 0.73 g/mL, 0.19 mmol) were dispensed in MeOH (25 mL) and set under a hydrogen atmosphere for 2 hours. The reaction mixture was filtered and evaporated to dryness. The residue was purified on silica using a heptane to EtOAc gradient yielding compound 221 (25 mg) as a white powder after crystallisation from a DCM:DIPE mixture. 1H NMR (400 MHz, DMSO-^) δ ppm 1.02 - 1.09 (m, 5 H), 2.64 - 2.68 (m, 1 H), 3.00 (br s, 2 H), 3.19 - 3.29 (m, 1 H), 3.71 (s, 3 H), 7.29 (s, 1 H), 7.34 (t, J=6.2 Hz, 1 H), 7.40 - 7.46 (m, 3 H), 7.73 (br d, J=7.3 Hz, 1 H), 7.80 - 7.91 (m, 1 H), 8.44 (dd, J=4.7, 1.7 Hz, 1 H), 8.51 (d, J=1.5 Hz, 1 H), 10.38 (s, 1 H); Method B; Rt: 0.94 min. m/z : 459 (M-H)" Exact mass: 460.1.
Compound 222 : 3 -( 1 -aminoethyl)-7-methyl- 1 , 1 -dioxo-N-(3 ,4,5 -trifluorophenyl)- 2,3,4,5-tetrahydropyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000214_0002
To a suspension of compound 104 (740 mg, 1.42 mmol) in EtOAc (200 mL) was added 2-iodoxybenzoic acid (477 mg, 1.70 mmol). The suspension was heated at reflux for 2 hours. The reaction mixture was filtered and the solids were washed with THF. The filtrate was concentrated. To the residue in EtOAc (200 mL) was added
2-iodoxybenzoic acid (1.99 g, 7.09 mmol). The suspension was heated at reflux for 20 hours. The reaction mixture was filtered and the solids were washed with THF. The filtrate was concentrated in vacuo. The residue was triturated in boiling DCM (20 mL) and the white solid was filtered and washed with DCM (3 mL) yielding (3R)-3-acetyl-7- methyl- 1 , 1 -dioxo-N-(3 ,4,5 -trifiuorophenyl)-2,3 ,4,5 -tetrahydropyrrolo[3 ,4-fJthiazepine- 6-carboxamide (350 mg). Method B; Rt: 0.93 min. m/z : 414 (M-H)" Exact mass:
415.1. To a stirred solution of (3R)-3-acetyl-7-methyl-l,l-dioxo-N-(3,4,5-trifluorophenyl)- 2,3,4,5-tetrahydropyrrolo[3,4-fJthiazepine-6-carboxamide (150 mg, 0.36 mmol) in dry MeOH (2 mL) and dry THF (2 mL), under nitrogen, was added zinc chloride
(0.071 mL, 1 M in diethylether , 0.071 mmol). After stirring at ambient temperature for 30 minutes, this mixture was treated with ammonium formate (274 mg, 4.30 mmol). After stirring another hour at ambient temperature molecular sieves (1 g) were added followed by sodium cyanoborohydride (47 mg, 0.71 mmol). The reaction was then stirred at ambient temperature overnight. The reaction mixture was filtered over decalite and the solids were washed with 2-MeTHF (3 X 20 mL). The filtrate was washed with water, Brine, dried (Na2S04), filtered and concentrated. The residue was purified using preparative HPLC (Stationary phase: RP XBridge Prep C18 OBD-ΙΟμιη, 50x150mm, Mobile phase: 0.25% NH4HCO3 solution in water, ACN) yielding compound 222a (17 mg); 1H NMR (400 MHz, DMSO-^) δ ppm 0.99 (d, J=6.6 Hz, 3 H), 1.30 (q, J=12.0 Hz, 1 H), 2.01 (br dd, J=14.0, 6.7 Hz, 1 H), 2.66 - 2.81 (m, 2 H), 3.02 (br dd, J=15.1, 6.5 Hz, 1 H), 3.16 - 3.25 (m, 1 H), 3.69 (s, 3 H), 7.44 (s, 1 H), 7.55 - 7.64 (m, 2 H), 10.07 - 11.08 (m, 1 H); Method B; Rt: 0.75 min. m/z : 415 (M-H)~ Exact mass: 416.1; MP: 227.5 °C and compound 222b (43 mg); 1H NMR (400 MHz, DMSO- ¾ δ ppm 0.97 (d, J=6.4 Hz, 3 H), 1.35 - 1.46 (m, 1 H), 1.87 (br s, 1 H), 2.75 - 2.86 (m, 2 H), 2.95 - 3.04 (m, 1 H), 3.23 - 3.29 (m, 1 H), 3.69 (s, 3 H), 7.45 (s, 1 H), 7.56 - 7.64 (m, 2 H), 10.60 (br s, 1 H); Method B; Rt: 0.76 min. m/z : 415 (M-H)~ Exact mass: 416.1; MP: 281.2 °C.
Compound 223: 3-[(2-chloro-4-pyridyl)methyll-N-(3,4-difluorophenyl)-3,7-dimethyl- l,l-dioxo-2H-pyrrolo[3,4-f|thiazepine-6-carboxamide
Figure imgf000215_0001
2-amino-3-(2-chloro-4-pyridyl)-2-methyl-propan-l-ol (an intermediate used in the synthesis of compound 190) (1047 mg, 5.22 mmol), methyl 3-bromo-4-chlorosulfonyl- 1 -methyl-pyrrole -2-carboxylate (1.65 g, 5.22 mmol) and Hunig's base (2.7 mL, 0.75 g/mL, 15.7 mmol) were dissolved in ACN (20 mL) and the reaction mixture was stirred overnight. The volatiles were removed under reduced pressure and the residue was purified on silica using a heptane to EtOAc gradient yielding methyl 3-bromo-4- [[ 1 -[(2-chloro-4-pyridyl)methyl]-2-hydroxy-l -methyl-ethyljsulfamoyl]- 1 -methyl- pyrrole -2-carboxylate (880 mg) as a white powder. Methyl 3-bromo-4-[[ 1 -[(2-chloro-4-pyridyl)methyl]-2-hydroxy- 1 -methyl - ethyl]sulfamoyl]-l-methyl-pyrrole-2-carboxylate (150 mg, 0.31 mmol) was dissolved in ACN (15 mL). 2-iodoxybenzoic acid (131 mg, 0.47 mmol) was added and the reaction mixture was heated at 80°C for 90 minutes. The reaction mixture was filtered while still hot, evaporated to dryness and the residue was purified on silica using a heptane to EtOAc gradient yielding methyl 3-bromo-4-[[l-[(2-chloro-4-pyridyl)methyl]-l-methyl- 2-oxo-ethyl]sulfamoyl]-l -methyl-pyrrole -2-carboxylate (107 mg). KOtBu (251 mg, 2.23 mmol) was added to a stirred suspension of
methyltriphenylphosphonium bromide (798 mg, 2.23 mmol) in THF (10 mL) at 0 °C. The suspension was stirred at 0 °C for 10 min and then at room temperature for 1 hour, methyl 3 -bromo-4-[ [ 1 - [(2-chloro-4-pyridyl)methyl] - 1 -methyl-2-oxo-ethyl] sulfamoyl] - 1 -methyl-pyrrole -2-carboxylate (107 mg, 0.22 mmol) in THF (5 mL) was added dropwise to this solution at 0 °C. The reaction mixture was allowed to warm to room temperature and stirred overnight. The volatiles were removed under reduced pressure and the residue was purified on silica using a heptane to EtOAc gradient yielding methyl 3-bromo-4-[[ 1 -[(2-chloro-4-pyridyl)methyl]-l -methyl-allyljsulfamoyl]- 1 - methyl-pyrrole-2-carboxylate (78 mg).
Methyl 3-bromo-4-[[ 1 -[(2-chloro-4-pyridyl)methyl]- 1 -methyl-allyljsulfamoyl]- 1 - methyl-pyrrole-2-carboxylate (78 mg, 0.16 mmol), bis(tri-tert- butylphosphine)palladium(O) (4 mg, 0.008 mmol) and Hunig's base (0.031 mL,
0.75 g/mL, 0.18 mmol) were dissolved in DMF (3 mL) and heated in the microwave at 150 °C for 10 minutes. The reaction mixture was directly loaded on a silica cartridge and a gradient from heptane to EtOAc was applied yielding methyl 3-[(2-chloro-4- pyridyl)methyl]-3,7-dimethyl-l,l-dioxo-2H-pyrrolo[3,4-f]thiazepine-6-carboxylate (51 mg). Methyl 3-[(2-chloro-4-pyridyl)methyl]-3,7-dimethyl-l,l-dioxo-2H-pyrrolo[3,4- fJthiazepine-6-carboxylate (51 mg, 0.13 mmol) and 3,4-difluoroaniline (0.014 mL, 1.29 g/mL, 0.14 mmol) were dissolved in THF (5 mL). Lithium
bis(trimethylsilyl)amide (0.64 mL, 1 M in THF, 0.64 mmol) was added and the reaction mixture was stirred overnight at room temperature. The reaction mixture was quenched with NH4C1 (sat., aq., 10 mL) and the organic layer was removed. The aqueous layer was extracted with DCM (2 X 5 mL) and the combined organic layers were filtered and evaporated to dryness. The residue was purified via preparative HPLC (Stationary phase: RP XBridge Prep C18 OBD-ΙΟμιη, 30x150mm, Mobile phase: 0.25% NH4HCO3 solution in water, ACN) yielding compound 223 (11 mg). 1H NMR (400 MHz, DMSO- ¾ δ ppm 1.15 (s, 3 H), 2.84 (d, J=12.8 Hz, 1 H), 3.46 (d, J=12.8 Hz, 1 H), 3.71 (s, 3 H), 5.59 (d, J=13.0 Hz, 1 H), 6.43 (br d, J=13.9 Hz, 1 H), 7.38 - 7.51 (m, 5 H), 7.66 (br s, 1 H), 7.81 - 7.88 (m, 1 H), 8.35 (d, J=4.8 Hz, 1 H), 10.72 (br s, 1 H); Method B; Rt: 1.02 min. m/z : 491 (M-H)~ Exact mass: 492.1
Compound 224: N-(3,4-difluorophenyl)-3-methyl-l,l-dioxo-2,3-dihydrothieno[3,4- f|thiazepine-6-carboxamide
Figure imgf000217_0001
Methyl 3-bromothiophene-2-carboxylate (5 g, 22.6 mmol) was added portion wise to chlorosulfonic acid (7.6 mL, 1.73 g/mL, 113 mmol) at 0° C. The reaction mixture was allowed to warm to room temperature and was heated at 120 °C for 3 hours. The resulting mixture was added dropwise to a stirred ice-water mixture (250 mL) keeping the temperature below 5 °C. The precipitate was filtered and dissolved in 2-MeTHF, dried (MgS04), filtered and concentrated in vacuo to yield 3-bromo-4-chlorosulfonyl- thiophene-2-carboxylic acid (6.9 g) as a brown oil.
Oxalyl chloride (10 mL) was added to 3-bromo-4-chlorosulfonyl-thiophene-2- carboxylic acid (6.9 g, 22.582 mmol), DMF (87 μί, 0.944 g/mL, 1.13 mmol) in DCM (350 mL) and stirred overnight. The reaction mixture was concentrated yielding 3-bromo-4-chlorosulfonyl-thiophene-2-carbonyl chloride (7.5 g) as a yellow resin which was used as such.
3-bromo-4-chlorosulfonyl-thiophene-2-carbonyl chloride (7.5 g, 23.1 mmol) was dissolved in toluene (180 mL). The mixture was brought to reflux and 3,4- difluoroaniline (2.34 mL, 1.29 g/mL, 23.1 mmol) was added. The mixture was heated at reflux for 45 minutes. The mixture was cooled and concentrated in vacuo. The residue was purified by column chromatography using a gradient from 0 till 100% EtOAc in heptane yielding 4-bromo-5-[(3,4-difluorophenyl)carbamoyl]thiophene-3- sulfonyl chloride (5.7 g) .
3-buten-2-amine hydrochloride (762 mg, 7.08 mmol) was added to ACN (20 mL) and the mixture was cooled on an ice bath. DIPEA (3.66 mL, 0.75 g/mL, 21.2 mmol) was added and the mixture was stirred untill a clear solution was obtained. 4-bromo-5-[(3,4- difluorophenyl)carbamoyl]thiophene-3-sulfonyl chloride (2.95 g, 7.08 mmol) was added and the mixture was stirred at room temperature for 16 hours. The mixture was concentrated in vacuo and the residue was partioned between water and DCM. The organic layer was separated, dried (MgS04), filtered and concentrated in vacuo. The residue was recrystallized from ACN and the precipitate was filtered off to yield 3 -bromo-N-(3 ,4-difluorophenyl)-4-( 1 -methylallylsulfamoyl)thiophene-2-carboxamide (800 mg). Method B; Rt: 1.04 min. m/z : 451 (M+H)+ Exact mass: 450.0.
A microwave vial was charged with 3-bromo-N-(3,4-difluorophenyl)-4-(l- methylallylsulfamoyl)thiophene-2-carboxamide (200 mg, 0.443 mmol), Hunig's base (0.084 mL, 0.75 g/mL, 0.49 mmol) and DMF (5 mL) and purged with N2 for 5 minutes. Bis(tri-tert-butylphosphine)palladium(0) (11 mg, 0.022 mmol) was added and the vial was capped. The mixture was irradiated for 10 minutes at 150 °C. The mixture was concentrated in vacuo and the residue was purified via preparative HPLC (Stationary phase: RP XBridge Prep C18 OBD-ΙΟμιη, 50x150mm, Mobile phase: 0.25% NH4HCO3 solution in water, MeOH) yielding compound 224 (65 mg) as a white solid after crystallization from ACN. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.33 (d, J=7.3 Hz, 3 H), 4.31 (br s, 1 H), 5.79 (dd, J=13.1, 2.3 Hz, 1 H), 6.82 (dd, J=13.1, 2.3 Hz, 1 H), 7.43 - 7.44 (m, 1 H), 7.44 - 7.46 (m, 1 H), 7.79 - 7.84 (m, 1 H), 8.07 - 8.11 (m, 1 H), 8.30 (s, 1 H), 10.76 (br s, 1 H); Method B; Rt: 0.96 min. m/z: 369 (M-H)~ Exact mass: 370.0; MP: 220.8 °C.
Compound 225 : N-(3 ,4-difluorophenyl)-3 ,7-dimethyl- 1 , 1 -dioxo-3 ,4-dihydro-2H- thieno[3,2-bl[l A51oxathiazepine-6-carboxamide
Figure imgf000218_0001
Chlorosulfonic acid (1 mL, 1.73 g/mL, 16.109 mmol) was added to chloroform (15 mL) and cooled on an ice bath. Ethyl 4-hydroxy-2-methylthiophene-3-carboxylate (1 g, 5.37 mmol) dissolved in chloroform (5 mL) was added dropwise to the cooled solution. The mixture was allowed to rise to r.t. and was stirred at r.t. for 1 hour. The mixture was poured out in ice water and the organic layer was separated. The organic layer was dried (MgS04), filtered and concentrated in vacuo. The residue was purified by column chromatography using a gradient from 0 till 100% EtOAc in heptane to yield ethyl 5-chlorosulfonyl-4-hydroxy-2-methyl-thiophene-3-carboxylate (523 mg).
2-[(4-methoxyphenyl)methylamino]propan-l-ol (286 mg, 1.46 mmol) and Hunig's base (0.757 mL, 0.75 g/mL, 4.39 mmol) was dissolved in ACN (7 mL). Ethyl 5-chlorosulfonyl-4-hydroxy-2-methyl-thiophene-3-carboxylate (417 mg, 1.46 mmol) was added and the mixture was stirred at room temperature for 16 hours. The mixture was concentrated in vacuo and the residue was purified by column chromatography using a gradient from 0 till 100% EtOAc in heptane yielding ethyl 4-hydroxy-5-[(2- hydroxy- 1 -methyl-ethyl)-[(4-methoxyphenyl)methyl]sulfamoyl]-2-methyl-thiophene-3- carboxylate (359 mg). Method B; Rt: 1.20 min. m/z: 442 (M-H)~ Exact mass: 443.1.
Ethyl 4-hydroxy-5 - [(2-hydroxy- 1 -methyl-ethyl)- [(4-methoxyphenyl)methyl] sulfamoyl] - 2-methyl-thiophene-3-carboxylate (359 mg, 0.81 mmol) was dissolved in dry THF (8 mL). Triphenylphosphine (234 mg, 0.89 mmol) and di-tert-butyl azodicarboxylate (205 mg, 0.89 mmol) were added at room temperature. The mixture was stirred for 30 minutes and then concentrated in vacuo. The residue was purified by column chromatography using a gradient from 0 till 100% EtOAc in heptane to yield ethyl 2-[(4-methoxyphenyl)methyl]-3 ,7-dimethyl- 1 , 1 -dioxo-3 ,4-dihydrothieno[3 ,2- b][l,4,5]oxathiazepine-6-carboxylate (275 mg).
Ethyl 2- [(4-methoxyphenyl)methyl] -3 ,7-dimethyl- 1 , 1 -dioxo-3 ,4-dihydrothieno [3,2- b][l,4,5]oxathiazepine-6-carboxylate (275 mg, 0.65 mmol) and 3,4-difluoroaniline (0.078 mL, 1.29 g/mL, 0.78 mmol) was dissolved in THF (5 mL). Lithium
bis(trimethylsilyl)amide (1.9 mL, 1 M in THF, 1.9 mmol) was added dropwise and the mixture was stirred at room temperature for 2 hours. The mixture was quenched with NH4CI (aq., sat.). The mixture was diluted with 2-MeTHF and the organic layer was separated, dried (MgS04), filtered and concentrated in vacuo. The product was purified by column chromatography using a gradient from 0 till 50% EtOAc in heptane yielding N-(3 ,4-difluorophenyl)-2- [(4-methoxyphenyl)methyl] -3 ,7-dimethyl- 1 , 1 -dioxo-3 ,4- dihydrothieno[3,2-b][l,4,5]oxathiazepine-6-carboxamide (232 mg).
N-(3 ,4-difluorophenyl)-2- [(4-methoxyphenyl)methyl] -3 ,7-dimethyl- 1 , 1 -dioxo-3 ,4- dihydrothieno[3,2-b][l,4,5]oxathiazepine-6-carboxamide (116 mg, 0.23 mmol) was dissolved in dry DCM (3 mL) and TFA (3 mL, 1.49 g/mL, 39 mmol) was added under N2. The mixture was stirred at room temperature for 16 hours. The mixture was concentrated in vacuo and the residue was purified by column chromatography using a gradient from 0 till 50% EtOAc in heptane yielding compound 225 (63 mg). 1H NMR (400 MHz, DMSO- 6) δ ppm 1.19 (d, J=7.0 Hz, 3 H), 2.50 (s, 3 H), 3.79 (q, J=7.5 Hz, 1 H), 4.05 (dd, J=12.8, 8.3 Hz, 1 H), 4.50 (dd, J=12.8, 2.6 Hz, 1 H), 7.33 - 7.44
(m, 2 H), 7.77 - 7.85 (m, 1 H), 8.02 (d, J=8.2 Hz, 1 H), 10.18 (s, 1 H); Method D; Rt: 1.90 min. m/z: 387 (M-H)" Exact mass: 388.0. MP: 221.5 °C. Compound 226: N-(3,4-difluorophenyl)-3,7-dimethyl-l,l-dioxo-2,3- dihydropyrazolo[4,3-f|thiazepine-6-carboxamide
Figure imgf000220_0001
Methyl 5-amino-2-methyl-pyrazole-3-carboxylate (2.00 g, 12.9 mmol) was dissolved in THF (50 mL) and N-bromosuccinimide (2.52 g, 14.2 mmol) was added and stirred for 2 hours. The solution was concentrated in vacuo, redissolved in DCM and washed with water. The combined organics are evaporated till dryness and the crude purified on silica using DCM/MeOH 100/0 to 90/10. The obtained crude was redissolved in DIPE, and the remaining salts removed by filtration. The filtrate was then concentrated in vacuo to yield methyl 5-amino-4-bromo-2-methyl-pyrazole-3-carboxylate (2.0 g) as a light orange solid.
To a cooled (0 °C) solution of water (3.5 mL) was added SOCl2 (0.642 mL, 1.64 g/mL, 8.84 mmol) and allowed to warm to room temperature and stirred for 1 h. Then cuprous chloride (19 mg, 0.20 mmol) was added and the solution cooled to -5 °C.
In another solution of HC1 (1.97 mL, 37 % in H20, 1.18 g/mL, 23.6 mmol) was added methyl 5-amino-4-bromo-2-methyl-pyrazole-3-carboxylate (500 mg, 1.97 mmol) and cooled to -5 °C before a solution of sodium nitrite (149 mg, 2.16 mmol) in water (1 mL) was added to it. This solution was then added to the first solution dropwise and cooling was maintained at -5 °C. The solution was then allowed to warm to 0 °C and stirring was continued at this temperature for 2 hours, before it was allowed to warm to room temperature. EtOac (20 mL) was added and the organic layer was concentrated in vacuo. The residue was purified on silica using a heptane to EtOAc gradient yielding methyl 4-bromo-5-chlorosulfonyl-2-methyl-pyrazole-3-carboxylate (544 mg).
Methyl 4-bromo-5-chlorosulfonyl-2-methyl-pyrazole-3-carboxylate (383 mg,
1.04 mmol) was dissolved in ACN (5 mL, 0.786 g/mL, 104 mmol). DIPEA (0.715 mL, 0.75 g/mL, 4.15 mmol) and but-3-en-2-amine hydrochloride (223 mg, 2.08 mmol) were added and the reaction mixture was stirred 5 hours. The solution was then concentrated in vacuo and directly purified on silica using heptane/EtOAc 100 to 50/50 to yield methyl 4-bromo-2-methyl-5-(l-methylallylsulfamoyl)pyrazole-3-carboxylate (98 mg).
Methyl 4-bromo-2-methyl-5-(l-methylallylsulfamoyl)pyrazole-3-carboxylate (98 mg, 0.278 mmol) was dissolved in THF (5 mL) and 3,4-difluoroaniline (0.030 mL,
1.302 g/mL, 0.31 mmol) and LiHMDS (0.835 mL, 1 M in THF, 0.84 mmol) was added at room temperature. After 2 hours the solution was diluted with EtOAc and washed with water. The combined organic layers were dried with MgS04, filtered, concentrated in vacuo and purified on silica using heptane/EtOAc 100/0 to 50/50 yielding 4-bromo- N-(3,4-difluorophenyl)-2-methyl-5-(l-methylallylsulfamoyl)pyrazole-3-carboxamide (70 mg).
To a solution of 4-bromo-N-(3,4-difiuorophenyl)-2-methyl-5-(l- methylallylsulfamoyl)pyrazole-3-carboxamide (70 mg, 0.16 mmol) in DMF (2 mL) was added Hunig's base (0.054 mL, 0.75 g/mL, 0.31 mmol) and flushed under nitrogen. The mixture was first heated to 100 °C before bis(tri-tert-butylphosphine)palladium(0)
(8 mg, 0.016 mmol) was added and the solution was then heated to 150 °C for 5 minutes in the microwave. The reaction mixture was directly purified on preparative HPLC (Stationary phase: RP XBridge Prep C18 ODB- 5μιη, 30x250mm, Mobile phase: 0.25% NH4HC03 solution in water, ACN) yielding compound 226 (26 mg). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.36 (d, J=7.3 Hz, 3 H) 3.97 (s, 3 H) 4.20 - 4.29 (m, 1 H) 5.75 (dd, J=12.2, 2.5 Hz, 1 H) 6.40 (dd, J=12.1, 2.6 Hz, 1 H) 7.41 - 7.50 (m, 2 H) 8.02 (br s, 1 H) 7.81 - 7.90 (m, 1 H) 11.14 (br s, 1 H); Method B; Rt: 0.90 min. m/z: 367 (M-H)~ Exact mass: 368.1.
The following compounds were also synthesized according to the procedures described above:
Figure imgf000221_0001
Figure imgf000222_0001
Figure imgf000223_0001
Figure imgf000224_0001
Biological examples - anti-HBV activity of compounds of Formula (A)
The anti HBV activity was measured using the HepG2.117 cell line, a stable, inducibly HBV producing cell line, which replicates HBV in the absence of doxicycline (Tet-off system). For the antiviral assay, HBV replication was induced, followed by a treatment with serially diluted compound in 96-well plates in duplicate. After 3 days of treatment, the antiviral activity was determined by quantification of intracellular HBV DNA using realtime PCR and an HBV specific primer set and probe.
Cytotoxicity of the compounds was tested using HepG2 cells, incubated for 4 days in the presence of compounds. The viability of the cells was assessed using a Resazurin assay. Results are displayed in Table 1.
Table 1 : anti HBV activity and cytotoxicity
Figure imgf000224_0002
Figure imgf000225_0001
Figure imgf000226_0001
Figure imgf000227_0001
Figure imgf000228_0001
Figure imgf000229_0001
Figure imgf000230_0001
Figure imgf000231_0001
Figure imgf000232_0001
Figure imgf000233_0001

Claims

Claims
1. A compound of Formula (I- A)
Figure imgf000234_0001
or a stereoisomer or tautomeric form thereof, wherein
Figure imgf000234_0002
represents a monocyclic 5 or 6 membered aryl optionally containing one or two heteroatoms, such aryl optionally being substituted with one or more substituents each independently selected from the group consisting of Ci-C3alkyl, in particular methyl, C3-C4cycloalkyl, -CN and halogen;
represents a 6 membered aryl optionally containing one nitrogen atom; X represents -CR2R3-;
Y represents Ci_C7alkanediyl or C2-C7alkenediyl, each optionally substituted with one or more substituents each independently selected from the group consisting of Ci-C4alkyl, fluoro, and -OH;
Z represents a heteroatom, preferably NH or oxygen and more preferably oxygen, or a single bond;
Ra, Rb, Rc and Rd are each independently selected from the group consisting of hydrogen, halogen, -CHF2, -CF2-methyl, -CH2F, -CF3, -OCF3, -CN, C3-C4cycloalkyl and -Ci-C4alkyl;
R1 is hydrogen or Ci-Cioalkyl optionally substituted with one or more substituents each independently selected from the group consisting of -OH, fluoro, and oxo; 2
R is selected from the group consisting of hydrogen; Ci-Cioalkyl optionally substituted with one or more substituents each independently selected from the group consisting of -OH, fluoro, methoxy, oxo, and -C(=0)OCi-C4alkyl; Ci-C3alkyl-R7; C2-C4alkynyl; a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N; and monocyclic aryl optionally containing one or two heteroatoms; wherein the Ci-C3alkyl-R7, 3-7 membered saturated ring or the monocyclic aryl are each
Q
optionally substituted with one or more R substituents; R is hydrogen or Ci_6alkyl optionally substituted with -OH; in particular, hydrogen or methyl; or R 2 and R 3 taken together with the carbon atom to which they are attached form a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, and optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, fluoro, methoxy, oxo, -C(=0)OCi-C4alkyl, benzyl, and
Ci-C4alkyl optionally substituted with one or more substituents each independently selected from fluoro and/or -OH;
R7 represents a monocyclic aryl optionally containing one or two heteroatoms, and optionally being substituted with one or two substituents each independently selected from the group consisting of halo and Ci_3alkyl; a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N; or -NR9R10; wherein R9 and R10 are each independently selected from hydrogen and Ci-C3alkyl optionally substituted with one or more fluoro substituents;
Q
each R is independently selected from the group consisting of -OH, fluoro, methoxy, oxo, -C(=0)OCi-C4alkyl, Ci-C4alkyloxyCi-C4alkyloxy, and Ci-C4alkyl optionally substituted with one or more substituents each independently selected from fluoro and/or -OH; or a pharmaceutically acceptable salt or a solvate thereof.
2. The compound according to claim 1 , wherein
Figure imgf000236_0001
nocyclic 5 or 6 membered aryl optionally containing one or two heteroatoms, such aryl optionally being substituted with one or more substituents each independently selected from the group consisting of Ci-C3alkyl, in particular methyl, C3-C4cycloalkyl, -CN and halogen;
Figure imgf000236_0002
represents a 6 membered aryl optionally containing one nitrogen atom; X represents -CR2R3-;
Y represents Ci_C7alkanediyl or C2-C7alkenediyl each optionally being substituted with one or more substituents each independently selected from Ci-C4alkyl and -OH; Z represents a heteroatom, preferably oxygen, or a single bond;
Ra, Rb, Rc and Rd are each independently selected from the group consisting of Hydrogen, halogen, -CHF2, -CF2-methyl, -CH2F, -CF3, -OCF3, -CN, C3-C4cycloalkyl and -Ci-C4alkyl;
R1 is Hydrogen or Ci-C6alkyl, such Ci-C6alkyl optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, Fluoro, oxo, and Ci-C4alkyl optionally substituted with one or more Fluoro and/or -OH;
R 2 is selected from the group consisting of hydrogen, Ci-C6alkyl, Ci-C3alkyl-R 7 , a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, and monocyclic aryl optionally containing one or two heteroatoms, such Ci-C6alkyl, Ci-C3alkyl-R7, 3-7 membered saturated ring or monocyclic aryl optionally being substituted with one or more R ;
R is hydrogen or Ci_6alkyl; or R 2 and R 3 taken together form together with the carbon atom to which they are attached a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N,
Q
such 3-7 membered saturated ring optionally being substituted with one or more R ; R7 represents a monocyclic aryl optionally containing one or two heteroatoms; a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N; or -NR9R10; wherein R9 and R10 are each independently selected from Hydrogen and Ci-C3alkyl;
Q
each R independently is selected from the group consisting of -OH, Fluoro, methoxy, oxo, -C(=0)OCi-C4alkyl and Ci-C4alkyl optionally substituted with one or more substituents each independently selected from Fluoro and/or -OH.
3. The compound according to claim 1 or 2, wherein
Figure imgf000237_0001
represents a monocyclic 5 or 6 membered aryl optionally containing one or two heteroatoms, such aryl optionally being substituted with one or more substituents each independently selected from the group consisting of Ci-C3alkyl,
C3-C4cycloalkyl, -CN and halogen;
represents a 6 membered aryl optionally containing one nitrogen atom;
X represents -CR2R3-;
Y represents Ci_C7alkanediyl or C2-C7alkenediyl each optionally being substituted with one or more substituents each independently selected from Ci-C4alkyl and -OH;
Z represents a heteroatom, preferably oxygen, or a single bond;
Ra, Rb, Rc and Rd are each independently selected from the group consisting of hydrogen, halogen, -CHF2, -CF2-methyl, -CH2F, -CF3, -OCF3, -CN, C3-C4cycloalkyl and -Ci-C4alkyl; R1 is Hydrogen or Ci-C6alkyl, such Ci-C6alkyl optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, Fluoro, oxo, and Ci-C4alkyl optionally substituted with one or more Fluoro and/or -OH;
R 2 is selected from the group consisting of hydrogen, Ci-C6alkyl, Ci-C3alkyl-R 7 , a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, and monocyclic aryl optionally containing one or two heteroatoms, such Ci-C6alkyl, Ci-C3alkyl-R7,
3-7 membered saturated ring or monocyclic aryl optionally being substituted with one or more R8;
R is hydrogen; or R 2 and R 3 taken together form together with the carbon atom to which they are attached a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such
Q
3-7 membered saturated ring optionally being substituted with one or more R ;
R7 represents a monocyclic aryl optionally containing one or two heteroatoms; a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N; or -NR9R10; wherein R9 and R10 are each independently selected from Hydrogen and Ci-C3alkyl;
Q
each R independently is selected from the group consisting of -OH, Fluoro, methoxy, oxo, -C(=0)OCi-C4alkyl and Ci-C4alkyl optionally substituted with one or more substituents each independently selected from Fluoro and/or -OH.
4. The compound according to any one of claims 1 to 3, having Formula (A)
Figure imgf000238_0001
or a stereoisomer or tautomeric form thereof, wherein:
Figure imgf000238_0002
represents a monocyclic 5 or 6 membered aryl optionally containing one or two heteroatoms, such aryl optionally substituted with one or more methyl, -CN or halo en;
Figure imgf000238_0003
represents a 6 membered aryl optionally containing one nitrogen atom; X represents -CR2 R3-;
Y represents a Ci_C7alkanediyl or C2_C7alkenediyl each optionally substituted with one or more Ci-C4alkyl or -OH;
Z represents a heteroatom, preferably oxygen, or a single bond;
Ra, Rb, Rc and Rd are independently selected from the group consisting of Hydrogen, halogen, -CHF2, -CF2-methyl, -CH2F, -CF3, -OCF3, -CN, C3-C4cycloalkyl
and -Ci-C4alkyl;
R1 is hydrogen or Ci-C6alkyl, such Ci-C6alkyl optionally being substituted with one or more substituents each independently selected from the group consisting of -OH, Fluoro, oxo, and Ci-C4alkyl optionally substituted with one or more Fluoro and/or -OH; R 2 is selected from the group consisting of hydrogen, Ci-C6alkyl, Ci-C3alkyl-R 7 , a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, and monocyclic aryl optionally containing one or two heteroatoms, such Ci-C6alkyl, Ci-C3alkyl-R7,
3-7 membered saturated ring or monocyclic aryl optionally being substituted with one or more R8;
R is hydrogen; or R 2 and R 3 taken together form together with the carbon atom to which they are attached a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such
Q
3-7 membered saturated ring optionally substituted with one or more R ;
R7 represents a monocyclic aryl optionally containing one or two heteroatoms;
Q
each R independently is selected from the group consisting of -OH, Fluoro, methoxy, oxo, -C(=0)OCi-C4alkyl and Ci-C4alkyl optionally substituted with one or more Fluoro and/or -OH;
or a pharmaceutically acceptable salt or a solvate thereof.
5. The compound according to any one of claims 1 to 3, wherein .-'' represents
R6 , wherein R4 is hydrogen, -Ci-C3alkyl or C3-C4cycloalkyl; and R6 is selected from hydrogen, methyl, -CN and halogen.
Figure imgf000240_0001
6. The compound according to any one of claims 1 to 4, wherein represents
Figure imgf000240_0002
gen or halogen; and R6 is selected from hydrogen, methyl, -CN and halogen.
7. The compound according to any one of claims 1 to 6, wherein ring C consists of 6 to 8 atoms, preferably 7 atoms.
8. The compound according to claim 5 or 7, wherein R4 is methyl.
9. The compound according to any one of claims 5 to 8 wherein R6 is hydrogen.
10. The compound according to any one of claims 1 to 9, wherein R is Ci-C6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of -OH, fluoro, and methoxy.
ΛΛ/j β
11. The compound according to any one of claims 1 to 10, wherein represents phenyl, and Ra is selected from hydrogen and halogen; Rb is hydrogen or a halogen; Rc is selected from halogen, CH3, CHF2, CF3, and -CN; and Rd is selected from hydrogen and halogen.
12. The compound according to any one of the previous claims wherein R2 is
Ci-C4alkyl optionally substituted with one or more Fluoro.
13. The compound according to any one of the previous claims wherein R2 is
Ci-C6alkyl optionally substituted with one or more -OH substituents.
14. The compound according to any one of the previous claims wherein R is hydrogen.
15. A compound as defined in any one of claims 1 to 14, for use as a medicament.
16. A compound as defined in any one of claims 1 to 14, for use in the prevention or treatment of an HBV infection in a mammal.
17. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 14, and a pharmaceutically acceptable carrier.
18. A product containing (a) a compound as defined in any one of claims 1 to 14 or the pharmaceutical composition of claim 17, and (b) another HBV inhibitor, as a combined preparation for simultaneous, separate or sequential use in the treatment of HBV infections.
19. A method of treating a warm-blooded animal, in particular a human, infected by HBV, or being at risk of infection by HBV, said method comprising the administration of a therapeutically effective amount of a compound as defined in any one of claims 1 to 14 or a pharmaceutical composition as defined in claim 17.
20. A process for the preparation of a compound as defined in any one of claims 1 to 14, comprising the step of (a) reacting a compound of Formula (V) with an amine of Formula (VI) in the presence of a base in a solvent to form a compound of Formula (la) and optionally subjecting the compound of Formula (la) to hydrogenation
Figure imgf000241_0001
(b) subjecting a compound of Formula (XXXIV) to Heck conditions to form a compound of Formula (la) and optionally subjecting the compound of Formula (la) to hydrogenation
Figure imgf000242_0001
(c) reacting a compound of Formula (XXXX) with an amine of Formula (VI) in the presence of a suitable base in a suitable solvent
Figure imgf000242_0002
wherein the amine of Formula (VI) is
H2N^"''† RC
(vi), Y* is C2-C7alkenediyl, Y** is Ci-C7alkanediyl, and all other variables are as defined in any one of claims 1 to 14.
Figure imgf000242_0003
wherein
Y is C2-C7alkenediyl, Y** is Ci-C7alkanediyl, and all other variables are as defined in any one of claims 1 to 14.
PCT/EP2016/065488 2015-07-02 2016-07-01 Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b WO2017001655A1 (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
PL16733102T PL3317286T3 (en) 2015-07-02 2016-07-01 Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
SI201630448T SI3317286T1 (en) 2015-07-02 2016-07-01 Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
MDE20180475T MD3317286T2 (en) 2015-07-02 2016-07-01 Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
MA42292A MA42292B1 (en) 2015-07-02 2016-07-01 Cyclized sulfamoylarylamide derivatives and their use as drugs for the treatment of hepatitis b
UAA201800908A UA124054C2 (en) 2015-07-02 2016-07-01 Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
AU2016287472A AU2016287472B2 (en) 2015-07-02 2016-07-01 Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
MX2017016781A MX2017016781A (en) 2015-07-02 2016-07-01 Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b.
EA201890200A EA036629B1 (en) 2015-07-02 2016-07-01 Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
DK16733102T DK3317286T3 (en) 2015-07-02 2016-07-01 CYCLIZED SULFAMOYLARYLAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES TO TREAT HEPATITIS B
KR1020187001757A KR20180022818A (en) 2015-07-02 2016-07-01 Cyclic Sulfamoyl Aryl Amide Derivatives and Their Uses as Agents for the Treatment of Hepatitis B
RS20191509A RS59609B1 (en) 2015-07-02 2016-07-01 Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
BR112017028504A BR112017028504A2 (en) 2015-07-02 2016-07-01 cyclized sulfamoylamyl amide derivatives and their use as medicines for the treatment of hepatitis b
EP16733102.4A EP3317286B1 (en) 2015-07-02 2016-07-01 Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
EP19186044.4A EP3590943A1 (en) 2015-07-02 2016-07-01 Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
CR20180069A CR20180069A (en) 2015-07-02 2016-07-01 CYCLED SULFAMOILARILAMIDE DERIVATIVES AND ITS USE AS MEDICATIONS FOR THE TREATMENT OF HEPATITIS B
CN201680038835.3A CN107735400B (en) 2015-07-02 2016-07-01 Cyclic sulfamoyl arylamide derivatives and their use as medicaments for the treatment of hepatitis B
TNP/2017/000535A TN2017000535A1 (en) 2015-07-02 2016-07-01 Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
ES16733102T ES2759775T3 (en) 2015-07-02 2016-07-01 Cyclic sulfamoylarylamide derivatives and their use as medicines for the treatment of hepatitis B
JP2017567064A JP6914201B2 (en) 2015-07-02 2016-07-01 Cyclic sulfamoylarylamide derivatives and their use as pharmaceuticals for the treatment of hepatitis B
CA2986344A CA2986344A1 (en) 2015-07-02 2016-07-01 Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
CONC2017/0012268A CO2017012268A2 (en) 2015-07-02 2017-11-29 Cyclic sulfamoylarylamide derivatives and their use as medicines for the treatment of hepatitis b
PH12017502316A PH12017502316A1 (en) 2015-07-02 2017-12-14 Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
IL256392A IL256392A (en) 2015-07-02 2017-12-18 Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
HK18109558.5A HK1250031A1 (en) 2015-07-02 2018-07-24 Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
HK18112631.0A HK1253337B (en) 2015-07-02 2018-10-03 Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
HRP20191901TT HRP20191901T1 (en) 2015-07-02 2019-10-21 Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
CY20191101240T CY1122688T1 (en) 2015-07-02 2019-11-26 CYCLIC SULFAMOYLARYLAMIDE DERIVATIVES AND THEIR USE AS DRUGS FOR THE THERAPEUTIC TREATMENT OF HEPATITIS B
IL276333A IL276333B (en) 2015-07-02 2020-07-28 Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP15175021 2015-07-02
EP15175021.3 2015-07-02
EP15189903.6 2015-10-15
EP15189903 2015-10-15
EP15201332.2 2015-12-18
EP15201332 2015-12-18
EP16157726.7 2016-02-16
EP16157726 2016-02-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP19186044.4A Previously-Filed-Application EP3590943A1 (en) 2015-07-02 2016-07-01 Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b

Publications (1)

Publication Number Publication Date
WO2017001655A1 true WO2017001655A1 (en) 2017-01-05

Family

ID=56289521

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/065488 WO2017001655A1 (en) 2015-07-02 2016-07-01 Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b

Country Status (36)

Country Link
US (2) US10875876B2 (en)
EP (2) EP3317286B1 (en)
JP (1) JP6914201B2 (en)
KR (1) KR20180022818A (en)
CN (1) CN107735400B (en)
AU (1) AU2016287472B2 (en)
BR (1) BR112017028504A2 (en)
CA (1) CA2986344A1 (en)
CL (1) CL2017003459A1 (en)
CO (1) CO2017012268A2 (en)
CR (1) CR20180069A (en)
CY (1) CY1122688T1 (en)
DK (1) DK3317286T3 (en)
EA (1) EA036629B1 (en)
ES (1) ES2759775T3 (en)
GE (1) GEP20207117B (en)
HK (2) HK1250031A1 (en)
HR (1) HRP20191901T1 (en)
HU (1) HUE046283T2 (en)
IL (2) IL256392A (en)
MA (2) MA50482A (en)
MD (1) MD3317286T2 (en)
MX (2) MX2017016781A (en)
NI (1) NI201700169A (en)
PE (1) PE20180410A1 (en)
PH (1) PH12017502316A1 (en)
PL (1) PL3317286T3 (en)
PT (1) PT3317286T (en)
RS (1) RS59609B1 (en)
SG (1) SG10202002302UA (en)
SI (1) SI3317286T1 (en)
TN (1) TN2017000535A1 (en)
TW (1) TWI705058B (en)
UA (1) UA124054C2 (en)
UY (1) UY36766A (en)
WO (1) WO2017001655A1 (en)

Cited By (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108456216A (en) * 2017-02-22 2018-08-28 上海长森药业有限公司 Sulfonyl hydrazines compound and application thereof
WO2019086142A1 (en) 2017-11-02 2019-05-09 Aicuris Gmbh & Co. Kg Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
WO2019086141A1 (en) 2017-11-02 2019-05-09 Aicuris Gmbh & Co. Kg Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
WO2019097479A1 (en) 2017-11-17 2019-05-23 Novartis Ag Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
US10328053B2 (en) 2016-08-26 2019-06-25 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
WO2019165374A1 (en) 2018-02-26 2019-08-29 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
WO2019166951A1 (en) 2018-02-28 2019-09-06 Novartis Ag Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
WO2019193542A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides
WO2019193543A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides
WO2019193533A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'2'-cyclic dinucleotides
WO2019200247A1 (en) 2018-04-12 2019-10-17 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
EP3597637A1 (en) 2018-07-19 2020-01-22 Irbm S.P.A. Inhibitors of hepatitis b virus
EP3597653A1 (en) 2018-07-19 2020-01-22 Irbm S.P.A. Cyclic inhibitors of hepatitis b virus
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
EP3608326A1 (en) 2018-08-10 2020-02-12 Irbm S.P.A. Tricyclic inhibitors of hepatitis b virus
US10590076B2 (en) 2018-06-11 2020-03-17 VenatoRx Pharmaceuticals, Inc. Hepatitis B capsid assembly modulators
WO2020092621A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
WO2020089452A1 (en) 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg Novel urea 6,7-dihydro-4h-pyrazolo[4,3-c]pyridines active against the hepatitis b virus (hbv)
WO2020089455A1 (en) 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine indole-2-carboxamides active against the hepatitis b virus (hbv)
WO2020089456A1 (en) 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg Novel urea 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazines active against the hepatitis b virus (hbv)
WO2020089453A1 (en) 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg Novel 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine indole-2-carboxamides active against the hepatitis b virus (hbv)
WO2020089460A1 (en) 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg Novel urea 6,7-dihydro-4h-thiazolo[5,4-c]pyridines active against the hepatitis b virus (hbv)
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
WO2020089459A1 (en) 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg Novel urea 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazines active against the hepatitis b virus (hbv)
US10662416B2 (en) 2016-10-14 2020-05-26 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome
WO2020167984A1 (en) * 2019-02-14 2020-08-20 Aligos Therapeutics, Inc. Bicyclic sulfonamides
JP2020526569A (en) * 2017-07-14 2020-08-31 シャンハイ ロングウッド バイオファルマシューティカルズ カンパニー リミテッドＳｈａｎｇｈａｉ Ｌｏｎｇｗｏｏｄ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．，Ｌｔｄ． Intracyclic thiamidinoamide-arylamide compounds and their uses for the treatment of hepatitis B
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
WO2020178769A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
WO2020214663A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020214652A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020221811A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel oxalyl piperazines active against the hepatitis b virus (hbv)
WO2020221824A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv)
WO2020221816A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv)
WO2020221826A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel indole-2-carboxamides active against the hepatitis b virus (hbv)
EP3741762A1 (en) 2019-05-23 2020-11-25 Irbm S.P.A. Oxalamido-substituted tricyclic inhibitors of hepatitis b virus
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2020234483A1 (en) 2019-05-23 2020-11-26 Istituto Nazionale Di Genetica Molecolare - Ingm Oxalamido-substituted tricyclic inhibitors of hepatitis b virus
WO2020239861A1 (en) * 2019-05-28 2020-12-03 Janssen Sciences Ireland Unlimited Company Azepines as hbv capsid assembly modulators
WO2020255012A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being sulfonamide derivatives
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
US10947226B2 (en) 2016-10-17 2021-03-16 Genentech, Inc. Bicyclic pyridone lactams and methods of use thereof
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2021067181A1 (en) 2019-09-30 2021-04-08 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
US10977927B2 (en) 2018-10-24 2021-04-13 Rapidsos, Inc. Emergency communication flow management and notification system
US10988459B2 (en) 2015-07-02 2021-04-27 Genentech, Inc. Bicyclic lactams and methods of use thereof
US11008346B2 (en) 2014-06-11 2021-05-18 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP3825318A1 (en) 2019-11-25 2021-05-26 Promidis S.r.l. Oxalamido-substituted tricyclic inhibitors of hepatitis b virus
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
EP3865489A1 (en) 2020-02-11 2021-08-18 Promidis S.r.l. Spirocyclic inhibitors of hepatitis b virus
WO2021160617A1 (en) 2020-02-11 2021-08-19 Irbm S.P.A. Spirocyclic inhibitors of hepatitis b virus
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
JP2021531320A (en) * 2018-07-27 2021-11-18 アービュタス バイオファーマ コーポレイション Substituted tetrahydrocyclopenta [c] pyrrole, substituted dihydropyrrolidine, analogs thereof, and methods of using them.
US11197145B2 (en) 2017-12-05 2021-12-07 Rapidsos, Inc. Social media content for emergency management
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2022031894A1 (en) 2020-08-07 2022-02-10 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
US11247965B2 (en) 2017-12-11 2022-02-15 VenatoRx Pharmaceuticals, Inc. Hepatitis B capsid assembly modulators
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
JP2022517984A (en) * 2019-01-11 2022-03-11 シャンハイ ロングウッド バイオファルマシューティカルズ カンパニー リミテッド Intracyclic thiamidinoamide-arylamide compounds and their use for the treatment of hepatitis B
EP3985010A1 (en) 2020-10-14 2022-04-20 Promidis S.r.l. Spirocyclic inhibitors of hepatitis b virus
WO2022087149A2 (en) 2020-10-22 2022-04-28 Gilead Sciences, Inc. Interleukin-2-fc fusion proteins and methods of use
US11332485B2 (en) 2017-05-26 2022-05-17 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2022241134A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11634436B2 (en) 2018-04-20 2023-04-25 Genentech, Inc. Pyridine lactam compounds and methods of use thereof
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11866432B2 (en) 2018-10-11 2024-01-09 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI519515B (en) 2011-12-21 2016-02-01 諾維拉治療公司 Hepatitis b antiviral agents
EA027280B1 (en) 2012-08-28 2017-07-31 Янссен Сайенсиз Айрлэнд Юси Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
CA2899706C (en) 2013-02-28 2021-10-19 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
US9895349B2 (en) 2013-04-03 2018-02-20 Janssen Sciences Ireland Us N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
JO3603B1 (en) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
BR112015028538A2 (en) 2013-05-17 2017-07-25 Janssen Sciences Ireland Uc sulfamoylthiophenamide derivatives and their use as medicines for the treatment of hepatitis b
NO3024819T3 (en) 2013-07-25 2018-07-21
CA2923712C (en) 2013-10-23 2021-11-02 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
RU2702109C1 (en) 2014-02-05 2019-10-04 Новира Терапьютикс, Инк. Combined therapy for treating hepatitis b infections
CN110483484A (en) 2014-02-06 2019-11-22 爱尔兰詹森科学公司 Sulfamoyl pyrrole amides derivative and its purposes for being used to treat hepatitis B as drug
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
EP3442524A2 (en) 2016-04-15 2019-02-20 Novira Therapeutics Inc. Combinations and methods comprising a capsid assembly inhibitor
CN108264520B (en) * 2017-01-03 2021-12-07 上海长森药业有限公司 Compound for treating hepatitis B and application thereof
US10973801B2 (en) 2018-03-14 2021-04-13 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
CN110437232B (en) * 2018-05-04 2022-04-12 上海长森药业有限公司 Bicyclourea nucleocapsid inhibitor and pharmaceutical use thereof
US11096931B2 (en) 2019-02-22 2021-08-24 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
US11491148B2 (en) 2019-05-06 2022-11-08 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
CN115160344A (en) * 2021-04-06 2022-10-11 上海长森药业有限公司 Inhibition of CD4 by oral administration + Medicaments and methods for Treg cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014033176A1 (en) * 2012-08-28 2014-03-06 Janssen R&D Ireland Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
WO2014184350A1 (en) * 2013-05-17 2014-11-20 Janssen R&D Ireland Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b

Family Cites Families (216)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843662A (en) 1971-12-09 1974-10-22 Pfizer 2-halo-5-(substituted piperidino sulfonyl)benzoic acids
AU1508183A (en) 1982-06-04 1983-12-08 Beecham Group Plc Benzamide and anilide derivatives of 8-azabicyclo-(3.2.1)- -octane
WO1984003281A1 (en) 1983-02-19 1984-08-30 Beecham Group Plc Azabicycloalkyl benzamide and anilide derivatives
JPS62142164A (en) 1985-12-13 1987-06-25 Ishihara Sangyo Kaisha Ltd 4,5-dichloroimidazole based compound and pest controlling agent containing said compound
IN164880B (en) 1986-01-30 1989-06-24 Ishihara Sangyo Kaisha
US5272167A (en) 1986-12-10 1993-12-21 Schering Corporation Pharmaceutically active compounds
CA1339133C (en) 1987-03-13 1997-07-29 Rikuo Nasu Imidazole compounds and biocidal composition comprising the same for controlling harmful organisms
US5571821A (en) 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
GB8904174D0 (en) 1989-02-23 1989-04-05 British Bio Technology Compounds
US4962101A (en) 1989-08-21 1990-10-09 Merck & Co., Inc. 2-(Heterocyclylalkyl)phenyl carbapenem antibacterial agents
GB9023082D0 (en) 1990-10-24 1990-12-05 Schering Agrochemicals Ltd Fungicides
GB9109557D0 (en) 1991-05-02 1991-06-26 Wellcome Found Chemical compounds
US5308826A (en) 1993-04-22 1994-05-03 Zeneca Limited Herbicidal 4-substituted pyridyl-3-carbinols
GB9405347D0 (en) 1994-03-18 1994-05-04 Agrevo Uk Ltd Fungicides
JPH10504525A (en) 1994-05-27 1998-05-06 ジェイムズ・ブラック・ファウンデーション・リミテッド Gastrin and CCK antagonist
US5795907A (en) 1994-05-27 1998-08-18 James Black Foundation Limited Gastin and CCK receptor ligands
US5763618A (en) 1995-05-12 1998-06-09 Konica Corporation Manufacturing method of sulfides
US5723411A (en) 1995-10-31 1998-03-03 E. I. Du Pont De Nemours And Company Herbicidal pyridazinones
DE19540995A1 (en) 1995-11-03 1997-05-07 Hoechst Ag Substituted sulfonimidamides, process for their preparation, their use as a medicament or diagnostic agent, and medicament containing them
GB9612884D0 (en) 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
EP0912550A1 (en) 1996-06-25 1999-05-06 Smithkline Beecham Plc Sulfonamide derivatives as 5ht7 receptor antagonists
WO1998023285A1 (en) 1996-11-29 1998-06-04 Smithkline Beecham Plc Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis b
US5939423A (en) 1997-04-16 1999-08-17 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US5994396A (en) 1997-08-18 1999-11-30 Centaur Pharmaceuticals, Inc. Furansulfonic acid derivatives and pharmaceutical compositions containing the same
AU759255B2 (en) 1998-01-29 2003-04-10 Amgen, Inc. PPAR-gamma modulators
HUP0101275A3 (en) 1998-03-26 2002-12-28 Japan Tobacco Inc Amide derivatives and pharmaceutical compositions containing them as nociceptin antagonists
US6251893B1 (en) 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
BR0007527B1 (en) 1999-01-15 2011-12-27 phenylphenanthridines with inhibitory activity of pde-iv, their use, as well as medicament comprising them.
HUP0202319A3 (en) 1999-07-16 2004-12-28 Warner Lambert Co Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
JP2003506406A (en) 1999-08-10 2003-02-18 ザ・チャンセラー・マスターズ・アンド・スカラーズ・オブ・ザ・ユニバーシティ・オブ・オックスフォード Long-chain N-alkyl compounds and oxa derivatives thereof
MX226123B (en) 1999-09-17 2005-02-07 Millennium Pharm Inc BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa.
PE20010628A1 (en) 1999-10-01 2001-06-18 Takeda Chemical Industries Ltd CYCLIC AMINE COMPOUNDS, THEIR PRODUCTION AND THEIR USE
AP2002002565A0 (en) 1999-12-28 2002-06-30 Pfizer Prod Inc Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases.
AU2882801A (en) 2000-01-28 2001-08-07 Kaken Pharmaceutical Co., Ltd. Azepine derivatives
US6511980B2 (en) 2000-05-05 2003-01-28 Ortho Mcneil Pharmaceutical, Inc. Substituted diamine derivatives useful as motilin antagonists
EP1193268A1 (en) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases
WO2002051410A2 (en) 2000-12-22 2002-07-04 Akzo Nobel N.V. Phenylthiazole and thiazoline derivatives and their use as antiparasitics
EP1535924A1 (en) 2000-12-27 2005-06-01 Sumitomo Pharmaceuticals Company, Limited Novel carbapenem compounds
US7015012B2 (en) 2001-02-09 2006-03-21 Massachusetts Institute Of Technology Methods of identifying agents that mediate polypeptide aggregation
US6650463B2 (en) 2001-03-13 2003-11-18 Seiko Epson Corporation Electrophoretic display device
KR100713137B1 (en) 2001-06-28 2007-05-02 동화약품공업주식회사 Novel 2,4-difluorobenzamide derivatives
WO2003007955A2 (en) 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
DE10136043A1 (en) 2001-07-25 2003-02-13 Degussa Process for the production of modified carbon black
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
AU2002347982A1 (en) 2001-11-20 2003-06-10 Eli Lilly And Company 3-SUBSTITUTED OXINDOLE Beta3 AGONISTS
SE0201635D0 (en) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
AU2003242127A1 (en) 2002-06-05 2003-12-22 Institute Of Medicinal Molecular Design, Inc. Inhibitors against the activation of ap-1 and nfat
JP4881559B2 (en) 2002-06-27 2012-02-22 ノボ・ノルデイスク・エー／エス Arylcarbonyl derivatives as therapeutic agents
RU2340605C2 (en) 2002-06-27 2008-12-10 Ново Нордиск А/С Arylcarbonyl derivatives as therapeutic agents
AU2003254177A1 (en) 2002-07-31 2004-02-16 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
WO2004010943A2 (en) 2002-07-31 2004-02-05 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
JP4399862B2 (en) 2002-08-09 2010-01-20 味の素株式会社 Treatment for bowel disease and visceral pain
US20040110802A1 (en) 2002-08-23 2004-06-10 Atli Thorarensen Antibacterial benzoic acid derivatives
RU2005106274A (en) 2002-09-06 2005-11-10 Янссен Фармацевтика, Н.В. (Be) HETEROCYCLIC COMPOUNDS
SE0202838D0 (en) 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
US7378525B2 (en) 2002-12-23 2008-05-27 Millennium Pharmaceuticals, Inc. CCR8 inhibitors
US7320989B2 (en) 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
ATE524452T1 (en) 2003-03-27 2011-09-15 Cytokinetics Inc SULFONAMIDES FOR TREATING CONGESTIVE HEART FAILURE, COMPOSITIONS AND USES THEREOF.
JP2006525366A (en) 2003-04-30 2006-11-09 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー Heterocyclic carboxylic acid substituent
US7592352B2 (en) 2003-05-06 2009-09-22 Smithkline Beecham Corporation Substituted thieno and furo-pyridines
TW200510405A (en) 2003-05-13 2005-03-16 Schering Corp Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors
US7915293B2 (en) 2003-05-30 2011-03-29 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
US20110275630A1 (en) 2003-06-02 2011-11-10 Abbott Laboratories Isoindolinone kinase inhibitors
EP1631559A4 (en) * 2003-06-06 2008-08-27 Smithkline Beecham Corp Il-8 receptor antagonists
AR045047A1 (en) 2003-07-11 2005-10-12 Arena Pharm Inc ARILO AND HETEROARILO DERIVATIVES TRISUSTITUIDOS AS MODULATORS OF METABOLISM AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THEMSELVES
GB0319151D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
EP1678147B1 (en) 2003-09-15 2012-08-08 Lead Discovery Center GmbH Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US7498050B2 (en) 2003-12-15 2009-03-03 Kraft Foods Global Brands Llc Edible spread composition and packaged product
DE102004009238A1 (en) 2004-02-26 2005-09-08 Merck Patent Gmbh New aryl amide compounds are kinase inhibitors useful for the treatment and/or prophylaxis of e.g. tumors, psoriasis, rheumatoid arthritis, contact dermatitis, inflammations, endometriosis, scar and benign prostatic hyperplasia
US8404747B2 (en) 2004-03-05 2013-03-26 The General Hospital Corporation Compositions and methods for modulating interaction between polypeptides
EP1758856A2 (en) 2004-05-04 2007-03-07 Novo Nordisk A/S Indole derivatives for the treatment of obesity
US20090105218A1 (en) 2004-05-29 2009-04-23 7Tm Pharma A/S CRTH2 Receptor Ligands For Therapeutic Use
ATE444066T1 (en) 2004-06-22 2009-10-15 Schering Corp LIGANDS FOR THE CANNABINOID RECEPTORS
WO2006012642A2 (en) 2004-07-30 2006-02-02 Exelixis, Inc. Pyrrole derivatives as pharmaceutical agents
DE102004042441A1 (en) 2004-08-31 2006-04-06 Sanofi-Aventis Deutschland Gmbh Amino acid substituted hexahydro-pyrazino (1,2-a) pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments
CN101048388A (en) 2004-08-31 2007-10-03 阿斯利康(瑞典)有限公司 Quinazolinone derivatives and their use as B-Raf inhibitors
AU2005295788A1 (en) 2004-10-13 2006-04-27 Wyeth N-benzenesulfonyl substituted anilino-pyrimidine analogs
MX2007004699A (en) 2004-10-19 2007-06-14 Novartis Vaccines & Diagnostic Indole and benzimidazole derivatives.
WO2006053109A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
US20060122236A1 (en) 2004-12-06 2006-06-08 Wood Michael R Substituted biaryl-carboxylate derivatives
WO2006067445A2 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
CA2589773A1 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Pyridine carboxamide derivatives for use as anticancer agents
FI117653B (en) 2005-02-21 2006-12-29 Eigenor Oy Procedure and arrangement for sensing objects with a radar
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
WO2006128172A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating b cell regulated autoimmune disorders
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
US7790726B2 (en) 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
PT1940786E (en) 2005-09-16 2010-10-04 Arrow Therapeutics Ltd Biphenyl derivatives and their use in treating hepatitis c
EP1976829A2 (en) 2005-12-12 2008-10-08 Genelabs Technologies, Inc. N-(6-membered aromatic ring)-amido anti-viral compounds
MX2008008340A (en) 2005-12-21 2008-09-03 Schering Corp Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist.
EP1981849A1 (en) 2005-12-29 2008-10-22 LEK Pharmaceuticals D.D. Heterocyclic compounds
EP2019830A4 (en) 2006-05-04 2011-01-19 Inst Hepatitis & Virus Res Inhibitors of secretion of hepatitis b virus antigens for treatment of a chronic hepatitis virus
US20080021063A1 (en) 2006-07-18 2008-01-24 Kazantsev Aleksey G Compositions and methods for modulating sirtuin activity
US8153803B2 (en) 2006-07-18 2012-04-10 The General Hospital Corporation Compositions and methods for modulating sirtuin activity
FR2903985B1 (en) 2006-07-24 2008-09-05 Sanofi Aventis Sa N- (AMINO-HETEROARYL) -1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2904316B1 (en) 2006-07-31 2008-09-05 Sanofi Aventis Sa N- (AMINO-HETEROARYL) -1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
WO2008022171A1 (en) 2006-08-17 2008-02-21 Boehringer Ingelheim International Gmbh Methods of using aryl sulfonyl compounds effective as soluble epoxide hydrolase inhibitors
CA2665007A1 (en) 2006-10-06 2008-05-08 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
WO2008076270A2 (en) 2006-12-13 2008-06-26 Temple University-Of The Commonwealth System Of Higher Education Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof
US8071779B2 (en) 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
US20100022517A1 (en) 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
FR2910473B1 (en) 2006-12-26 2009-02-13 Sanofi Aventis Sa N- (AMINO-HETEROARYL) -1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
JP2008179621A (en) 2006-12-28 2008-08-07 Taisho Pharmaceutical Co Ltd Nitrogen-containing saturated heterocyclic compound
JP2008184403A (en) 2007-01-29 2008-08-14 Japan Health Science Foundation New hepatitis c virus inhibitor
PE20090188A1 (en) 2007-03-15 2009-03-20 Novartis Ag HETEROCYCLIC COMPOUNDS AS MODULATORS OF THE HEDGEHOG PATH
US8097728B2 (en) 2007-04-30 2012-01-17 Philadelphia Health & Education Corporation Iminosugar compounds with antiflavirus activity
EP2152688A1 (en) 2007-05-04 2010-02-17 Irm Llc Compounds and compositions as c-kit and pdgfr kinase inhibitors
WO2008154819A1 (en) 2007-06-18 2008-12-24 Zhang, Zhongneng Carbethoxy-substituted thiazolyl dihydropyrimidines
US8597949B2 (en) 2007-07-28 2013-12-03 The University Of Chicago Methods and compositions for modulating RAD51 and homologous recombination
BRPI0815038A2 (en) 2007-08-02 2015-03-17 Hoffmann La Roche USE OF BENZAMIDE DERIVATIVES FOR TREATMENT OF CNS DISORDERS
CN101429166B (en) 2007-11-07 2013-08-21 上海特化医药科技有限公司 Quinazoline ketone derivant, preparation method and application thereof
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
FR2926555B1 (en) 2008-01-22 2010-02-19 Sanofi Aventis BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2926556B1 (en) 2008-01-22 2010-02-19 Sanofi Aventis N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2926554B1 (en) 2008-01-22 2010-03-12 Sanofi Aventis AZABICYCLIC CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
FR2926553B1 (en) 2008-01-23 2010-02-19 Sanofi Aventis SILANYL SUBSTITUTED INDOLE-2-CARBOXAMIDE AND AZAINDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
CU20080028A6 (en) 2008-02-29 2011-02-24 Ct Ingenieria Genetica Biotech CHEMICAL COMPOUNDS OBTAINED IN SILICO FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS TO ATTENE OR INHIBIT INFECTION BY DENGUE VIRUSES AND OTHER FLAVIVIRUS
WO2009146013A1 (en) 2008-03-31 2009-12-03 Georgetown University Myosin light chain phosphatase inhibitors
EP2280001B1 (en) 2008-04-24 2014-10-15 Msd K.K. Long-chain fatty acid elongation enzyme inhibitor comprising arylsulfonyl derivative as active ingredient
US20090325960A1 (en) 2008-06-26 2009-12-31 Fulcher Emilee H Method for treating inflammatory diseases using rho kinase inhibitor compounds
US20100008968A1 (en) 2008-06-26 2010-01-14 Lampe John W Method for treating cardiovascular diseases using rho kinase inhibitor compounds
US20090325959A1 (en) 2008-06-26 2009-12-31 Vittitow Jason L Method for treating ophthalmic diseases using rho kinase inhibitor compounds
US8207195B2 (en) 2008-06-26 2012-06-26 Inspire Pharmaceuticals, Inc. Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds
US8410147B2 (en) 2008-06-26 2013-04-02 Inspire Pharmaceuticals, Inc. Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds
WO2009158587A1 (en) 2008-06-26 2009-12-30 Inspire Pharmaceuticals, Inc. Method for treating pulmonary diseases using rho kinase inhibitor compounds
CA2735392A1 (en) 2008-08-15 2010-02-18 F. Hoffmann-La Roche Ag Bi-aryl aminotetralines
US9040488B2 (en) 2008-09-02 2015-05-26 Baruch S. Blumberg Institute Imino sugar derivatives demonstrate potent antiviral activity and reduced toxicity
US8143269B2 (en) 2008-10-03 2012-03-27 Calcimedica, Inc. Inhibitors of store operated calcium release
WO2010043592A1 (en) 2008-10-15 2010-04-22 Revotar Biopharmaceuticals Ag Lipase inhibitors for use for the treatment of obesity
AR074199A1 (en) 2008-11-20 2010-12-29 Glaxosmithkline Llc COMPOSITE OF 6- (4-PYRIMIDINYL) -1H-INDAZOL, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE IT AND ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OR DECREASE OF CANCER GRAVITY.
EP2400969A4 (en) 2008-12-04 2012-05-16 Inspire Pharmaceuticals Inc Method for treating pulmonary diseases using rho kinase inhibitor compounds
CA2748174A1 (en) 2008-12-30 2010-07-08 Arqule, Inc. Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
WO2010088000A2 (en) 2009-02-02 2010-08-05 Angion Biomedica Corp. Antifibrotic compounds and uses thereof
WO2010123139A1 (en) 2009-04-24 2010-10-28 持田製薬株式会社 Arylcarboxamide derivative having sulfamoyl group
WO2010133336A1 (en) 2009-05-19 2010-11-25 Bayer Cropscience Ag Insecticidal arylpyrrolines
TWI574961B (en) 2009-05-27 2017-03-21 Ｐｔｃ治療公司 Methods for treating cancer and non-neoplastic conditions
AU2010266570A1 (en) 2009-06-30 2012-01-19 Siga Technologies, Inc. Treatment and prevention of Dengue virus infections
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20120252792A1 (en) 2009-09-17 2012-10-04 The Regents Of The University Of Michigan Methods and compositions for modulating rho-mediated gene transcription
US9051296B2 (en) 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers
CN102093320B (en) 2009-12-09 2013-08-28 扬子江药业集团上海海尼药业有限公司 Soluble epoxide hydrolase inhibitor
WO2011088015A1 (en) 2010-01-15 2011-07-21 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
WO2011088561A1 (en) 2010-01-20 2011-07-28 University Of Manitoba Anti-viral compounds and compositions
US20130045203A1 (en) 2010-03-02 2013-02-21 Emory University Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP
WO2011112191A1 (en) 2010-03-11 2011-09-15 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
CN102206172B (en) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 Substituted diaryl compound and preparation method and antiviral application thereof
EP2552208A4 (en) 2010-03-31 2014-07-09 Glaxo Group Ltd Imidazolyl-imidazoles as kinase inhibitors
BR112012028556A2 (en) 2010-05-07 2014-04-01 Glaxosmithkline Llc INDOS
US8993622B2 (en) 2010-06-11 2015-03-31 Eirium Ab Antiviral compounds
WO2011163593A2 (en) 2010-06-25 2011-12-29 Philadelphia Health & Education Corporation D/B/A Drexel Induction of immune response
CA2805242A1 (en) 2010-07-19 2012-01-26 Inspire Pharmaceuticals, Inc. Bifunctional rho kinase inhibitor compounds, composition and use
WO2012018635A2 (en) 2010-07-26 2012-02-09 Neurotherapeutics Pharma, Inc. Arylsulfonamide derivatives, compositions, and methods of use
CA2803689A1 (en) 2010-07-27 2012-02-02 Inspire Pharmaceuticals, Inc. Method for treating ophthalmic diseases using kinase inhibitor compounds in prodrug forms
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
WO2012033956A1 (en) 2010-09-08 2012-03-15 Mithridion, Inc. Cognition enhancing compounds and compositions, methods of making, and methods of treating
WO2012047856A2 (en) 2010-10-04 2012-04-12 Institute For Hepatitis And Virus Research Novel inhibitors of secretion of hepatitis b virus antigens
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
WO2012075235A1 (en) 2010-12-02 2012-06-07 Bristol-Myers Squibb Company Alkyl amides as hiv attachment inhibitors
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
GB201103419D0 (en) 2011-02-28 2011-04-13 Univ Aberdeen
SI2694484T1 (en) 2011-04-08 2018-10-30 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
US8889716B2 (en) 2011-05-10 2014-11-18 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
CN106166157B (en) 2011-07-01 2019-08-02 巴鲁·S·布隆伯格研究所 As the sulfonamides heterocyclic carbamate derivatives for preventing hepatitis b virus infected antivirotic
TWI519515B (en) 2011-12-21 2016-02-01 諾維拉治療公司 Hepatitis b antiviral agents
US9233933B2 (en) 2012-01-06 2016-01-12 Janssen Sciences Ireland Uc 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis B
US9657013B2 (en) 2012-02-29 2017-05-23 Baruch S. Blumberg Institute Inhibitors of hepatitis B virus covalently closed circular DNA formation and their method of use
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
WO2013144129A1 (en) 2012-03-31 2013-10-03 F. Hoffmann-La Roche Ag Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
UY34824A (en) 2012-05-25 2013-11-29 Janssen R & D Ireland NUCLEOSIDES OF URACILO SPYROOXETHANE
KR101945578B1 (en) 2012-06-01 2019-02-07 드렉셀유니버시티 Modulation of hepatitis b virus cccdna transcription
JO3300B1 (en) 2012-06-06 2018-09-16 Novartis Ag Compounds and compositions for modulating egfr activity
TW201408652A (en) 2012-07-11 2014-03-01 Hoffmann La Roche Aryl sultam derivatives as RORc modulators
EA026957B1 (en) 2012-08-28 2017-06-30 Янссен Сайенсиз Айрлэнд Юси Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b
KR20150054795A (en) 2012-09-10 2015-05-20 에프. 호프만-라 로슈 아게 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
SG11201504740UA (en) 2012-12-27 2015-07-30 Univ Drexel Novel antiviral agents against hbv infection
CA2899706C (en) 2013-02-28 2021-10-19 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
AU2014221775B2 (en) 2013-02-28 2017-08-24 Eisai R&D Management Co., Ltd. TETRAHYDROIMIDAZO[1,5-d][1,4]OXAZEPINE DERIVATIVE
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9895349B2 (en) 2013-04-03 2018-02-20 Janssen Sciences Ireland Us N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
BR112015028538A2 (en) 2013-05-17 2017-07-25 Janssen Sciences Ireland Uc sulfamoylthiophenamide derivatives and their use as medicines for the treatment of hepatitis b
CN105209470B (en) 2013-05-17 2018-02-06 豪夫迈·罗氏有限公司 For treating and preventing the heteroaryl dihydro-pyrimidin of 6 hepatitis b virus infected bridgings
PE20160874A1 (en) 2013-05-28 2016-09-04 Astrazeneca Ab CHEMICAL COMPOUNDS
EP3003042B1 (en) 2013-05-28 2017-06-21 Bayer CropScience Aktiengesellschaft Heterocyclic compounds as pest controllers
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
NO3024819T3 (en) 2013-07-25 2018-07-21
CA2927560A1 (en) 2013-10-18 2015-04-23 Indiana University Research And Technology Corporation Hepatitis b viral assembly effectors
WO2015055764A1 (en) 2013-10-18 2015-04-23 Syngenta Participations Ag 3-methanimidamid-pyridine derivatives as fungicides
CA2923712C (en) 2013-10-23 2021-11-02 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JP6490686B2 (en) 2013-11-14 2019-03-27 ノヴィラ・セラピューティクス・インコーポレイテッド Azepane derivative and method for treating hepatitis B infection
JO3466B1 (en) 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co Tetrahydropyridopyrazines modulators of gpr6
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
EP4023294A1 (en) 2014-01-31 2022-07-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating alzheimer's disease
RU2702109C1 (en) 2014-02-05 2019-10-04 Новира Терапьютикс, Инк. Combined therapy for treating hepatitis b infections
CN110483484A (en) 2014-02-06 2019-11-22 爱尔兰詹森科学公司 Sulfamoyl pyrrole amides derivative and its purposes for being used to treat hepatitis B as drug
PT3114128T (en) 2014-03-07 2019-02-27 Hoffmann La Roche Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
DK3116316T3 (en) 2014-03-13 2019-08-19 Univ Indiana Res & Tech Corp ALLOSTERIC MODULATORS OF HEPATITIS B CORE PROTEIN
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
MX2016012573A (en) 2014-03-28 2018-02-19 Sunshine Lake Pharma Co Ltd Dihydropyrimidine compounds and their application in pharmaceuticals.
CA2950807C (en) 2014-05-30 2022-05-31 Medshine Discovery Inc. Dihydropyrimido fused ring derivative as hbv inhibitor
DK3227262T3 (en) 2014-12-02 2020-08-10 Novira Therapeutics Inc SULFIDALKYL AND PYRIDYL-REVERSE SULPHONAMIDE COMPOUNDS FOR HBV TREATMENT
US9550779B2 (en) 2014-12-30 2017-01-24 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis B infections
MA41338B1 (en) 2015-01-16 2019-07-31 Hoffmann La Roche Pyrazine compounds for the treatment of infectious diseases
CN107847762A (en) 2015-03-19 2018-03-27 诺维拉治疗公司 Azacyclooctane and azacyclo- nonane derivatives and the method for treating hepatitis B infection
WO2016161268A1 (en) 2015-04-01 2016-10-06 Enanta Pharmaceuticals, Inc. Hepatitis b antviral agents
WO2016168619A1 (en) 2015-04-17 2016-10-20 Indiana University Research And Technology Corporation Hepatitis b viral assembly effectors
WO2016183266A1 (en) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Ehpatitis b antiviral agents
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
EP3356328A1 (en) 2015-09-29 2018-08-08 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
CN109251212A (en) 2017-07-14 2019-01-22 上海长森药业有限公司 Inner ring sulfide amide-arylamides and its purposes for treating hepatitis B

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014033176A1 (en) * 2012-08-28 2014-03-06 Janssen R&D Ireland Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
WO2014184350A1 (en) * 2013-05-17 2014-11-20 Janssen R&D Ireland Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b

Cited By (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11008346B2 (en) 2014-06-11 2021-05-18 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US10988459B2 (en) 2015-07-02 2021-04-27 Genentech, Inc. Bicyclic lactams and methods of use thereof
US10874640B2 (en) 2016-08-26 2020-12-29 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
US10328053B2 (en) 2016-08-26 2019-06-25 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
US11274285B2 (en) 2016-10-14 2022-03-15 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the Hepatitis B virus genome
US10662416B2 (en) 2016-10-14 2020-05-26 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome
US10947226B2 (en) 2016-10-17 2021-03-16 Genentech, Inc. Bicyclic pyridone lactams and methods of use thereof
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
CN108456216B (en) * 2017-02-22 2021-12-28 上海长森药业有限公司 Sulfonyl hydrazide compound and application thereof
WO2018153326A1 (en) * 2017-02-22 2018-08-30 上海长森药业有限公司 Sulfonyl hydrazine compound and use thereof
CN108456216A (en) * 2017-02-22 2018-08-28 上海长森药业有限公司 Sulfonyl hydrazines compound and application thereof
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11332485B2 (en) 2017-05-26 2022-05-17 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
JP7079527B2 (en) 2017-07-14 2022-06-02 シャンハイ ロングウッド バイオファルマシューティカルズ カンパニー リミテッド Intracyclic thiamidinoamide-arylamide compounds and their uses for the treatment of hepatitis B
EP3653630A4 (en) * 2017-07-14 2021-03-24 Shanghai Longwood Biopharmaceuticals Co., Ltd. Endocyclic thiamidinoamide-arylamide compound and use thereof for treating hepatitis b
JP2020526569A (en) * 2017-07-14 2020-08-31 シャンハイ ロングウッド バイオファルマシューティカルズ カンパニー リミテッドＳｈａｎｇｈａｉ Ｌｏｎｇｗｏｏｄ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．，Ｌｔｄ． Intracyclic thiamidinoamide-arylamide compounds and their uses for the treatment of hepatitis B
WO2019086141A1 (en) 2017-11-02 2019-05-09 Aicuris Gmbh & Co. Kg Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
WO2019086142A1 (en) 2017-11-02 2019-05-09 Aicuris Gmbh & Co. Kg Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
WO2019097479A1 (en) 2017-11-17 2019-05-23 Novartis Ag Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
US11197145B2 (en) 2017-12-05 2021-12-07 Rapidsos, Inc. Social media content for emergency management
US11247965B2 (en) 2017-12-11 2022-02-15 VenatoRx Pharmaceuticals, Inc. Hepatitis B capsid assembly modulators
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US11420974B2 (en) 2018-02-26 2022-08-23 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
US10836769B2 (en) 2018-02-26 2020-11-17 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
WO2019165374A1 (en) 2018-02-26 2019-08-29 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
WO2019166951A1 (en) 2018-02-28 2019-09-06 Novartis Ag Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
US11149052B2 (en) 2018-04-06 2021-10-19 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′-cyclic dinucleotides
WO2019193533A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'2'-cyclic dinucleotides
US11292812B2 (en) 2018-04-06 2022-04-05 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotides
WO2019193543A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides
WO2019193542A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides
US11788077B2 (en) 2018-04-12 2023-10-17 Precision Biosciences, Inc. Polynucleotides encoding optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
WO2019200247A1 (en) 2018-04-12 2019-10-17 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
US11634436B2 (en) 2018-04-20 2023-04-25 Genentech, Inc. Pyridine lactam compounds and methods of use thereof
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
US10590076B2 (en) 2018-06-11 2020-03-17 VenatoRx Pharmaceuticals, Inc. Hepatitis B capsid assembly modulators
US11566001B2 (en) 2018-06-11 2023-01-31 VenatoRx Pharmaceuticals, Inc. Hepatitis B capsid assembly modulators
US11014881B2 (en) 2018-06-11 2021-05-25 VenatoRx Pharmaceuticals, Inc. Hepatitis B capsid assembly modulators
EP3597637A1 (en) 2018-07-19 2020-01-22 Irbm S.P.A. Inhibitors of hepatitis b virus
EP3597653A1 (en) 2018-07-19 2020-01-22 Irbm S.P.A. Cyclic inhibitors of hepatitis b virus
WO2020016434A1 (en) 2018-07-19 2020-01-23 Ospedale San Raffaele S.R.L. Cyclic inhibitors of hepatitis b virus
WO2020016427A1 (en) 2018-07-19 2020-01-23 Ospedale San Raffaele S.R.L. Inhibitors of hepatitis b virus
JP2021531320A (en) * 2018-07-27 2021-11-18 アービュタス バイオファーマ コーポレイション Substituted tetrahydrocyclopenta [c] pyrrole, substituted dihydropyrrolidine, analogs thereof, and methods of using them.
JP7416757B2 (en) 2018-07-27 2024-01-17 アービュタス バイオファーマ コーポレイション Substituted tetrahydrocyclopenta[c]pyrroles, substituted dihydropyrrolidines, analogs thereof, and methods of using them
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
JP2021534132A (en) * 2018-08-10 2021-12-09 オスペダーレ・サン・ラッファエーレ・エッセエッレエッレ Tricyclic inhibitor of hepatitis B virus
US11504382B2 (en) 2018-08-10 2022-11-22 Antios Therapeutics, Inc. Tricyclic inhibitors of Hepatitis B virus
JP7436454B2 (en) 2018-08-10 2024-02-21 イエッレビエンメ・エッセ・ピ・ア Tricyclic inhibitor of hepatitis B virus
WO2020030781A1 (en) 2018-08-10 2020-02-13 Ospedale San Raffaele S.R.L. Tricyclic inhibitors of hepatitis b virus
EP3608326A1 (en) 2018-08-10 2020-02-12 Irbm S.P.A. Tricyclic inhibitors of hepatitis b virus
US11866432B2 (en) 2018-10-11 2024-01-09 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US10977927B2 (en) 2018-10-24 2021-04-13 Rapidsos, Inc. Emergency communication flow management and notification system
US11741819B2 (en) 2018-10-24 2023-08-29 Rapidsos, Inc. Emergency communication flow management and notification system
WO2020092621A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
WO2020089456A1 (en) 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg Novel urea 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazines active against the hepatitis b virus (hbv)
WO2020089452A1 (en) 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg Novel urea 6,7-dihydro-4h-pyrazolo[4,3-c]pyridines active against the hepatitis b virus (hbv)
WO2020089459A1 (en) 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg Novel urea 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazines active against the hepatitis b virus (hbv)
WO2020089460A1 (en) 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg Novel urea 6,7-dihydro-4h-thiazolo[5,4-c]pyridines active against the hepatitis b virus (hbv)
WO2020089453A1 (en) 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg Novel 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine indole-2-carboxamides active against the hepatitis b virus (hbv)
WO2020089455A1 (en) 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine indole-2-carboxamides active against the hepatitis b virus (hbv)
EP3909957A4 (en) * 2019-01-11 2022-09-07 Shanghai Longwood Biopharmaceuticals Co., Ltd. Internal cyclic sulphiamidine amide-aryl amide compound and use thereof for treating hepatitis b
JP2022517984A (en) * 2019-01-11 2022-03-11 シャンハイ ロングウッド バイオファルマシューティカルズ カンパニー リミテッド Intracyclic thiamidinoamide-arylamide compounds and their use for the treatment of hepatitis B
US11033556B2 (en) 2019-02-14 2021-06-15 Aligos Therapeutics, Inc. Bicyclic sulfonamides
WO2020167984A1 (en) * 2019-02-14 2020-08-20 Aligos Therapeutics, Inc. Bicyclic sulfonamides
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020178769A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020214663A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020214652A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020221824A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv)
WO2020221826A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel indole-2-carboxamides active against the hepatitis b virus (hbv)
WO2020221811A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel oxalyl piperazines active against the hepatitis b virus (hbv)
WO2020221816A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv)
EP3741762A1 (en) 2019-05-23 2020-11-25 Irbm S.P.A. Oxalamido-substituted tricyclic inhibitors of hepatitis b virus
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2020234483A1 (en) 2019-05-23 2020-11-26 Istituto Nazionale Di Genetica Molecolare - Ingm Oxalamido-substituted tricyclic inhibitors of hepatitis b virus
WO2020239861A1 (en) * 2019-05-28 2020-12-03 Janssen Sciences Ireland Unlimited Company Azepines as hbv capsid assembly modulators
WO2020255012A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being sulfonamide derivatives
TWI772823B (en) * 2019-06-18 2022-08-01 愛爾蘭商健生科學愛爾蘭無限公司 Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
WO2021067181A1 (en) 2019-09-30 2021-04-08 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
EP3825318A1 (en) 2019-11-25 2021-05-26 Promidis S.r.l. Oxalamido-substituted tricyclic inhibitors of hepatitis b virus
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
WO2021160617A1 (en) 2020-02-11 2021-08-19 Irbm S.P.A. Spirocyclic inhibitors of hepatitis b virus
EP3865489A1 (en) 2020-02-11 2021-08-18 Promidis S.r.l. Spirocyclic inhibitors of hepatitis b virus
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
WO2022031894A1 (en) 2020-08-07 2022-02-10 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
EP3985010A1 (en) 2020-10-14 2022-04-20 Promidis S.r.l. Spirocyclic inhibitors of hepatitis b virus
WO2022087149A2 (en) 2020-10-22 2022-04-28 Gilead Sciences, Inc. Interleukin-2-fc fusion proteins and methods of use
WO2022241134A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds

Also Published As

Publication number Publication date
PH12017502316A1 (en) 2018-06-25
IL276333A (en) 2020-09-30
MA42292B1 (en) 2019-12-31
EA201890200A1 (en) 2018-06-29
MX2017016781A (en) 2018-07-06
US20170002025A1 (en) 2017-01-05
JP2018524333A (en) 2018-08-30
TWI705058B (en) 2020-09-21
EP3590943A1 (en) 2020-01-08
CL2017003459A1 (en) 2018-05-11
EP3317286A1 (en) 2018-05-09
JP6914201B2 (en) 2021-08-04
PT3317286T (en) 2019-12-09
SG10202002302UA (en) 2020-05-28
GEP20207117B (en) 2020-06-10
EA036629B1 (en) 2020-12-01
CA2986344A1 (en) 2017-01-05
AU2016287472B2 (en) 2020-11-05
RS59609B1 (en) 2020-01-31
MA50482A (en) 2020-09-02
NI201700169A (en) 2018-08-01
PE20180410A1 (en) 2018-03-01
PL3317286T3 (en) 2020-03-31
HRP20191901T1 (en) 2020-01-24
CN107735400B (en) 2021-02-02
IL256392A (en) 2018-02-28
HK1253337B (en) 2020-05-08
US10875876B2 (en) 2020-12-29
KR20180022818A (en) 2018-03-06
AU2016287472A1 (en) 2017-11-30
CO2017012268A2 (en) 2018-05-31
MA42292A (en) 2018-05-09
CN107735400A (en) 2018-02-23
CY1122688T1 (en) 2021-03-12
EP3317286B1 (en) 2019-09-11
CR20180069A (en) 2018-06-27
TN2017000535A1 (en) 2019-04-12
HK1253337A1 (en) 2019-06-14
DK3317286T3 (en) 2019-12-02
ES2759775T3 (en) 2020-05-12
UY36766A (en) 2016-12-30
TW201713635A (en) 2017-04-16
HUE046283T2 (en) 2020-02-28
MD3317286T2 (en) 2019-12-31
IL276333B (en) 2021-07-29
HK1250031A1 (en) 2018-11-23
MX2020010737A (en) 2020-11-09
UA124054C2 (en) 2021-07-14
SI3317286T1 (en) 2020-02-28
BR112017028504A2 (en) 2018-08-28
US20210179635A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
AU2016287472B2 (en) Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
DK2981536T3 (en) N-PHENYLC CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
AU2014338947B2 (en) Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CA3029688A1 (en) Oxadiazepinone derivatives and their use in the treatment of hepatitis b infections
TWI803467B (en) Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
EP3024819A1 (en) Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
AU2020285718A1 (en) Fused heterocyclic derivatives
EP3877387A1 (en) Inhibitors of human immunodeficiency virus replication
US20230076319A1 (en) Inhibitors of hepatitis b virus
OA19579A (en) Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2020234483A1 (en) Oxalamido-substituted tricyclic inhibitors of hepatitis b virus
CN117881661A (en) Condensed heterocyclic derivative
JP2022535208A (en) Fused Heterocyclic Derivatives as Antiviral Agents
EP3741762A1 (en) Oxalamido-substituted tricyclic inhibitors of hepatitis b virus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16733102

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2986344

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: NC2017/0012268

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2016287472

Country of ref document: AU

Date of ref document: 20160701

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 002525-2017

Country of ref document: PE

WWE Wipo information: entry into national phase

Ref document number: 12017502316

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 11201710368T

Country of ref document: SG

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/016781

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2017-000169 I

Country of ref document: NI

ENP Entry into the national phase

Ref document number: 2017567064

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20187001757

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: CR2018-000069

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 14690

Country of ref document: GE

WWE Wipo information: entry into national phase

Ref document number: A201800908

Country of ref document: UA

Ref document number: 201890200

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2016733102

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017028504

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112017028504

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20171228